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Abstract 
The discovery and use of antibiotics in the chemotherapy of bacterial infections has 
revolutionised medicine as it is today. Unfortunately, the progressive use of antibiotics 
has promoted the evolution of bacterial defences against these mediators and thus the 
emergence of antibiotic resistance. Multidrug resistance (MDR) in bacterial pathogens 
has grown with such rapid progression that it now threatens to compromise the effective 
chemotherapy of a plethora of diseases. This thesis aspires to elucidate the molecular 
resistance mechanisms adopted by these bacteria, in order to expand our knowledge and 
to assist in the development of new therapeutic approaches to circumvent these 
mechanisms. 
On this basis, this thesis presents insights into a novel Vibrio cholerae antibiotic 
resistance, var, operon that encodes a metallo-P-lactamase (MPl), VarG, and a tripartite 
ATP-binding cassette-type (ABC-type) transport system, VarACDEF that has substrate 
specificities for antimicrobial peptides and macrolide antibiotics. MPls are fast 
emerging as a primary resistance mechanism, possibly as a consequence of the 
introduction of newer P-lactam antibiotics such as the carbapenems in response to 
increasing Gram-negative bacterial resistance. Fascinatingly, the ABC transporter, 
through secondary structure predictions, has been envisaged to adopt a tripartite 
structure similar to the MDR transporter, AcrAB-TolC, from the resistance nodulation 
and cell division (RND) family. The structural characterisation of this system would be 
the first such tripartite system to be elucidated and may bring new insights into how 
Gram-negative bacteria may have evolved to tackle the issue that threatens its existence. 
The resistance mechanisms in the var operon are believed to be under the 
control of a LysR-type transcriptional regulatory protein (LTTR), VarR. L TTR proteins 
form one of the largest transcriptional regulatory families with extremely diverse 
functions ranging from amino acid biosynthesis to C02 fixation. V arR binds to three 
distinct promoter regions, varRG, varGA and varBC located upstream and adjacent to 
VarG, VarA an AcrA-like membrane fusion protein and VarC a TolC-like outer 
membrane protein, respectively. VarR has also been shown to act as a repressor at the 
varRG promoter region in the absence of its substrate. Interestingly, the mechanism of 
regulation by VarR is strikingly similar to the well documented LTTR, AmpR and 
serine P-lactamase AmpC system that are found in m'lny pathogenic bact~t:ia. It could 
be that V cholerae has evolved from this regular system and developed a P-lactamase 
that would prove more beneficial in light of current selective pressures. 
Contrary to L TTRs being notoriously recalcitrant to purification due to their low 
solubility, this thesis reports the successful purification and crystallisation of full-length 
V arR in the presence and absence of its cognate promoter DNA. Elucidating the 
structural characteristics of V arR would be the first such regulator associated with MDR 
in the LTTR family. This would advance the knowledge on the only currently existing 
full-length crystal structure of a LTTR, CbnR, and will provide further insights into how 
structural conformations may lead to dissociation from the promoter and induction ~f 
gene expression. Understanding the mechanism by which V arR induces expression of 
these resistance mechanisms is paramount for future strategies to prevent the emergence 
of MDR microorganisms. 
Although these mechanisms of MDR maybe elucidated in V cholerae, the 
evolutionary relatedness and conservation of structure and function in all families will 
enable this information to be related to similar systems in alternative bacterial species. 
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Chapter 1 introduction - Antibiotic Resistance 
1.1 Antibiotics 
Antibiotics are substances that are produced by or derived from a microorganism that 
inhibit (bacteriostatic) or eradicate (bactericidal) bacterial development (Martin, 1998). 
These mediators are often classed into a larger group termed antimicrobials, which 
includes anti-virals, anti-fungal and anti-parasitic substances. 
Antimicrobials are used in many areas including human and veterinary 
medicine, agriculture (livestock) and botany (plant protection), for the prophylaxis, 
control and treatment of disease, and for the maintenance of health (McKellar, 1998). 
However, the excessive and indiscriminate use of broad-spectrum antibiotics in these 
areas has exerted remarkable selective pressures on these bacteria, ultimately 
contributing to the creation and spread of antibiotic resistance (Wise et al., 1998; 
Wegener and Frimodt-Moller, 2000; Witte, 2001; Sack et al., 2001). 
1.2 Antibiotic resistance 
The discovery and use of antibiotics in the chemotherapy of bacterial infections has 
revolutionised medicine as it is known today. Unfortunately, the progressive 
development of antibiotics has promoted the evolution of bacterial defences against 
these mediators and thus the emergence of antibiotic resistance (Powers et al., 1999; 
Rang et al., 1999). 
The development of resistance against antimicrobials is not solely a process of 
natural selection in response to naturally occurring environmental sources. Resistance is 
often exaggerated when antibiotics are used indiscriminately in the treatment of 
disorders with no efficacy such as viral infections and during prophylaxis rather than 
treatment (Guillemot, 1999; Walsh, 2000; Thomson & Bonomo, 2005; Xu et al., 2006). 
This exposes more bacteria to immense selective pressures leading to the development 
and exchange of resistance determinants, ultimately leading to the emergence of 
antibiotic resistance. 
Multidrug resistance (MDR) of bacterial pathogens has grown with such rapid 
succession that it now threatens to compromise the effective chemotherapy of a plethora 
of diseases (Borges-Walmsley and Walmsley, 2001; Borges-Walmsley et al., 2003 ). 
However, the development of multidrug resistant strains is not unexpected, for the 
evolutionary principle states that organisms adapt genetically to selective pressures 
(Rang et al., 1999; Saier and Paulsen, 2001; McKeegan et al., 2002). 
1 
The emerging global crisis of MDR has lead to a sense of urgency for the 
development of new therapeutic approaches to circumvent resistance mechanisms 
(McKeegan et al., 2004). These include inhibitors of multidrug efflux systems and new 
antibacterial agents (Poole, 2004; McKeegan et al., 2004; Kumar and Schweizer, 2005; 
Vediyappan et al., 2006). Such approaches require extensive knowledge and a thorough 
understanding of the molecular mechanisms underlying the development of MDR. 
1.3 Mechanisms of multidrug resistance 
MDR in bacterial cells can manifest through various mechanisms. Intrinsic resistance 
occurs naturally without the requirement for genetic alteration in the organism. These 
natural resistance mechanisms include reduced outer membrane permeability, energy-
dependent multidrug efflux systems and chromosomally encoded ~-lactamases 
(Hancock & Speert, 2000). Acquired resistance often evolves from mutations 
(substitutions, deletions, inversions or insertions) and/or genetic rearrangement within 
the host genome or through horizontal transfer of resistance genes between genetic 
elements (plasmids, prophages, transposons, integrons and resistance islands) within or 
between bacteria (conjugation, transduction and transformation) (Kumar and Schweizer, 
2005). Resistance to antibiotics may also encompass physiological aspects through the 
formation of bacterial biofilms (Whiteley et al., 2001; Hoffman et al., 2005; Hung et 
al., 2006). 
In general, mechanisms of resistance involve ( 1) drug inactivation due to 
degradation (e.g. ~-lactamase hydrolysis of ~-lactam antibiotics) or modification; (2) 
target alteration (mutation or enzymatic alteration resulting in the reduced affinity of the 
antibiotic for the target); (3) reduced accumulation (decreased permeability of the outer 
membrane or mutated porins) and/or increased export (upregulation of efflux systems) 
(Livermore, 1995; Nikaido, 1998; Saier and Paulsen, 2001; Grkovic et al., 2002; 
McKeegan et al., 2002; Huda et al., 2003a; Poole, 2004). 
A bacterium exhibiting natural, acquired and physiological resistance to many 
structurally and functionally diverse antibiotics can be exemplified by the opportunistic 
respiratory tract pathogen, Pseudomonas aeruginosa (Hancock & Speert, 2000). P. 
aeruginosa is notoriously difficult to eradicate with antibiotics (Gillis et al., 2005), 
mainly due to the impenetrability of the outer membrane and the expression of 
multidrug efflux pumps (Nakae et al., 1999; Nikaido, 2001). Expression of an inducible 
chromosomally encoded AmpC-like ~-lactamase, further increases resistance to ~­
lactam antibiotics (Nakae et al., 1999; Hancock & Speert, 2000). These organisms, 
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already with a high intrinsic resistance, have the potential to develop mutations leading 
to further resistance to a broader range of antimicrobials (Normark & Normark, 2002). 
Another form of defence exhibited by P. aeruginosa has been hypothesised to be 
through the formation of biofilms in the presence of antibiotics (Hoffman et al., 2005; 
Hung et al., 2006). The biofilm may then act as a diffusion barrier against these 
antibiotics, enabling the bacterium to respond to the insult by inducing specific 
mechanisms to resist that particular agent (Whiteley et al., 2001; Mah et al., 2003; 
Gillis et al., 2005). 
However, the most important mechanism of resistance in pathogenic bacteria, 
with regards to exploitation and development of drug targets, is the reduced uptake and 
pump-mediated extrusion of antimicrobials from the cell (Kumar & Schweizer, 2005). 
This synergistic process maintains cytoplasmic antimicrobial concentrations at 
sustainable levels for the organism (Borges-Walmsley & Walmsley, 2001; Van Veen, 
2001; McKeegan et al.., 2003; Venter et al., 2005). These transport systems often 
confer resistance to a multitude of structurally distinct compounds (Zgurskaya & 
Nikaido, 2000; Borges-Walmsley et al., 2003; McKeegan et al., 2003, 2004) including 
antibiotics, antiseptics, disinfectants, detergents (including naturally occurring 
detergents such as bile salts), fatty acids, heavy metals (Kobayashi et al.., 2001) and 
solvents (Paulsen et al.., 1996a; Koronakis et al.., 2000; Poole, 2001; Grkovic et al., 
2002). The ability to export a broad range of antimicrobials could be explained by the 
accommodating nature of their substrate binding pockets. These pockets often present 
multiple binding sites which consist of hydrophobic and charged residues capable of 
interacting with ligands and anionic-cationic substrates through hydrogen-bonding and 
electrostatic attractions, respectively (Paulsen, 2003) and stacking and cation-pi 
interactions. Exploitation of this mechanism would undoubtedly ease the global crisis of 
MDR through the development of inhibitors of efflux systems, to enable the re-
establishment of a broad range of antimicrobials rendered obsolete in the chemotherapy 
of multidrug resistant organisms (McKeegan et al., 2004). 
1.4 Multidrug Resistance Families 
Successive advances in the genomic sequencing of bacterial genomes have allowed for 
the identification, analysis and characterisation of five structurally diverse MDR 
superfamilies (Paulsen et al., 1996). Multidrug efflux systems are found ubiquitously in 
microorganisms and human cancer cells and are characterised according to their 
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sequence similarities, bioenergetics and structural criteria (van Veen and Konings, 
1997; Saier et al., 1998; Saier and Paulsen, 2001; McKeegan et al., 2004). 
MDR families are further classified into primary or secondary multidrug 
transporters (Huda et al., 2001) as illustrated in figure 1.1. Primary multi drug 
transporters, belonging to the ATP-binding cassette (ABC) superfamily, utilise the 
energy from A TP hydrolysis to extrude cytotoxic compounds that habitually enter the 
cell by passive diffusion (Putman et al. , 2000; Borges-Walmsley et al., 2003). 
Conversely, secondary multidrug transporters utilise the chemiosmotic energy derived 
from the electrochemical gradient of the proton/sodium motive force to drive the 
extrusion of drugs across the cytoplasmic membrane (Pao et al., 1998). These include 
the Major Facilitator (MF) superfamily, the Small Multidrug Resistance (SMR) family, 
the Resistance Nodulation Cell Division (RND) family, the Multidrug and Toxic 
compound Extrusion (MATE) family (Paulsen et al., 1996; Putman et al., 2000; 
McKeegan et al., 2004). 
Figure 1.1 
Drugs 
Cytoplasm 
A schematic illustration of the five main bacterial multidrug 
transport systems. Transporters utilising the proton motive force in the 
extrusion of drugs are represented by the SMR, RND and MF families. 
Members of the MATE family utilise a sodium-drug anti port system. 
ABC transporters couple the energy from ATP hydolysis in the efflux of 
drugs. Members of the RND family (and some MF and ABC 
transporters) often form multiprotein complexes mediated by a 
membrane fusion protein (MFP) together with an outer membrane 
protein (OMP) to bypass both membranes of a Gram-negative organism. 
Adapted from McKeegan et al., 2004. 
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1.5 Multidrug resistance in Vibrio cholerae 
Vibrio cholerae is a Gram-negative pathogen and is the aetiological agent of the acute 
and potentially fatal diarrhoeal disease, cholera (Kaper et al., 1995). Treatment of 
cholera typically entails intensive rehydration therapy. So why is there a growing 
concern for the development of antibiotic resistance in Vibrio cholerae? Cholera tends 
to develop at epidemic levels in developing countries where supplies and assistance is 
limited. Therefore the use of antibiotics such as tetracycline and erthromycin, in these 
countries is essential to greatly reduce the duration of illness (Sack et al., 2001 ), the 
chances of re-infection (Kaper et al., 1995) and to reduce mortality rates. The use of 
antibiotics may also hinder the formation of new epidemics caused by resistant strains 
that develop as a result of acquiring novel genetic elements from lysogenic filamentous 
bacteriophages, which encode diverse resistance and virulence determinants (Faruque et 
al., 1998; Heilpern and Waldor, 2000). Resistance may be further exaggerated by 
extensive genetic exchange that is hypothesised to occur naturally within their innate 
ecosystem, between environmental strains of V. cholerae that constitute a reservoir of 
evolutionary favourable genetic material (Faruque et al., 2004). The promiscuous 
exchange of genetic information between bacteria may lead to resistance that is aquired 
from one species, which is subsequently spread through natural microbial populations 
(Saier and Paulsen, 2001 ). 
Acquired MDR in V. cholerae mediated as a result of exogenous transferable 
genetic elements, often lead to consistent alterations in resistance mechanisms that are 
specific, frequent and exhaustive (Waldor et al., 1996; Kazama et al., 1999; Falbo, 
1999; Hochhut et al., 2001; Iwanaga et al., 2004). However, chromosomally encoded 
intrinsic resistance mechanisms prove to be the most perilous of all, often contributing 
to MDR of a diverse range of structurally disparate compounds. 
Analysis of the completed genome sequence of V. cholerae 01 Biovar Eltor 
strain N16961 (Heidelberg et al., 2000), has revealed at least 28 putative multidrug 
transporter genes and 1 chromosomally encoded metallo-~-lactamase. Of these 
multidrug transporter genes, 11 are known to be from the MF, 1 SMR, 7 RND, 6 MATE 
and 4 ABC superfamily (Huda et al., 2003a; Begum et al., 2005). This is not surprising 
as marine isolates of V. cholerae have been implicated in the resistance to chemically 
diverse antibiotics, including ampicillin, penicillin, streptomycin, nitrofurantoin, and 
erythromycin in addition to toxic metals of Pb2+ and Zn2+ (Choudhury and Kumar, 
1996). No plasmids have been detected in these isolates that may confer these 
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resistances (Choudhury and Kumar, 1996), therefore my focus will remam with 
chromosomally encoded MDR systems. 
To date, several publications of multidrug efflux systems and two bile resistance 
efflux pumps in V. cholerae have been described. The H+/Na+ antiport multidrug efflux 
systems include VceCAB (Colmer et al., 1998; Woolley et al., 2005); VcrM (Huda et 
al., 2003a); VemA (Huda et al., 2001), VcmB, VcmD, VcmH, and VcmN (Begum et 
al., 2005). The efflux systems involved in bile resistance include VexAB and VexCD 
(Bina et al., 2006). Although the ABC-type superfamily constitutes the largest of all 
MDR families characterised, only one ABC-type transporter VcaM (Huda et al., 2003b) 
has been identified in V. cholerae. 
In relevance to this thesis, only MDR attributed by P-lactamases and transporters 
from the ABC-type superfamily will be discussed in detail in subsequent sections. 
1.5 .1 P-Iactam resistance 
P-lactam resistance in clinical bacterial isolates have been linked to the loss of one or 
more outer membrane porin proteins (Ochs et al., 1999). However, resistance is most 
often mediated in conjunction with expression of a P-lactamase (Mallea et al., 1998; 
Barnet et al., 2000). 
P-lactamase activity remains the most abundant cause of bacterial resistance to 
P-lactam antibiotics in Gram-negative bacteria (Nass and Nordmann, 1994). P-
lactamases in these bacteria are believed to have evolved in defence against naturally 
occurring P-lactams produced by environmental microorganisms prior to the antibiotic 
era (Livermore, 1995; Walsh et al., 2005). The catalytic mechanisms by which these 
enzymes inactivate P-lactam antibiotics are through the hydrolysis of the amide bond of 
the P-lactam ring (Livermore, 1995; Frere, 1995). 
Currently two classification systems exist for P-lactamases; the Ambler 
(Ambler, 1980) and the Bush-Jacoby-Medeiros (Bush et al., 1995). The Bush-Jacoby-
Medeiros system classify P-Iactamases into four groups 1, 2 (with sub-groups), 3 and 4 
based on functional characteristics of substrate and inhibitor profiles. The Ambler 
classification categorises P-Iactamases into four classes A, B, C and D according to the 
following biochemical properties and isoelectric focusing patterns (table 1.1 ): (1) 
Isoelectric point (pi), (2) molecular mass, (3) substrate profile, ( 4) interaction with 
inhibitors and inactivators, (5) the nature of the active site, (6) amino acid sequence, and 
(7) 3D structure. 
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Table 1.1 Classification of ~-lactamases based on the Ambler and Bush-
Jacoby-Medeiros systems. Adapted from Ambler, 1980; Bush et al., 
1995; Livermore, 1995. 
Structur:al Class Functional Group 
(Ambler) (Bush .. Jacoby- Substrate specificity Inhibition l\lledeiros) 
Serine 13-lactamases 
2a Penicillins 0.1mM Clavulanate 
213 
Penicillins, 0.1mM 
cephalosporins Clavulanate 
Penicillins, narrow and 
2be extended spectrum 0.1mM 
cephalosporins, Clavulanate 
A monobactams (Penicillinases) 
2br Penicillins Resistant 
2c Penicillins, 0.1mM 
carbenicillin Clavulanate 
2e Cephalosporins 0.1mM Clavulanate 
2f Penicillins, 0.1mM 
cephalosporins Clavulanate 
c 1 Cephalosporins Oxacillin and ( Cephalopori nases) Aztreonam 
D 2d Penicillins, cloxacillin 0.1mM (Oxacillinases) Clavulanate 
Undetermined 4 Penicillins ? 
Metallo-j3-lactamases 
Most 13-lactams 
B 3 including 1mM EDTA 
carbapenems 
Classes A (either chromosomally or plasmid mediated), C (chromosomally 
located) and D (plasmid mediated) comprise of the serine ~-lactamases (S~ls) and class 
B (mainly chromosomally located) of the metallo-~-lactamases (M~ls). Class B M~ls 
are functionally similar to the S~ls, but are distinguished through their dependence for a 
coordinated zinc ion (Zn2+) as the reactive nucleophile (Ambler, 1980; Nass and 
Nordman, 1994 ). Although these classes can be further distinguished by inhibition with 
O.lmM clavulanate or 1mM EDTA, many organisms often encode multiple ~­
lactamases which could ultimately lead to distortion of inhibition patterns (Livermore, 
1995). 
Class B or M~ls in Gram-negative organisms present an increasingly significant 
challenge to the clinical effectiveness of ~-lactam antibiotics. Their ability to hydrolyse 
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all classes of P-lactam antibiotics, including the carbapenems and to abstain from P-
lactamase inhibitors has further increased concern (Concha et al., 1996; Therrien & 
Levesque, 2000; Spencer et al., 2005; Walsh et al., 2005). MPls mediate resistance 
through the coordinate use of one or two Zn2+ at their active site (figure 1.2). The active 
site orientates and polarises the amide bond to enable the Zn2+ to employ two water 
molecules to create zinc-bound hydroxides for the nucleophilic attack of this bond 
(Spencer et al., 2005; Walsh, 2005). 
Figure 1.2 
A 
The catalytic hydrolysis of (A) benzylpenicillin by a mononuclear-
zinc Mpl from B. cereus (top) and (B) nitrocefin by a binuclear-zinc 
MPl from B. fragilis (bottom). (A) Binding of a Zn2+ -bound hydroxide 
to the P-lactam ring carbonyl initiates a nucleophilic attack on the 
carbonyl carbon, leading to the formation of a stable oxyanion. Asp90 
deprotonates the oxyanion to yield a dianionic tetrahedral intermediate. 
Further general acid catalysis by Asp90 facilitates the breakdown of this 
intermediate. (B) Nitrocefin binding to the MPl polarises the carbonyl 
oxygen of the P-lactam bond to the Zn2+ -bound hydroxide from active 
site 1 (Zn1), and the nitrogen to the Zn2+-bound hydroxide from active 
site 2 (Zn2). Nucleophilic attack by the Zn 1 hydroxide leads to oxyanion 
stabilisation, followed by subsequent cleavage of the C-N bond. The P-
lactam nitrogen is expelled as an anion, which is then stabilised by Zn2. 
General acid hydrolysis and protonation by Zn2 follows as described in 
the mononuclear reaction to yield hydrolysed products. Adapted from 
Wangetal., 1999a. 
A'lf~--r-,-s 
V o J-N-:f ? ) COOH 
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The direct hydrolysis of the ~-lactam by this zinc/hydroxide complex leaves M~ls 
impervious to serine inhibitors such as clavulanate due to the absence of a covalent 
intermediate for which these inhibitors may act upon (Page, 2000). Chromosomally 
encoded M~ls have been well documented in many bacterial species (Walsh et al., 
2005; Spencer et al., 2005) and are listed in table 1.2. 
Table 1.2 Chromosomally encoded Metallo-~-lactamases in bacteria. 
Adapted from Walsh et al., 2005. 
Metallo-p-lactamases 
Organism P-lactamase 
Bacillus cereus 
BCII-5/B/6 
BCII-569/H 
Bacillus anthracis Bla2 
Alkalophilic Bacillus spp. Bee 170 
Chryseobacterium indologenes IND-1 
IND-2, 2a, 3, 4 
BlaB 
Chryseobacterium meningosepticum BlaB2, BlaB3 
BlaB4-8 
Chryseobacterium gleum CGB-1 
Myroides ordoratus TUS-1 
Myroides odoratimimus MUS-1 
Flavobacterium johnsoniae JOHN-1 
Aeromonas hydrophilia CphA 
Aeromonas veronii lmiS 
AsbM1 
Serratia fontico/a SFH-1 
Caulobacter crecentus Mb11B 
CAU-1 
Janthinobacterium lividium THIN-B 
Legionella gormanii FEZ-1 
Chryseobacterium meningosepticum GOB-1-7 
L1a 
Stenotrophomonas maltophilia L 1-BiaS 
L1c, L1d, L1e 
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1.5.2 The ATP-binding cassette (ABC) superfamily 
The A TP-binding cassette (ABC) superfamily is one of the largest of all MDR families 
characterised with transporters from the prokaroyotic kingdom and often dominant in 
the eukaryotic kingdom (Higgins et al., 1988; Holland & Blight, 1999; Saurin et al., 
1999; Borges-Walmsley et al., 2003; Huda et al., 2003b; Davison and Chen, 2004). 
ABC transporters (or traffic ATPases) couple the free energy generated from ATP 
binding/hydrolysis in the import or export of a broad range of chemically diverse 
substrates across biological membranes (Schneider & Hunke, 1998; Putman et al., 
2000; Borges-Walmsley et al., 2003; McKeegan et al., 2003, 2004; Poole, 2004). 
Hydrophilic antimicrobials such as P-lactams and fluoroquinolones habitually 
enter into the periplasm by passive diffusion and through generic outer membrane pores 
known as porins in Gram-negative organisms (Putman et al., 2000; Poole, 2002; 
Borges-Walmsley et al., 2003; Davidson and Chen, 2004). Certain ABC transporters 
therefore recruit auxiliary proteins such as periplasmic binding proteins (PBPs) or 
MFPs, which provide the primary substrate binding site for substrate uptake by 
cytoplasmic transmembrane domains (Linton & Higgins, 1998; Saier & Paulsen, 2001). 
Gram-negative ABC exporters often require additional OMPs (e.g. TolC) to circumvent 
both cytoplasmic and peri plasmic membranes (Koronakis et al., 2000; Bina & 
Mekalanos, 2001; Andersen et al., 2002; Nishino et al., 2003), thus maintaining 
intracellular substrate concentrations at below toxic sustainable levels (Borges-
Walmsley and Walmsley, 2001). 
In humans, clinically relevant ABC transporters include the multidrug resistance 
protein, MDRI, (also known asP-glycoprotein or ABCB1) and MRPl (also known as 
ABCC1), which mediate MDR in cancer cells through the extrusion of cytotoxic drugs 
used in cancer chemotherapy (van Veen & Konings, 1998). ABC transporters 
homologous to the MDR1 system have also been identified in bacteria, which export a 
diverse range of substrates from drugs to cellular compounds. These include LmrA from 
Lactococcus lactis (van Veen et al., 1996) and MsbA from E. coli (Karow and 
Georgopoulos, 1993; Polissi and Georgopoulos, 1996) and V. cholerae (Chang, 2003). 
However, bacterial ABC transporters function not only to export diverse substrates, but 
to mediate the import or uptake of nutrients and lipids essential for cell viability (Chang 
and Roth, 2001; Chang, 2003; Davidson & Chen, 2004). The vitamin B12 importer, 
BtuCD, from E. coli is one such example (Locher et al., 2002). 
VcaM was the first experimentally proven ABC-type multidrug transport pump 
to be functionally characterised in V. cholerae (Huda et al., 2003b). VcaM shares 30% 
10 
sequence identity and 48% similarity with each half of P-glycoprotein and 29% identity 
and 53% similarity with LmrA. The presence of VcaM in E. coli offered broad range 
specificity with resistance against fluoroquinolones, tetracyclines, ethidium bromide, 
TTPCl, rhodamine 6G and acridine orange. However, substrates of P-glycoprotein such 
as the vinca alkaloids, kanamycin, erythromycin, and chloramphenicol were determined 
not to be substrates for VcaM. Conversely, clinical relevance of VcaM is still great as 
the overexpression of V caM in V. cholerae infected individuals would seriously 
compromise the effective use of tetracyclines and fluoroquinolones in the treatment of 
cholera (Huda et al., 2003b ). 
V. cholerae MsbA (VC-MsbA), a homolog of E. coli-MsbA (EC-MsbA, Chang 
and Roth, 2001), was the first ABC transporter to be structurally characterised in V. 
cholerae (Chang, 2003). VC-MsbA is a lipid flippase that transports a major component 
of the bacterial outer cell membranes, lipid A, making it a potential target for the 
rational design of novel antibiotics. VC-MsbA shows 68% sequence identity with EC-
MsbA and confers similar substrate specificities to the bacterial P-glycoprotein 
homologue, LrnrA (Reuter et al., 2003). VC-MsbA is also 27% identical to both halves 
of P-glycoprotein indicating it may have a common evolutionary origin and similar 
structural architecture. The requirement of A TP for transport function was confirmed by 
using a potent ATPase inhibitor, sodium a-vanadate, during drug extrusion experiments. 
The recently reported structure of Sav1866 (Dawson & Locher, 2006) has 
indicated invalidities in the structures of MsbA in E. coli and V. cholerae, respectively 
(Chang & Roth, 2001; Chang, 2003). Subsequently, three research articles detailing the 
structures of MsbA in E. coli (Chang & Roth, 2001; Reyes & Chang, 2005) and ErnrE 
in complex with a substrate (Pornillos et al., 2005) have been retracted. As the crystal 
structure of MsbA in V. cholerae was also processed using the same program as for the 
above structures, the interpretation for this model has also been annulled. The 
deficiency of structurally characterised ABC transporters for V. cholerae means for the 
benefit of this section, we will use examples of other bacterial ABC transporters, where 
necessary, to provide an accurate description of the structural arrangements. 
The phylogenetic analysis of ABC transporters 
The ubiquitous nature of ABC proteins in all known kingdoms implies that these 
proteins share a common ancestral protein of early evolutionary origin (Higgins et al., 
1988). Indicative of a common evolutionary origin, each half of a full-size ATP 
transporter protein exhibits rotational symmetry, suggesting the possibility of gene 
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duplication prior to divergence of family members (McKeegan et al., 2003; Dawson & 
Locher, 2006). The ABC superfamily is subdivided into importer and exporter 
subfamilies based on their function and phylogeny (Saier et al., 1998; Dassa & Bouige, 
2001; Davidson & Chen, 2004; Igarashi et al., 2004). A phylogenetic tree (figure 1.3) 
modified from Dassa and Bouige (2001) and Saurin et al. (1999) shows the early 
segregation of three major subdivisions of ABC transporters from both prokaryotic and 
eukaryotic systems. 
Figure 1.3 
ABC-A 
ABC-B 
The phylogenetic tree of ABC transporter systems. These include the 
class 1 ABC-A family associated export systems (Blue), class 2 family 
of non-transpmt systems involved in cellular processes such as gene 
regulation and DNA repair (green) and class 3 ABC-B family associated 
import systems (Pink). The ABC-A and B families are further divided 
into distinct subfamilies according to their substrate specificities or 
process (Saier et al., 1998; Saurin et al., 1999). Adapted from Dassa and 
Bouige (2001) and Saurin et al. (1999). 
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The architecture of ABC transporters 
An intrinsic property of the superfamily of ABC transporters is the ability to organise 
into hetero- or homologous halves typically consisting of a cytoplasmic transmembrane 
domain (TMD) putatively arranged into six a-helices, and a conserved nucleotide 
binding domain (NBD) peripherally associated at the cytoplasmic face of the membrane 
(Liu et al., 1999; Saier and Paulsen, 2001; Borges-Walmsley et al., 2003; McKeegan et 
al., 2003; Dawson & Locher, 2006). 
In bacterial ABC transporters these domains are generally expressed as 
individual polypeptides, whereas in their eukaryotic counterparts they are fused as 
multi-polypeptides in a TMD-NBD-TMD-NBD conformation encoded from a single 
gene as illustrated in figure 1.4 (Linton & Higgins, 1998; van Veen and Konings, 1998; 
Putman et al., 2000; Saier & Paulsen, 2001; Locher et al., 2002; McKeegan et al., 
2003). Another arrangement termed a 'half-transporter' is encoded on a single gene, and 
consists of a TMD fused to a NBD that often assembles as dimers to form a functional 
unit (Dean et al., 2001; Chang, 2001; Dawson & Locher, 2006). Examples are EC- and 
VC-MsbA and the mammalian adrenoleukodystrophy protein (ALDP), responsible for 
an X-linked neurodegenerative disorder (Mosser et al., 1993). 
Figure 1.4 Structural arrangements of ABC transporters. A typical ABC 
transporter consists of four core domains, two TMDs represented as 
alternating loops and two cytoplasmic NBDs represented as shaded 
ovals. (A) All domains are encoded individually with the potential for 
homo- or heterologous association of TMDs. (B) As described 
previously with exception that NBDs are fused. (C) and (D) All four 
domains are fused. (E) Homo- or hetero half-transporters. (F) Fused 
TMDs. Adapted from van Veen and Konings, 1998. 
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The topography of conserved motifs within the NBD 
Although little homology is detected in the TMD of different subfamilies, some degree 
of homology is maintained in the NBD (25-30%) across the entire ABC superfamily, 
indicative of a similar mechanism of ATP-dependent transport (Locher et al., 2002; 
Davidson & Chen, 2004; Igarashi et al., 2004). NBDs possess highly conserved 
domains unique to all ABC transporters and are required for A TP binding and 
hydrolysis (Fath and Kolter, 1993; Putman et al., 2000; Davidson and Chen, 2004; 
Locher et al., 2002; Dawson & Locher, 2006). These include the consensus sequences 
of the Walker A and B motifs (Walker eta/., 1982), the ABC signature (Hyde et al., 
1990) and other shorter regions of homology as described in table 1.3 (Hung et al., 
1998; Holland & Blight, 1999; Gaudet & Wiley, 2001; Locher et al., 2002). 
Table 1.3 Conserved sequence motifs in the NBD. Adapted from Davidson & 
Chen, 2004. 
Motif Consensus 
sequence Location Function of residues 
K and Sff crucial for binding. 
Walker A or P- Forms loop for stabilisation of 
loop GxxGxGKSff# ABC a/~ domain ATP via hydrogen bonds of a-
and ~-phosphates of di- and 
tri-nucleotides 
Linker between core a interacts with y-phosphate 
a loop a a1~-domain and through H-bond of water to 
a-helical domain Mg of attacking nucleophile 
Subsequent to the Possible y-phosphate sensor Walker A motif and ABC Signature LSGGaxaR" preceded immediately in opposing molecule of dimer 
or Linker peptide of the Walker Bin the or signal transducer to the 
a-helical domain TMDs 
Preceded by the ABC D co-ordinates the catalytic 
signature and at a Mg2+ ion critical for ATP 
Walker B hhhhDE* more C-terminal hydrolysis 
location than Walker A E binds to attacking water 
in the a1~-domain and to Mg2+ 
H polarises attacking water 
by H-bond to y-phosphate 
Distal to the Walker B during hydrolysis. Potential Switch region H 
motif in the a1~-domain signal transducer, propagating conformational 
changes triggered by ATP 
hydrolysis. 
~here x represents any amino acid and final site occupied by a serine or threonine. 
"where x represent any amino acid. 
*Where h represents any hydrophobic amino acid. 
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The structural architecture of NBDs 
Several NBDs also referred to as ABC-ATPases have been structurally determined in 
nucleotide-free and bound states and exhibit similar core and ATP binding sites (Story 
& Steitz, 1992; Hung et al., 1998; Diederichs et al., 2000; Yuan et al., 2001; Karpowich 
et al., 2001; Gaudet & Wiley, 2001; Locher et al., 2002; Smith et al., 2002; Schmitt et 
al., 2003; Verdon et al., 2003; Watanabe et al., 2005). 
The overall architecture can be represented by the most recent crystal structure 
of an NBD, SufC, bound to ADP from Thermus thermophilus (Watanabe et al., 2005), 
which presents a fold typical of other structurally characterised NBDs (figure 1.5). The 
NBD has two characteristic thick L-shaped domains (arm I and IT); the larger a/~ 
domain (Arm-I) consists of two ~-sheets and five a-helices incorporating the Walker A 
and B motifs, and Switch region, which form the nucleotide-binding site. This domain 
is structurally similar to the NBD of RecA (Story & Steitz, 1992) and constitutes the 
core of the ABC-ATPase architecture. The smaller second a-helical domain (Arm-m is 
composed of three a-helices, is connected to the a/~ domain by a a-helix and ~-strand 
of a region formed from part of the Q-loop, and contains the ABC signature at the 
periphery of the cassette (Moody et al., 2002; Watanabe et al., 2005). 
Figure 1.5 Crystal structure of the ABC-ATPase SufC from T. thermophilus. 
Bound ADP is represented as a stick model. Adapted from Watanabe et 
al., 2005. 
Sheet I 
ABC a/~ domain a Helical domain 
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The majority of ABC transporters appear to have two NBDs and the process of A TP 
hydrolysis seems to be highly cooperative (Davidson & Chen, 2004). Stable dimeric 
arrangements of the glycine-rich Walker A motif of one NBD and the ABC signature of 
another NBD cooperate to create two ATP binding and hydrolysis sites at a shared 
interface (figure 1.1 0) (Hopfner et al.. 2000; Locher et al., 2002; Dawson & Locher, 
2006). Although both NBDs are required to be present for correct functioning 
(Walmsley et al., 200 1) it has been suggested that only one NBD is required for A TP 
hydrolysis (Nikaido & Ames, 1999). The presence of these conserved residues and 
residues from the Q-loop motif and Switch region at the dimer interface, suggests that 
this arrangement may be common to all members of the family (Locher et al., 2002; 
Dawson & Locher, 2006) as illustrated for BtuD in figure 1.6. 
Mutations in these highly conserved sequence motifs are poorly tolerated and 
severely diminish or eliminate transport through the loss of ATPase activity (Jones & 
George, 1999; Liu et al., 1999; Davison and Chen, 2004). In human ABC transporters 
essential for cellular function, the loss of utility can underlie disease states such as 
cystic fibrosis, hypercholesterolemia and adrenoleukodystrophy (Welsh & Smith, 1993; 
Linton & Higgins, 1998; Schnieder & Hunke, 1998; Moody et al., 2002). 
Figure 1.6 Structure of the ABC-ATPase BtuD in dimer formation. 
Cyclotetravanadate is located within the A TP-binding site and is 
represented in ball and stick model. Two vandates closely superimpose 
the a- and ~-phosphates of bound ATP. Adapted from Locher et al., 
2002. 
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The structural architecture of complete ABC transporters 
The complete three dimensional (3D) crystallographic structures of the vitamin B 12 
ABC importer, BtuCD, from E. coli and the MDR ABC homologue of P-glycoprotein, 
Sav1866, from Staphylococcus aureus, have been resolved to 3.2 and 3 angstroms, 
respectively (Locher et al., 2002; Dawson & Locher, 2006). The structural arrangement 
of Sav1866 is consistent with that observed by cross-linking and electron microscopy 
studies of P-glycoprotein, but is fundamentally dissimilar from the reported MsbA 
(Dawson & Locher, 2006). These intact structures provide detailed insights into the 
anangement and interaction of TMDs with NBDs, TMDs with TMDs, the putative roles 
of conserved motifs and the conformational changes observed during A TP recognition 
and hydrolysis (Figure 1.7). These mechanisms are intrinsic for understanding how ATP 
hydrolysis couples the translocation of substrates. 
Figure 1.7 
A 
A 
Structures of bacterial ABC transporters. (A) E. coli Vitamin B12 
transporter. (B) S. aureus multidrug Sav1866 transporter. Adapted from 
Locher et al., 2002 and Dawson and Locher, 2006, respectively. 
TMDs 
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Structure of the transmembrane domains 
Consistent with previous topological descriptions of ABC exporters, each subunit of 
Sav1866 consists of an amino-terminal (N-terminal) TMD of six transmembrane helices 
(TMH1-TMH6) and a carboxyl-terminal (C-terminal) cytoplasmic NBD. However, 
some ABC transporters may adopt more than six-helices per TMD and is exemplified 
by BtuC, which encapsulates 10 TMH per TMD (Locher et al., 2002). This variability 
has been hypothesised to reflect the diverse range of molecules translocated by 
members of the ABC superfamily. This is true of BtuCD which imports large substrates 
of vitamin B 12 that would normally exceed the diffusion limit of most ABC transporter 
channels (Locher et al., 2002; Oloo & Tieleman, 2004). The difficulties in predicting 
TMD may also lead to an underestimation in other ABC transporters (Locher et al., 
2002). 
The TMHs in Sav1866 are intricately arranged in a unidirectional manner of 
discrete membrane embedded 'wings'. In contrast the TMHs in BtuC seem disordered, 
but are arranged in a bidirectional intricate fashion. The TMHs in Sav 1866 and to some 
extent the TMHs of BtuC deviate towards an outer facing conformation from the centre 
of the membrane. Each 'wing' in Sav1866 is formed from TMH1 and 2 of one TMD 
and TMH3 and 6 of the other, whereas in BtuC the outer conformation is formed by 
TMH5 and TMHlO of both TMDs. The TMD-NBD interface of Sav1866 also defies the 
widely accepted model of being aligned side-by-side as in BtuCD, rather the two 
subunits are intricately interleaved. In Sav1866, the TMHs are extended beyond the 
lipid bilayer by short extracellular loops and long cytoplasmic loops 1 and 2 (formed 
from TMH2 and 3 and TMH4 and 5, respectively), which protrude 25 angstroms into 
the cytoplasm. Cytoplasmic loops 1 and 2 contain short helices, ICL1 and ICL2 
('coupling helices') orientated approximately parallel to the membrane of the shared 
interface formed by the TMDs (figure 1.8). Although the majority of the TMHs in BtuC 
assume an atypical configuration to Sav 1866, a similar structure is adopted by the 
prominent cytoplasmic loop between TMH6 and TMH7, which folds into two short 
helices, Ll and L2 (Locher et al., 2002). These 'coupling helices' form crucial contacts 
with the Q-loop of the NBD that transmit the mechanistic conformational changes to the 
TMDs during ATP binding and hydrolysis (Dawson & Locher, 2006). It must be noted 
that the coupling helices, ICLl of Sav1866, contacts both NBDs of each subunit 
whereas ICL2 interacts wholly with the opposite subunit. In contrast, the TMD of BtuC 
contacts only one NBD on the same side, resulting in the formation of a large fissure 
between the four domains (Dawson & Locher, 2006). 
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Figure 1.8 
A 
B 
Interactions mediated between the TMD and NBD as illustrated by 
(A) BtuCD and (B) Sav1866. Subunit contacts are mediated through 
'coupling helices' of the TMDs, which interrelate with the NBDs. 
Adapted from Locher et al., 2002 and Dawson and Locher, 2006, 
respectively. 
The substrate translocation pathway 
Both BtuCD and Sav1866 are hypothesised to adopt a substrate translocation pathway 
with an outward conformation afforded by the TMHs of each TMD. This creates a large 
conical cavity that opens to the periplasmic space, but is shielded from the cytoplasm 
and spans two thirds of the lipid membrane. Residues of all the TMHs in Sav1866 
contribute to the surface of the translocation pathway. At the interior face of the 
membrane, the pathway is lined by a hydrophilic surface of charged and polar amino 
acid side chains from TMH2-TMH5 with no significant hydrophobic patches. The 
entrance to the translocation cavity at the exterior face of the membrane is lined with 
residues from TMHl, 3 and 6 (Dawson & Locher, 2006). In contrast, the interior of the 
cavity of BtuC is lined by hydrophobic residues from TMH5 and TMH 10 and by the 
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stretches preceding TMH3 and TMH8 (Locher et al., 2002). The residues lining the 
periplasmic entrance to the translocation cavity of BtuC are undetermined due to partial 
resolution in this area. Residues lining the translocation pathway may have an important 
role in substrate recognition and specificity (Chang & Roth, 2001). The predominance 
of hydrophilic residues observed in the cavity of Savl866 may reflect an extrusion 
pathway with little or no affinity for hydrophobic drugs or substrates (Dawson & 
Locher, 2006). 
Conformational states between NBDs and TMDs during ATP hydrolysis 
Conformational changes in the NBD of ABC transporters during ATP hydrolysis and 
the means by which they are transmitted to the TMDs is fundamental to substrate 
translocation. The interface between the TMDs and NBDs of BtuCD are provided by 
extensive contacts of the Ll and L2 helices of TMD, BtuC, as described previously with 
the Q-loop on the surface of the NBD, BtuD (Davidson & Chen, 2004). This interface 
has also been observed for Sav1866 where the ICLl and ICL2 of the TMDs contact the 
NBDs which are lined with residues of the Q-loop. Therefore the absence or presence of 
ATP in the NBD has the potential to influence the conformation of the Q-loop as well 
as its interactions with the TMD (Davison & Chen, 2004; Dawson & Locher, 2006). 
ABC transporter function may thereby be initiated by A TP binding at the NBD, creating 
moderate conformational rearrangements in the Q-loop at the interface of the two 
NBDs, which then propagate towards the TMDs causing rearrangement and therefore 
substrate translocation (Davison & Chen, 2004; Dawson & Locher, 2006). 
The intricate nature between the subunits of Sav1866 dispel the theory that NBD 
dimerise upon A TP binding (Zaitseva et al., 2005) and dissociate upon completion of a 
transport cycle in order to exert their function (Liu et al., 1999). Rather, limited 
separation would be exhibited during the A TP cycle due to the close association 
between all subunits (Dawson & Locher, 2006). 
The mechanism of A TP hydrolysis coupled substrate translocation 
The cavity is representative of an open outward-facing conformation for Sav1866, in an 
ATP-bound state (Dawson & Locher, 2006, 2007). This is consistent with the 
alternating two-cylinder engine model of LmrA where the ATP-bound state is coupled 
to the movement of the high-affinity inward-facing binding site to the outside, resulting 
in the release of drug into the extracellular space, and a concomitant change to low-
affinity (figure 1.9 (B)). ATP hydrolysis is then believed to facilitate the return of the 
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outward-facing low-affinity binding conformation back to the inward-facing high-
affinity binding site, once again granting access from the interior of the cell (van Veen 
et al. , 2000; Dawson & Locher, 2006). The opposite would be seen for substrate uptake 
by BtuCD (figure 1.9 A). ATP binding and hydrolysis is therefore hypothesised to 
control conversion of alternate states, rather than by substrates as is the case for 
transporters of the MF superfamily (Dawson & Locher, 2006). However, further 
structural analyses are required to fully elucidate the mechanism of substrate 
translocation. 
Figure 1.9 
1.6 
Mechanisms of ATP hydrolysis-based substrate translocation. (A) 
A TP binding and hydrolysis is coupled to opening of the translocation 
pathway to the cytoplasm, leading to substrate import. (B) Conversely, 
ATP binding and hydrolysis is coupled to closing of the translocation 
pathway to the cytoplasm and opening to the extracellular milieu, leading 
to substrate export. Adapted from Davidson and Chen, 2004. 
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The Outer Membrane Proteins, ToiC and homologue V ceC 
Gram-negative bacteria such as E. coli and P. aeruginosa routinely form tripartite 
systems that transport a broad range of substrates from small drugs to large polypeptide 
toxins from the cytoplasm to the extracellular milieu (Fralick, 1996; Zhao et al. , 1998). 
TolC or TolC homologous OMPs are central to this process by spanning the periplasm 
and interacting with an MFP associated with a substrate specific integral membrane 
protein (IMP) from the ABC, RND or MF superfamily (for reviews see Sharff et al., 
2001 and Koronakis et al., 2004). 
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Some transport systems in E. coli have evolved to share a single talC gene as 
their outer membrane component, where as transport systems in other bacterial species 
such as Francisella tularensis, P. aeruginosa and V. cholerae encode their own cognate 
TolC homologues (Bina & Mekalanos, 2001; Federici et al., 2005; Gil et al., 2006). For 
example the MexAB, MexCD and MexEF transport systems of P. aeruginosa encode 
TolC homologues OprM, OprJ and OprN, respectively (Li et al., 1995; Poole et al., 
1996; Kohler et al., 1997). In V. cholerae, the TolC homologue, V ceC, forms the outer 
component of the MDR MF transporter VceAB (Colmer et al., 1998; Woolley et al., 
2005; Federici et al., 2005). 
The structures of the homotrimeric OMPs, TolC from E. coli (Koronakis et al., 
2000) and VceC from V. cholerae (Federici et al., 2005), have been resolved by x-ray 
crystallography to 2.1A and 1.8A, respectively. Although considerable differences exist 
between the sequences of these two OMPs, both can be readily superimposed upon one 
another showing strong structural similarities. The differences in the familial origin of 
their retrospective transporters, RND for TolC and MF for VceC, may result in the 
formation of altered protein-protein interactions in accordance with the perception that 
different architectures underlie these systems (Federici et al., 2005; Vediyappan et al., 
2006). 
The evolutionary origin from an ancient ancestor 
The importance of TolC-like OMPs in Gram-negative bacteria can be epitomised by its 
ubiquitous nature in these organisms (Sharff et al., 2001). A phylogenetic tree of TolC 
family members based on sequence similarity that correlate to export processes is split 
into three subfamilies; protein secretion, drug efflux and cation efflux (Andersen et al., 
2000). 
Indicative of a common evolutionary hexameric ancestor, an approximate two-
fold symmetry reflected in both sequence and structure of the TolC and VceC 
monomers, respectively, suggests the structural features are conserved and family 
members may have been created by a gene duplication event (Koronakis et al., 2000; 
Federici et al., 2005). 
The architecture of the ~-barrel and a-helical domains 
TolC and VceC have a general architecture consistent of a uniform cylinder with total 
length of -140A (figure 1.10). A channel is formed that traverses the outer membrane 
through a 40A ~-barrel attached to a a-helical barrel domain that protrudes 1 ooA into 
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the periplasm. At the equatorial region of the TolC a-barrel, which is less defined in 
VceC, lies a 'belt' with varied alP structures that envelope the internal 35A (30A for 
VceC) diameter of the channel. Three homologous monomers each contribute four p 
strands that associate in a right-handed antiparallel fashion to form the 12-stranded P-
barrel. Similarly the periplasmic a-barrel is formed from neighbouring a-helices 
forming six pairs of two-stranded coiled-coils, but is conversely packed into a left-
handed conformation. An abrupt turn in the linker between the P-strands and a-helices 
is believed to be mediated by two prolines conserved in the family of bacterial OMPs. 
The a-barrel is constructed from two types of helices that traverse the entire length of 
the helical barrel: long helices (H3 and H7) consist of 67 residues and short helices of 
23 (H2 and H6) and 34 residues (H4 and H8), respectively. Shorter helices stack end to 
end to form pseudocontinuous helices (H2 and H4: H6 and H8) and together the a-
helices of the a-barrel further arrange into two-stranded coiled-coils conformations 
(Koronakis et al., 2000; Federici et al., 2005). 
Figure 1.10 The overall structure of (A) E. coli ToiC and (B) V. cholerae Tole-
like V ceC. Adapted from Koronakis et al., 2000 and Federici et al., 
2005, respectively. 
A 8 
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In contrast to VceC and other OMPs where the outer membrane, lipid embedded porin-
like ~-barrel remains completely sealed, the ~-barrel channel of TolC is constitutively 
open to the surrounding environment. In VceC, loops between two ~-strands of all three 
monomers are longer than those in TolC and rest over the concave face of the barrel. 
This forms a pore that is likely to occlude entry of substrates from the extracellular 
milieu and may be opened upon induction (Federici et al., 2005). 
The distal fraction of the a-barrel to the centre of the substrate translocation 
cavity is predominantly hydrophilic and from the centre to the proximal fraction the 
cavity becomes more electronegative. This is more evident in V ceC, which contains two 
rings of clustered negative charge located near the equatorial domain and at the 
boundary between the a- and ~-barrel domains, an attribute not seen in TolC. 
Therefore, substrate translocation may be mediated by translocase-dependent specificity 
followed by charge dependent expulsion from the channel (Federici et al., 2005). 
At the proximal a-barrel, cylindrical TolC and VceC diameter decreases to a 
virtual close, owing to an inward fold from a coiled coil of each monomer, establishing 
a resting state of the proteins (figure 1.11 (A) and (B), respectively). However, the 
conserved residues involved in stabilising the closed state of TolC are not conserved in 
V ceC; instead intramonomer interactions are believed to mediate the closed state in 
VceC. Disparity in the equatorial domain between TolC and VceC may reflect differing 
structural binding requirements of their retrospective MFPs, AcrA and V ceA, 
respectively (Federici et al., 2005). Substrate translocation is hypothesised to be 
mediated by partial unfolding of the substrate and an iris-like realignment of entrance 
coiled coils to the open state (figure 1.11 (C)) (Koronakis et al., 2000; Andersen et al., 
2002; Koronakis, 2003). 
TolC and VceC are distinct in architecture compared to other known OMPs: (A) 
the formation of a single ~-barrel requires three monomers compared to accustomed 
one; (B) the channel is considerably wider allowing the passage of larger molecules 
such as polypeptides; (C) TolC lacks the inward folded loop that constricts the channel 
of thj:! ~-barrel; (D) the most prominent difference is the 100A long a-helical 
periplasmic tunnel (Andersen et al., 2000). 
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Figure 1.11 Resting 'closed'-state of the proximal a-helical barrels of (A) ToiC 
and (B) VceC. Proposed active opened-state of (C) ToiC. Adapted 
from Koronakis et al., 2000 and Federici et al., 2005, respectively. 
A 8 
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The divergences observed between TalC and VceC structures may reflect the co-
variation adopted between different members of the OMP family, which in turn are 
involved with different processes associated with transporters of the MF, RND or ABC 
families. Within a family, the tripartite architecture of a transport system is accepted to 
be conserved. Between different families, variations in transporters such as VceA-
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VceB-VceC and AcrA-AcrB-TolC, protein-protein interaction and subunit 
stoichiometry are hypothesised to occur (Federici et al., 2005). However, it has been 
demonstrated that E. coli TolC can function with the V. cholerae VceAB efflux pump 
and that V ceC mutants with amino acid substitutions at the peri plasmic tip were able to 
functionally interface the E. coli AcrAB efflux pump (Vediyappan et al., 2006). This 
indicates that the overall architectural assembly of the OMP component with the IMP-
MFP complex of VceAB-VceC pump may not differ substantially from that of AcrAB-
TolC, but rather its ability to transit to an open state and form a functional interface 
(Vediyappan et al., 2006). The limiting factor is the ability to function efficiently upon 
recruitment of TolC-like OMPs between different families. 
The structural and functional role of MFPs 
A review by Borges-Walmsley and colleagues (2003) has indicated that the TolC a-
helical barrel is approximately 1 ooA which would be insufficient to span the 
periplasmic space estimated at between 130-250A in depth. Therefore MFPs anchored 
by a single transmembrane helix or lipid moiety to the inner membrane may bridge this 
distance between the IMP and TolC, by forming a channel between or pulling together 
the two membranes. Channel formation may be supported by the notion that MFPs have 
been predicted to have similar structures to that of TolC. This can be supported by the 
partial structure of MexA (28 and 101 residues of theN- and C-terminals, respectively, 
are unsolved) from P. aeruginosa (figure 1.12) (Higgins et al., 2004). Monomers of 
MexA consist of three domains: (a) a P-barrel with a single a-helix situated at the 
entrance formed by N- and C-termini residues, (b) a lipoyl domain comprising of two 
interlocking motifs of four P-stands separated by, (c) intervening sequences forming a 
conserved a-helical hairpin (figure 1.12 (A)). The structural role of MexA in the 
tripartite complex is described on the following page. 
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Figure 1.12 Structure of the P. aeruginosa MFP, MexA. (A) Structure of the 
MexA monomer. (B) A model arrangement of nine MexA monomers 
forming a a-helical barrel. Adapted from Higgins et al., 2004. 
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Structural model of a tripartite transport system 
Eswaran and associates (2004) have proposed a structural model of a complete tripartite 
system for the transport of substrates in Gram-negative bacteria (figure 1.13). The 
model is based on the RND transport system, AcrAB-TolC from E. coli (Tikhonova & 
Zgurskaya, 2004), which determines resistance to many antibiotics, dyes, detergents, 
fatty acids, bile salts and organic solvents (Nishino et al., 2003; Rosenberg et al., 2003; 
Augustus et al., 2004; Murakami et al., 2006). However, due to the lack of structural 
data for AcrA, the MFP is substituted with its close homologue, MexA (Higgins et al., 
2004). The structure of trimeric IMP, AcrB (Murakami et al., 2002), indicates minimal 
interaction via hairpins to the coiled-coil domains of TolC. Nine MexA monomers are 
predicted to form a sheath around AcrB and the a-barrel of TolC stabilising their 
interaction. Therefore it seems reasonable that the function of AcrA in the AcrAB-TolC 
system, principally serves to stabilise TolC docking onto AcrB rather than for 
recruitment as for HlyD in HlyB-TolC. 
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Figure 1.13 Structural model of an assembled RND-type tripartite complex in a 
Gram-negative bacterium. Three monomers of TalC form the OMP 
(red), nine MexA monomers form the periplasmic MFP (blue), and AcrB 
forms the inner membrane domain (green). Reproduced from Eswaran et 
al., 2004. 
extracellular 
OM 
l ' 0 i 
periplasm 
_'_ :_i 
IM 
cytosol 
The dynamic role of MFPs 
MFPs of ABC transporters may also have a dynamic role (Andersen et al., 2000) in 
addition to the stabilisation and extension of the substrate translocation pathway. An 
example is that of a transient complex formed by recruitment and bridging of TalC by 
an ATP energised inner membrane translocase (ATPase), HlyB, for the export of a large 
llOKDa haemolysin toxin, HlyA (figure 1.14) (Thanabalu et al., 1998). Substrate 
engagement at the cytoplasmic face of HlyB results in signal transduction from theN-
terminal cytosolic domain of the MFP, HlyD, through a single transmembrane helix to 
the large coiled-coil periplasmic domain, triggering the recruitment of TolC 
(Balakrishnan et al., 2001). Upon ATP hydrolysis and substrate translocation the 
HlyBD-TolC bridging is reversed and the components of the complex separate and 
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revert back to their resting states. However, when a system harbours a mutant ATPase, 
and ATP is bound but unhydrolysed, the substrate is not exported but accumulated in 
the assembled HlyBD-TolC complex. This suggests that ATP binding opens the 
entrance of HlyB to allow HlyA to enter the pre-assembled complex. However, A TP 
hydrolysis is required to close the entrance of HlyB and through signal propagation to 
HlyD, opens the entrance of the ~-barrel of TolC. This could be achieved through HlyD 
interacting with the equatorial domain of TolC, constricting the channel at this point, 
which consequently opens the channel at the entrance and allows the substrate to 
translocate across the equatorial region and into the extracellular milieu. Rounds of A TP 
binding and hydrolysis therefore may be required to open and close the HlyB entrance, 
which may be inversely correlated with the state of the TolC entrance, so that the 
channel would open at one end or the other, but not both. The end result would be a 
repeated engagement and expulsion of substrate (Thanabulu et al., 1998). 
Figure 1.14 Structural model of an assembled ABC-type tripartite complex in a 
Gram-negative bacterium. The pre-assembled haemolysin transporter, 
HlyBD recruits TolC for the export of HlyA. Reproduced from 
Koronakis, 2003. 
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For systems utilising the chemiosmotic energy derived from the electrochemical 
gradient, the tripartite system appears constitutively assembled independent of substrate. 
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The apparent difference is thought to reflect the requirements imposed by different 
substrates and the fact that frequent association and dissociation may not be 
energetically favourable for these systems. This is exemplified by the P. aeruginosa 
MexAB-OprM system, which is estimated to expel approximately 500 toxic ethidium 
molecules per second (Eswaran et al., 2004). 
1.7 Regulation of MDR transporters 
The broad substrate specificities of bacterial MDR transporters necessitate strict 
transcriptional control by regulatory proteins to prevent excessive expression, which 
may be deleterious to the bacterium through the disruption of membrane integrity and 
the undesirable export of essential metabolites (Grkovic et al., 2001a). Regulatory 
proteins themselves bind many of the same diverse antimicrobials that are also 
substrates of the MDR transporters they regulate (Schumacher et al., 2002). 
Transcriptional regulation can be a complex process involving regulatory 
proteins encompassing repressors and/or activators functioning at the local and/or 
global level. Local regulators tend to have a modulatory role in the regulation of MDR 
genes, whilst global regulators are responsible for the activation and synthesis of MDR 
transporters (Grkovic et al., 2001a). Global regulation is believed to be activated as part 
of a global stress response to extracellular stimuli, allowing the bacterium to take 
advantage of its inherent broad substrate specificities through the modulation of various 
protective mechanisms (Grkovic et al., 2001a). Upregulation of MDR gene expression 
is often in response to detrimental conditions produced by permeating antimicrobials 
that threaten to overwhelm existing MDR transporters (Schumacher et al., 2002; 
Borges-Walmsley et al., 2003). Typically, regulators of MDR transport systems belong 
to one of four regulatory families, the AraC, MarR, MerR and TetR families (as 
reviewed by Grkovic et al., 2002). An example of a local regulator is that of QacR from 
Staphylococcus aureus which represses the MDR MF transporter, QacA (Schumacher 
et al., 2001). An example of a global regulator, MarA activates >60 genes in E. coli 
(Alekshun et al., 2001), including the MDR transport AcrAB-TolC, which is also under 
the control of its own divergently transcribed local repressor, AcrR (Grkovic et al., 
2002). 
Regulatory proteins are classified into their retrospective families based solely 
on similarities detected within their DNA-binding domains (DBD). The majority of 
bacterial regulators characterised possess one of three DNA binding motifs located at 
their N-termini: the a-helix-tum-a-helix (HTH), the winged helix (WH) and the two P-
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stranded ~-ribbon motifs (Huffman & Brennan, 2002; Grkovic et al., 2002). The HTH 
motif is the most prevalent and widely used DNA-binding motif in prokaryotes, often 
showing a high degree of structural homology (figure 1.15). The archetypal HTH motif 
consists of two a-helices orientated at -120°C from one another, tethered by a four 
residue turn, and is stabilised into a globular domain by a third a-helix. The second 
helix in the HTH motif is termed the 'recognition helix', which inserts into the major 
groove of the dsDNA and is responsible for making sequence-specific contacts 
(Huffman & Brennan, 2002). A characteristic WH motif generally has a HTH motif 
followed by one or two ~-hairpin wings (Gajiwala and Burley, 2000). The topological 
order of a WH DBD is al-~1-a2-T-a3-~2-Wl -~3-W2, where a2 & a3 represent the 
HTH motif and a3 operates as the recognition helix (Huffman & Brennan, 2002). 
Figure 1.15 Superimposed DNA-binding domains of QacR (red) and TetR 
(green) showing the highly conserved HTH motif. Reproduced from Schumacher et 
al., 2002. 
Regulatory proteins often form homodimers with each motif binding to one half-site of 
a symmetry related promoter DNA. Significant changes in the conformation of 
promoter DNA may be induced by the DNA-binding motifs themselves to facilitate 
recognition and binding of the second motif within the groove of dsDNA (Schumacher 
& Brennan, 2002). Residues of the regulatory protein not involved in the formation of 
the DBD have been implicated as signal sensors through direct binding of substrates of 
their retrospective MDR transporters, consequently inducing the expression of relevant 
transport protein(s) in response to the presence of noxious compounds (Grkovic et al., 
2002). 
Therefore it is not only important to elucidate the mechanisms of regulatory 
control of MDR gene expression, but also the molecular mechanisms employed in the 
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recognition of structurally disparate MDR transporter substrates that cooperate to 
activate or induce transcription. Elucidation of these mechanisms is paramount to the 
understanding MDR. Hence the soluble cytoplasmic properties of transcriptional 
regulators make them an attractive alternative target for clarifying these mechanisms 
due to their amenability to structural characterisation compared to their membrane 
localised counterparts. 
The structures of several MDR gene regulators have been characterised in the 
presence of both DNA and substrate. These DNA-substrate-bound structures provide an 
insight into the molecular basis of multidrug recognition and MDR transporter gene 
regulation. Structures include the MarR repressor from E. coli bound to salicylate 
(Alekshun et al., 2001); the BmrR activator from Bacillus subtilis bound to DNA and 
tetraphenylphosphonium (TTP+) (Heldwein & Brennan, 2001); and the QacR repressor 
from S. aureus bound to DNA (Schumacher et al., 2002) and several structurally 
diverse antimicrobials (Schumacher et al., 2001; Murray et al., 2004; Schumacher et al., 
2004). 
MarR in complex with salicylate 
The structure of the E. coli regulatory repressor, MarR, has been resolved to 2.3A and 
contains a novel a/~ fold representative of the MarR structural family (figure 1.16) 
(Alekshun et al., 2001). MarR negatively regulates the multiple Witibiotic resistance 
marRAB locus for which it is encoded together with MarA, an activator from the AraC 
family of transcriptional regulators, and MarB a protein of unknown function. The 
activity of MarA is responsible for the Mar phenotype of E. coli, evident as resistance to 
structurally disparate and clinically relevant antibiotics, and the global regulation of >60 
chromosomal genes (Alekshun & Levy, 1997). MarR binds two sites upstream of the 
marRAB locus at the mar operator (marO) and functions as a dimer with each subunit 
adopting a WH motif (Alekshun et al., 2001). The binding of MarR to its cognate DNA 
sites can be inhibited by anionic compounds including sodium salicylate and 2,4-
dinitrophenol (Alekshun et al., 1997). 
The overall structure of the MarR dimer consists of two distinct domains: the 
N/C terminal domain ( a1, a5 & a6) responsible for subunit dimerisation and protein 
function and the WH DBD ( a2-4 and ~ 1-3). Two salicylate substrate binding sites (Sail 
and Sal2) were identified on the surface of each of the WH DNA binding motif at 
opposite ends of a4. Binding is mediated by a combination of van der Waals and 
electrostatic contacts and extensive hydrogen bonding between salicylate and residues 
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of MarR. The current structural organisation of the two WH DNA-binding motifs of 
MarR would strongly interfere with docking into the major grooves of the DNA 
backbone. Therefore it has been hypothesised that binding of one WH DNA-binding 
motif to its cognate binding site causes reorientation of the other in order to dock 
successfully at its second cognate binding site. However, this mechanism may only be 
clarified upon structural determination of MarR bound to DNA. 
Figure 1.16 The structure of the MarR dimer. Adapted from Alekshun et al., 2001. 
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BmrR in complex with promoter DNA and TTP+ 
BmrR from B. subtillus is a member of the MerR family characterised by their 
homologous N-terrninal HTH coiled-coil domains and divergent C-terminal domains 
responsible for binding co-activator molecules. BmrR upregulates the transcription of a 
multiple drug transporter, bmr, in response to certain lipophillic cationic substrates 
which are also substrates of the transporter (Heldwein & Brennan, 2001). 
The structure of BmrR bound to promoter DNA and substrate TTP+ has been 
resolved to 3.0A and reveals an unexpected mechanism of transcriptional activation 
(Heldwein & Brennan, 2001). BmrR forms a dimer with each monomer consisting of 
three domains: an N-terminal WH DNA-binding domain (composed of a1 & a.2, a 
HTH motif bridging two wings, W 1 formed from ~2 & ~3 and W2 formed from a novel 
HTH of a 3 & a.4), a a-helical linker that connects the N- and C-terminals (a.5), and a 
C-terminal substrate-binding domain (composed of a 6 & a7 and ~ 4-11) (figure 1.17). 
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Figure 1.17 The structure of the BmrR monomer featuring a substrate-binding 
domain (green), the linker helix (red) and the winged-HTH DNA-
binding domain (yellow). Adapted from Heldwein and Brennan, 2001. 
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Heldwein & Brennan (2001) have described dimeric BmrR bound to DNA as that 
resembling a butterfly with monomers of each dimer being intricately linked (figure 
1.18). The a-helical linkers of each monomer are essential for dimerisation and form an 
antiparallel coiled-coil at the axis with two fold rotational symmetry. The a6 of one 
monomer packs against a1 and a3 of the C-terrninal domain of the other monomer. 
Also the ~ 10 & ~ 11 of one monomer wedge between the a3 & a4 of the other 
monomer. The BmrR dimer binds to two consecutive major grooves of the dsDNA 
through the two 'wings', W1 and W2, connected by a HTH motif of each N-terrninal 
WH domain. The most remarkable aspect of the BmrR-TPP+-DNA complex highlighted 
by the authors is the structure adopted by the DNA. An overall 50° bend in the DNA 
that faces away from the protein is observed in the middle of the promoter towards the 
major groove; however this is not unusual for DNA-binding proteins. The unique 
feature is the ability of the BmrR-TIP+ complex to shorten the bmr promoter through 
breaking of the A-T basepairs surrounding the p eudo dyad and the sliding away of the 
unpaired A and T bases from each other. This reconfiguration at the centre of the BmrR 
binding site repositions the -35 and -10 elements from a 19bp conformation that places 
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them at opposite sides of the DNA to a 17bp one that brings them onto the same side. 
This configuration forms a transcriptionally favourable conformation that enables the 
RNA polymerase to access both elements simultaneously. 
Figure 1.18 The structure of dimeric BmrR bound to DNA and TTP+. Adapted 
from Heldwein and Brennan, 2001. 
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Binding of TTP+ to BrnrR induces unfolding and relocation of a a-helix in the C-
terrninal domain to expose a substrate-binding pocket, lined with a single glutamate and 
multiple aromatic residues. The glutamate residue may participate in selectivity and 
specificity to cationic TTP+, and indeed other cationic substrates, via electrostatic 
interactions. The aromatic residues may rotate to accommodate different drugs and bind 
TIP+ via van der Waals and aromatic stacking interactions (Heldwein & Brennan, 
2001). 
The mechanism of DNA-binding and drug recognition by BrnrR is relatively 
well defined. However, in the absence of a BrnrR-DNA complex, the mechanisms of 
drug binding coupled to DNA distortion and transcriptional activation remains elusive. 
It has been hypothesised that drug binding may result in signal transduction through the 
coiled-coil to the other subunit towards the protein-DNA interface (Heldwein & 
Brennan, 2001). Unfortunately, like MarR, clarification requires the structures of a 
BrnrR-DNA complex. However, the following structural complexes of QacR bound to 
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DNA and various substrates, respectively, offer an opportunity to clarify these 
mechanisms. 
QacR a multidrug regulator bound to DNA and substrate(s) 
Plasmid borne QacR, a multiple drug-binding protein from S. aureus is a member of the 
TetR family of transcriptional repressors (Ramos et al., 2005), and is divergently 
transcribed from the qacA MDR transporter gene that it regulates (Grkovic et al., 1998, 
2001b). Attributable to members of TetR family are a homologous N-terminal HTH 
DNA-binding domain and a diverse C-terminal substrate binding domain (Murray et al., 
2004). Distinct from other members of the TetR family, QacR binds an abnormally long 
28bp operator site (IR1) compared to the approximated 15bp, binds as a pair of dimers, 
only binds one drug per homodimer and does not autoregulate its own expression 
(Grkovic et al., 1998, 2001b; Schumacher et al., 2001, 2002). In the absence of 
substrate, QacR binds to the pseudo-palindromic IR1 site located downstream of the 
qacA promoter and overlaps the qacA transcriptional start site (Grkovic et al., 1998). 
This implies that QacR represses transcription of qacA by hindering the transition of the 
RNA polymerase-promoter complex into a productively transcribing state, rather than 
blocking RNA polymerase binding (Schumacher & Brennan, 2002; Ramos et al., 2005). 
Repression of qacA expression was reversed in the presence of structurally diverse 
monovalent and bivalent cationic QacA substrates such as rhodamine 6G (R6G), crystal 
violet, ethidium bromide and 4',6'-diamidino-2-phenylindole (Grkovic et al., 1998, 
2003). Such diverse substrate profiles for QacR make it an ideal model for the study of 
multidrug recognition, binding and mechanisms of induction. 
The structure of QacR is entirely composed of nine a-helices, where the first 
three helices form anN-terminal three-helix DBD with an embedded HTH motif (a2 & 
a3). The linker-dimerisation region is formed from a4 and the C-terminal substrate-
binding domain from a5-9 (figure 1.19). Upon dimerisation, 1530A2 of surface area 
from each QacR monomer is buried in which lies the substrate-binding pocket. 
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Figure 1.19 The structure of the QacR monomer. Adapted from Schumacher et al., 
2001. 
Substrate-
binding Domain 
DNA-binding 
domain 
The crystal structure of a QacR-DNA complex has been resolved to 2.90A and reveals 
that binding to DNA is a cooperative process involving a dimer of dimers (Schumacher 
et al., 2002). Several further QacR-substrate complexes have also been resolved, which 
give a unique insight into the architecture of a multidrug binding pocket and 
mechanisms of drug induction (Schumacher et al., 2001, 2004; Murray et al., 2004). 
The structure of the QacR-DNA complex is formed from two dimers (four 
monomers) of QacR, each binding identically a distinct 'half-site' of the extended 28bp 
IRl operator DNA (figure 1.20). The short a3 from the HTH motif of each dimer 
deeply contact successive major grooves of the dsDNA forming over 60 connections to 
the DNA, some specific to the operator. This binding unveiled the presence of a pseudo-
palindrome in the DNA bound by the HTH motifs. Binding is enhanced further by the 
complementary electrostatic fields of the basic DBD of QacR and the phosphate 
backbone of DNA (Schumacher et al., 2002). Binding to IRl operator site has been 
determined to be cooperative as a pair of dimers (Grkovic et al., 2001 b) as DNA 
fragments lacking the other IRl half-site are not bound by QacR (Grkovic et al., 1998). 
The QacR-DNA structure reveals that such cooperation is not mediated by protein-
protein interactions as the interface between the dimers is >5A. Rather binding 
cooperation appears to be mediated by partial unwinding of the DNA resulting in a 
global bend of 3A and widening of the major groove (from 11A to 12.6A) throughout 
the entire binding site. A conformation suited for binding by the recognition helices of 
each QacR dimer that are spaced 37 A apart, rather than the 34A for proteins that bind 
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consecutive major grooves of native DNA. Distortion of the DNA is thought to be 
mediated by the binding of the first dimer, invoking an energetically unfavourable 
conformational change in the DNA that produces optimal major groove interaction 
between DNA and protein. This conformational change would therefore allow the 
second dimer to bind readily, effectively locking the IR1 site into an unwound 
conformation (Schumacher et al. , 2002). The structure of QacR-DNA complex 
therefore provides us with an insight into a unique mechanism of recognition and 
binding of promoter DNA. 
Figure 1.20 The structure of QacR bound to DNA as a dimer of dimers. One 
dimer is shown in red and green and the other as purple and cyan. 
Reproduced from Schumacher and Brennan (2002). 
The crystal structures of QacR-substrate(s) have revealed that the architecture of the 
expansive substrate binding pocket of QacR is well suited as a general feature of MDR 
transporter proteins (Schumacher & Brennan, 2002). This is consistent with 
accumulated data indicating the presence of multiple, potentially overlapping, drug 
binding sites within primary and secondary MDR transporters (Paulsen et al., 1996; van 
Veen et al., 1998; Mitchell et al., 1999; Putman et al., 1999; van Veen, 2001). 
Initial QacR substrate-bound structures reveal that a single drug binds per dimer 
and induction i identical in all cases (Schumacher et al., 2001). The ability of QacR to 
bind such structurally diverse compounds has been determined to be due to the 
accommodating nature of the substrate binding pocket that contains four glutamates and 
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multiple aromatic and polar residues (Schumacher et al., 2001). The pocket therefore 
provides an opportunity for drugs to bind to several specific sites and to be stabilised via 
electrostatic, aromatic stacking, hydrophobic and hydrogen bond interactions (Grkovic 
et al., 2003). The presence of glutamate residues that line the substrate-binding pocket 
aid to neutralise positively charged substrates, the importance of which is emphasised 
by their repeated observation in most QacR-substrate complexes (Murray et al., 2004; 
Schumacher et al., 2001; 2004 ). Furthermore, the presence of aromatic residues is 
critical for the construction of the substrate-binding pocket and conformational 
transitions in substrate-binding (Schumacher et al., 2004) as described later. 
Comparison of the structural complexes of QacR-R6G with the QacR-DNA 
complex reveals that substrate-binding triggers a coil-to-helix transition (as previously 
mentioned for the BmrR-DNA-TPP+ complex), in the substrate-bound subunit of the 
dimer that creates an expansive and multifaceted substrate-binding pocket (Schumacher 
& Brennan, 2002; Schumacher et al., 2004). In the substrate-free state (or DNA-bound 
form) a Tyr92 residue acts as a drug substitute and stabilises the substrate-binding site 
through formation of a hydrophobic core. Upon substrate binding, Tyr92 is expelled 
from the core into the solvent. Another Tyr93 residue which also acts as a drug substitute 
is repositioned to the periphery thus creating the substrate-binding pocket (Schumacher 
et al., 2001). 
The coil-to-helix transition not only facilitates substrate-binding, but also is 
important for induction. Expulsion of the tyrosines leads to the formation of an 
additional tum that elongates a5, subsequently impinging and relocating a6 towards the 
tethered DBD. a6 engages in multiple interactions with a1 of the DBD consequently 
requiring the entire DBD to rotate and translate relative to the DNA-bound QacR, a 
movement that also causes the a4 linker/ dimerisation region to deviate out. The 
outcome of these movements increases the distance between the two recognition helices 
of the HTH motifs from 37 A (DNA-bound form) to 48A (substrate-bound form), 
causing disruption of IR1 DNA binding and induction of qacA transcription 
(Schumacher et al., 2001; Huffman & Brennan, 2002). 
A feature of the QacR substrate-binding pocket, which may extend to other 
MDR-binding proteins, is the presence of several 'mini-pockets' within the larger 
substrate-binding pocket (Schumacher et al., 2004). Understanding the mechanisms 
involved in the simultaneous binding by two different substrates within the same 
substrate-binding pocket is critical for elucidating the mechanisms of multiple drug 
recognition and transport in both regulators and MDR transporters. The recent structural 
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complexes of QacR simultaneously bound to two different drugs and bivalent 
compounds aims to address this issue (Murray et al., 2004; Schumacher et al., 2004 ). 
The structure of QacR bound to the bacteriostatic compound 3,6-diaminoacridine (Pf) 
and ethidium bromide (Et) simultaneously has been refined to 2.96A resolution 
(Schumacher et al., 2004). Superimposition of the structures of QacR-Pf-Et ternary 
complex and the QacR-Et and QacR-Pf binary complexes reveal that no additional 
overall structural changes result from dual drug binding to QacR. Furthermore, the 
volume of the multidrug-binding pocket remains constant at -1100A3 in the presence of 
both drugs indicating that expansion is not necessary. 
The structure of the QacR-Pf-Et ternary complex and near-UVCD measurements 
provides an insight into the mechanisms of competitive, non-competitive, uncompetitive 
and cooperative multidrug binding demonstrated by other MDR transporters 
(Schumacher et al., 2004). Competitive multidrug binding is illustrated by the binding 
of R6G and Pf to the same mini-pocket, sterically hindering the binding of the other. 
Non-competitive multidrug binding is demonstrated by the binding of Pf and Et to their 
respective partially overlapping binding pockets leading to the formation of favourable 
van der Waals interactions between the two. Although binding is non-competitive, Pf 
binding shows dominance over Et in that it remains static in the pocket upon binding, 
with Et having to adjust its binding site to accommodate Pf. Simultaneous binding is 
aided by the flexibility of the substrate-binding pocket and an aromatic residue, which 
by side-chain rotation allows Et to slide into a new site proximal to that of its binary 
complex-binding site, effectively locking Et into its site. At this site, there is a reduction 
in binding affinity by Et and only core connections made with the protein (Schumacher 
et al., 2004). Another observation of Pf dominance can be demonstrated by a change in 
the Et binding site as a consequence of Pf binding, whereby the side chain of the 
aromatic residue, Tyr123, rotates to a position that is identical to that assumed in the 
QacR-Pf binary structure (Schumacher et al., 2004). 
Once again, the accommodating nature of the multiple substrate-binding pocket 
in terms of flexibility can be accentuated by the structures of the QacR-hexamidine and 
QacR-pentamidine complexes, resolved to 2.90A and 2.62A, respectively (Murray et 
al., 2004). These divalent aromatic diamidines are structurally very similar differing by 
only one methylene carbon in the alkyl chain linker. However, this minute difference 
results in very dissimilar binding approaches. The difference in the methylene group in 
pentamidine resulted in a significant twist about its central linker forming a 
conformation that 'bent into the core of the protein' instead of spanning the substrate-
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binding pocket as for hexamidine, which created a novel substrate-binding pocket 
(Murray et al., 2004). In conclusion, QacR has the ability to bind both similar and 
dissimilar substrates that exhibit different binding approaches due to the plasticity and 
myriad of potential binding affinities in its multiple substrate-binding pocket, a feature 
highly likely to be observed in other MDR-binding proteins. 
V ceR negatively regulates the vceCAB operon in V. cholerae 
Although the above mentioned structures provide a unique insight into the mechanisms 
of transcriptional regulation through defining protein-substrate interactions and 
substrate-induced conformational changes, relatively little is known about the dynamics 
of ligand binding. A study by Borges-Walmsley and colleagues (2005) report a dynamic 
mechanism of drug induced expression of the veeCAB operon encoding a MDR 
transporter by a member of the TetR family of transcriptional regulators, VeeR. This 
mechanism proposes that induction of expression is dependent on the shift in the 
equilibrium between that of substrate-bound VeeR and that of the unbound VeeR that 
can bind its cognate DNA, which is in contrast to the dissociation phenomenon whereby 
substrate binding to repressor-DNA complex induces dissociation (Schell, 1993; Ramos 
et al., 2005). 
The recognition and binding characteristics of V ceR are similar to that of QacR, 
which may be in part due to VeeR having similar N-terminal sequence similarity and 
28bp operator sequence to QacR. The veeR gene is divergently transcribed from the 
veeCAB operon and is predicted to encode a protein of 200 residues. Through 
electrophoretic mobility shift assays (EMSAs), VeeR was established to bind a 28bp 
imperfect palindromic repeat, termed IR 1, identified from the 120bp intergenic region 
spanning the veeR and veeC genes. Analytical size exclusion chromatography (SEC) 
further established that VeeR binds to the double stranded IR1 as a tetramer. Using 
stopped-flow spectroscopy, the authors established a specific substrate, CCCP, for 
VeeR previously described as a substrate for its cognate VceAB transporter (Colmer et 
al., 1998). Most proteins have a degree of innate fluorescence created by aromatic 
residues of tyrosine or tryptophan, the latter being the most common. Stopped-flow 
spectroscopy exploits this fluorescence through measuring changes in the wavelength 
induced under specific conditions. V ceR possess two tryptophan residues, Trp 129 and 
Trp151, located at the C-terminal domain. The binding of CCCP to VeeR induced a 
quench in protein fluorescence, which indicates that a tryptophan residue becomes 
buried within the protein possibly due to the drug overlaying the residue(s). It is 
41 
-----------------------------
therefore likely the substrate-binding site is located at the C-terminal domain, which is a 
common location for members of the TetR family (Ramos et al., 2005) and those of 
other regulatory families such as the previously described BrnrR from the MerR family 
(Markham et al., 1996; Heldwein & Brennan, 2001). 
Also a greater quench in protein fluorescence was observed for binding of 
CCCP to the VeeR-DNA complex than for binding to VeeR alone, even when 
fluorescence was corrected against the increase detected for VeeR binding to DNA 
(Borges-Walmsley et al., 2005). The difference in fluorescence quench could be 
afforded by dissociation of DNA from VeeR upon CCCP-binding. 
The apparent rate of binding of CCCP to VeeR and the VeeR-DNA complex 
increased to a saturating level indicative of a two-step process; (a) the relatively fast 
binding of CCCP, followed by (b) a slower conformational change. The authors state 
that DNA competes with CCCP for binding to VeeR and therefore stabilising mutually 
exclusive conformations (Borges-Walmsley et al., 2005). However, if like in most 
regulators where the DBD is located at the N-terminal and the substrate-binding domain 
at the C-terminal, there should be no requirement for competition as the binding sites 
are in two very separate locations, therefore in the presence of DNA and substrate will 
be able to bind both simultaneously. 
Borges-Walmsley and colleagues discover that dsDNA stabilises the formation 
of a tetramer from a pair of dimers and also show that dsDNA-bound tetrameric VeeR 
can be dissociated into dimers in the presence of CCCP. They state that this could be 
due to the presence of multiple binding sites in each dimeric V ceR subunit that can 
simultaneously accommodate CCCP and interact with one another. They also note that 
half-stoichiometric concentration of CCCP is sufficient to dissociate the VeeR-DNA 
complex indicating that occupancy of one substrate binding site is sufficient to promote 
the recruitment of VeeR into the non-DNA-binding conformation (Borges-Walmsley et 
al., 2005). The ability to detect the occupancy of a single substrate-binding site without 
accurate structural information remains speculative. There is no doubt that V ceR may 
function as a tetramer whist bound to dsDNA, nevertheless the dissociation into its 
retrospective dimers could be as a result of limited protein-protein contacts between the 
dimers when bound to DNA, as described previously for QacR (Schumacher et al., 
2002). 
The authors argue against the widely accepted model that expression is induced 
by dissociation of the repressor from its bound cognate DNA upon substrate binding, 
and stipulate that the inducer simply stabilises the non-DNA-binding conformation. 
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They state that this would be beneficial allowing the repressor to respond to minor 
changes in the inducer concentration enabling it to switch on or off expression at above 
or below a critical drug concentration, respectively (Borges-Walmsley et al., 2005). 
Conversely, de-repression by substrate-induced dissociation could occur at a critical 
drug concentration that promotes dissociation from cognate DNA rather then 
association. This would also result in more substrate-bound non-DNA-binding 
conformations being detected at above the critical drug concentration. 
Schumacher and authors (2002) state that proteins originating from the same 
family, and that share a homologous function such as transcriptional repression could 
utilise considerably different mechanisms of action. The data of Borges-Walmsley and 
colleagues (2005) clearly represents this notion. However, the conclusion drawn by 
Schumacher et al., (2002) was ascertained on the basis of structural comparison 
between QacR and TetR binding specificity to cognate DNA, whereas in the functional 
study of Borges-Walmsley and authors (2005) the mechanism of expression is based on 
the binding affinity of substrate to free repressor at certain concentrations and the 
establishment of and equilibrium between free VeeR and VeeR-substrate that controls 
expression. Therefore further functional and structural characterisation of TetR family 
members is required to clarify these differences in mechanisms of action. 
1.7.1 LysR-type transcriptional regulation ofMDR transporters 
The LysR family of transcriptional regulators (LTTRs) were first described in 1988 
(Henikoff et al., 1988) and are believed to be the largest family of all DNA-binding 
transcriptional factors to be found in the prokaryotic kingdom (Schell, 1993; Perez-
Rueda & Collado-Vides, 2000, 2001). In some cases members have been associated 
with mobile genetic elements, further diversifying their regulatory function (Schell, 
1993; Perez-Rueda & Collado-Vides, 2001). 
Proteins of this family have a dual regulatory function implicated in 
transcriptional repression and/or activation of genes and complex systems with 
extremely diverse functions including amino acid biosynthesis (Tyrrell et al., 1997), 
antibiotic resistance (Lindberg et al., 1985), C02 fixation, homeostasis (Choi et al., 
2001), and the synthesis of virulence factors (Goldberg et al., 1991; Schell, 1993; Cotter 
and DiRita, 2000). A review by Schell (1993) details the diversity, distribution, 
evolution and phylogeny and biochemical and molecular mechanisms of regulation of 
LysR family members. However, due to the increased pace at which LysR family 
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members are being characterised, especially through structural methods, an updated 
review detailing more recent findings would be more than welcomed. 
LTTR proteins are mainly cytoplasmic, but some seem membrane-bound 
(Henikoff et al., 1988; Schell, 1993). Members of this family are similarly sized, 
ranging from 270-330 amino acid residues, and share amino acid sequence similarities 
over -280 residues. Sequence homology is greatest in the 66 residues of theN-terminal 
DBD and least in their C-terminal substrate-binding domain (SBD). A highly conserved 
DNA-binding signature, the HTH motif, is located within the central N-terminal 
(between residues 23-42) and is required for sequence specific recognition and binding 
to their cognate promoters (Henikoff et al., 1988). This structural motif may be highly 
conserved in all LTTR proteins due to the similarities in their regulated DNA sequences 
which also occupy similar position in the promoter. In contrast, the C-terminal exhibits 
extensive sequence divergence which could represent the different functions employed 
by LTTR proteins requiring recognition of function-specific, but structurally diverse co-
inducers or substrates. A ligand-binding pocket is formed from residues 96-173 with 
residues 196-206 involved in cognate substrate recognition (Schell, 1993). Therefore in 
the absence of a cognate substrate, DNA-binding via the HTH motif of theN-terminal 
may repress transcriptional initiation and thus expression by RNA polymerase. 
Conversely, in the presence of cognate substrate, C-terminal substrate recognition and 
binding may occur in a similar process to that of the previously described QacR, 
whereby a conformational change in the LTTR may cause full or partial dissociation 
from the promoter and thus inducing transcription. The C-terminal domain (residues 
227-253) has also speculated to be involved in multimerisation with other LTTR 
subunits (Schell, 1993; Tyrrell et al., 1997; Choi et al., 2001). 
LTTR proteins are often divergently transcribed from the genes they regulate 
and bind a promoter that is close to or overlaps their own promoter. Therefore 
transcription is controlled in a simultaneous bidirectional manner, with most LTTRs 
repressing their own transcription through a process of autoregulation as well as that of 
their regulated gene(s). LTTRs tend to engage long sequences of 50-60bp frequently 
interacting at multiple sites of within their promoters suggesting that L TTRs bind as a 
tetramer in its biologically active form (Choi et al., 2001; Muraoka et al., 2003). Most 
engage their cognate promoters at a -15bp partial palindromic sequence centred at -65 
recognition-binding site (RBS) that has the conserved T-N wA motif critical for 
binding. Sequences adjacent to this binding motif confer recognition specificity and 
often overlap the promoter of the LTTR, so that binding at this site (which is insensitive 
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to cognate substrate) is responsible for autoregulation. LTTRs also bind at another 
dissimilar downstream sequence, termed the activation-binding site (ABS), which is 
located near the -35 RNA polymerase binding site. Binding of LTTRs to their 
respective promoter DNA induces a bend in the target DNA. Dissociation of LTTRs 
from these sites requires the presence of a cognate substrate, which is a prerequisite for 
transcriptional activation. Substrate-binding to LTTR may relax bending of promoter 
DNA, exposing the -35 transcriptional start site that enables the RNA polymerase to 
bind with increased affinity initiating transcription (Henikoff et al., 1988; Schell, 1993). 
The overexpression of a LTTR activator protein, MexT, has been implicated in 
elevated resistance in clinical isolates of P. aeruginosa expressing the mexEF-oprN 
operon (Kohler et al., 1997) and in the emergence of MDR strains (Grkovic et al., 
2002). The MexEF-OprN efflux system confers resistance to quinolones, 
chloramphenicol, and trimethroprim (Kohler et al., 1997). MexT is encoded by a gene 
upstream and in the same direction as the MexEF-OprN system, which shows sequence 
similarity to the MDR transporters MexAB~OprM (Li et al., 1995) and MexCD-OprJ 
(Poole et al., 1996; Kohler et al., 1997). MexT simultaneously activates the 
overexpression of MexEF-OprN efflux system, whilst in part downregulates the 
expression of OprD, an outer porin involved in the uptake of the carbapenam ~-lactam 
antibiotics and other cellular metabolites (Kohler et al., 1999; Ochs et al., 1999). 
Therefore not only is MexT responsible for the MDR resistance observed in P. 
aeruginosa, but also the cross resistance against ~-lactam antibiotics mediated by 
reduced uptake rather then increased efflux. 
To date (May 2007), only four LTTR proteins have been structurally 
characterised (Tyrrell et al., 1997; Choi et al., 2001; Muraoka et al., 2003; Stec et al., 
2006). Of these structures, only one full length structure exists (Muraoka et al., 2003) 
and three truncated C-terminal domain protein structures (Tyrrell et al., 1997; Choi et 
al., 2001; Stec et al., 2006), none of which have been implicated in MDR. The difficulty 
in obtaining LTTR proteins for crystallisation has been hampered due to their solubility 
difficulties (Bishop and Weiner, 1993; Verschueren et al., 2001; Stec et al., 2004). 
Although information on the C-terminal substrate-binding domains in the truncated 
protein structures reveals the mechanism of substrate-binding, the lack of structural 
information on the N-terminal DNA-binding domain ensures that understanding the 
mechanisms of promoter recognition and transcriptional activation remain elusive. 
However, the structure of the first full length LTTR, CbnR from Ralstonia eutropha 
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NH9, may represent a common structure adopted by all LTTRs and provides an insight 
into the general mechanism of transcriptional regulation (Muraoka et al., 2003 ). 
Structure of the LTTRs C-terminal substrate-binding domain 
The LTTRs CysB from Klebsiella aerogenes (Tyrrell et al., 1997) has dual regulatory 
function and the activator Cbl from E. coli (Stec et al., 2006) are responsible for the 
expression of genes associated with the biosynthesis of cysteine in Gram-negative 
bacteria. Cbl is closely related to CysB having 41% identity and 60% similarity in 
amino acid sequence (Stec et al., 2006). For CysB, transcriptional regulation is 
responsive to the substrate inducer N-acetylserine and the anti-inducers thiosulphate and 
sulphide (Tyrrell et al., 1997). In contrast to CysB, Cbl activates transcription from 
target promoters in the absence of an inducer and is inhibited by adenosine 5'-
phosphosulphate (APS) (Stec et al., 2006). 
Another LTTR, OxyR is activated through oxidation by H20 2, which then 
induces cooperative binding of the RNA polymerase for the transcription of genes 
essential for bacterial defence against oxidative stress. Activation is in response to the 
oxidation of the C-terminal located redox active Cys 199 residue to a sulfenic acid 
intermediate which then forms a disulphide bond with a second distant Cys208. 
Biochemical analyses revealed significant differences between the reduced (uniduced) 
and oxidised (induced) forms of OxyR, which bind DNA at two and four consecutive 
major grooves, respectively. Oxidised OxyR is inactivated upon reduction of the 
Cys199-Cys208 disulfide bond (Choi et al., 2001). 
The structures of the C-terminal LTTRs, CysB (residues 88-324 referred herein 
as CysB-CT), Cbl (residues 88-307 referred herein as Cbl-CT), OxyR (residues 80-305) 
reduced form (C199S referred herein as OxyR-CTR) and oxidised form (referred herein 
as OxyR-CTO) have been resolved to 1.8A, 2.8A, 2.7 A and 2.3A, respectively (Tyrrell 
et al., 1997; Choi et al., 2001; Stec et al., 2006). The structures of OxyR-CTR and 
OxyR-CTO reveal that reversible disulfide bond formation between distantly located 
cysteines introduces large structural changes in the C-terrninal SBD. Disulfide bond 
formation is augmented in the reduced form by the positively charged environment 
surrounding the H20 2-sensitive Cys199 increasing the reactivity of the cysteine sulphur 
atom. In the oxidised state, the formation of the stable disulfide bond enables OxyR-
CTO to remain activated for a period of time (Choi et al., 2001 ). 
The structures of all four C-terminal substrate-binding domains (SBD) adopt an 
overall similar fold that consist of two a/~ substrate-binding regions, SBR-1 and SBR-
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II. As a minimum, SBR-1 consist of five ~-strands and three a-helices and SBR-11 
consists of 5 ~-strands and two a-helices. The two regions are connected to one another 
by cross-over regions between two ~-strands. In both regions the ~-strands form core ~­
sheets flanked by a-helices and interconnecting loops (Figure 1.21). In OxyR-CTO, 
disulfide bind formation between the distant Cys 199 and Cys208 leads to the 
rearrangement of SBR II causing a structural switch. In comparison with OxyR-CTR, 
the short a3 on the face of the ~-sheet is looped out. The side chain of Cys 199 is 
flipped out from the hydrophobic pocket. The extended ~8 becomes a pseudo-helical 
loop and an exposed loop becomes a new strand, ~8' that forms the edge of the ~-sheet 
(Figure 1.21 (D)) (Choi et al., 2001). 
Figure 1.21 Crystal structures and topological arrangements of secondary 
structures of the C-terminal substrate-binding domains of (A) CysB, 
(B) Cbl, (C) Reduced OxyR and (D) Oxidised OxyR. NB alphabetical 
numbering in secondary structure arrangement corresponds to numerical 
numbering in text. Adapted from Tyrrell et al., 1997, Stec et al., 2006 
and Choi et al., 2001, respectively. 
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All four structures form dimers in an orientation that places the N -termini domains at 
the north and south poles of the dimer and the C-terrninals to the east and west of the 
dimer (Figure 1.22). In CysB-CT, OxyR-CTR and Cbl-CT, contacts between the two 
monomers are made between main-chain hydrogen bonds and hydrophobic interactions 
of the closest ~-strand of SBR-1 in one monomer and another ~-strand and/or a-helix of 
SBR-11 in the other monomer. The resulting conformation extends the ~-sheet from the 
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SBR-I of one monomer across to the ~-sheet of SBR-II in the neighbouring monomer to 
form an extended ~-sheet that stretches the length of the dimer. This extended ~-sheet is 
presumed to contribute to dimer stability (Tyrrell et al., 1997). 
Figure 1.22 Structures of dimeric C-terminal SBDs of (A) CysB, (B) Cbl, (C) 
Reduced OxyR and (D) Oxidised OxyR. Adapted from Tyrrell et al., 
1997, Stec et al., 2006 and Choi et al., 2001, respectively. 
A 
In contra t to the others, the monomer of the dimer in OxyR-CTO are r tated -30° 
compared to the reduced form dimer. This rotation between the monomers occurs by a 
lateral sliding of a4 of SBR II of the first monomer relative to al and ~2 of SBR I of 
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the second monomer (Figure 1.23). Following rotation these interactions are broken and 
a new salt-bridge interaction is formed between a.4 of the first monomer and a.1 of the 
second. A residue of the newly formed pseudo-helical loop of the first monomer 
interacts with residues of P2 in the second forming a hydrophobic core. 
Figure 1.23 The interface formed by the two monomers of the (A) reduced and 
(B) oxidised SBDs of OxyR. Reproduced from Choi et al., 2001. 
A B 
Dimerisation of OxyR-CTR and OxyR-CTO buries -2,100A2 of surface area and a 
cavity with a diameter of -sA is formed at the centre of OxyR-CTR (figure 1.22 (C)) 
(Choi et al., 2001). However, dimerisation of CysB-CT and Cbl-CT creates a buried 
surface area of -5,000A2, which is more than twice that observed for the OxyR-CT 
dimers. In CysB-CT, a cavity measuring -lOA deep and 6A in diameter is located 
between SBR-1 and SBR-ll and upon dimerisation forms a long horizontal internal 
channel (figure 1.24) (Tyrrell et al., 1997). 
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Figure 1.24 Substrate channel formation upon CysB-CT dimerisation. Sulphate 
anions (yellow) are surrounded by water molecules (red) and enclosed 
within the substrate-binding sites. Reproduced from Tyrell et al., 1997. 
In CysB a substrate-binding site is believed to be located between SBR-I and SBR-II in 
the SBD due to significant electron density being exhibited in this area which could not 
be accounted for by protein atoms, rather it was indicative of a binding site for a 
sulphate anion. Sulphate is a hydrogen-bond acceptor and forms extensive hydrogen 
bonds with the proteins main chain and side chain groups. Dimerisation limits access to 
the cavity where the sulphate anion is located forming an internal channel with the two 
sulphate anions lying 22A apart (figure 1.24). The structural similarities of the anti-
inducer, thiosulphate, to sulphate ensure its possibility to occupy this cavity through 
competitive inhibition of cysteine biosynthesis. Mutational analyses of the side chains 
whose residues contribute to the sulphate-binding cavity of CysB and the ABS-binding 
cavity of Cbl further suggest that substrate-binding site located between SBR I and SBR 
II (Tyrrell et al., 1997; Muroaka et al., 2003; Stec et al., 2006). 
Transcriptional activation in OxyR-CTO involves a Cys199 residue that resides 
within a narrow hydrophobic pocket between SBR I and SBR II consistent with 
previous observations in CysB-CT (corresponding Cys199 residue in CbnR is Ser201). 
The second redox-active Cys208 is located proximal of SBR II and is separated by a 
large distance (figure 1.25) (Choi et al., 2001 ). 
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Figure 1.25 Superimposition of the reduced (purple) and oxidised (red) forms of 
the SBR-11 of OxyR-CT. Reproduced from Choi et al., 2001. 
Both OxyR-CTR and OxyR-CTO structures do not show any notable patches of 
hydrophobic surface, even following transition between the states. Within the reduced 
form, a3 containing the redox-active Cys199 is stabilised through hydrophobic 
interactions with surrounding amino acids and charge interaction between ionised 
Cys199 and Arg266. These hydrophobic and charge interactions are broken during the 
transition from the reduced to oxidised form during the formation of a sulfenic acid 
intermediate from Cys 199 oxidation by H20 2• The limited space and the overall 
hydrophobic environment drive the oxidised cysteine out of the pocket. The residues in 
the loop region surrounding Cys208 weakly cover the hydrophobic residues of the 
central ~-sheet in the SBD and may show some degree of plasticity as described 
previously for QacR. This flexibility is thought to 'flip' the loop containing Cys208 up 
towards Cys 199 bring them in closer proximity for the formation of a disulfide bond 
(figurel.26). Disulfide bond formation highly stabilises this region and covers the newly 
made hydrophobic core comprising of the redox-active loop and residues of the central 
~-sheet. Cleavage of the disulfide bond by cellular reductants such as glutaredoxin 
destabilises the loop structure and hydrophobic core and OxyR-CT reverts back to the 
reduced conformation. Transition from the oxidised to the reduced state is less efficient 
than transition from the reduced to oxidised states (Choi et al., 2001). 
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Figure 1.26 Transitions of the redox-active cysteines in the (A) reduced and (B) 
oxidised forms of OxyR-CT. Reproduced from Choi et al., 2001. 
A 
Insights into the mechanism of DNA binding by CysB are limited due to the lack of 
DBD in the observed structure and the observation that full length CysB forms a 
tetramer not dimer as in CysB-CT. Differences between the two oligomeric structures 
may have significant implications for DNA binding. This can be exemplified by 
comparing CysB with the lac repressor that has an overall similar structure. Although 
CysB-CT has a similar fold found in the lac repressor, the dimer of CysB-CT has an 
organisation profoundly different from the dimers that make up the lac tetramer. This 
implies that CysB adopts a different mode of DNA binding. The structure of an intact 
CysB tetramer is therefore required for understanding the DBD and its contribution to 
formation of the tetramer and also its mechanism of DNA binding and activation. 
Advances have been made through the successful crystallisation of full length CysB and 
it is anticipated that structural characterisation will be completed in the near future 
(Verschueren et al., 2001). However, an alternative method of DNA binding by OxyR 
has been proposed as described below. 
Interestingly, tetrameric interactions formed from a dimer of dimers have been 
identified in the crystals of OxyR-CT. This may represent dormant and functional states 
adopted by the tetrameric reduced and oxidised states of OxyR, respectively (Choi et 
al. , 2001). This 'conformational switching' may alter DNA-binding topology and/or 
stoichiometry at cognate promoter DNA that ensures appropriate contacts with RNA 
polymera e (Stec et al., 2004). his is functionally plausible for OxyR as the relative 
rotation within oxidised OxyR-CT dimer with respect to the reduced form, aligns theN-
termini of the SBD towards one side, which may lead to the rearrangement of the N-
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terminal DBD relative to the DNA, facilitating correct DNA binding by oxidised OxyR. 
Further mutational analyses supports this notion where it was demonstrated that the 
oxidised form of OxyR tetramer binds four adjacent major grooves (grooves 1, 2, 3, 4), 
whereas the reduced form binds two pairs of adjacent grooves separated by a helical 
tum (grooves 1, 2, 4, 5). Moreover, it was shown that grooves 1 and 2 were exactly the 
same parts of the DNA molecule in both cases leading authors to propose that each of 
the two OxyR dimers, occupying the same site, binds two adjacent major grooves. This 
model therefore proposes that reduction of OxyR causes a conformational change that 
influences interaction between dimers in a way that one of them remains bound to 
grooves 1 and 2, while the other is shifted to the neighbouring binding site (grooves 4 
and 5) (Zaim & Kierzek, 2003). 
The structure of the OxyR DBD dimer has been modelled by superimposing two 
monomers of OxyR onto monomers composing the dimer of a regulator, ModE DBD 
from E. coli (Zaim & Kierzek, 2003). LTTR DBDs share the same fold of the WH DBD 
from the ModE of transcriptional regulators. The only structure present from this family 
was from the E. coli transcriptional regulator, ModE. This model provides an insight 
into the structure of the full-length dimer of OxyR and may clarify its mode of protein-
DNA interaction as hypothesised above. 
According to the models of reduced and oxidised OxyR dimers, the overall 
structure of a DBD is composed of a globular region plus a long a-helix backbone 
responsible for interactions between DBD monomers (figure 1.27 (A)). The dimeric 
structure is formed from two long C-terminal anti-parallel a-helices (a4 and a4') from 
each monomer (figure 1.27 (C) and (D)). The core of the globular region is formed from 
a cluster of hydrophobic residues. Within the globular region, lies the WH structural 
motif formed from three a-helices (a1-3), where a2 and a3 form the HTH structure 
and the wing is formed from the loop joining the ~2 and ~3 strands (figure 1.27 (B)). 
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Figure 1.27 Structure of the full length OxyR. (A) Full length reduced form of 
Ox yR. (B) DNA-binding domain. (C) Oxidised form of OxyR dimer. (D) 
Reduced form of OxyR dimer. Adapted from Zaim and Kierzek, 2003. 
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The theoretical model affects the ability to study the finer details of protein-DNA 
interactions due to limitations in the resolution; therefore the HTH of the OxyR DBD 
was superimposed onto the HTH structures of several known transcription factors. In 
general it has been hypothesised that residues located within and outside the recognition 
helix of the WH motif of OxyR may be implicated in interactions with residues within 
the major groove of the DNA molecule (Zaim & Kierzek, 2003). The lack of N-terminal 
DBDs in the structures of the C-terminal SBDs only emphasi es the uncertainty 
regarding how DNA-protein interactions occur and how these interactions are altered 
upon substrate binding. However, more detailed information regarding the interactions 
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between the DBDs and SBDs, and more importantly the putative protein-DNA 
interactions can be elucidated in the following structure of a full length L TTR, CbnR. 
Structural characterisation of the full length LTTR, CbnR 
The LTTR, CbnR from the bacterium Ralstonia eutropha NH9, is divergently 
transcribed from and activates the expression of the cbnABCD genes responsible for 
degradation of chlorocatechol converted from 3-chlorobenzoate (Muraoka et al., 2003). 
The tetrameric structure of CbnR was resolved to 2.2A and functional analysis indicates 
this structure is the biologically active form. 
From the side, tetrameric CbnR resembles that of a diamond with four C-
terminal substrate-binding domains (a5-10, 3 10a1-3 and ~3-12) located at the top ofthe 
structure and four N-terminal DBDs (al-3 and ~1&2) at the bottom (figure 1.28). Like 
in the previously described C-terminal structures, the SBD can be divided into SBR I 
(aS-7, 310aJ an9 ~3-1 and SBR II (a8-10, 310a2 and ~8-12) which are connected by 
cross-over regions formed from ~6 to ~7 and ~ 11 to ~ 12. In each SBR a core ~-sheet is 
formed from the five ~-strands and is packed in by the a-helices of that SBR (figure 
1.29). 
Figure 1.28 Structure of full length tetrameric CbnR. Adapted from Muraoka et 
al., 2003. 
The DBD consists of a conserved WH motif responsible for promoter recognition and is 
compri ed of a2 & 3 and ~ 1 & 2 with the wing formed from ~ 1 & 2. The highly 
conserved hydrophobic residues Leu39, Leu43 and Leu47, are clustered to form a 
hydrophobic core of the DBD. Polar residues, including Ala22 and Pro30, are located 
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on the surface of the WH DBD and are responsible for interactions with cognate DNA. 
However, exposed residues Arg4 and Lys7, on al are also likely to interact with target 
DNA suggesting all structures in the DBD are responsible for promoter DNA 
recognition. 
Figure 1.29 Topological arrangements of the secondary structures of CbnR. 
Reproduced from Muraoka et al., 2003. 
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The CbnR structure is regarded as a dimer of dimers as each dimer adopts different 
conformations (dimers A/C as compact and BID as extended) in the tetramer (figure 
1.30). The two DBD and the a4 coiled-coil in the dimers are related by a two-fold 
rotational symmetry; conversely, the SBDs are related by a 112° rotation around an axis 
between the two domains (figure 1.30 (C)). Within the tetramer lies a large cavity of 
dimensions approximately 30Ax15A.x10A, which possesses three holes that connect to 
the outside of the tetramer. The two holes on either side of the tetramer have a diameter 
of lOA and each is surrounded by three SBD and a coiled-coil linker. This space allows 
a large positional shift of adjacent monomers in the tetramer, which may allow changes 
in the quaternary structure of the tetramer (Muraoka et al., 2003). 
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Figure 1.30 Structure of the CbnR dimer. (A) Compact form and (B) Extended 
form. (C) The CbnR dimer with extended form (purple) and compact 
form (red). Adapted from Muraoka et al. , 2003. 
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As in the OxyR model, the DBD and SBD of each CbnR monomer are linked through a 
near centrally positioned a-helical linker ( a4 ), with each monomer dimerised by a 
coiled-coil formed from the interactions of their anti-parallel a4 linkers (figure 1.30 
(C)). Different inter-monomeric interactions are exhibited by monomers A (or C) and B 
(or D) of tetrameric CbnR. Monomer A (or C) interacts with the other three monomers 
B, C (or A) and D, however, monomer B (or D) only interacts with its two adjacent 
monomers A (or B) and C. Each monomer also consists of three hinge regions; (llinge 
1) located between DBD and a4, (Hinge 2) a4 and SBD responsible for the 
conformational changes seen between the compact and extended forms, and (Hinge 3) 
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connects SBR I and SBR II in the SBD (figure 1.34 (A) and (B)) . The 50° angle formed 
by Hinge 2 in the compact form of CbnR enables the a4 linker and SBR I of the SBD to 
interact through three direct hydrogen bonds. However, this interaction is lost in the 
extended form due to the formation of a 130° angle by hinge 2 (Muroaka et al., 2003). 
The lack of structural information for CbnR bound to substrate has hindered 
detailing of the substrate-binding site in the present structures. However, mutational 
analysis of other LTTRs involving OxyR, CysB and NahR were used to identify the 
binding-site of LTTRs. Mutations in the amino acid residues between SBR I and SBR II 
in NahR result in changes in the property of transcriptional activation (Muroaka et al., 
2003). Mutational analysis strongly suggests that substrate-binding site of LTTRs are 
located between the SBR I and SBR II as in CysB and OxyR. 
The recognition and binding of tetrameric CbnR to double-stranded promoter 
DNA was predicted by a docking study. The ribosome-binding site (RBS) and the 
activation-binding site (ABS) are located in the major grooves of dsDNA can be 
recognised and accessed simultaneously by either of the two DBD of dimers AB or CD 
due to the suitable distances formed between the two a3 in the dimers (figure 1.31 ). The 
overall V-shaped bend in the dsDNA-bound CbnR structure resembles the curved 
arrangement of the four DNA-binding domains of the CbnR tetramer. Also the linear 
arrangement of the four DBDs is required for interaction with long promoter regions 
where the RBS is often separated from the ABS by -35bp a feature characteristic to 
LTTRs. This indicates that the tetrameric arrangement of CbnR may be a functional 
requirement for binding to promoter DNA (Muroaka et al., 2003). 
Figure 1.31 Proposed structure of the CbnR tetramer in complex with ds-DNA 
Reproduced from Muroaka et al., 2003. 
t 
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The interaction between the RBS and LTTR is stronger than that between ABS and 
LTTR which could be due to the lack of an inverted repeat at the ABS (Schell, 1993; 
Muroaka et al., 2003). Therefore binding may proceed in a similar manner to QacR 
whereby binding of the first dimer to the RBS invokes an energetically unfavourable 
conformational change in the DNA and protein. This conformational change would 
therefore allow the second dimer to bind readily to the ABS thereby anchoring the 
whole tetramer to the dsDNA. 
Once again, due to the lack of structural information of CbnR bound to 
substrate, the mechanism of substrate-binding leading to the activation of transcription 
is largely unknown. Substrate-binding to the SBD has therefore been hypothesised to 
cause a conformational change, which propagates throughout the tetramer via domain-
domain interaction (Muroaka et al., 2003; Stec et al., 2006). This results in a global 
conformational change in CbnR that may lead to transcriptional activation by a similar 
mechanism to the coil-to-helix transition in QacR as described previously. Activation 
by CbnR may be likened to a clothes peg whereby binding of substrate at one of the 
SBD 'nips' the substrate-bound domain only, forcing the limitations of the DBD 
through a conformational change that increases the distance between the two dimers 
subsequently disrupting binding of the a3 recognition helices of the DBD to the ABS 
leading to induction of transcription. This mechanism of transcriptional activation may 
only be confirmed upon successful structural characterisation of a CbnR-DNA complex 
bound to substrate. 
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1.8 Discovery and characterisation of the V. cholerae var operon 
The database of the National Center for Biotechnology Information (NCBI) was used to 
examine the chromosomes of V. cholerae El Tor 01 Biovar Eltor strain N16961 in 
which the genome has been sequenced (Heidelberg et al., 2000). A set of putative 
structural genes (open reading frames (ORFs) VC1563-VC1568) were identified on 
chromosome I of the strain N16961, which were indicative of a multi-component 
tripartite ABC transport system, a connection also established by a previous study (Bina 
and Mekalanos, 2001 ). 
The putative structural proteins were identified to have functional and structural 
homologies to other MDR transporters against various macrolide antibiotics and 
antimicrobial peptides. Interestingly, the potential increase in the MDR phenotype of V. 
cholerae N16961 to other antibiotics such as the ~-lactams, were further enhanced by 
the presence of a M~l (ORF VC1562) encoded downstream of these structural genes. 
The identification of a regulatory protein (ORF VC1561), encoded adjacent to the M~l, 
is hypothesised to control expression of these putative MDR genes and completes this 
operon. The operon was named the var (Vibrio cholerae antibiotic resistance) locus and 
each gene was assigned this three-letter designation along with an upper case letter, 
abbreviated for the phenotype of the strain, in accordance with standard genetic 
nomenclature (figure 1.32). 
Figure 1.32 The V. cholerae antibiotic resistance var operon. The locality of the ~­
lactamase, varG, the MDR varABCDEF transporter complex and the 
divergently transcribed regulatory varR genes are shown. Arrows 
indicate orientation of transcription. Three intergenic regions varRG, 
varGA and varBC to which V arR is hypothesised to regulate 
transcription are also illustrated. 
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The unique characteristic of this operon is that it is hypothesised to be under the 
control of a single divergently transcribed regulatory protein, VarR, which may co-
regulate the expression of two distinct resistance mechanisms ( 1) MPl (encoded by 
varG) and (2) an ABC-type MDR efflux system (encoded by the varABCDEF genes). 
The three intergenic regions within the var operon in which VarR is hypothesised to 
regulate transcription were designated varRG, varGA and varBC (figure 1.32). 
Preliminary analysis of the putative structural genes, V arA to YarF are 
indicative of forming an ABC-type tripartite complex, typical of gram-negative 
organisms, whereby noxious compounds bypass both membranes of V. cholerae, 
thereby reducing the concentration of drugs to sustainable levels for the bacterium 
(figure 1.33). Two adjacently encoded inner membrane translocases, YarD and YarE, 
may form a fully functioning heterooligomeric translocation pore. However, the lack of 
half transporter characteristics suggest they could even act independently of each other 
thus providing a more comprehensive and versatile antimicrobial transport system. 
Through multiple sequence alignment with other known translocases, V arD and 
YarE are both hypothesised to have substrate specificities for macrolide antibiotics and 
antimicrobial peptides (refer to chapter 3). Antimicrobial peptides represent the first line 
of host defence against invading pathogens. They are present in certain phagocytotic 
cells and their synthesis can be induced by epithelial cells that line the mucosal surfaces 
of the epithelium following infection (Shafer et al., 1998). So it is not unusual for V. 
cholerae to have developed a strategy to overcome this lethal bombardment to enable it 
to exert its pathogenicity upon entering the human host. 
The tripartite transport complex is hypothesised to be formed through the 
interactions of the IMPs with a TolC-like OMP, YarC, the association of which is 
mediated and/or stabilised by the MFPs, VarA and VarB, respectively. MFPs are 
generally associated with transporters of tripartite systems of the MF and RND 
superfamilies (Thanabalu et al., 1998). A conserved ATP-binding protein, VarF, forms 
the 'power house' to fuel the translocation of antimicrobials through utilising the energy 
released from the hydrolysis of A TP and completes the transport complex (figure 1.33). 
This thesis proposes a novel ABC transporter that utilises a tripartite complex in 
order to mediate MDR, elucidation of which would be the first to be described in a 
Gram-negative bacterium. 
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Figure 1.33 Schematic representation of the putative tripartite VarACDEF2 
transporter. The ABC-type IMPs, YarD and/or YarE, located in the 
cytoplasmic membrane utilise the energy derived from ATP hydrolysis 
by the ATPase, YarF to drive efflux. Upon entering the periplasmic 
space the IMPs interact with an AcrA-like MFP, YarA, and the TalC-like 
OMP, YarC, to form a continuous translocation pathway whereby 
antimicrobial agents are extruded into the extracellular milieu. 
Periplasmic Membrane 
Cvtoplasmic Membrane 
\ 
ADP+Pi 
Antimicrobial 
Unlike other MDR transporters such as the MexAB-OprM in P. aeruginosa that 
display a wide substrate specificity to many antibiotics including ~-lactams (Li et al., 
1995), macrolides, tetracyclines, quinolones and sulfamethoxazole (Kohler et al., 1997, 
1999), the novel V. cholerae var efflux system, through sequence homology, shows 
distinct specificity to macrolide antibiotics and antimicrobial peptides only. Therefore 
encoding of a M~l preceding this transport system may provide further resistance to ~­
lactam antibiotics. Currently no literature has been published with regards to 
chromosomally encoded M~ls in V. cholerae. Therefore this thesis initiates the first 
description of a novel putative M~l, YarG, in this organism. Analysis of the completed 
genome sequence of V. cholerae 01 Biovar Eltor strain Nl6961 (Heidelberg et al., 
2000) has failed to detect the presence of further chromosomally encoded ~-lactamases 
so for this rea on our focus will remain with the M~l . 
The combination of ~-lactamase activity and an ABC-type MDR system may 
provide a 'super' defence mechanism in V. cholerae and would seriously compromise 
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the effective treatment of cholera with current antibiotics. As genetic information is 
often exchanged promiscuously between pathogenic and environmental strains of V. 
cholerae, the potential for this resistance mechanism to subsequently spread through 
other natural microbial populations is great. 
Typically, transcriptional regulatory controls elucidated for MDR transporters 
belong to the MF and RND families (Grkovic et al., 2002). Previous reports of 
transcriptional control by LTTR proteins in V. cholerae have been localised to the 
regulation of virulence (ToxR DiRita et al., 1991; IrgB iron-regulated virulence 
Goldberg et al., 1991) and none to date (May 2007) have been described in the 
regulation of MDR transporters. However, LTTR proteins have been previously 
described to regulate antibiotic resistance ~-lactamase activity in other 
Enterobacteriacae including Citrobacter freundii (Lindberg et al., 1985), Enterobacter 
cloacae (Honore et al., 1986; Naas & Nordman, 1994), Morganella morganii, Proteus 
vulgaris (Yang & Livermore, 1988) and P. aeruginosa (Lodge et al., 1990). 
A regulatory system involving a LTTR protein, AmpR, that regulates the ~­
lactamase, AmpC, has been elucidated in C. freundii (Lindquist et al., 1989) and shows 
striking similarities in the mechanism of transcriptional control to that of the VarR-
VarG system in V. cholerae (see chapter 5). The only difference, nonetheless important 
distinction, between that of the AmpR-AmpC system and the VarR-VarG system is the 
type of ~-lactamase regulated. AmpC belongs to the class of S~l (Ambler class C) 
whereas VarG belongs to the class of M~l (Ambler class B), which target two very 
different classes of ~-lactam antibiotics as described previously. Although, this thesis 
proposes a regulatory mechanism similar to AmpR, the mechanism of resistance is 
unique from AmpC in that resistance is against most ~-lactam antibiotics including the 
carbapenems that are not substrates for AmpC. Elucidation of this system (see chapter 5 
and 7) will therefore provide insights into the mechanism of regulation of a M~l that 
brings increasing concerns into the future clinical effectiveness of ~-lactam antibiotics. 
It has been reported that ~-lactamase, AmpC, resistance is coupled to other 
MDR mechanisms such as RND efflux e.g. MexAB-OprM in P. aeruginosa (Masuda et 
al., 1999; Nakae et al., 1999), however, these have not been explicitly linked as being 
co-expressed from the same operon or by the same regulatory system. Rather resistance 
being initiated by the presence of substrate or mutation in a regulatory gene, MexR, 
resulting in overexpression of efflux pump MexAB-OrpM (Masuda et al., 1999; Ziha-
Zarifi et al., 1999). Elucidation of the VarABCDEF transport system together with the 
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P-lactamase resistance mechanism would be the first such MDR operon to be described 
in V. cholerae and as far as I am aware in Gram-negative bacteria. 
This thesis endeavours to provide new insights, to contribute towards the 
existing literature and to understand the mechanisms of regulatory control and MDR in 
V. cholerae and thus Gram-negative bacterium as a whole. 
1.9 Concluding remarks 
The emergence of MDR microorganisms has emphasised the importance for 
development of novel therapeutic approaches to circumvent resistance mechanisms 
(McKeegan et al., 2004). These include inhibitors of multidrug efflux systems and new 
antibacterial agents (Poole, 2004; McKeegan et al., 2004; Kumar and Schweizer, 2005; 
Vediyappan et al., 2006). Such approaches require extensive knowledge and a thorough 
understanding of the molecular mechanisms underlying the development of MDR. 
However, this is by no means a straight forward process. MDR is mediated by a variety 
of soluble and membranous proteins, which are expressed at basal levels in bacteria. 
These levels of proteins are insufficient for research scientists to define the exact 
molecular mechanisms underlying MDR in structural applications such as 
crystallisation and solid state NMR (ss-NMR). A large proportion of proteins, especially 
those located in the cellular membrane, are notoriously recalcitrant to overexpression 
and purification and often result in the formation of insoluble and dysfunctional proteins 
termed 'inclusion bodies'. Therefore the overexpression and purification of biologically 
active, stable, soluble protein remains the limiting factor for the study of most protein 
based systems. Most membrane proteins and some soluble proteins are purified in the 
presence of detergents or reconstituted as proteoliposomes so as to mimic their native 
environment and to assist in their solubilisation for use in crystallisation and ss-NMR 
(Lorch et al., 2005). However, obtaining protein in sufficient purity and quantity for 
crystallisation and NMR is still complicated by their amphiphilic nature during the 
production of crystals and their manipulation during NMR studies. 
Recent advances in the structural characterisation of regulatory and membrane 
proteins in MDR represent a significant breakthrough towards the understanding and 
elucidation of these mechanisms. However, it has been shown that structurally 
homologous proteins of the same family, which share a homologous function can utilise 
significantly different mechanisms of action. Therefore the structure of one family 
member is not sufficient to represent all members and that further structural 
characterisation of other members is required (Schumacher et al., 2002). There are also 
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limitations in the crystal structures generated in that they are essentially only a 'snap-
shot' in time of a complex adopted during a dynamic catalytic cycle. Therefore data 
from crystallographic structures alone is not sufficient for complete representation of 
function and requires supplementary biochemical, genetic and biophysical information. 
Biophysical and biochemical analyses indicate the secondary structure and topological 
arrangements of proteins. Examples of biophysical and biochemical analyses include 
circular dichroism (CD) spectroscopy, which assess the secondary structure content of 
proteins, and the use of monoclonal antibodies to identify exposed conserved motifs, 
respectively. Genetic analyses involve construction of ~-galactosidase (lacd) or alkaline 
phosphatase (phoA) fusions within membrane proteins to identify the location the loops 
connecting the TMDs (Borges-Walmsley et al., 2003). 
Elucidating the mechanism of regulatory control in the expression of 
components of the MDR operon is essential for gaining a complete understanding of 
how bacteria recruit transport systems for the sole purpose of providing antibiotic 
resistance. The information gained would prove invaluable for the development of novel 
targets or inhibitors that disrupt the MDR circuit through transcriptional regulation. The 
elucidated structures of regulatory proteins bound to DNA and substrate as described 
previously provide the first steps in making this a reality. The features exhibited in these 
structures are highly likely to be observed in other MDR-binding proteins making the 
development of novel strategies transferable. 
Defining the structural and functional interactions between components of the 
ABC transporter and substrates, respectively, would allow the design of novel drugs 
that hinder the formation of the transport apparatus (Pages et al., 2005; Lynch, 2006). 
From the current structural data available, a potential target would be the MFP, as 
disruption of this protein at its interaction site would either destabilise and/or lead to 
failure of the effective recruitment of the tripartite system. Disruption at the substrate 
and/or A TP binding site of the translocase would prevent drug extrusion and provides a 
further target site. 
The WHO recommends 'accelerated research on the burden of cholera and how 
best to manage the growing problem of drug resistance' as part of the effective 
management and control of cholera outbreaks and epidemics (WHO, 2003). This thesis 
therefore aspires to address this issue through the functional and structural 
characterisation of individual components of a V. cholerae antibiotic resistance operon, 
consisting of an M~l and a multi-complex MDR ABC transporter. My ultimate 
objective is to contribute to the current literature and to use the knowledge gained to 
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halt the emerging crisis of MDR through the rational design and creation of innovative 
antibacterial therapies and inhibitors against these resistance mechanisms. Although 
these mechanisms of MDR may be elucidated in V. cholerae, the evolutionary 
relatedness and conservation of structure and function in all families will enable this 
information to be related to similar systems in alternative bacterial species. 
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Chapter 2 Materials and Methods 
Experimental procedures detailed herein have been adapted accordingly from Sambrook 
et al (1989) or as per manufacturer's instructions. 
2.1 Computational methods 
This thesis was constructed using Microsoft Office Word and Excel programs for the 
creation text documents and graphical representation of data, respectively. Adobe 
Photoshop and lllustrator programs were used for the enhancement of DNA/protein 
images and modification of diagrams/illustrations, respectively for this thesis. The 
molecular biology data management program, Vector NTI Advance 10 (Invitrogen), 
was used for the creation, mapping, analysis, and design of oligonucleotides and for the 
construction of alignments of DNA and protein sequences for comparison. 
The National Center for Biotechnology Information (NCBI, 
http://www.ncbi.nlm.nih.gov) was used as a resource for structural, functional and 
comparative analysis of genomes. The database was a source of molecular biology 
literature and computational software for the comparative analysis of gene and protein 
sequences. Putative homologous regions were identified by the Basic Local Alignment 
Search algorithm (BLAST, Altschul et al., 1997). The Research Collaboratory for 
Structural Bioinformatics (RCSB) protein data bank 
(www.rcsb.org/pdb/home/home.do) was used as a source for protein structures. 
Prediction of transmembrane regions and topology of proteins was performed 
through the analysis of their amino acid sequences using an automated server from 
http://www.predictprotein.org (Rost et al., 2004). This server also uses the PROSITE 
database to search for highly conserved functional motifs (Bairoch et al., 1997) to 
enable the prediction of the structural and functional properties of the putative proteins. 
A secondary structure prediction server, Jpred 
(http://www.compbio.dundee.ac.uk/-www-jpred/), from the University of Dundee (The 
Barton Group) was also used to predict topology and the a-helical, ~-sheet, or random 
coil content of relevant proteins where necessary (Cuff et al., 1998). This server also 
performed BLAST searches limited to the RCSB PDB. The presence and location of N-
terrninal signal peptide cleavage sites in amino acid sequences was predicted using the 
server, SignaliP (http://www.cbs.dtu.dk/services/SignalP/) by Hendrik Nielsen and 
colleagues (Nielsen et al., 1997; Nielsen and Krogh, 1998; Bendtsen et al., 2004). 
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2.2 Laboratory Apparatus- Centrifugation 
The category of centrifuge selected was dependent on the centrifugation requirements of 
specific applications. Table 2.1 lists the types of centrifuges used throughout this work 
with further details being outlined in specific protocols in subsequent chapters. 
Table 2.1 Centrifugation apparatus. 
Fixed 
Centrifuge Rotor angle Capacity 
rotor 
Eppendorf F-45-24-11 Yes 24x 1.5ml benchtop 54150 
Jouan CR3i T20 No 
Beckman Coulter JLA-a.1000 Yes Avanti J20 XP 
Beckman Coulter JA-10 Yes 
Avanti JE JA-20 Yes 
Beckman La-70M Type 50.2 Tl Yes 
Beckman Coulter Type 50.2 Tl Yes Optima L-90K 
2.3 
2.3.1 
Laboratory media and reagents 
Sources of media and reagents 
ax 50ml 
6x 11itre 
6x 500ml 
ax 50ml 
ax 25ml 
ax 25ml 
Max 
Speed Temperature 
(rpm) 
13,200 Ambient 
4,100 4°C to ambient 
a,ooo 4°C to ambient 
10,000 4°C to ambient 20,000 
50,000 4°C to ambient 
90,000 4°C to ambient 
Microbiological growth media was sourced from BD Biosciences and Difco 
laboratories. Reagents were of analytical molecular biology grade and sourced from 
BDH Laboratory supplies, Difco, Melford and Sigma laboratories unless otherwise 
stated. 
2.3.2 Sterilisation 
Sterilisation of laboratory equipment and media was achieved through autoclaving in a 
Priorclave Tactrol 2 on a liquid cycle at 121°C for 15 minutes at four atmospheres 
pressure. Heat labile solutions were filter sterilised through 0.22Jlm membranes. 
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2.3.3 Preparation of media and reagents 
Gross quantities of media and reagents were measured on a Mettler BD202 digital scale 
whilst more accurate or smaller quantities were measured on an analytical Mettler 
Toledo AB204-S digital scale. All solutions were prepared using laboratory grade 
distilled and deionised water obtained from a Purlte Prestige Analyst HP purifier. 
2.3.3.1 Bacterial growth media 
Liquid and solid media used in the culturing of E. coli and V. cholerae were as follows: 
Luria-Bertani (LB) Medium 
NaCl 
Tryptone 
Yeast extract 
LBAgar 
NaCI 
Tryptone 
Yeast extract 
Agar N°1 
Mueller-Hinton Medium 
Mueller-Hinton powder 
SOC Medium 
NaCl 
KCl 
Tryptone 
Yeast extract 
lOg/litre 
lOg/litre 
5gllitre 
lOg/litre 
lOg/litre 
5g/litre 
15g/litre 
23gllitre 
0.585g/litre 
0.1865g/litre 
20g/litre 
5g/litre 
The above were autoclaved and the following filter sterilised components were added: 
1M MgCh•6HzO 
1M MgS04 
lOml 
10ml 
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NZY+Medium 
NZ amine (casein hydrosylate) 
Yeast extract 
lOg/litre 
5g/litre 
5g/litre NaCl 
Medium adjusted to pH 7.5 using NaOH, autoclaved and the following filter sterilised 
components added: 
lMMgCh 
1M MgS04 
20% (w/v) glucose 
12.5ml 
12.5ml 
20ml 
2x Yeast Tryptone (2x YT) Medium 
NaCl 5g/litre 
Tryptone 
Yeast extract 
2x YT Agar 
NaCl 
Tryptone 
Yeast extract 
Agar N°1 
RMMedium 
Casamino acids 
Glucose 
16g/litre 
lOg/litre 
5g/litre 
16g/litre 
lOg/litre 
15gllitre 
20g/litre 
2g/litre 
The above were autoclaved and the following filter sterilised components were added: 
1M MgCh•6HzO 
1 Ox M9 Salts* 
* 1 OxM9 Salts 
NazHP04 
KHzP04 
NaCl 
NH4Cl 
1rnl 
100rnl 
60g/litre 
30g/litre 
5g/litre 
lOg/litre 
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Medium adjusted to pH 7.4 using 10M NaOH, autoclaved and the following filter 
sterilised component added: 
1M Thiamine 1 ml 
2.3.3.2 Antibiotics and Reagents 
Antibiotics 
The use of antibiotics in bacterial growth media is essential for the preservation of 
genetic integrity, principally during recombinant protein expression, and to minimise 
infection from exogenous microorganisms. 
Antibiotics used in these studies were routinely prepared at 1000 times the 
required working concentration in either water or ethanol. Those prepared using water 
were filter sterilised through a 0.22~m membrane and stored in 1rnl aliquots at -20°C. 
Carbenicillin was consistently used over ampicillin in cloning and expression cultures 
due to its relative stability against P-lactamases secreted by resistant bacteria. 
Working concentrations of antibiotics used were: Penicillin G 1 OO~g/rnl , 
Ampicillin lOO~g/rnl, Carbenicillin lOO~g/ml, Kanamycin 15, 25 and 30~g/ml, 
Streptomycin 25~g/ml, Spectinomycin 25~g/ml, Oleandomycin 15~g/rnl, Nafcillin 
50~g/rnl, Amoxicillin 50~g/rnl (1M Ammonium hydroxide), Azithromycin 12.5~g/ml 
(60% ethanol), Chloramphenicol 34~g/rnl (100% ethanol), Erthromycin 15~g/rnl (95% 
ethanol), Spiramycin 50~g/rnl (100% methanol), and Tetracycline 12.5~g/rnl (70% 
ethanol). 
Reagents 
Reagents used in these studies are described in Table 2.2. 
Table 2.2 Reagents 
Reagent stock solutions 
Reagent Concentration Working concentration 
IPTG 0.1-1M 0.1-0.SmM 
X-gal 20mg/ml in N,N' - 801-lg/ml dimethylformamide (DMF) 
L-Arabinose 20% in dH20 0.02-0.2% (v/v) 
IPTG and L-Arabinose were 0.2211-M filter-sterilised and stored in 1 ml 
aliquots at -20°C 
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2.4 Growth and preservation of bacterial strains and plasmids 
2.4.1 Bacterial strains 
The Vibrio cholerae vaccine strain CVD 101 was used as a source of chromosomal 
DNA for PCR of various components of the var operon. PCR products were ligated into 
pGEM-T Easy vector (Promega) and propagated in Escherichia coli NovaBlue 
(Novagen). The vector pBAD/Myc-His B and E. coli strains LMG194 and BL21 (AI) 
(Invitrogen) were used in the expression of soluble proteins. For complementation 
studies the E. coli strain KAM3/KAM3 (DE3) with LlacrAB was used due to its 
hypersensitivity to many drug substrates. ADE3 bacteriophage was integrated into 
KAM3 host chromosome (ADE3 lysogenisation Kit, Novagen) enabling the expression 
of heterologous protein from T7 expression vectors. 
Sources of bacterial strains and their associated genotypes used in these studies 
are described in Table 2.3 on the following page. 
2.4.2 Growth of bacterial strains 
Bacterial colonies were grown at 37°C statically for 20-24 hours. Liquid cultures were 
grown between 25-37°C with 180-250rpm agitation from several hours up to 24 hours. 
2.4.3 A.DE3 Lysogenisation of bacterial strains 
A.DE3 bacteriophage encapsulates the gene for T7 RNA polymerase under the control of 
lacUV5. Integration of recombinaQt A.DE3 bacteriophage into specific E. coli host 
chromosomes (ADE3 lysogenisation Kit, Novagen) enables expression of heterologous 
DNA from T7 expression vectors. The integration of ADE3 bacteriophage into E. coli 
host chromosome is performed as stated in the manufacturer's manual. 
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Table 2.3 E. coli and V. cholerae strains and their associated genotypes. 
Strain Genotype Application Source/ Reference 
Escherichia coli 
endA1 hsaR17 (rk12-mk12+) supE44 
NovaBiue thi-1 recA 1 gyrA96 re/A 1 lac General cloning Novagen 
[F' proA +s+ /aclqZ~M 15: :T n 1 O(tetR)] 
F-mcrA ~ (mrr-hsaRMS-mcrBC) 
<t>80d/acZ~M15 ~/acX74 
E. cloni® endA 1 recA 1 araD 139 General cloning Lucigen 
~(ara, /eu)7697 gall.J gaiK rpsl 
nupG A.- tonA 
BL21 (DE3) F ompT hsoS8 (r8-m8 ) gal dcm met Protein Strata gene (DE3) expression 
BL21 Star F ompT hsoS8 (r8 -m8 ) gal dcm rne1 Protein Invitrogen 31 (DE3) expression 
BL21(AI) F ompT hsoS8 (r8-m8 ) gal dcm Protein Invitrogen 
araB:: TlRNA-tetA expression 
M15 F lac ara gal mtl recA uvr Protein Qiagen 
expression 
F-mcrA ~ (mrr-hsaRMS-mcrBC) 
<t>80d/acZ~M15 ~lacX74 
TOP10 deoR recA 1 araD139 General cloning Invitrogen 
~(araA- leu)7697 gall.J gaiK rpsl 
endA nupG 
LMG194 F ~lacX74 galE thi rpsL !:JphoA Protein Invitrogen (pvu II) ~ara714 /eu::Tn 10 expression 
TetR ~ (mcrA) 183 ~ (mctCB-
hsoSMR-mrr) 173 endA 1 supE44 Site directed XL10-Gold thi-1 recA 1 gyrA96 reiA 1 lac Hte [F' 
mutagenesis Stratagene proAB /acflZ~M15 Tn10 (TetR) 
AmyCamRt 
C43 F ompT hsoS8(r8 -m8 ) gal dcm Protein Miroux and (DE3) expression Walker, 1996 
KAM3 ~acrAB Complementation Morita et a/., 
analysis 1998 
KAM3 (DE3) ~acrAB Complementation Morita eta/., 
analysis 1998 
N43 F/ac ara mal xyl mtl gal rpsL acrA1 Complementation Ma eta/., to/C::Tn 10 analysis 1993 
Vibrio cholerae 
CT-A-, CT-B+ deletion derivative of Source of Levine et al., CVD101 classical biotype Ogawa serotype chromosomal 1988 395 DNA 
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2.4.4 Plasmids 
Plasmid used in these studies and their associated description and sources are described 
in Table 2.4. 
Table 2.4 Plasmids. 
! Source/ Plasmid Description Reference 
pGEM-T Easy Cloning vector compatible with a-complementation, ApR Prom ega 
pSMART High copy cloning vector for expression of proteins Lucigen HC-Kan from native promoters, KnR 
pET21a(+) T7/ac expression vector for C-terminal His6 tagged proteins, ApR Novagen 
pET28b(+) T7/ac expression vector for N- or C-terminal Hisa tagged proteins, KnR Novagen 
pET33b(+) T7/ac expression vector for C-terminal His6 tagged proteins, KnR Novagen 
pQE-100 TS expression vector for N-terminal His6 tagged proteins, ApR Qiagen 
Expression of lac repressor protein encoded by lac/ 
pREP4 gene for highly regulated co-expression with pOE 
series of vectors, KnR 
Qiagen 
Dose-dependent expression vector for C-terminal Guzman et pBAD/ Myc-His B Hisa tagged proteins, ApR a/., 1995 Invitrogen 
pETDuet™-1 
T7/ac expression vector for the co-expression of 
multiple N-terminal Hisa tagged and C-terminal S 
tagged proteins, ApR 
Novagen 
T7/ac expression vector for the co-expression of 
pACYCDuet TM -1 multiple N-terminal His6 tagged and C-terminal S Novagen 
tagged proteins, CmR 
pRSFDuet™-1 
T7/ac expression vector for the co-expression of 
multiple N-terminal His6 tagged and C-terminal S 
tagged proteins, KnR 
Novagen 
T7/ac expression vector for the co-expression of 
pCDFDuet™-1 multiple N-terminal His6 tagged and C-terminal S 
tagged proteins, SmR 
Novagen 
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2.4.5 Preservation of bacterial strains and plasmids 
Cryogenic stocks of both native and recombinant bacterial strains were prepared to 
maintain long term genetic integrity and viability. Stocks were generated by mixing 
800J.Ll of an overnight culture with 200J.Ll of sterile 80% glycerol in sterile 2ml 
cryogenic vials and stored at -80°C. Samples were retrieved by scraping and streaking a 
small amount of the frozen stock, with a sterile loop, and then plating onto solid growth 
medium for incubation at 37°C overnight. 
2.5 DNA analysis and purification 
2.5.1 Agarose gel electrophoresis 
Nucleic acid manipulations were routinely analysed and assessed on agarose gel 
preparations. 
Molecular grade agarose powder (VWR) and lx TAE (Tris-acetate-EDTA) 
buffer (from 25x concentrate, NBS Biologicals) were mixed to the desired concentration 
(typically 0.8-2% w/v) and dissolved by heating. DNA staining agent ethidium bromide 
was added to a final concentration of O.lJ.Lg/ml to facilitate visualisation of DNA 
following electrophoresis. The molten solution was poured into a casting tray, fitted 
with a comb at one end, and allowed to solidify at room temperature. To allow for 
equilibration prior to sample loading, the comb was removed carefully and the solid 
agarose slab submerged with lx T AE buffer in an electrophoresis chamber. 
A 6x DNA loading buffer* was added to each of the samples to be analysed to 
aid loading into the wells of the gel and to track the migration of the samples during 
electrophoresis. A ready load lKb plus DNA marker (Invitrogen) was loaded into at 
least one well of the gel to aid size approximation and quantitation of the experimental 
DNA sample. A potential difference of 115V was applied across the gel, promoting the 
migration of the DNA in the sample towards the positive electrode (anode) of the 
electrophoresis tank. Adequate migration of the DNA can be assessed visually by 
monitoring the migration of the tracking dye from the loading buffer. 
The DNA in the samples were visualised by placing the gel on an ultraviolet 
transilluminator and a permanent record was taken by photographing the relevant area 
of the gel using a gel dock (GENE Genius Bioimaging System, Syngene). 
*6x DNA Loading buffer 
Bromophenol Blue 
Glycerol 
2.5gllitre 
30% 
76 
2.5.2 Purification of plasmid DNA 
The alkaline lysis procedure is used for the small scale isolation and purification of 
plasmid DNA from bacterial cultures. A technique modified from this using the 
QIAprep Miniprep kit (Qiagen) is summarised below. All buffers mentioned were 
supplied with the kit. 
Bacteria grown from a 5rnl overnight are harvested by centrifugation at 
4,100rpm for 8 minutes at 4°C. The bacterial cell pellet is resuspended in 250~1 Buffer 
P 1 and transferred to a 1.5ml microcentrifuge tube. The cells are lysed and the proteins 
and DNA denatured by addition of 250~1 Buffer P2. The tube is inverted several times 
to ensure complete mixing and cell lysis. The solution is neutralised by the addition of 
360~1 of Buffer N3. The plasmid solution is separated from the cellular debris by 
centrifugation at 13,000rpm for 10 minutes. The supernatant fraction is then carefully 
decanted into a QIAprep spin column fitted with a 2rnl collection tube and spun at 
13,000rpm for 1 minute. The supernatant is discarded and the immobilised plasmid 
DNA is washed with 750~1 Buffer PE and centrifuged as described previously. Residual 
Buffer PE is removed by an additional centrifugation step for 1 minute. The spin 
column is transferred into a clean, sterile 1.5ml microcentrifuge tube and 50~1 Buffer 
EB added. The column is allowed to equilibrate at room temperature for 1 Y2 minutes 
and the immobilised plasmid DNA eluted by centrifugation for 1 minute. The plasmid 
DNA is then used in subsequent procedures or stored at -20°C. 
2.5.3 Agarose gel DNA extraction 
DNA fragments are routinely extracted from agarose gels following analysis, and used 
in subsequent reactions such as ligation. A QIAquick Gel Extraction kit (Qiagen) was 
used and is summarised below. 
DNA fragments on an agarose gel are identified by visualising with a UV 
transilluminator on a low setting. The fragments of interest are excised using a clean 
scalpel blade ensuring any excess agarose is removed. The gel slice is weighed and 
750~1 Buffer QG added to solubilise ~400mg gel. The slice is dissolved in Buffer QG 
by incubation at 50°C in a water bath for 10 minutes, inverting intermittently to aid 
solubilisation. The resultant solution is then carefully decanted into a QIAquick spin 
column fitted with a 2rnl collection tube and spun at 13,000rpm for 1 minute. The spin 
columns consist of a silica-membrane which adsorbs and immobilises the DNA. The 
flow through is discarded and a further 750~1 Buffer QG is applied to the column. The 
immobilised DNA is washed with 750~1 Buffer PE and centrifuged as described 
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previously. Residual Buffer PE is removed by an additional centrifugation step for 1 
minute. The spin column is transferred into a clean, sterile 1.5ml microcentrifuge tube 
and 30J..Ll Buffer EB added. The column is allowed to equilibrate at room temperature 
for 1 Y2 minutes and the immobilised DNA eluted by centrifugation for 2 minutes. The 
DNA is then used in subsequent procedures or stored at -20°C. 
2.6 DNA amplification, cloning and sequencing 
2.6.1 Polymerase chain reaction (PCR) 
The PCR technique was used extensively throughout this work for the amplification and 
modification of specific DNA sequences of interest from the V. cholerae genome. V. 
cholerae 01 classical Ogawa strain CVD101, which lacks the A subunit of CT (Levine 
et al., 1988) was used as a source of chromosomal DNA for PCR amplification of 
various genes from the var operon. 
Primers were synthesised by Invitrogen Custom Primers, on a 50nmol scale, 
desalted, between 24-33 nucleotides and of similar melting temperature (T m). 
Restriction endonuclease sites were routinely incorporated into the primers to facilitate 
unidirectional cloning of the amplified sequences into expression vectors. Stock 
solutions were prepared by resuspending primers with sterile, distilled water to a final 
concentration of 50pmol/J..Ll and stored at -20°C. Oligonucleotide primers used in this 
work are presented in Table 2.5 on the following pages. 
Table 2.5 
Oligo/ 
Primer 
var1Fwd 
var1 Rev 
var2Fwd 
var2Rev 
Oligonucleotide primers used for EMSA and PCR. Primer names 
ending with 'Fwd' and 'Rev' represent forward and reverse primers 
pairs. Highlighted green sequences specify restriction endonuclease sites. 
Highlighted red sequences specify stop codons incorporated to prevent 
addition of vector sequences into the transcript. Highlighted blue 
sequences specify additional nucleotides inserted to keep expression 'in-
frame' with the start codon. Italicised sequences indicate incorporation 
of His6 tag. 
Nucleotide Sequence (5'-3') Application (Reference) 
5'- CAT ATGGTCGCCCCCGAAATCAATTIGCGCAGCATT -3' PCR (Chapter 4) 
5'- CTCGAGTTICTI ATCGATCTCTICATAGACTAAA TI -3' PCR (Chapter 4) 
5'-GGATCCGTCGCCCCCGAAATCAATTIGCGCAGC-3' PCR (Chapter 4) 
5'-AAGCTTTI ATTICTI ATCGATCTCTTCATAGAC-3' PCR (Chapter 4) 
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var3Fwd 5' -CCATGGGCGTCGCCCCCGAAATCAATTTGCG PCR (Chapter 4) CAGCATT-3' 
var3Rev 5'-TCT AGATCAATGATGATGATGATGATGATGTT PCR (Chapter 4) TCTT ATCGATCTCTTCAT AGACT AAA TT -3' 
var4Fwd 5'-GGTTGGCTCAT ATTCAATGCTTGTGCGGCT -3' PCR (Chapter 5) 
var4Rev 5' -GCCTTT AGCACTTGCA TT AAAAGT AAGT AG-3' PCR (Chapter 5) 
var5Rev 5'-TCA TTT ACGCACGAAA TT A TT AGGTGATGA-3' PCR (Chapter 5) 
var6Fwd 5'-TAT ACAT ACT AT AACAAGCATGCATTTTTG-3' PCR (Chapter 5) 
var7Fwd 5'-CTCATCACCT AA T AATTTCGTGCGT AAA TGA-3' EMSA (Chapter 5) 
var7Rev 5'-TCATTT ACGCACGAAA TT A TT AGGTGATGAG-3' EMSA (Chapter 5) 
var8Fwd 5'-TAT ACAT ACT AT AACAAGCATGCA TTTTTGAT -3' EMSA (Chapter 5) 
var8Rev 5'-ATCAAAAATGCATGCTTGTT AT AGT ATGT AT A-3' EMSA (Chapter 5) 
var9Fwd 5' -CT AT AACAAGCATGCA TTTTTGAT ATGTTT -3' EMSA (Chapter 5) 
var9Rev 5' -AAACAT ATCAAAAATGCATGCTTGTT AT AG-3' EMSA (Chapter 5} 
var10Fwd 5-ATTCCCGTTTCAGTTGACTTGCGACCAGCG-3' EMSA (Chapter 5) 
var10Rev 5' -CGCTGGTCGCAAGTCAACTGAAACGGGAAT -3' EMSA (Chapter 5) 
var11 Fwd 5'- CAT ATGCTCATCACCT AA T AA TTTCGTGCGT AAA TG-3' PCR (Chapter 5) 
var11 Rev 5' -CTCGAGGTGATCAA TCAT ATCTGCGAGAA TCA TTGC-3' PCR (Chapter 5) 
var12Fwd 5'- CAT ATGTTTCTT ATCGATCTCTTCAT AGACT AAA TT -3' PCR (Chapter 5) 
var12Rev 5' -CTCGAGTT AGTGATCAA TCAT ATCTGCGAGAA TCAT -3' PCR (Chapter 5) 
var13Fwd 5'-TT A TTTCTT ATCGATCTCTTCAT AGACT AAA TTTTT -3' PCR (Chapter 5) 
var13Rev 5'-TT AGTGATCAATCAT ATCTGCGAGAA TCA TTGC-3' PCR (Chapter 5) 
var14Fwd 5' -CTCATCACCT AA T AA TTTCGTGCGT AAA TG-3' PCR (Chapter 5) 
var15Fwd 5'-TCT A GATT A TTTCTT ATCGATCTCTTCAT AGACT AA-3' PCR (Chapter 5) 
var15Rev 5' -CAT ATGATCAAAAATGCATGCTTGTT AT AGTAT -3' PCR (Chapter 5) 
var16Fwd 5' -CAT ATGGAGAAAAAAATCACTGGAT AT ACCACC-3' PCR (Chapter 5) 
var16Rev 5' -CTCGAGTT ACGCCCCGCCCTGCCACTCATCGCA-3' PCR (Chapter 5) 
var17Rev 5'-TT ACGCCCCGCCCTGCCACTCATCGCAGT A-3' PCR (Chapter 5) 
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var18Fwd 5'-TCT A GATT A TTTCTT ATCGATCTCTTCAT AGACT AA-3' PCR (Chapter 5) 
var18Rev 5' -CAT ATGGTGATCAA TCAT ATCTGCGAGAATCA TTGC-3' PCR (Chapter 5) 
var19Fwd 5' -CAT ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGG-3' PCR (Chapter 5) 
var19Rev 5' -CTCGAGTT ACTTGT ACAGCTCGTCCATGCCGAGAGT -3' PCR (Chapter 5) 
var20Fwd 5' -AGATCACT AACAATGTACAT ACCGCACTGG-3' PCR (Chapter 5) 
var20Rev 5'-CCGGCTGACGTTGAGGGTCGGT AA TGGGGA-3' PCR (Chapter 5) 
var21 Rev 5' -ATGCGAAGGGAAAAAT AAAAAGCCCTGTCC-3' PCR {Chapter 5} 
var22Fwd 5' -GTT AAAAAACAACG I I I I I I I GAACTTTCC-3' PCR (Chapter 5) 
var23Fwd 5'-TT AGACGACCTTCTCT ATCTCTTCT A TTCT -3' PCR (Chapter 5} 
var23Rev 5'-AAAAAACTCA TTT A TTTCATCAATCAA TT A-3' PCR (Chapter 5) 
var24Rev 5'-ATGCGAAGGGAAAAA T AAAAAGCCCTGTCC-3' PCR (Chapter 5) 
var25Fwd 5'-GTT AAAAAACAACGT I I I I I I GAACTTTCC-3' PCR {Chapter 5) 
var26Fwd 5' -GAT ATGA TTGATCACT AA TT AGACGACCTT -3' EMSA (Chapter 5) 
var26Rev 5' -AAGGTCGTCT AA TT AGTGATGAA TCAT ATC-3' EMSA (Chapter 5) 
var27Fwd 5' -CTCT ATCTCTTCT A TTCTCACGGACT AAGC-3' EMSA (Chapter 5) 
var27Rev 5' -GCTT AGTCCGTGAGAA T AGAAGAGAT AGAG-3' EMSA {Chapter 5) 
var28Fwd 5' -CCTGTTCAT ACAGCATGGACAGGGCTTTTT -3' EMSA (Chapter 5) 
var28Rev 5' -AAAAAGCCCTGTCCATGCTGT ATGAACAGG-3' EMSA {Chapter 5) 
Var29Fwd 5' -A TTTTTCCCTTCGCATGTT AAAAAACAACG-3' EMSA (Chapter 5) 
Var29Rev 5'-CGTTG I I I I I I AACATGCGAAGGGAAAAAT-3' EMSA (Chapter 5) 
var30Fwd 5'-1 I I I I I I GAACTTTCCTTATCATCCTTAGT-3' EMSA (Chapter 5) 
var30Rev 5' -ACT AAGGATGAT AAGGAAAGTTCAAAAAAA-3' EMSA (Chapter 5) 
var31Fwd 5'-CTGAATCCCGTCTCTAATTGATTGATGAAA-3' EMSA (Chapter 5} 
var31 Rev 5'-TTTCATCAA TCAA TT AGAGACGGGATTCAG-3' EMSA (Chapter 5) 
var32Fwd 5'-T AAA TGAG I I I I I I ATGGCAAAACGTTGGA-3' EMSA (Chapter 5) 
var32Rev 5'-TCCAACGTTTTGCCAT AAAAAACTCA TTT A-3' EMSA (ChapterS} 
var33Fwd 5'-AACAACG Ill II I I GAACTTTCCTTATCAT-3' EMSA (Chapter 5) 
var33Rev 5'-ATGAT AAGGAAAGTTCAAAAAAACGTTGTT -3' EMSA (Chapter 5) 
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var34Fwd 5' -GCGT ACAGGTTGAGATCTT AGAAGGCGTAG-3' PCR (Chapter 5) 
var34Rev 5'-TGTGTGCATCGGGTGA TTGTTGCTTGGCTT -3' PCR (Chapter 5) 
var35Rev 5'-TGCGGTGAGAAAGCCCTT A TTCATGCTGGC-3 PCR (Chapter 5) 
var36Fwd 5'-TGTGT ACTGACT AGCCTGATGGCATCTTCT -3' PCR (Chapter 5) 
var37Fwd 5' -AT AACAGCATGCTGGGAGGCCAGCA-3' EMSA (Chapter 5) 
var37Rev 5'-TGCTGGCCTCCCAGCATGCTGTT AT -3' EMSA (Chapter 5) 
Mtr1Fwd 5'-TTTTT ATCCGTGCAA TCGTGT ATGT AT AA TG -3' EMSA (Chapter 5) 
Mtr1 Rev 5' -CATT AT ACAT ACACGA TTGCACGGAT AAAAA -3' EMSA (Chapter 5) 
var38Fwd 5' -CAT ATGTTTGTTTCTCA TTT ATCTTTTCCCCAC-3' PCR (Chapter 7) 
var38Rev 5' -CTCGAGTT AGTGATCAA TCAT ATCTGCGAGAA TCAT -3' PCR (Chapter 7) 
var39Fwd 5' -CAT ATGTTGA TTGATGAAAT AAA TGAGTTT -3' PCR (Chapter 8) 
var39Rev 5' -CTCGAGGCACCATGGCGTTTCGCCCTCAAA -3' PCR (Chapter 8) 
var40Fwd 5' -CAT ATGAAT AAGGGCTTTCTCACCGCATGT -3' PCR (Chapter 8) 
var40Rev 5' -GAT ATCACGAAAGGCTCCTGAAAGCTGAGC -3' PCR (Chapter 8) 
var41Fwd 5' -GGATCCCGCCTCTTGTT ACAGCAATCTTGGCAA -3' PCR (Chapter 8) 
var41 Rev 5' -AAGCTTTT AACTCCGACT ACTGAGCGCAATGAC -3' PCR (Chapter 8) 
var42Fwd 5' -CAT ATGTTGCCAA T AAGACAAA TT ATGCAG -3' PCR (Chapter 8) 
var42Rev 5' -CTCGAGTTCACTCTGT AATGCTTGT AACGG -3' PCR (Chapter 8) 
var43Fwd 5' -GGATCCGATGAAGTCTTT ATCTCCTGCTCCT -3' PCR (Chapter 8) 
var43Rev 5' -GAGCTCAGCAGTGGGCTCATCACTGACGAC -3' PCR (Chapter 8) 
var44Fwd 5' -CAT ATGAAGTCTTT ATCTCCTGCTCCTTTGGTGG PCR (Chapter 9) AGCTACAG -3' 
var44Rev 5' -GCGGCCGCAGCAGTGGGCTCATCACTGACG -3' PCR (Chapter 9) 
var45Fwd 5' -CCATGGGCAAGTCTTT ATCTCCTGCTCCTTTGGTG-3' PCR (Chapter 9) 
var45Rev 5'-AGATCTTCAATGATGATGA TGATGATGAGCAGTG PCR (Chapter 9) GCCTCATCACTGACGACTTG -3' 
PCR was performed using HotStarTaq DNA polymerase (Qiagen) originally derived 
from the thermophilic bacterium, Thermus aquaticus and ProofStart DNA polymerase 
from Pyrococcus woesei. HotStarTaq DNA polymerase has 5' to 3' exonuclease 
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activity and generates single deoxyadenosines at the 3' end of an amplified fragment, 
whereas ProofStart DNA polymerase posses 3' to 5' proofreading activity and generates 
blunt-ended fragments. Selection of the DNA polymerase was dependent on the desired 
end product required and the future applications for which it would be used. Successful 
PCR is dependent on the optimisation of a range of variables from primer annealing 
temperature, incubation times and the type and amount of template DNA used. 
Where genomic DNA was required for PCR amplification, the following method 
was used to extract and prepare. Several colonies from the desired strain were taken and 
mixed in 300~1 of lOmM Tris-HCl pH 8.5. Mixture was incubated at 100°C for 5 
minutes in a thermostatic heat block and then cooled on ice for a further 5 minutes. The 
resultant supernatant used for PCR was extracted by centrifugation at 13,000rpm for 5 
minutes. Approximately 5~1 was used as template DNA in PCR amplification reactions. 
Temperature changes were achieved using an Eppendorf Mastercycler Gradient 
5331 with the lid preset to 105°C to prevent evaporation of samples during cycling. 
PCR reactions were prepared in sterile 0.5ml thin walled PCR tubes (Eppendorf) 
free of DNase and RNase contamination. A dNTP stock was prepared using lOmM of 
each deoxynucleotide dATP, dTTP, dGTP and dCTP (Promega) and aliquots of 50~1 
were stored at -20°C. 
A reaction mix for PCR involving HotStarTaq DNA polymerase was prepared 
as follows: 
Component Reaction volume Final Stock Concentration Concentration 
1 Ox PCR Buffer 1 OJ.LI 1x 10x 
5x Q-Solution 20J.LI 1x 5x 
dNTP mix 2J.LI 200J.LM each dNTP 1 OmM each dNTP 
Primer Fwd 1 J.LI 0.5pmoi/J.LI 50pmoi/J.LI 
Primer Rev 1j.l.l 0.5pmol/lll 50pmoi/J.LI 
HotStarTaq DNA 0.5J.LI 2.5 units/reaction 5 units/J.LI Polymerase 
ddH20 Up to 100J.LI - -
Template DNA Variable S1 J.LQ/reaction Variable 
Total volume 100J.LI - -
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Typical cycling parameters for HotStarTaq DNA polymerase are as follows: 
Step Cycle Number of Temperature Time 
cycles 
1 HotstarTaq 1 95°C 15 minutes Activation 
Denaturation 94°C 1 minutes 
2 Annealing 25-35 50-68°C* 1 minutes 
Extension 72°C 1-3 minutes# 
3 Final 1 72°C 10 minutes Extension 
4 Hold 1 4°C Indefinitely 
*The annealing temperatures should be approximately 5°C below the T m of the primers. The T m 
can be calculated as T m= 4(G+C) +2(A+ T) or can be found in the accompanying custom primer 
documentation. 
#1 minute per kb DNA 
A reaction mix for PCR involving ProofStart DNA polymerase was prepared as 
follows: 
Component Reaction Final Concentration Stock 
volume Concentration 
1 Ox ProofStart 5!ll 1x 10x Buffer 
5x Q-Solution 101-11 1x 5x 
dNTP mix 1.5!ll 300!lM each dNTP 10mM each dNTP 
Primer Fwd 2!ll 2pmol/!ll 50pmol/!ll 
Primer Rev 2!ll 2pmol/!ll 50pmol/!ll 
ProofStart DNA 1!ll 2.5 units/reaction 2.5 units/Ill Polymerase 
ddH20 Up to 50!ll - -
Template DNA Variable 1 00ng-1!lg genomic DNA Variable 1-50ng plasmid DNA 
Total volume 50!ll - -
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Typical cycling parameters for PCR using ProofStart DNA polymerase are as follows: 
Step Cycle Number of Temperature Time 
cycles 
1 Proof Start 1 95°C 5 minutes Activation 
Denaturation 94°C 1 minutes 
2 Annealing 35-45 50-68°C 1 minutes 
Extension 72°C 2-4 minutes 1\ 
3 Final 1 72°C 4 minutes Extension 
4 Hold 1 4°C Indefinitely 
"2 minute per kb DNA 
PCR reactions and protocols used are discussed in more detail in associated experiments 
in later chapters. Amplified PCR products were visualised by agarose gel 
electrophoresis and purified by agarose gel extraction, in preparation for cloning and 
propagation in pGEM-T Easy vector. 
2.6.2 Cloning of PCR products into pSMAR'f HCKan vectors 
High copy pSMART HCKan vectors (CloneSmart, Lucigen) were chosen for the 
expression of regulatory proteins under the control of its own native promoter. The 
presence of terminating sequences either side of the cloning site eliminates vector 
driven transcription through the inserted heterologous DNA and native promoter driven 
expression of vector DNA. The pSMART vectors were supplied pre-digested, consist of 
blunt phosphorylated ends and possessed kanamycin resistance marker. 
The pSMART ligation reaction constituents were added as follows: 
Component Volume 
Purified PCR product (1 00-500ng) 4Jll 
dH20 2.51JI 
4x Vector premix (pSMART vector, ATP 2.51JI and buffer) 
DNA ligase (2 units/Jll) 1 Jll 
Total 10Jll 
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The ligation reactions were incubated at room temperature for 2 hours followed by 4°C 
overnight to maximise number of recombinant plasmids generated. DNA ligase in the 
reaction was heat inactivated at 70°C for 15 minutes. The ligation reaction was 
incubated on ice for 5 minutes before centrifugation at 12,000rpm for 1 minute. 
2.6.3 Cloning of PCR products into pGEM-T Easy vectors 
Cloning of the purified PCR product into pGEM-T Easy enables propagation of 
multiple copies for further manipulation and to stabilise and maintain exogenous 
plasmid DNA in host E. coli. 
The pGEM-T Easy vector system (Novagen) utilises single 3' thymidine 
overhangs on either side of the multiple cloning site (MCS) to clone PCR products 
possessing complimentary 3' adenosine overhang generated by Taq DNA polymerases 
(TA mediated cloning). 
The following pGEM-T Easy ligation reaction constituents were added in order 
to a sterile 0.5ml microcentrifuge tube and mixed by pipetting as described on the 
following page. 
Component Volume 
2x Rapid Ligation buffer SJ.!I 
SOng pGEM-T Easy vector 1 Jll 
Purified PCR product 3Jll 
T4 DNA ligase {3 Weiss units/Jll) 1 Jll 
Total 10J.LI 
The ligation reactions were incubated at room temperature for 1 hour or alternatively at 
4°C overnight to maximise number of recombinant plasmids generated. 
Blue/ white selection was used for determining the insertional effectiveness of 
DNA cloning. Selection plates are often supplemented with lOOf..lg/ml Ampicillin, 40f..ll 
of 20mg/ml X-Gal (5-bromo-4-chloro-3-indolyl-~-D-galactoside) and 4J..ll of 200mg/ml 
IPTG (Isopropyl ~-D-1-thiogalactopyranoside ). 
2.6.4 DNA sequencing 
DNA sequencing of recombinant vectors was performed to ensure sequence integrity by 
the Durham University sequencing service (Durham, United Kingdom). Sequencing 
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reactions were performed using a PTC-1 00 programmable thermal controller (MJ 
Research) and an Applied Biosystems 3730 DNA analyzer. Sequence data, presented as 
text and chromatogram file formats, were analysed using the molecular biology data 
management software Vector NTI Advance 10.0 (Invitrogen). 
2. 7 Enzymatic DNA manipulation 
2. 7.1 Restriction endonucleases 
The principle use of RE in this work was to facilitate the unidirectional cloning of 
specific genes into expression vectors. This was achieved through the artificial 
introduction of two different RE recognition sites in the synthetic primers used for PCR, 
both of which are compatible with the corresponding vector. This situation forces the 
DNA fragment to insert into the vector in the desired orientation. 
REdigests were prepared in sterile 0.5ml rnicrocentrifuge tubes and incubated at 
37°C statically for 3Y2 hours. Reactions were terminated by heat inactivation of the 
enzymes at 65°C for 15 minutes. The reaction components of dual restriction digests 
were assembled in order as stated below: 
Component Volume Working Stock Concentration Concentration 
Sterile, distilled water Up to 20fll - -
1 Ox RE buffer 2fll 1x 10x 
Bovine Serum 0.2fll 2flQ 1 OflQ/fll Albumin 
Recombinant DNA 5-1 Ofll Up to 1fl9 -
Restriction 
1 fll 1 Ounits 1 Ounits/fll Endonuclease 1 
Restriction 
1 fll 1 Ounits 1 Ounits/fll Endonuclease 2 
Final volume 20f..LI - -
Single restriction digests using EcoRI were performed for the identification of correct 
DNA insertion during pGEM-T Easy mediated cloning. This method was also used for 
independent digests with two enzymes if buffers were incompatible for a one step 
digest. The reaction components were assembled in order as stated on the following 
page. 
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Component Volume Working Stock Concentration Concentration 
Sterile, distilled water Up to ~I - -
1 Ox RE buffer 2~1 1x 10x 
Bovine Serum 0.2~1 2~g 10~g/~l Albumin 
Recombinant DNA 5-10~1 Up to 1~g -
Restriction 1~1 1 Ounits 10units/f..ll Endonuclease 
Final volume 20f..ll - -
2.7.2 5'-Dephosphorylation using Shrimp Alkaline Phosphatase 
Shrimp alkaline phosphatase (SAP, Promega) catalyses the removal of phosphate 
groups from 5' ends of pre-digested DNA and vectors. Dephosphorylation of 5' DNA 
ends reduces the background of false positives during cohesive end applications and 
enables end-labelling of probes. The components of the reactions were prepared in 
order, in sterile 0.5rnl microcentrifuge tubes, as stated below:-
Component Volume Working Stock Concentration Concentration 
Sterile, distilled water Up to 30-SOf..ll - -or TE buffer 
1 Ox SAP buffer 3 or Sf..ll 1x 10x 
Digested DNA Variable Variable -
SAP (Promega) 1~1 1 unit/~g DNA 1 units/~1 
Final volume 30-SOf..ll - -
Reactions were and incubated at 37°C for 15 minutes and terminated by heat 
inactivation of SAP at 65°C for 15 minutes. A 1-2~.J.l aliquot of the reaction mix was 
then used directly for ligation at 4°C overnight. 
2.7.3 5'-Phosphorylation using T4 Polynucleotide Kinase 
Certain applications such as blunt ended ligations require insert DNA to be 
phosphorylated at their 5' ends. This is especially true of synthetic oligonucleotides that 
are not 5' phosphatased. T4 polynucleotide kinase (Fermentas) was used to 
phosphorylate standard primers (Invitrogen Custom Primers) prior to performing PCR. 
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The reactions were performed in sterile, 0.5ml PCR tubes (Eppendorf) and components 
were added in order as follows: 
Component Volume Working Stock Concentration Concentration 
Dephosphorylated primer Variable 1-20pmol 50pmol 
1 Ox Reaction buffer A 21.11 1x 10x 
ATP 1111 1.8J!M 2mM 
Sterile, distilled Water Up to 16J!I - -
T 4 Polynucleotide Kinase 1111 1 Ounits 1 Ounits/Jll 
Final volume 20J!I - -
The reaction mixture was incubated at 37°C for 30 minutes and terminated by heat 
inactivation of T4 polynucleotide kinase at 65°C for 15 minutes. 
2.7.4 End repair of 5' overhang using T4 DNA Polymerase 
DNA with 3' or 5' overhangs generated by PCR using Taq polymerases or through 
restriction enzyme digest requires end repair for ligation into blunt ended vectors. End 
repair is mediated by T4 DNA polymerase which fills 5' protruding ends with dNTPs 
generating blunt ended DNA with 5' phosphates. The resultant DNA fragments are 
compatible for ligation into blunt ended vectors. 
Restriction enzyme digests with 0.5-2J..Lg of DNA of interest (total reaction 
volume of 50J..Ll) were performed, purified and eluted in 50J..Ll sterile, distilled water. T4 
DNA polymerase reactions were performed in sterile, 0.5ml PCR tubes (Eppendorf) and 
components were added as follows. 
Component Volume Working Stock Concentration Concentration 
Purified digested DNA Variable 0.5-2119 -
dH20 Up to 50J!I - -
1 Ox T 4 DNA Polymerase 
5J!I 1x 10x buffer 
dNTPs 0.5Jll 1 OOJ!M of each 10mM dNTP 
T 4 DNA Polymerase 0.3-1.3J!I 5units/Jlg DNA 7.9units/Jll 
Total 50Jll 
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The reaction mixture was incubated at 37°C for 5 minutes and terminated by heat 
inactivation of T4 DNA polymerase at 75°C for 10 minutes. 
2.7.5 DNA mass estimation using a low molecular mass marker 
A low molecular mass marker (Low DNA Mass Ladder, Invitrogen) was used to 
estimate the amount of linear DNA (in nanograms) and vector DNA obtained from gel 
extraction purification prior to ligation. DNA loading buffer was mixed in a ratio of 1 to 
4 volumes of low molecular mass marker. The same ratio was applied to the sample 
preparation. Samples were loaded onto an appropriate agarose gel and electrophoresed 
as described in section 2.5 .1. Mass estimation conducted as per manufacturer's 
instruction. 
2.7 .6 Spectrophotometric quantification of DNA 
The concentration of PCR amplified DNA fragments were determined through 
spectrophotometric analysis in preparation for use in Electrophoretic mobility shift 
assays (EMSAs). 
Using the Beer-Lambert equation A=Ecl (where A= absorbance, E= molar 
extinction coefficient, c= concentration of solute, and 1= length of light path in solution 
in centimetres (usually 1cm)) and assuming a molar extinction coefficient of 0.02 
(mg/mlr1 cm-1, dsDNA has a concentration of 50~g/ml. As there is a linear relationship 
between absorbance and DNA concentration, the concentration of an unknown solution 
can be determined using the following equation: 
X ~g/ml = 50~g/ml x Abs260nm x recipricol of the dilution factor 
In brief, the DNA concentration of an unknown solution was determined as follows. To 
conserve the amount of DNA solution used, 10~1 was added to a 5ml universal tube 
containing 1.99ml of TE buffer* and thoroughly mixed (dilution factor of 0.005). The 
diluted test solution was then transferred to a 2.5ml plastic cuvette and the absorbance 
measured at 260nm (Abs26onm) against a TE buffer blank. NB the reciprocal of the 
dilution factor 110.005 (200) was incorporated into the equation below to account for 
the dilution of the original solution. The absorbance measured was entered into the 
equation below to determine the concentration of the original solution. 
X J.Lg/ml = SPJ.Lg/ml X Abs260nm X 200 
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*TE (Tris-EDT A) buffer 
1M Tris-HCl pH 8.0 
0.2M EDTA 
dHzO 
5ml 
2.5ml 
Up to 500ml 
2. 7. 7 Cohesive end DNA ligation 
T4 DNA ligase (Promega) catalyses the ligation of the complimentary ends of the DNA 
fragment and the dephosphorylated and linearised vector, generated from digestion with 
the same RE. The efficiency of the ligation reaction is thought to be influenced by the 
molar ratios of the insert and vector DNA used. Ligation reactions consisting of 
approximately 3:1 molar ratio of vector over insert were adequately successful. Ligation 
reactions were performed in 0.5ml microcentrifuge tubes and components were added in 
order as follows: 
Component Volume Working Stock Concentration Concentration 
Insert DNA Variable - 1 Molar -
Vector DNA Variable - 3 Molar -
1 Ox T 4 ligase buffer 1.5,.tl 1x 10x 
T 4 DNA ligase 1.5)11 4.5units 3units/)11 
Final volume 15)11 - -
The ligation reactions were incubated at 4°C overnight to maximise the number of 
recombinant vectors generated. 
2.8 Chemically Competent Escherichia coli 
E. coli cells were employed as robust hosts for recombinant plasmids utilised for the 
maintenance of DNA and in the expression of exogenous V. cholerae proteins due to the 
relative pathogenic potential of the organism. Expression of genes in E. coli is assisted 
by its relative ease of manipulation, growth efficiency and high yield production of 
proteins. The use of E. coli for manipulation and functional analysis of genes from V. 
cholerae prevent complications which may arise as a result of transcriptional expression 
of chromosomally similar genes within a native strain. Chemically competent E. coli 
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were incorporated with the recombinant vectors through a process of genetic 
transformation. 
2.8.1 Preparation of chemically competent E. coli 
A chemical method for the induction of competence in E. coli is described as follows. 
Cells of the desired bacterial strain were streaked from a frozen stock onto an LB plate 
(no selection) to obtain single colonies. A single colony was used to inoculate 5ml 
liquid LB medium and incubated overnight at 37°C with 225rpm rotary agitation. A 
millilitre of overnight culture was used to inoculate 50ml of pre-warmed liquid LB 
medium in a 250ml baffled conical flask. The cells were incubated at 37°C with 220rpm 
rotary agitation until an optical density at 600nm (OD600) of 0.4. The culture was cooled 
on ice for 5 minutes, harvested at 4,000rpm for 5 minutes at 4°C and the supernatant 
carefully discarded. The bacterial cell pellet was resuspended in 30ml cold, sterile TFBJ 
buffer* and the suspension kept on ice for 90 minutes. The cells were harvested at 
3,800rpm for 5 minutes at 4°C, and the supernatant discarded. The cell pellet was 
resuspended in 2ml cold TFB2 buffel and kept on ice for a further 45 minutes. 
Following this incubation period, competent cells were harvested furthermore as 
described previously and resuspended in 2ml cold TFB2 buffer. Aliquots of 50J.Ll 
(cloning strains) or lOOJ.Ll (expression strains) were transferred to 1.5ml microcentrifuge 
tubes and flash frozen in a dry ice/ ethanol bath. Chemically competent cells were 
stored at -80°C. 
*TFB 1 Buffer - lOOmM rubidium chloride, 50mM manganese chloride, 30mM 
potassium acetate, 10mM calcium chloride, 15% glycerol, pH 5.8. 
#TFB2 Buffer- lOmM MOPS, 10mM rubidium chloride, 75mM calcium chloride, 15% 
glycerol, pH 6.8. 
2.8.2 Transformation of chemically competent E. coli 
Chemically competent cells were removed from -80°C storage and allowed to 
completely thaw on ice. To ensure equal distribution of cells the tube was tapped gently. 
To 50J.Ll or lOOJ.ll of the chemically competent cells, 5J.Ll or lOJ.Ll of the ligation mixture 
was transferred, respectively. The suspension was mixed with the tip of pipette and 
incubated on ice for 30 minutes. Cells were heat shocked in a 42°C water bath for 40 
seconds and incubated on ice for a further 2 minutes. 500J.ll of liquid SOC medium* was 
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added to newly transformed cells and incubated at 37°C with 225rpm rotary agitation 
for 1-1 Y2 hours. The transformed cells were plated in 25, 50 or 1 OOJ..Ll volumes onto solid 
growth medium supplemented with appropriate selection antibiotic and incubated 
inverted at 37°C overnight. 
*See Bacterial Growth Media section 2.3.3.1 
2.8.3 Transformation of chemically competent CloneSmart E. cloni 
Chemically competent E.cloni cells (CloneSmart, Lucigen) were removed from -80°C 
storage and allowed to completely thaw on ice. To ensure equal distribution of cells the 
tube was tapped gently. To 49J..Ll of the competent E .cloni cells, 1f..Ll of heat inactivated 
ligation mixture was transferred. The suspension was mixed with the tip of pipette and 
incubated on ice for 30 minutes. Cells were heat shocked in a 42°C water bath for 45 
seconds exactly and incubated on ice for a further 2 minutes. 950J..Ll of liquid recovery 
medium (supplied with the kit) was added to newly transformed cells and incubated at 
37°C with 250rpm rotary agitation for 1 hour. The transformed cells were plated in 
1 OOJ..Ll and 200f..Ll volumes onto solid YT agar plates supplemented with appropriate 
selection antibiotic and incubated inverted at 37°C overnight. 
*See Bacterial Growth Media section 2.3.3.1 
2.8.4 Screening of recombinant E. coli 
All plasmids used in this thesis carried genes conferring resistance to specific 
antibiotics, which assisted in the identification and isolation of transformed recombinant 
clones. Growth on antibiotic supplemented plates would only be viable for successfully 
transformed bacterial colonies. Subsequent colonies were isolated and the DNA 
fragment identified by restriction enzyme digest and subject to DNA sequencing to 
confirm sequence integrity. 
2.9 Site directed mutagenesis 
The in vitro site directed mutagenesis experiments in this thesis were performed as 
described for the QuikChange Multi Site-Directed Mutagenesis system (Stratgene). This 
technique was used for the study of gene and protein structure/function relationships. 
Three mutagenic primers were designed to incorporate a centrally located 
desired point mutation in specific amino acid sites (Table 2.6). The amino acid alanine 
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was chosen to substitute at these sites due to its generally neutral properties and small 
steric limits to protein conformation. Primers were of similar length (37 -40bp ), similar 
melting temperatures of 79.3°C, terminate at one or more Cor G bases at the 3' end and 
designed to anneal the same strand of the ds-DNA template. 
Table 2.6 Mutagenic oligonucleotides used for site directed mutagenesis. 
Primers Nucleotide sequence (5'-3') Application (Reference) 
C75A 5'- GCAAAAGGTGAGCGCCTCGCGAGTGAACTGGAGAGAAC-3' Mutagenesis Fwd (Chapter 5) 
C180A 5'- CAACT ATGCTGTGGTCATGGCT AGAAACCATCCA TT AGCC-3' Mutagenesis Fwd (Chapter 5) 
C196A 5'- GAT AACACTGGAGAGTT ATGCCCAGAGTCGACATGTGATC-3' Mutagenesis Fwd (Chapter 5) 
Nucleotides highlighted in red indicate mutation substitutions. 
2.10 
2.10.1 
Recombinant protein expression 
Overexpression of recombinant proteins from pET vectors 
Target proteins from V. cholerae were initially expressed from a combination of pET 
classified expression vectors (Novagen) and E. coli BL21 DE3 lysogens. E. coli BL21 
Star (DE3) encodes a bacteriophage T7 RNA polymerase, which can be induced from 
the lacUV5 promoter by measured doses of IPTG (0.5mM-1mM) at mid log phase 
(Miroux and Walker, 1996). Bacteriophage T7 RNA polymerase allows high level 
expression of proteins initiated from the T7 promoter of pET classified vectors. BL21 
strains and their derivatives also lack several proteases enabling the efficient 
overexpression of recombinant proteins (Studier and Moffatt, 1986). 
An overnight culture was prepared by inoculating 5rnl LB media supplemented 
with the appropriate antibiotic (for selection and maintenance of vector in E. coli), with 
a single E. coli colony containing the desired pET recombinant plasmid. A litre of 2xYT 
liquid medium (see bacterial growth media section 2.3.3.1) supplemented with 
appropriate antibiotic was inoculated with 3rnl of overnight culture. Cultures were 
grown in baffled flasks to promote aeration at a temperature of 37°C with 180rpm rotary 
agitation. Growth of the culture was determined by measuring the change in optical 
93 
density at 600nm (OD600). The OD6oo at which the E. coli is most efficient at expressing 
proteins is at 0.5 (correlating to mid-log phase). Protein expression was initiated by the 
addition of various inducer concentrations from 100j..LM-lmM IPTG (and 0.002-0.02 
(w/v) % L-arabinose when using BL21-AI). Induction initially results in chromosomal 
encoded bacteriophage expression which then initiates expression of recombinant 
protein from the pET classified vectors. Standard expression conditions are continued at 
a temperature of 37°C with 180-200rpm rotary agitation for 3-4 hours. If toxicity is 
experienced by the host, optimised expression conditions are adopted where the culture 
is initiated with low concentrations of inducer and continued at a temperature of 25°C 
with 120rpm rotary agitation for 16 hours. 
2.10.2 Overexpression of recombinant proteins from pQE vectors 
The relative toxicities experienced during initial expression of certain proteins 
necessitated the use of other expression systems such as those of the pQE classified 
vectors. The expression of these recombinant plasmids from the T5 promoter can be 
highly repressed at the transcriptional level by lac repressor protein encoded on the 
pREP4 plasmid. The pREP4 repressor plasmid can be expressed simultaneously with 
the recombinant pQE plasmid when transformed in an appropriate strain such as E. coli 
M15. Expression is initiated by induction with 0.5mM to 1mM IPTG at mid-log phase, 
which dissociates and inactivates the lac repressor protein. This allows host RNA 
polymerase to initiate T5 promoter mediated gene expression. 
Cultures were expressed as described in section 2.1 0.1 with the following 
omissions: the media were supplemented with both 100j..Lg/rnl carbenicillin and 25j..Lg/ml 
kanamycin and induced with IPTG only. 
2.10.3 Overexpression of soluble proteins from pBAD vectors 
Soluble proteins were regularly expressed from pBAD/ Myc-His vectors (Invitrogen) in 
E. coli LMG 194. LMG 194 was the preferred host for expression of proteins showing 
toxicity or those proteins inclined to form inclusion bodies. Basal expression of the gene 
of interest from the PsAo (araBAD) promoter, prior to induction, can be highly 
repressed by growth in a minimal medium (RM media, see bacterial growth media 
section 2.3.3.1) supplemented with glucose. 
An overnight culture was prepared by inoculating 5rnl LB media (supplemented 
with 100j..Lg/rnl carbenicillin), with a single colony containing the desired pBAD 
recombinant plasmid. A litre of RM media supplemented with 1 OOj..Lg/ml carbenicillin 
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was inoculated with 3ml of overnight culture. Cultures were grown in baffled flasks to 
promote aeration at a temperature of 37°C with 180rpm rotary agitation. At an OD6oo of 
0.5, protein expression was initiated by the addition of L-arabinose to a final 
concentration of 0.02 % (v/v). Expression continued at a temperature of 37°C or 25°C 
with 180-120rpm rotary agitation for 3Y2 - 16 hours, respectively. 
2.11 
2.11.1 
Recombinant protein purification methods 
Cellular lysis and fractionation by differential centrifugation 
Differential centrifugation was consistently used throughout all purification procedures 
as a technique for the separation, identification and enrichment of proteins from 
different cellular fractions using increasing centrifugal force. 
All manipulations from herein were performed on ice or at 4°C unless otherwise 
stated to minimise the activity of cell free hydrolases. After separation of bacterial cells 
from liquid culture at low speed centrifugation (figure 2.1) the cell pellet was 
resuspended in cold buffer A (50rnl/ 2 litre cell pellet) to maintain physiological cell 
stability. Buffer composition was typically 20mM Tris-HCl (biological buffer) at pH 8.0 
(to suppress nucleic and proteolytic enzymes), 300mM NaCl, and 10% glycerol (for 
cryogenic storage). Further repression of nucleic acid/ proteolytic cleavage and 
disulphide bond formation was maintained through the addition of DNase I (500 units/ 
50rnl, Sigma-Aldrich), EDT A-free protease inhibitor tablet (1 tablet/ 50rn1, Roche) and 
THP reducing agent (lmM tris(hydroxypropyl)phosphine, Novagen) to buffer A. THP 
was used due to its increase stability and effectiveness over dithiothreitol (DTT) 
(Novagen). 
Resuspended cells were homogenised by passage through a Constant Systems 
Cell Disruptor. An enriched supernatant fraction containing cytosolic proteins aspirated 
from bacterial cell components was acquired through differential centrifugation, as 
illustrated in figure 2.1. Cytosolic proteins from the resultant supernatant fraction were 
further extracted and refined using purification protocols described later. 
Integral membrane proteins were extracted from membranous pellet obtained 
from the final centrifugation process. Briefly, the membrane pellet was homogenised by 
repetitive passage through a syringe using a small volume of buffer A. 50ml of buffer A 
containing 2% (w/v) detergent DDM (n-Dodecyl-~-D-maltoside) was added to the 
homogenate to liberate membrane proteins and rotated end-over-end at 4°C for 40 
minutes. Solubilised membrane proteins from the lipid membrane were extracted by 
ultracentrifugation of the homogenate mixture at 220,000 x g for 1 hour at 4°C. The 
95 
resultant supernatant containing detergent solubilised membrane proteins were refined 
by further purification. 
Proteins from the supernatant fraction were further extracted and refined by 
three phases of 'capture ', 'intermediate' and 'polishing' protein purification as 
described below. 
Figure 2.1 Schematic illustration of the fractionation and enrichment of 
bacterial cell components by differential centrifugation. 
Bacterial cell culture 
1 Centrifuge at 6,300rpm for 8 minutes at 4°C (Beckman JLA 8.1000 rotor) 
Pellet of whole cells 1 Resuspension and Homogenisation at25KPsi 
Homogenate 
Centrifuge at 12,000 x g for 15 minutes at 4°C 
(Beckman JA-20 rotor) 
Pellet of nuclei , 
cell debris and 
whole cells 
Supernatant 
/ ""' Centrifuge at 20,000 x g for 30 minutes at 4°C 
2.11.2 
~(Beckman JA-20 rotor) 
Pellet of Supernatant 
mitochondria, 
lyposomes and 
microsomes / 
Pellet of membranes, 
endoplasmic reticulum, 
microsomes and Golgi 
""' Centrifuge at 220,000 x g for 1.5 hours at 4°C 
~ (Beckman Type 50.2 Tl rotor) 
Enriched supernatant fraction 
containing soluble proteins 
Purification of His6-tagged proteins by IMAC 
IMAC (immobilised metal affinity chromatography) was consistently employed 
throughout this work for the selective 'capture ' and purification of affinity tagged 
proteins from crude extracts. The affinity tags routinely used consisted of six 
consecutive histidine residues (His6) located at the amino or carboxyl terminus of 
proteins. As the e His6-tags are smaller than other tags such as glutathione S-transferase 
(GST) and maltose binding protein (MBP), they do not interfere with the structure and 
function of the recombinant protein. These residues were incorporated artificially 
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during custom primer design or produced as fusions to either theN- or C-termini during 
genetic recombination of expression vectors. The His6-tags of recombinant fusion 
proteins chelate divalent metals enabling selective purification from a complex 
biological preparation via IMAC (immobilised metal affinity chromatography). 
The basic principle of IMAC used during this work involves specific covalent 
binding and retention of the fusion protein via its His6 tag to cationic nickel (Ni2+) 
immobilised on a solid support of sepharose (6 Fast Flow -40mg/rnl binding capacity, 
Amersharn Biosciences) or agarose (nickel-nitrotriacetic acid (Ni-NTA), Qiagen) within 
a column. Selectively retained proteins were subjected to further purification and 
displacement from the column by competition with an analogue of histidine 
(imidazole). In general, non-specific interactions by background contaminants with Ni-
NTA were prevented by the addition of 0.5-1M NaCl (hydrophobic and ionic 
interactions) and 1 0-90mM imidazole (between histidine residues of background 
proteins) in binding and wash buffers. The inability to remove contaminants whilst 
using >90mM imidazole will require further purification with other methods such as 
ion-exchange or SEC. The pH of the buffers were 0.5-1 units above the calculated 
isoelectric point (pi) of the protein (pH at which protein carries no net charge), which 
gives an overall negative charge that has a high affinity for the Ni-NT A. 
One millilitre of Ni-NTA has a binding capacity of 5-20mg/rnl of protein. Ni-
NT A resin was primed from stock by collection at low speed centrifugation at 4K rpm 
for 5 minutes and decanting carefully the 20% ethanol (EtOH) storage solution. The Ni-
NT A resin was resuspended with an equal amount of Buffer A in preparation for IMAC. 
Typically, to 50rnl of the supernatant obtained from differential fractionation, NaCl was 
added to a final concentration of 600mM (NB 300mM NaCl previously present in 
buffer A) and imidazole to 10mM. The supernatant was allowed to equilibrate by end-
to-end rotation at 4°C for 5 minutes prior to addition of Ni-NTA. One millilitre of Ni-
NT A was added to the supernatant and the binding mixture was rotated for 1 Y2 hours at 
4°C in cold room. The binding miture was packed into a gravity flow column (Econo-
colurnn 1.0 x 30cm, Bio-Rad) for purification using increasing concentrations of 
imidazole in buffer. 
Optimisation of protein purification was achieved through the modification of 
variables including the affinity resin, sample binding procedure, washing techniques 
and buffer composition to ensure high purity and high yield. A histidine analogue, 
imidazole, was typically added at low concentrations to wash buffers to remove weakly 
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bound protein contaminants and host cell proteins and at high concentrations to the 
elution buffer to elute bound His6_proteins in the final step of purification. 
2.11.3 Purification of His6-tagged proteins by Ion-Exchange 
Chromatography 
Ion-exchange chromatography was used extensively throughout this work for the 
enrichment and 'intermediate' purification of proteins for further analysis. Ion-exchange 
chromatography was performed on an AKT A purifier (Amersham) using Hi Trap SP and 
Q HP columns for cation and anion exchange, respectively. Elution profiles of protein 
were monitored at 280nm. 
Protein solutions obtained from IMAC were further purified by ion-exchange 
chromatography as briefly detailed as follows. Protein solutions were loaded onto pre-
equilibrated (with low ionic strength buffer) anion or cation exchange columns (HiTrap 
HP, Amersham) depending on the pH of the protein to be purified. Once bound, 
proteins were effectively concentrated onto the resin and non-binding proteins and 
contaminants were removed by equilibration with a low ionic strength starting buffer. 
Protein purification commenced when a gradient of increasing ionic strength was 
introduced into the eluent buffer. Proteins were monitored and detected by their 
ultraviolet absorbance at 280nm. Regeneration of the column for subsequent exchanges 
was achieved by removing highly bound residual proteins through washing with a very 
high ionic strength buffer prior to equilibration with low ionic strength starting buffer. 
2.11.4 Purification of His6-tagged proteins by Preparatory Size Exclusion 
Chromatography (SEC) 
SEC purification of proteins was performed on an AKTA purifier (Amersham) using a 
Supedex200PrepGradeHiLoad16/60 column (Amersham). Elution profiles of protein 
were monitored at 280nm. 
Peak fractions of protein obtained from ion-exchange chromatography were 
polished by SEC under ambient conditions as briefly detailed as follows. The 
Supedex200PrepGradeHiLoad16/60 column was equilibrated with 2 column volumes 
(CV) of dH20 to remove storage buffer and then with 3 CV of an appropriate running 
buffer. Typically, protein samples of 0.5-2% of the total CV were loaded in a controlled 
manner onto the pre-equilibrated column, by means of a peristaltic syringe pump 
connected to the AKT A Purifier. An additional 3ml bolus of running buffer was 
injected to ensure that the sample was fully introduced onto the column and to improve 
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resolution. Running buffer was pumped onto the column at a steady flow rate of 0.5-
lml/min for separation and purification of proteins. Proteins were monitored and 
detected by their ultraviolet absorbance at 280nm and salts detected by monitoring the 
conductivity of the buffer. Regeneration of the column for subsequent purification was 
achieved by equilibration with 1 Y2 CV of running buffer. 
2.12 
2.12.1 
Recombinant protein analysis 
SDS-PAGE 
Throughout this work recombinant proteins were consistently resolved by SDS-PAGE 
(sodium dodecyl sulfate polyacrylamide gel electrophoresis) to determine the efficiency 
of expression and purification. All SDS-PAGE experiments were conducted using 
commercially sourced pre-cast Bis-Tris polyacrylamide gels (NuPage, Invitrogen). 
Depending on the degree of separation required for resolving proteins of a certain 
molecular range, two gels of 4-12% gradient or 12% Bis-Tris acrylamide, were used. 
Protein samples of 30~1 were solubilised with 10~1 4x LDS loading buffer 
(NuPage, Invitrogen). A pre-cast gel was clamped vertically in an electrophoresis 
apparatus (a plastic buffer dam was used if running a single gel) and both inner and 
outer chambers were submerged in lx MOPS running buffer*. Samples of 20~1 were 
loaded into separate wells of either a 4-12% or 12% gradient Bis-Tris acrylamide gel, 
together with 20~1 of a pre-stained molecular weight marker (SeeBlue Markers, 
Invitrogen). Proteins were resolved by applying a potential difference of 200V through 
the gel for 50 minutes. 
Proteins were visualised by immersing in Coomassie blue stain# for 30 minutes 
then Coomassie blue destainA for 10 hours. This process was performed with gentle 
agitation on an orbital shaker (Stovall, The Belly Dancer) set at 1 revolution per second 
unless otherwise stated. 
* 1 Ox MOPS Running Buffer Coomassie Blue stain# 
MOPS 104g Methanol 40% v/v 
Tris base 61g Acetic acid 10% v/v 
SDS lOg Coomassie Brilliant Blue R-250 0.1% w/v 
EDTA 3g dH20 50% v/v 
dH20 up to 1 litre 
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Coomassie blue destainA 
Methanol 40% v/v 
Acetic acid 10% v/v 
2.12.2 Identification of Histidine-tagged fusion proteins 
2.12.2.1 Western Blot analysis 
Western blot was consistently used during this work for the detection of newly 
expressed recombinant proteins via their His6-tag. All incubations and washes for 
Western blot were performed at room temperature in a square Petri dish, with gentle 
agitation on an orbital shaker at 1 revolution per second. 
The experimental protein was resolved by SDS-PAGE in duplicate (control) as 
described previously. The control gel was stained in the usual process, whilst the second 
gel was washed thoroughly with dH20 to remove remnants of running buffer and 
soaked in 25ml Transfer buffe/ for 30 minutes. Whilst the gel was soaking a piece of 
PVDF transfer membrane (lmmobilon) together with several pieces of Whatman filter 
paper were cut to size (8cm x 10cm). The PVDF transfer membrane was soaked in 
100% methanol for 30 seconds, washed 5 times with ddH20 and then soaked in 25ml 
transfer buffer for 15 minutes. 
The blotting apparatus was assembled as a sandwich of abrasive nylon sponge 
pads and filter paper so that the gel from SDS-PAGE was orientated towards the 
cathode and the PVDF membrane towards the anode, respectively. The transfer of 
proteins onto the membrane was achieved through applying a potential of 
175mAMPeres for 1 Y2 hours. 
The PVDF membrane was soaked in 25ml ELISA wash buffer2 for 15 minutes, 
decanted and 25ml of blocking buffer3 was added and washed for 1 hour. The blocking 
process was allowed to proceed statically overnight at 4°C. 
The membrane was washed in triplicate with 25ml fresh ELISA wash buffer for 
5 minutes, respectively. The primary antibody (8J.Ll), mouse monoclonal antibody 
(Sigma) was raised against the Histidine tag as follows. A solution consisting of a 1 in 
3125 dilution of the primary antibody with 25ml of fresh ELISA Wash buffer and 0.5% 
(w/v) BSA was prepared. The membrane was incubated with this solution for 1 Y2 hours 
and then washed in triplicate with 25ml ELISA Wash buffer for 10 minutes, 
respectively. During this time, the secondary antibody, anti-mouse IgG 
(immunoglobulin G) conjugated with alkaline phosphatase was prepared as described 
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previously for the primary antibody. Once again, the membrane was incubated with this 
secondary antibody for 1 hour and washed in triplicate with 25ml ELISA Wash buffer 
for 10 minutes, respectively. 
Following probe association the PVDF membrane blot development can be 
achieved using either colorimetric (AP (alkaline phosphatase) conjugate substrate kit, 
Bio-Rad) or chemiluminescence (lmmun-Star substrate, Bio-Rad) detection methods. 
Both methods are described as follows. 
Colorimetric detection method 
A 1x AP colour development buffer was prepared fresh from a 1:25 dilution of a 25x 
stock solution. To this 25ml solution, 400jll of AP colour reagent A and 400jll colour 
reagent B was added. The membrane was transferred to a clean Petri dish and immersed 
with this solution for 1 minute or until colour development was complete. The colour 
development solution was decanted and the membrane washed thoroughly with dH20 
for 10 minutes to remove residual solution. The membrane was air dried and kept for 
reference. 
Chemiluminescence detection method 
The Immun-Star substrate solution was provided ready to use. The membrane was 
transferred to a clean Petri dish and immersed with 2ml of this solution and incubated 
for 5 minutes statically. The membrane was covered in a piece of Saran film and 
securely attached to the interior of an autoradiographic cassette. Finally, the blot was 
exposed to x-ray film for periods of between 1 and 5 minutes (or until an optimal signal 
was produced) under dark room conditions. 
'Transfer buffer 
Glycine 
Tris-base 
SDS 
Methanol 
2ELISA Wash buffer 
Phosphate stock* 
NaCI 
Tween 20 
2.9g/litre 
5.8g/litre 
0.37 g/litre 
20% (v/v) 
30ml 
8. 76g/litre 
0.05% (v/v) 
*Phosphate stock 
KH2P04 6.465g/litre 
3 5 .3 g/li tre 
Adjusted to pH 7.4 
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3Blocking buffer 
Blot qualified BSA (Bovine serum albumin) 
ELISA Wash buffer 
2.12.2.2 Fluorescence detection 
0.75g 
25ml 
The fluorescence detection method (In Vision His-tag In-gel Stain) is an alternative to 
Western blotting for the detection of His-tagged fusion proteins. This method harnesses 
the use of a fluorescent dye conjugated to Ne+: nitrilotriacetic acid (NTA) complex for 
the detection of the hexahistidine domain of His-tagged fusion proteins. 
The experimental protein was resolved together with 5).11 BenchMark molecular 
standard (Invitrogen) by SDS-PAGE as described previously. All wash and incubation 
steps that proceed hence forth were performed at room temperature in a square Petri 
dish with gentle rotary agitation provided by an orbital shaker. After electrophoresis the 
gel was soaked in 100ml fixing solution 1 for 1 hour. The fixing solution was decanted 
and the gel washed in triplicate with 100ml dH20 for 10 minutes, respectively. The gel 
was immersed and incubated in 25ml ready-made In Vision His-tag In-gel stain for 16 
hours. The stain was decanted and the gel washed in triplicate with phosphate buffer2 
for 10 minutes, respectively. The gel was immediately visualised using a UV 
transilluminator set at 302nm and imaged with a 4-8 second exposure time using a 
camera capable of integration. The gel was then stained using conventional Coomassie 
blue for reference. 
1Fixing solution 
Ethanol or methanol 
Acetic acid 
2Phosphate buffer 
NaH2P04 
40ml 
10ml 
Up to lOOml 
2.6g/litre 
Adjusted to pH 7.8 with 3M NaOH 
2.12.3 Protein buffer exchange, desalting and dialysis 
Protein preparations following purification were consistently buffer exchanged or 
dialysed to remove low molecular weight contaminants in preparation for downstream 
manipulations. Proteins showing stable characteristics may be subjected to lengthy 
102 
periods of dialysis using dialysis cassettes (lOKDa MWCO Slide-A-Lyzer, Pierce), 
however unstable proteins would be best suited to rapid gravity flow based buffer 
exchange using desalting columns (Hi Trap or PD-1 0 desalting/buffer exchange 
columns, Amersham). 
In brief, dialysis proceeded with a loaded dialysis cassette (size depends on 
volume to be dialysed, see manufacturers instructions), equilibrated against an 
appropriate buffer (200-500x volume of sample) chosen for use in future experiments, 
for 3 hours at 4°C with gentle stirring. The dialysis cassette was transferred to an equal 
volume of fresh buffer midway through the procedure to improve the rate of 
equilibration. 
For the PD-10 columns, after equilibrating with 25ml of an appropriate buffer, 
2.5ml of the protein preparation was loaded and the flow through discarded. The protein 
was eluted with 3.5ml of equilibration buffer. The resulting protein solutions were 
either used immediately for further experiments or stored at -80°C. 
2.12.4 Protein concentration 
Purified protein solutions were condensed using 'Vivaspin' centrifugal concentrators 
(Sartorius). The principle use of protein concentrators are for the purification, 
concentration and desalting of proteins from low molecular weight contaminants. This 
is achieved through a process of ultrafiltration of low molecular weight contaminants 
through a molecular sieved membrane, culminating in the retention of proteins above 
the membrane. 
Proteins purified in the presence of detergent were initially concentrated using 
ion-exchange chromatography via a one step 1M NaCl elution. This reduced the total 
volume to be concentrated and the amount of free detergent micelles present. The 
majority of proteins in this work were concentrated using 20,000Da molecular weight 
(MW) cut off Vivaspin columns, chosen to be approximately 1/3 to 112 the molecular 
weight of the proteins. The membrane of the vivaspin columns were washed with 2rnl 
dH20 at 4,000 x g centrifugation for 5 minutes within a Beckman JA-10 fixed angle 
rotor adapted with a holder. The eluent was discarded and up to 2rnl of dilute protein 
sample was concentrated at 6,000 x g. Centrifugation times were variable depending on 
the protein purity, solubility and final concentration required. Protein recovery was 
mediated by inversion of the spin column at 4,000 x g centrifugation for 2 minutes. 
Subsequently, protein concentration measurements were conducted using the 
Coomassie (Bradford) protein assay (as detailed below) or stored at -80°C. 
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2.12.5 The Coomassie (Bradford) protein assay 
Accurate measurement of protein concentration is essential for the quantitation of total 
protein for biological studies. Protein concentrations were determined by the Coomassie 
(Bradford) protein assay kit (Pierce). This colorimetric assay is a modification of the 
Bradford assay (Bradford, 1976) and is based on the observation that the absorbance 
maximum shifts from 465nm to 595nm upon Coomassie Brilliant Blue G-250 binding 
to protein. An accompanying colour change from brown to blue is also associated with 
the shift. The purpose for using this assay over others was due to its simplicity, 
sensitivity and compatibility with a wide variety of substances including reducing 
agents and detergents. 
Briefly, protein samples were diluted 1 in 5 or 1 in 10 with buffer to ensure that 
the protein concentration measured was within the working range for the assay ( 100-
1,500flg/ml). Coomassie reagent was added at a volume of 1.5ml to 30fll of sample or 
standard of known BSA concentration (0 to 2,000flg/ml) and incubated for 10 minutes 
at room temperature. The samples were then transferred to a 2.5ml disposable, plastic 
cuvette and the absorbance measured at 595nm (Abs59snm) against a dH20 blank. A 
calibration curve was plotted using the Abs59snm generated from known concentrations 
of BSA standards and the concentration of the unknown samples determined. Both 
standard and experimental reactions were performed in duplicate to ensure consistency 
in the results. 
2.13 
2.13.1 
Biochemical assays 
Antimicrobial susceptibility assays 
Antimicrobial susceptibility assays using the microdilution technique were utilised to 
determine the in vivo susceptibility of KAM3 harbouring recombinant vectors. The 
microdilution broth method was performed according to the National Committee for 
Clinical Laboratory Standards guidelines (NCCLS, 2003). 
Briefly, a single colony was used to inoculate 5ml Mueller-Hinton broth 
(supplemented with appropriate antibiotic) and grown at 37°C with 225rpm shaking till 
an OD625 of 0.08-0.1 (0.5 McFarland standard or 1x108CFU/ml). If induction of 
expression of the target protein was required, the bacterial culture would be grown to an 
OD62s of 0.5 where upon 1mM IPTG would be added. The culture would be allowed 
incubate for a further 3 hours. The suspension was diluted to 2.5x 106 CFU/ml and a 
measured volume used to inoculate wells of a microtitre plate (final test density of 
bacteria of 5x 104 CFU/well) containing serial dilutions of antibiotics to be tested. 
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Mueller Hinton media was supplemented with 1mM IPTG if initiation of expression 
was required. Microtitre plates were incubated statically at 35°C and bacterial growth 
visually recorded after 16-20 hours. A valid test is indicated by the formation of 
bacterial precipitate ~2mm in diameter or defined turbidity in a positive control well. 
Cellular integrity and culturability were confirmed through taking 1 OJ.I.l sample 
of cells from the growth control well and diluting (1: 1000) with 10ml of 0.9% saline 
(9g/L NaCl). 100J.1.l of this mixture was plated onto a solid media plate with appropriate 
antibiotics and incubated overnight at 37°C. Visual growth of approximately 50 uniform 
colonies indicates integrity and an inoculum density of 5x105 cfu/ml. 
2.13.2 Nitrocefin disk method 
Chromogenic methods were used in the detection of ~-lactamase activity. ~-lactamase 
activity was determined using 6mm diameter filter paper discs impregnated with 
Nitrocefin (Fluka), which engenders a colour change from yellow to red upon 
hydrolysis of the ~-lactam. Two Nitrocefin discs were placed onto a clean, sterile Petri 
dish. Five J.l.l of a potential ~-lactamase (>95% purity) was dropped onto the surface of 
one disc and 5J.1.l of a non-~-lactamase or heat denatured protein (control) dropped onto 
the surface of the other. After 10 minutes the discs were observed for the development 
of colour. A negative outcome results in no colour change while the development of a 
red colour indicates a positive test. A positive result should be interpreted as resistance 
to penicillin or cephalosporin activity. Susceptibility should be confirmed by broth 
dilution ~-lactam susceptibility testing using the method described in section 2.13.1. 
2.13.3 Electrophoretic mobility shift assays (EMS As) 
The electrophoretic mobility shift assay (EMSA) is a sensitive technique used for the 
study of gene regulation and to determine protein-DNA interactions. The principle of 
this technique is based upon the observation that protein binding to DNA is retarded 
further than unbound DNA in a non-denaturing polyacrylamide gel during 
electrophoresis. The specificity for a putative site is established by competition 
experiments with the same unlabelled DNA, unrelated DNA or through dissociation 
experiments with known substrates of the protein. 
Oligonucleotides (between 25-31 bp in length) were synthesised by MWG 
Biotech .AG on a lf..Lmol scale with high purity salt free (HPSF) purification (Table 3.5). 
All reactions were performed in 1.5ml screw-capped microtubes and incubations in a 
digital dry bath (Techne Dri-Block DB2D), unless otherwise stated. 
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5' end labelling of oligonucleotides with [y-32P] ATP 
For visualisation purposes 25-30bp oligonucleotides or larger DNA fragments were 
labelled at the 5'end with [y-32P] ATP using T4 polynucleotide kinase as follows. 
Component Volume Final Concentration 
Forward oligonucleotide or ds-DNA Variable 300ng 
1 Ox Reaction Buffer 2jll 1x 
dH20 Variable -
T 4 Polynucleotide Kinase 1jll 10 Units 
[y-32p] 1jll 1011Ci 
Total 20jll -
Reaction components were mixed in order as stated above, incubated for 1 hour at 37°C 
and T4 polynucleotide heat inactivated at 65°C for a further 15 minutes. Unincorporated 
nucleotides were removed from labelled mixture using micro spin 30 columns (Bio-
Rad) as stated below. 
Removal of unincorporated [y-32P] A TP 
Spin columns were inverted several times to ensure even distribution of resin and 
centrifuged at 5,000rpm for 2 minutes. Collecting tube of spin column was replaced 
with sterile 1.5rnl microtube. The total volume of the reaction mixture was increased to 
50~1 by adding 30~1 dH20, applied to the centre of the column and centrifuged at 
5,000rpm for 4 minutes. Column purified single stranded labelled oligonucleotides were 
used for annealing reactions whilst labelled ds-DNA was stored at 4°C for gel 
purification described later. 
Annealing reaction with unlabelled reverse oligonucleotide 
A 3 fold excess of unlabelled reverse oligonucleotide was used for annealing to labelled 
forward oligonucleotide as follows. 
Component Volume Final Concentration 
Labelled forward oligonucleotide Variable 90ng 
Unlabelled reverse oligonucleotide Variable 270ng 
1 Ox SSC buffer* 1jll 1x 
dH20 Variable -
Total 40J.LI -
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Reaction components were mixed in order as stated above and incubated at 95°C for 2 
minutes. Annealing reactions contained within the heat block were removed from the 
dry bath and cooled gradually overnight at room temperature to facilitate annealing. 
* 1 Ox SSC buffer 
5M NaCl 
Sodium citrate tri-sodium salt 
3ml 
0.44g 
Up to lOrnl 
Adjusted to pH 7.0 with 1J..Ll volumes of0.1M NaOH and stored at -20°C. 
10% TBE polyacrylamide gel purification of [y-32Pl ATP labelled ds-DNA 
Annealing reactions were mixed with 7J..Ll Andy's dye 1 and loaded onto alternate wells of 
a 10% TBE polyacrylamide gef A potential difference of 190V was applied through 
the gel for 2 hours 15 minutes with buffer recirculation. After electrophoresis, the gel 
was transferred to an autoradiography cassette, exposed to X-ray film for 2 minutes and 
the film developed using an automatic X-ray film processor (Compact X4, Xograph 
Imaging Systems). X-ray film was used as a template for scalpel mediated extraction of 
labelled duplex-DNA. The extracted gel slice containing labelled duplex-DNA was 
placed in a 1.5rnl microtube filled with 300J..Ll TE buffer3 and allowed to diffuse out 
overnight at 4°C. Purified and labelled duplex-DNA was carefully extracted from the 
gel slice, placed in a sterile 1.5ml microtube and stored at 4°C. 
'Andy's dye 
Bromophenol blue 
Xylene cyanol 
Ficoll type 400 
dH20 
0.0025g 
0.0025g 
1.5g 
Up to lOml 
210% TBE (Tris, Boric acid and EDT A) polyacrylamide gel 
dH20 33.3rnl 
lOx TBE buffer* 6m1 
30% Bis-acrylamide 20ml 
10% AMPS (Ammonium persulfate) 0.8rnl 
TEMED (N,N,N,N- Tetramethyl-Ethylenediamine) 60J..Ll 
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* 1 Ox TBE buffer 
Tris base 
Boric acid 
EDTA 
54g 
27.5g 
2.92g 
dH20 Up to 500ml 
3TE (Tris-EDT A) buffer 
1M Tris-HCl pH 8.0 
0.2MEDTA 
dH20 
5ml 
2.5ml 
Up to 500ml 
Calculation of purified, labelled ds-DNA concentration via Scintillation 
Concentrations of duplex-DNA were determined using a liquid scintillation counter 
(Wallac 1450 MiroBeta TriLux Liquid Scintillation and Luminescence Counter). 
Briefly, lJ.ll of labelled single stranded-DNA (ss-DNA) was mixed with lOOJ.ll of 
scintillation fluid (Optiphase 'Supermix', Perkin Elmer). This was repeated using lJ.ll of 
purified and labelled duplex-DNA. Concentrations of duplex-DNA were calculated 
from measuring the counts per minute (cpm) of both ss-DNA and duplex-DNA with a 
liquid scintillation counter. 
EMS As 
Non-denaturing 4% low ionic strength (LIS) polyacrylamide gels1 were used to resolve 
protein-DNA complexes from unbound duplex-DNA. A 4% LIS gel was equilibrated at 
a constant voltage of 160V for 15 minutes to evenly distribute ions present in running 
buffer, remove trace AMPS and to maintain and stabilise the gel temperature. Binding 
reactions of 20J.ll total volume were prepared in order as stated below and incubated on 
ice for 15 minutes: 
Component Volume Final Concentration 
dH20 Variable -
Sx GBBG 4111 1x 
Duplex-DNA Variable 0.05-1 ng/111 
Protein Variable 5-200ng/lll 
Total 20j.ll -
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Sample volumes of 12J.!l were loaded onto a pre-equilibrated 4% LIS gel together with 
5J.!l of Andy's dye as a visual marker. A potential difference of 160V was applied 
through the gel for 1 hour 30 minutes with buffer recirculation. Following 
electrophoresis the gel was transferred to a sheet of 3MM paper and heat dried under 
vacuum (Model 583 gel dryer, Bio-Rad) for 30 minutes. The dehydrated gel was placed 
in an autoradiography cassette with screens and exposed to X-ray film overnight at -
80°C. The X-ray film was developed using an automatic X-ray film processor and the 
results analysed visually to identify any shifts. 
14% LIS polyacrylamide gel 
dH20 
lOx LIS buffer* 
30% Bis-acrylamide 
10% AMPS 
TEMED 
* 1 Ox LIS buffer 
1M Tris-HCl pH 8.0 
0.5M Sodium acetate 
0.2M EDT A pH 8.0 
dH20 
Stored at room temperature. 
25x GBBG 
1M Tris-HCl pH 8.0 
0.2MEDTA 
0.2MDTT 
45.4ml 
6ml 
8ml 
0.6ml 
50J.!l 
67ml 
66ml 
100ml 
Up to 1litre 
10mg/ml BSA (Bovine serum albumin) 
80% Glycerol 
dH20 
Stored in aliquots of 250J.!l at -20°C. 
250J.!l 
125J.!l 
25J.!l 
50J.!l 
324J.!l 
up to 1 OOOJ.!l 
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2.13.4 Malachite Green A TPase Assay 
Malachite Green assays were conducted (see chapter 9) to determine the extent of 
A TPase activity using a modified chromogenic method (Harder et al., 1994) developed 
by Hess and Derr (1975). The technique is based on the quantification of a green 
coloured complex formed as a result of inorganic phosphate (Pi) reacting with 
ammonium molybdate and Malachite Green dye. 
Standard curves were prepared in parallel to all A TPase experiments for the 
quantification of inorganic phosphate present within samples. Briefly, a known series 
of appropriately diluted NaH2P04 standards (between 0-1500 picomoles) were mixed 
with 5~1 500mM EDT A and the assay volume increased to 50~1 with Assay reaction 
buffer1• Addition of 100~1 Malachite green reagent2 causes rapid colour formation 
which was detected at Abs610 in a plate reader. A standard curve of picomoles phosphate 
versus Abs61o was plotted using linear regression. The enzymatic ATPase activity was 
calculated from this data in terms of nanomoles of Pi per minute per milligram of 
protein (nmoles/minlmg). 
The Malachite Green ATPase assay was performed as follows: 
1. 1~M of a putative ATPase protein and 250~M Adenosine 5'-triphosphate disodium 
salt (ATP) were added to two sterile 1.5rnl microtubes, A and B. Less than 300~M 
A TP was added to reduce precipitation and background absorbance from 
nucleotides. 
2. The final volume of each tube was increased to 450~1 with purification buffer and 
incubated for 10 minutes in a thermostatically controlled heat block set at 37°C. 
3. 50~1 of 10mM MgCh was added to tube A only (final concentration of 1mM 
MgCh). The Mg2+ in the MgCh initiates ATPase activity. An equal volume of 
purification buffer was added to tube B (control). 
4. At this time (zero minutes), 45~1 sample was taken from each tube and transferred 
to a well of a microtitre plate containing 5~1 500mM EDT A, which chelates Mg2+ to 
inhibit further A TPase activity. 
5. This was repeated for every minute thereafter for 10 minutes. 
6. After all samples have been collected, 1 00~1 of malachite green reagent was added 
to each well of the microtitre plate and the Abs610 measured immediately in a plate 
reader (Fusion-Alpha Packard Science, Perkin Elmer). Due to the relative low pH of 
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the reagent, measurements were taken immediately to prevent acid hydrolysis of 
native ATP. 
7. The absorbance determined at zero time was subtracted from all subsequent 
absorbance readings to adjust for non-enzymatic Pi release and exogenous free 
phosphate in buffers and lab wares. 
8. The standard curve was used to plot a graph of Pi (pmoles) release against time 
(minutes). 
9. Linear regression analysis was used to determine the amount of Pi present in each 
sample, which was then used to calculate enzymatic A TPase activity in terms of 
nmoles/minlmg. 
1 Assay reaction buffer 
50mM MOPS pH 7.4 
100mM NaCl 
2Malachite Green Reagent 
3 parts Malachite green solution* 
1 part 4.2% Ammonium molybdate solution# 
*0.45% (w/v) Malachite green solution 
0.025g Malachite Green dye 
50ml dHzO 
Stir for 30 minutes and filter sterilise through a 0.22Jlm membrane 
#4.2% Ammonium molybdate in HCl 
0.42g Ammonium molybdate 
6m110M HCl 
4ml dH20 
2.13.5 EnzChek Phosphate Assay 
The EnzChek phosphate assay (Molecular Probes, Invitrogen) was used in addition to 
the Malachite Green assays to determine A TPase activity (see chapter 9). The assay is a 
sensitive technique for the quantitation of Pi in solution through continuous 
spectrophotometric measurement (PiStar-180 spectrometer, Applied Photophysics) of 
ATPase activity. Release of Pi into the assay medium from ATPase-based ATP 
hydrolysis initiates phosphorolysis of an artificial substrate (MESG) by PNP (purine 
nucleotLde pho~phorylase). The product of-the phosphorolysis reaction is chromophoric 
and is detected by a change in absorbance from 330nm to 360nm. ATPase activity can 
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therefore be monitored as an increase in absorbance at 360nm over time with readings 
corrected against a phosphate deficient control. 
Standard curve for the EnzChek phosphate assay 
In brief, a standard curve was generated by adding variable amounts of a phosphate 
standard (0 -128~M) into the following experimental reaction: 
dHzO 
20x reaction buffer 
MESG substrate solution 
Phosphate standard (KH2P04) 
PNP 
740~1- x ~I (1ml final assay volume) 
50~1 
200~1 
X ~I 
10~1 
Components were added in order as listed above and the mixture incubated in a 
thermostatically controlled heat block at 22°C for 30 minutes. The absorbance for each 
sample was determined at 360nm (Abs360) and corrected against background absorbance 
using a no-phosphate control. A standard curve was generated using known amounts of 
phosphate (nmoles) plotted against the Abs36o using linear regression. 
Pi released continuously by enzymatic reaction 
The kinetics of Pi released during ATP hydrolysis by 1~M ATPase were monitored 
continuously using a PiStar-180 spectrometer (Applied Photophysics, UK). Sample 
handling was maintained at 25°C and the monochromator set to an absorbance of 
360nm. 
The system was calibrated using the standard reaction (as above) in the absence 
of phosphate to ensure an absorbance signal was registered. To ensure lamp stability 
was maintained, the system was also calibrated with a standard reaction incorporating 
lmM ATP. 
The experimental reaction proceeded as follows. Two 1.5ml microtubes (A and 
B) were prepared containing the standard reaction mixture, one in the presence of 2~ 
ATPase only (tube A) and the other in the presence of 2mM ATP only (tube B). 
Mixtures were pre-incubated at 22°C for 10 minutes then loaded into separate drive 
syringes of the kinetic sampling handling unit (KSHU). Four shots containing 50~1 
volumes of each sample were mixed in a 100~1 cuvette and driven through the system 
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for equilibration. A fifth shot was used to record the change in absorbance at 360nm due 
to the phosphorylase-catalysed reaction of MESO with Pi released from the hydrolysis 
of lmM ATP by 1~M ATPase, over a period of 600 seconds (10 minutes). A control 
was conducted as described previously, simply by preparing the 20x reaction buffer and 
omitting the 20mM MgC12. The values determined for the control were subtracted from 
the experimental values to adjust for spontaneous ATP hydrolysis. Linear regression 
was used to determine the amount of Pi present in each sample, which was then used to 
calculate enzymatic A TPase activity in nmoles/minlmg. 
2.13.6 Stopped-flow fluorescence spectroscopy 
Stopped-flow fluorescence spectroscopy and data collection was achieved usmg an 
Applied Photophysics (London, UK) SX.18MV stopped-flow instrument. Stopped-flow 
spectroscopy is an established technique used for the monitoring of transient changes in 
protein fluorescence in real-time upon substrate interaction. This technique was used for 
the detection of intrinsic fluorescence by naturally occurring fluorophores, tryptophan 
and tyrosine residues within the protein, upon DNA and substrate interaction. Binding 
of substrate to protein induces a conformational change causing a change in 
fluorescence due to movement of the aromatic residues. Different fluorescence profiles 
can therefore be detected between protein-substrate complex and that of liberated 
protein or substrate. 
Samples were sterilised through 0.22~m membrane filters or centrifuged at 13K 
rpm for 1 minute prior to conducting stopped-flow. Protein and substrate were 
introduced into separate reservoirs and effervescent removed by through repeat purging 
and filling of reservoirs in a controlled manner until no visible bubbles detected. A 
circulating water cooler maintained temperature of samples in reservoir at 25°C. The 
instrument was primed with protein sample in buffer, the photomultiplier tube voltage 
was increased to 4V, and the baseline readjusted. Sequential mixing of 100~1 of protein 
and substrate was achieved through purging of reservoir by nitrogen-driven syringe 
pistons. Samples were combined in a mixer chamber before entering an observation cell 
and then into a receiving syringe. Once the receiving syringe was filled completely, the 
flow was suddenly impeded and a trigger activated the software to acquire data. Within 
the observation cell an excitation light-source of 285nm was supplied by an argon lamp 
and dual monochromators connected in series. Fluorescent emission was monitored at 
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wavelengths above 335nm using a cut-off filter. Changes from baseline of the impeded 
solution in the tube were recorded as a function of time. 
2.14 
2.14.1 
Structural methods 
Circular Dichroism Spectroscopy 
Circular dichroism (CD) spectroscopy, is a structural technique used for the 
measurement of conformational changes in secondary structure of proteins in solution. 
CD spectroscopy and data collection was achieved using an Applied Photophysics 
PiStar-180 Kinetic CD instrument. 
Optical rotation exhibited by the bases of DNA (dextrorotary) and the amino acids 
of proteins (levorotary) due to their asymmetry, impart a distinct CD spectra, which is 
representative of their secondary conformation. Secondary structure observations by CD 
spectroscopy occurs in the far-ultraviolet (UV) region (190-250nm) due to the detection 
of Pi to Pi star transitions of the chromophores of both DNA and proteins in this region. 
Strong absorption of light by oxygen in the air in this region was such that CD 
experiments were resolved under pure nitrogen gas. This technique was also used for 
detecting conformational changes in secondary structure as a function of DNA and/ or 
substrate. 
Total protein required for performing CD spectroscopy was 0.15-2mg/ml (lml 
protein in solution with Abs280 of 0.5-1 ). Protein buffers consisting of high 
concentrations of imidazole or reducing agent were generally buffer exchanged or 
diluted into suitable buffers that did not interfere with absorption at critical points in the 
far-UV spectrum. All dH20 and buffers used were sterilised through a 0.2~Jm filter and 
degassed under vacuum with vigorous stirring for 30-45 minutes or until no visible 
effervescent detected. The buffers used consisted of 20mM Tris, pH adjusted to 8.25 
with sulphuric acid and lOOmM sodium fluoride (NaF). Chloride ions were eliminated 
from buffers by substitution of NaCl for NaF and pH adjustment was conducted with 
sulphuric acid rather than HCl. The basis for substitution was due to the fluoride ion 
absorbing less in the far-UV range (260-320nm), therefore reducing interfering or 
masking signals. To achieve adequate signal to noise ratio and for baseline adjustment 
the CD spectra was run for 2-3 hours. 
CD spectroscopy is not an accurate determinate of structure as the technique only 
estimates the overall percentage of secondary structure and cannot identify which 
residues are involved in certain structural configurations. Therefore data generated from 
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CD spectroscopy is normally used to compliment structural information of proteins 
generated from x-ray crystallography. 
2.14.2 Analytical Size Exclusion Chromatography (SEC) 
Analytical size exclusion chromatography (SEC) was used to determine statistical 
average molecular weights and molecular weight distribution of polymer complexes 
(see chapter 6). Analytical SEC of putative regulatory protein with promoter DNA was 
performed (see chapter 6) on an AKTA Purifier (Amersham Biosciences) using a 
Superdex200PC3.2/30 column (Amersham Biosciences) as per manufacturer's 
instructions. 
All dH20 and buffers used were sterilised through a 0.2jlm filter and degassed 
under vacuum with vigorous stirring for 30-45 minutes or until no visible effervescent 
detected. Column storage buffer was removed by equilibration with 3 column volumes 
of dH20 at a flow rate of 20-40jlllrnin prior to use. The column was then re-equilibrated 
with 3-4 column volumes running buffer or until the baseline remained stable. The flow 
rate used was .:540jll/rnin, which was dependent on the buffer composition, temperature 
and the purity of the sample(s) used. Resolution of samples improved with .:550jll 
sample injection followed by a bolus injection of buffer. DNA and protein elution 
profiles were monitored at 260nm (Abs26o) and 280nm (Abs280), respectively. 
The Mr of protein ± DNA complex was calculated from a calibration curve 
constructed using a series of molecular weight standards of ribonuclease A (15.6KDa), 
chymotrypsinogen A (22.8KDa), ovalbumin (48.9KDa), albumin (65.4KDa), aldolase 
(158KDa), catalase (232KDa), ferritin (440KDa) and dextran blue (void volume). The 
Kav values were calculated using their elution volumes (Ve), total bed volume of 2.4ml 
(V1) and the void volume (V0 ) in the equation Kav= (Ve-V0 )/(V1-V0 ). A calibration curve 
of log of the Mr of the standards versus their Kav values was plotted. 
2.14.3 Colorimetric Assay 
The colorimetric assay (Butler et al, 2004) was used to determine the concentration of 
detergent bound to protein through detection of the sugar component of the detergent 
(see chapter 6). 
A colorimetric assay was performed as follows: 
1. Purified protein was concentrated by anion exchange chromatography and the peak 
fraction collected for the colorimetric assay. 
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2. A sample of the anion exchange wash buffer was collected and used as a blank for 
correction of background during absorbance measurements. 
3. The concentration of protein (diluted 1 in 10) was determined by Coomassie 
(Bradford) protein assay (Pierce). 
4. In brief, a 60J.!l sample (diluted 1 in 5 or 1 in 10 with buffer from anion exchange) 
was mixed with 300J.!l 5% (w/v) Phenol. 
5. 720Jll of concentrated sulphuric acid was added and immediately vortexed for 5 
minutes (NB- This is a highly exothermic reaction). 
6. Samples were left to cool for 30 minutes. 
7. The absorbance was measured at 490nm using the anion exchange wash buffer 
(prepared as in points 4 to 6) as a background blank. 
8. A standard curve was plotted of various amounts of DDM (0, 4, 8, 12, 16, and 
20J.!g). 
9. Samples were prepared in triplicate. 
10. The molar ratio of detergent to protein was then calculated. 
2.14.4 Crystallisation 
Crystallography is an important tool for the structural determination of complex 
biological macromolecules through the use of X-ray diffraction for analysing atomic 
arrangement of crystals. 
Proteins especially those from the membrane are notoriously difficult to 
crystallise due to their diverse biochemical and biophysical properties. Obtaining 
sufficient quantities of protein for commencing crystallisation may be a challenge in 
itself! Those who succeed in the first hurdle often have limited quantities of crystal 
grade protein and are burdened with the number of combinations of experimental 
conditions available for crystallisation. For these reasons, proteins are often initially 
subjected to sparse crystal screening of a broad range of parameters to identify new 
crystallisation conditions. This can be achieved using a number of commercially 
acquired sparse matrix crystallisation screening kits (Emerald Biosystems, Hampton 
Research Molecular Dimensions and Qiagen). Commercial sparse matrix screening kits 
used (see chapter 7) were Wizard I and II (EBS-WIZ-1&2, Emerald Biosystems), 
PEG/Ion screen (HR2-126), and Grid screens PEG/LiCl, NaCl, ammonium sulfate, and 
PEG 6000 (HR2-217, 219,211 and 213, respectively, Hampton Research) and Structure 
screens 1 and 2 (Molecular Dimensions Ltd). 
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2.14.4.1 Vapour Diffusion by Hanging Drop Technique 
Crystallisation trials were undertaken (see chapter 6) using 24-well crystallisation 
supports and tools (EasyXtal, Qiagen). In brief, a small volume of protein solution was 
mixed with an equal amount of precipitant solution from the reservoir on a 
crystallisation support. The support was carefully inverted, secured and sealed to the 
crystallisation tool so to produce a hanging drop suspended above a reservoir of 
solution. Small drop volumes of 1 -lOJ.ll begin to equilibrate with larger lOOJ.ll -lml 
volumes of precipitant reservoir solution, causing supersaturating conditions of protein 
and induction of crystallisation in the drop. The screens were incubated at temperatures 
of 4 and l6°C in a vibration free environment and the crystallisation drops monitored 
intermittently by light microscopy to identify different stages of crystallisation. 
2.14.4.2 Preliminary, Custom and Optimisation of Crystallisation 
Firstly, preliminary crystallisation conditions using high purity, homogeneous protein 
preparations, were established using a sparse matrix screen. Secondly, modifications of 
biophysical and chemical properties of established crystallisation conditions allow 
supersaturation to be approached more slowly. Thirdly, optimisation using biological 
additives, is aimed at obtaining crystals that are of X-ray diffraction quality (diffract to 
3 angstroms resolution or less). These methods were applied during the crystallisation 
of a regulatory protein (see chapter 6). 
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Chapter 3 Analysis of the Vibrio cholerae antibiotic 
resistance operon 
3.1 Sequence analysis of the Vibrio cholerae antibiotic resistance operon 
The structural and functional properties of the proteins from the V. cholerae antibiotic 
resistance var operon (figure 3.1) were predicted through the analysis of their amino 
acid sequences using the PredictProtein (Rost et al., 2004) and Jpred (Cuff et al., 1998) 
servers and through BLAST (Altschul et al., 1997; Schaffer et al., 2001; Marchler-
Bauer & Bryant, 2004) searches of the NCBI database (protein-protein BLAST, blastp 
and conserved domains, rpsblast) and the Research Collaboratory for Structural 
Bioinformatics protein data bank (RCSB PDB). Multiple alignments were performed 
with proteins of known function in order to elucidate similarly conserved domains that 
would aid their characterisation. Identified protein matches were given an expectation 
value (E-value) representing the significance of the alignment (alignments with E-
values ~ 0.001 are deemed significant and are unlikely to occur by chance). 
Figure 3.1 
vatR 
VC1581 
A diagrammatic representation of the var operon. The locality of the 
~-lactamase, varG, the MDR varABCDEF transporter complex and the 
divergently transcribed regulatory varR genes are shown. Arrows 
indicate orientation of transcription. Three intergenic regions varRG, 
varGA and varBC to which V arR is hypothesised to regulate 
transcription are also illustrated. Diagram is not to scale. 
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The nucleotide sequences of the varR (VC1561) and varG (VC1562) genes belonging 
to segment 141 of 251 of chromosome I and are deposited in the GenBank genetic 
sequence database under the accession number AE004233. The nucleotide sequences of 
the varA (VC1563), varB (VC1564), varC (VC1565), varD (VC1566), varE (VC1567) 
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and varF (VC 1568) genes belonging to segment 142 of 251 of chromosome I and are 
deposited in the GenBank database under the accession number AE004234. 
Current literature has acknowledged the emergence of antibiotic resistance in V. 
cholerae so the identification of this novel var MDR operon does not come as a 
revelation. Antibiotic resistance in V. cholerae is largely controlled by secondary 
transporters who mediate the extrusion of structurally diverse drugs in a coupled 
exchange with ions (Colmer et al., 1998; Kazama et al., 1998, 1999; Huda et al., 2001, 
2003; Begum et al., 2005; Woolley et al., 2005). However, the var system utilises an 
ABC-type transporter requiring A TP as its main energy source for efflux, therefore 
structural elucidation of this system would be the first of its kind in V. cholerae. The 
exceptional attribute of the var operon is the presence of a secondary antibiotic defence 
mechanism in addition to the ABC-transport system in the form of a P-lactamase giving 
further resistance against a broad range of P-lactam antibiotics. If these two systems 
were to act symbiotically under the sole regulation of VarR, the result would be a potent 
transport mechanism capable of conferring resistance to a broad range of antimicrobial 
agents. It is therefore of my perspective that V. cholerae is evolving, adapting itself with 
more robustly conserved systems, crucial for tackling the moderate escalating pressures 
that threaten its survival. Functional and structural characterisation of the putative V. 
cholerae antibiotic resistance var operon is therefore imperative for determining the 
potential pathogenic ability and to map future treatment paths for this pathogen. 
In this chapter, we will analyse the amino acid sequences of all components of 
the var operon to identify conserved motifs that enable us to ascertain the functional and 
structural potentials of these proteins. Gapped amino acid sequence alignments of the 
translated V. cholerae var operon genes with proteins of similar function will also be 
conducted to determine whether sequence homology reflects conserved function. The 
three intergenic regions will also be analysed to identify putative sites for which the 
regulatory protein, V arR, is hypothesised to bind. 
119 
3.2 The regulatory protein, VarR (ORF VC1561) 
The ORF VC1561 was designated varR and consists of 930bp that encodes a protein, 
VarR of 309 amino acids (calculated molecular weight (Mr) of 35938.39 Daltons). The 
amino acid sequence is deposited in GenBank database under accession number 
AAF94715. 
3.2.1 The VarR sequence from V. cholerae Nl6961 
Comparison of amino acid sequences of L TTRs have shown that these proteins 
encompass sequence similarities throughout the vast proportion of the polypeptide with 
the strongest similarities are detected in the first 66 residues of the N-terminus. Amino 
acid sequence analysis of VarR using the previously described prediction methods has 
identified three putative conserved domains characteristic of members from the LysR-
type transcriptional regulatory (LTTR) family. The conserved domains include the N-
terminal DBD (residues 1-64), the LysR region (residues 29-305) and the C-terminal 
substrate binding domain (residues 100-300). Identified within the N-terminal DBD of 
VarR was a highly conserved HTH motif (PROSITE entry: PS00044) common to all 
transcriptional regulatory proteins (Bairoch et al., 1997). VarR can therefore be 
classified as a member of the LTTRs. 
Amino acid alignments of VarR with the sequences of LTTRs (Agrogacterium 
tumefaciens OccR Q00679; E. coli OxyR P11721; K. aerogenes CysB P45600; P. 
putida CatR P20667, ClcR Q05840, NahR P10183; and R. eutropha CbnR Q9WXC7) 
have identified identical conserved residues highlighted in red in figure 3.2 (sequence 
alignments not shown). Conserved residues identical in >50% of aligned sequences are 
highlighted in blue and those similar in >50% of aligned sequences in green. 
Figure 3.2 Amino acid sequence of VarR. The predicted secondary structure 
elements of V arR are drawn above the amino acid sequence with the a-
helices and P-sheets depicted as zigzag shapes and turquoise boxes, 
respectively. The predicted HTH structural motif (a2 and a3) is coloured 
red. The sequence encoding the predicted DBD is represented by a blue 
arrow, the dimerisation a-helix by a green arrow and the SBD by a red 
arrow. The most highly conserved residues in the HTH motifs of LTTRs 
have been identified in V arR and are as follows: alanine at HTH position 
5 (LTTR position Ala32), serine, glutamine and proline at HTH position 
11, 12 and 13, respectively (Ser38, Gln39 and Pro40, respectively), 
valine and serine at 1ITI:I position 15 and 16, respectively (Val42 and 
Ser43) and leucines at HTH position 19 and 22, respectively (Leu46 and 
Leu49) (Henikoff et al., 1988; Schell, 1993). The hydrophobic residues 
Val42, Leu46 and Leu49 may cluster to form a hydrophobic core of the 
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DNA-binding domain as described for CbnR (corresponding residues 
Leu39, Leu43 and Leu47). 
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Similar to the residues of CbnR (Ala22 and Pro30), the residues Ala32 and Pro40 of 
VarR may be important for recognition and interactions with the target DNA (Muroaka 
et al., 2003). This can be substantiated by mutational analysis of these conserved 
residues that result in the loss or reduced regulatory function including co-inducer 
stimulated transcriptional activation consequently from a loss of DNA-binding (Schell, 
1993). As VarR is hypothesised to act as a regulator to an adjacently encoded ~­
lactamase (discussed in chapter 5), a glycine residue at position 101 or 106 has been 
identified and is known to exist in all enterobacteriacae ~-lactamase regulators (Nass et 
al., 1995). Mutagenesis of this residue increases the ability of the regulator to act as a 
transcriptional activator for the ~-lactamase in the absence of ~-lactam inducers. 
The C-terminal domains of LTTR proteins tend to show less sequence 
conservation possibly as a consequence of substrate diversity between LTTRs. Co-
inducer recognition and possibly binding by LTTRs involves residues 95-173, which 
may function as a general substrate-binding pocket with specificity being conferred by 
surrounding less conserved residues (Schell, 1993). Consistent with this observation, a 
tripeptide motif, S-X-N (corresponding to Ser204 and Asn206 of VarR) that is 
conserved in penicillin-binding proteins (Fisher et al., 2005) has been identified within 
the proposed co-inducer recognition! binding site of VarR. The serine residue of this S-
X-N motif is suggested to be required for back-donation of a proton to the nitrogen 
atom of the ~-lactam ring after formation of an intermediate (Fisher et al., 2005). 
However, VarR does not possess other motifs such as KTG that are present in ~­
lactamases (Naas et al., 1995). The presence of a putative ~-turn-~ ligand-binding 
crevice motif (residues approximately 151-170) in VarR may also represent the co-
inducer recognition site. 
The extended sequence similarity among members of the LTTR family strongly 
suggests that they may share the same tertiary structure. This can be exemplified by the 
secondary structure prediction of VarR (figure 3.3), which shows a topological 
arrangement similar to that of the only full length structurally determined LTTR, CbnR 
(Muroaka et al., 2003). In general, three a-helices and a ~-strand form the DBD, a4 is 
hypothesised to form the putative dimerisation helix and links the SBD, which is 
formed from two ~-sheets (5 ~-strands each) surrounded by a minimum of three a-
helices each. This overall fold is consistent with predictions of protein globularity that 
suggested VarR to--be of a compact globular architecture (Rost et al., 2004). The 
predicted topological arrangement of the C-terminal of V arR is also consistent with the 
arrangements of other structurally characterised C-terminal LTTR proteins (Tyrrell et 
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al. , 1997; Choi et al., 2001 ; Stec et al. , 2006). Using the knowledge gained from these 
structures and the mutational analysis used to determine the binding-site in these 
LTTRs, the putative substrate-binding site for VarR may therefore reside between SBR-
I and SBR-II. 
Figure 3.3 
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Schematic illustration of the putative topological arrangement of the 
secondary structure of a VarR monomer. Cylinders and arrows 
represent a-helices and ~-strands, respectively. Red cylinders represent 
the HTH motif. 
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3.2.2 Amino acid sequence homology of VarR 
Using the NCBI database a protein-protein BLAST (blastp) of the amino acid sequence 
of V arR identified 100 matches (Altschul et al., 1997). The majority of these matches 
were uncharacterised, hypothetical proteins identified during genome sequencing 
projects. Of these only five proteins showed alignment of~ 200 amino acids with V arR. 
The highest scoring match was a LTTR protein from V. cholerae that exhibited a near 
perfect identity of 99% and similarity of 100%. The second and third matches were 
hypothetical LTTRs also from V. cholerae that also exhibited near identical identities of 
97% and 94% and similarities of 99% and 98%, respectively. However, due to their 
uncharacterised status they cannot be used to infer a function for VarR. The remaining 
two matches were LTTR proteins from V. vulnificus that both showed an identity of 
88% and similarities of 94% and 93%, respectively. The immense degrees of homology 
exhibited by the first and final two matches with V arR infer a similar function for V arR 
as that of a LTTR protein. 
Accession# Description Organism E-Value 
EAY40569 Transcriptional regulator LysR family V. cholerae 3e-171 
gil116217788 VchoR_02000507 protein* V. cholerae 3e-167 
gil116219008 VchoV5_02002863 protein* V. cholerae 4e-162 
AA008368 Transcriptional regulator LysR family V. vulnificus 5e-152 
BAC96347 Transcriptional regulator LysR family V. vulnificus 1 e-150 
*Hypothetical protein 
To determine if V arR showed similarities to other LTTRs that regulate serine P-
lactamase activity, the amino acid sequence of VarR was aligned with the well 
characterised proteins, AmpR from Citrobacter freundii (AAA64510) and Enterobacter 
cloacae (X04730) and BlaA from Proteus vulgaris (BAA07083) and Streptomyces 
cacoai (P33651 ). The alignments failed to identify any significant patches of analogous 
sequences (data not shown). However, the conserved residues Ala32, Ser43, and Leu49 
were identified at theN-termini of the aligned LTTRs, which is a characteristic trait of 
the presence of a universally conserved HTH motif within the DBD. These residues are 
often conserved as they mediate specific binding to a common structural motif at their 
regulated promoters. The dissimilarities in the reJ.!1ainder of the LTTR sequence 
alignments could be associated with the type of P-lactamase being regulated, as VarR is 
aligned against LTTR proteins involved in the regulation of serine P-lactamases 
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(Ambler class C). However, VarR is hypothesised to regulate a different class of P-
lactamase that belong to the metallo-P-lactamases (Ambler class B). These P-lactamases 
have very different substrate specificities (Garcia-Saez et al., 2003), which would 
account for the differences seen in the C-terminal halves of the LTTRs (substrate 
recognition and binding region) that regulate them. 
As mentioned previously, the serine P-lactamases and metallo-P-lactamases 
(MPls) are two very different enzymes that show little or no sequence or structural 
homology (Ambler, 1980). This may be due to the different mechanisms adopted for 
cleavage of the amide bond of the P-lactam ring. Serine P-lactamases utilise an active-
site serine to catalyse hydrolysis of the P-lactam bond whereas MPls have broader P-
lactam profiles (including the highly P-lactamase resistant carbapenems) stemming 
apparently from the utilisation of up to two bivalent Zn2+ ions in the active site (Garau 
et al., 2005; Xu et al., 2006). The active sites of serine-P-lactamases and penicillin 
binding proteins contain the sequence Ser-X-X-Lys, in which the serine is acylated by 
the P-lactam (Fisher et al., 2005; Wang et al., 2006). However, VarR does not contain 
this conserved sequence and therefore can be assured of being a MPL 
Consequently the V arR regulator may have evolved from the well characterised 
AmpR-AmpC regulatory system (Lindquist et al., 1989), as a result of selective 
pressures through the increased use of carbapenems. Carbapenems were introduced as a 
result of increased resistance against currently available P-lactams, showing strength 
against most P-lactamase-producing Gram-negative organisms (Rang et al., 1999). To 
date, the structure of the well known AmpR protein has yet still to be elucidated even 
after its function has been extensively studied. This thesis therefore proposes a 
regulator, VarR, which like AmpR is from the LTTR family, and seems to show a 
similar mechanism of induction of a P-lactamase (see later sections). However, this P-
lactamase is an alternative to the well characterised serine P-lactamases (Fisher et al., 
2005) that includes AmpC. This MPl, V arG will be discussed in more detail in the next 
section. 
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3.3 The ~-Iactamase, VarG (ORF VC1562) 
The ORF VC 1562 was designated as varG and consists of 1173bp that encodes M~l 
(Ambler class B), VarG of 360 amino acids (calculated Mr of 43591.52 Daltons). The 
amino acid sequence is deposited in GenBank database under accession number 
AAF94716. 
Many opportunistic and pathogenic bacteria from environmental habitats 
ubiquitously carry M~ls hypothesised to be acquired as a consequence of exposure to ~­
lactams or ~-lactam compounds over long periods of time. These M~l genes can be 
inducible and bacteria harbouring them can become highly resistant to ~-lactam 
antibiotics (Walsh et al., 2005). 
Chromosome one of V. cholerae 01 Biovar Eltor strain N16961 was analysed for 
additional chromosomally encoded ~-lactamases, however VarG was the only ~­
lactamase to be found. Interestingly, a clauvulanic acid synthase (CAS) gene, pvcB, 
gene locus VC1944 was identified on the same chromosome as VarG. Clavulanic acid 
is an inhibitor of ~-lactamases from classes A, C, and D, but not those of the M~l class 
B. This is surprising as chromosomally mediated M~ls are often coregulated with serine 
~-lactamases (Walsh et al., 2005). V. cholerae may have therefore developed a 
defensive mechanism against other bacterial strains expressing serine ~-lactamases 
(classes A, C or D) or may have evolved mechanisms to enable it to adapt to selective 
pressures resulting in its continued existence. For example, in the presence of ~-lactam 
antibiotics, V. cholerae may produce clauvulanic acid to eradicate competitive bacteria 
through inactivation of their serine ~-lactamases, allowing M~l possessing V. cholerae 
to survive in the face of adversity. 
M~ls are of fast emerging clinical importance (Fritsche et al., 2005; Thomson 
and Bonomo, 2005) owing to their ability to hydrolyse all existing ~-lactams including 
the newer generation cephalosporins and carbapenems. To exacerbate the situation the 
activity of these enzymes cannot be neutralised by ~-lactamase inhibitors such as 
clavulanate and penam sulfones, which are important for the treatment of Gram-
negative resistant infections (Wang et al., 1999; Fisher et al., 2005). 
3.3.1 The VarG sequence from V. cholerae Nl6961 
Although members of the M~l family exhibit considerable sequence diversity, they do 
share some degree of conserved sequences within the active sites of the enzyme. The 
conserved nature of the active sites in M~ls is such that the architecture can be virtually 
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super imposable on one another. Conserved residues are involved in forming 
interactions with one (monozinc-M~ls) or two (bizinc-M~ls) Zn2+ ions and exhibit a 
hallmark consensus sequence for two active sites (Zn1 and Zn2) of 
HXHXD(X)aH(X)bC(X)cH where X indicates any amino acid, a=55-74, b=18-24 and 
c=37-41 intervening residues, respectively (Wang et al., 1999). 
Amino acid alignments of V arG with the sequences of other M~ls (A. 
hydrophilia CphA CAA40386; B. cereus Bell AAA22276; B. fragilis CerA 
AAA22904; C. meningosepticum BlaB BAA07084; P. aeruginosa Imp-1 P52699; and 
S. maltophilia L1 CAA52968) have identified identical residues (highlighted in red in 
figure 3.4). Conserved residues identical in >50% of aligned sequences are highlighted 
in blue and those similar in >50% of aligned sequences in green. 
Residues His152, His154, Asp156, His238, Asp257, His301 of the conserved 
zinc binding motif in V arG have been identified and are highlighted in red. This zinc 
binding motif is hypothesised to form two metal-binding sites in VarG with residues 
His152, His154 and His238 forming the Znl site and residues Asp156, Asp257 and 
His30 1 form the Zn2 site. 
The absence of the single conserved cysteine in the consensus sequence of V arG 
(C257D) may affect binding affinity for Zn2+ compared to other M~ls with the complete 
motif. However, the role of the conserved cysteine in mono- and bizinc-M~ls for the 
coordination and binding of Zn2+ is not well understood. In monozinc-M~ls, the 
cysteine and an aspartic acid residue of the Zn2 site may be required for coordination of 
a Zn2+ and a water molecule for the formation of the Zn2+-hydroxide complex at Znl. In 
bizinc-enzymes it is understood that the cysteine residue is necessary for only binding 
of Zn2+ at the Zn2 site (Concha et al., 1996). However, mutational analysis has 
suggested the irrelevance of this cysteine for binding and hydrolysis in the bizinc 
enzyme as the respective cysteine was substituted and still demonstrated the ability of 
the mutant to bind two Zn2+ ions (Paul-Soto et al., 1999; Xu et al., 2006). Therefore 
monozinc ~-lactamases may require the conserved cysteine residue for efficient binding 
of Zn2+ for hydrolysis of the ~-lactam ring in contrast to the bizinc-enzyme where the 
cystine residue is not essential. This may therefore represent an evolved mechanism for 
some bizinc-M~ls that do not require the conserved cysteine (Paul-Soto et al., 1999). It 
must be noted that possession of one or two zinc ions does not significantly alter the 
catalytic efficiency of either mono- or bizinc enzymes; rather it is its ability to bind Zn 
that may be the limiting factor. 
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Figure 3.4 The amino acid sequence of VarG showing the conserved Zn2+ -binding 
residues of the hallmark consensus sequence (highlighted in red). Other 
exact conserved residues are highlighted in blue. Potential conserved 
residues highlighted green. The predicted secondary structure elements 
of VarG are drawn above the amino acid sequence with the a-helices and 
~-sheets depicted as zigzag shapes and turquoise boxes, respectively. 
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Regardless of the low sequence homology of M~ls, the overall folds of these enzymes 
are very similar adopting a a~/~a sandwich structure (figure 3.5) comprising of two ~­
sheets at the core and five a-helices on the external faces (Wang et al., 1999). The 
structure of M~ls is different from that of the serine ~-lactamases which adopt a a/~a 
sandwich arrangement. This could account for the differences in mechanism of 
hydrolysis between the two enzyme classes. Hydrolysis by serine ~-lactamases is 
initiated by an active serine residue, Ser70, located in the active site at the interface 
between the a and a~ domains (Wang et al. , 2006). Hydrolysis by M~ls is initiated at a 
zinc active site located between the two ~-sheets (Wang et al., 1999). In comparison to 
the serine ~-lactamases, the accommodating nature and the relative ease in the 
accessibility of the active site of M~ls may provide the structural basis for their broad 
substrate profiles (Wang et al., 1999). 
Figure 3.5 
A 
Structures of M~ls from (A) B. fragilis 1ZNB, (B) B. cereus 1BVT, and 
(C) S. maltophilia 1 SML. Zinc ions are represented as green spheres and 
the sodium ion in the B. fragilis structure is shown in yellow. Adapted 
from Wang et al., 1999. 
B c 
B. tragi/is B. cereus S. maltophilia 
Like other M~ls, the secondary structure prediction of V arG suggests a tertiary a~/~a 
structure is adopted, comprising two core ~-sheets surrounded by 10 a-helices (figure 
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3.6). The overall arrangement is consistent with predications of protein globularity that 
suggest VarG is of a compact globular structure (Rost et al., 2004). 
Figure 3.6 
N 
3.3.2 
Schematic illustration of the putative topological arrangement of the 
secondary structure of the VarG monomer. Cylinders and arrows 
represent a-helices and ~-strands, respectively. 
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Amino acid sequence homology of VarG 
Analysis of the amino acid sequence of VarG using the NCBI database blastp program 
has identified 100 homologous matches (Altschul et al., 1997). Of these only seven 
proteins showed significant alignments of ~ 200 amino acids with V arG and are listed 
on the following page. The highest scoring functional match was a zinc-dependent 
hydrolase from V. cholerae that exhibited a near perfect identity of 99% and similarity 
of 99%. The second and third matches were hypothetical proteins also from V. cholerae 
that both exhibited near identical identities of 98% and similarities of 99%. However, 
due to their uncharacterised nature these proteins cannot be used to infer a function for 
VarG and so will not be mentioned in this context in latter sections. The remaining three 
matches were Zn-dependent hydrolases, two of which were from V. vulniflcus and the 
last alignment from V. cholerae. The two hydrolases from V. vulniflcus both showed an 
identity of 82% and similarities of 90% and 91%, respectively. The hydrolase from V. 
cholerae exhibited an identity and similarity of 99%. 
Limiting the BLAST search to the RCSB protein data bank database, 40 close 
sequence M~l homologues for VarG were identified withE-values of less than 0.0001. 
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These include Bacillus fragilus CerA (RCSB PDB: 4ZNB and GenBank: AAA22904) 
and B. cereus Bell (RCSB PDB: 1DXK and GenBank: AAA22276), both withE-values 
of 2e-06. 
Accession# Description Organism E-Value 
giJ75826923 Zn-dependent hydrolase V. cholerae 0.0 
gil116217787 V choR_ 02000506* V. cholerae 0.0 
giJ116219007 VchoV5_02002862* V. cholerae 0.0 
BAC96346 Zn-dependent hydrolase V. vulnificus 0.0 
AA008367 Zn-dependent hydrolase V. vulnificus 0.0 
EAY40555 Zn-dependent hydrolase V. cholerae 4e-141 
The immense degrees of homology exhibited by the first and final three matches with 
VarG and the homologues identified from the RCSB PDB infer a similar function for 
VarGas that of a Zn-dependent hydrolase of the MPl class. 
MPls are further classified into three subgroups, B 1, B2 and B3 according to the 
Ambler classification. Subgroups B 1 and B2 are generally grouped together due to 
shared sequence homology. Subgroup B3 on the other hand is grouped separately from 
B 1 and B2 due to minimal sequence homology. However, substitutions in the conserved 
residues of the Zn2+ -binding sites have enabled some distinction between the three 
subclasses. In Zn1, the standard consensus sequence involving three histidines can be 
found in subclasses B 1 and B3, but a histidine residue is replaced by an asparagine in 
subclass B2. In Zn2, the cysteine in the aspartic acid-cysteine-histidine triad is 
substituted by a histidine in the subclass B3 (Xu et al., 2006). 
However, analysis of the conserved zinc binding motif of VarG still does not be 
verify the subclass for which it belongs as residues show none of these substitutions. As 
sequence homology is disparate, sequence alignments between members of different 
subclasses would be unfeasible as the presence of these sequences would disrupt the 
proper alignment of sequences that are homologous to each other. 
The uncertainty regarding the subgroup for which V arG belongs and the overall 
considerable sequence diversity between groups of the MPls ensures that an alignment 
would not give an accurate functional or evolutionary assignment for VarG. Precise 
classification of V arG would require further experimental research into its biochemical 
properties as described in chapter 1 section 1.9.1 and subsequently in chapter 7. 
131 
3.4 The membrane fusion protein, VarA (ORF VC1563) 
The ORF VC1563 was designated as varA and consists of 1014bp that encodes a 
protein, VarA of 338 amino acids (calculated Mr of 36816.60 Daltons). The amino acid 
sequence is deposited in GenBank database under accession number AAF94 717. 
3.4.1 The VarA sequence from V. cholerae Nl6961 
Preliminary analysis of the VarA amino acid sequence indicated conservation with a 
novel class of export proteins designated the membrane fusion protein (MFP) family 
(Schneider and Hunke, 1998). 
Consistent with current literature in which MFPs are anchored to the membrane 
by a single transmembrane helix or by N-terminal lipid modification (Higgins et al., 
2004 ), the secondary structure predictions of VarA have identified a single 
transmembrane helix (residues 3-25) at theN-terminal. Topological observations predict 
the first 15 residues of the N-terminus that includes a proportion of the cytoplasmic 
membrane spanning a-helix (residues 3-14 ), is located in the cytoplasm. The remainder 
of the protein extends across the membrane (residues 15-32) and into the periplasm 
forming the characteristic large periplasmic domain (residues 33- 338) (figure 3.7). 
This is similar to the predicted topology of HlyD, a MFP associated within an 
ABC-type tripartite complex in the transport of haemolysin (Thanabalu et al., 1998). 
HlyD consists of a large periplasmic domain (residues 81-478) linked by a single 
transmembrane helix to a small N-terminal cytosolic domain (residues 1-59). Deletion 
of the cytoplasmic domain of HlyD disabled the export of haemolysin, although HlyD 
was still able to trimerise and interact with the substrate-bound ABC transporter, HlyB. 
Further analyses showed that failure of export was due to the inability of mutant HlyD 
to bind the substrate and that binding of substrate to the ABC transporter solely was not 
sufficient to recruit the OMP TolC. This suggests that substrate binding to the 
cytoplasmic domain of HlyD is essential for correct TolC assembly and export function 
(Balakrishnan et al., 2001 ). 
Conserved residues m VarA were identified by comparison of the aligned 
structures of several MFPs (E. coli AcrA BA£76242, HlyD AAN82022; N. 
gonorrhoeae MtrC CAA81046; H. influenzae EmrA P44928; and P. aeruginosa MexA 
P52477, MexC AAB41956, MexE AAG05881) from Johnson and Church (1999). 
Conserved residues that were identical in all aligned sequences are highlighted red, 
conserved residues identical in >50% of aligned sequences in blue and those similar in 
>50% of aligned sequences in green. The majority of conserved residues were located 
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in or near the predicted coiled-coil hairpin region (residues 75-185), inferring that this 
structure may be conserved throughout the MFP family. This would not be surprising as 
coiled-coils have been predicted for several MFPs (Johnson and Church, 1999). 
Figure 3.7 The amino acid sequence of VarA. The predicted secondary structure 
elements of VarA are drawn above the amino acid sequence with the a-
helices and ~-sheets depicted as zigzag shapes and turquoise boxes, 
respectively. Horizontal arrows drawn above secondary structure depict 
protein topology with regards to the inner membrane of a Gram-negative 
organism (Blue arrow indicates cytoplasmic domain, red arrow indicates 
membrane spanning domain and green arrow indicates periplasmic 
domain). 
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Secondary structure predictions of VarA suggest the presence of a-helical and ~­
sandwich domains that are characteristic features of MFPs (Johnson & Church, 1999). 
The a-helical domain consists of a long a-helix (a2) with the potential to form a 
coiled-coil hairpin and the ~-strands adjacent to this helix may form a lipoyl domain 
and either a ~-barrel or a pair of ~-sheets with a single a-helix (a3) restricting the 
entrance at one end (figure 3.7 and 3.8). This is consistent with predictions of protein 
globularity that suggest VarF may be of a globular nature (formed from residues of the 
periplasmic domain) but not as compact as a domain (Rost et al., 2004). The predicted 
structure of VarA presents a similar fold to that observed in the crystal structure of 
MexA (Higgins et al., 2004). Unlike HlyD, MexA has a lipoprotein modification signal 
and is hypothesised to insert into the cytoplasmic membrane by an attached lipid moiety 
(Johnson and Church, 1999). The hypothesised ~-domain nearest the putative a-helical 
hairpin is structurally homologous to lipoyl and biotinyl domains. Nonetheless, like 
HlyD, MexA associates with its cognate transporter, MexB (RND family) and a TolC 
homologue OprM to form a tripartite complex in P. aeruginosa (Li et al., 1995). 
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Figure 3.8 Schematic illustration of the putative topological arrangement of the 
secondary structure of the VarA monomer. Cylinders and arrows 
represent a-helices and P-strands, respectively. 
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3.4.2 Amino acid sequence homology ofVarA 
A CD search of VarA has identified the presence of a conserved domain exhibited in 
other MFPs including the previously mentioned HlyD, AcrA and EmrA (Marchler-
Bauer and Bryant, 2004). VarA shows closest conserved sequence homology with AcrA 
with an E-value of 2e-18, followed by EmrA (E-value 5e-12) and HlyD (E-value 5e-8). 
These MFPs are all involved in the formation of functional multi-domain systems, often 
with OMP TolC that mediates the export of multiple drugs and bacterial toxins. 
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Analysis of the amino acid sequence of VarA using the blastp has identified 100 
homologous alignments (Altschul et al., 1997). The majority of the homologous 
alignments showed unequivocally a conserved AcrA region. The first 17 proteins 
showed alignments of;;::: 200 amino acids with VarA (data not shown) with the first five 
characterised matches listed below. The two highest scoring functional matches were 
AcrA-like MFPs from V. cholerae that exhibited minimum identities and similarities of 
99%. The remaining three matches were AcrA-like MFPs from V. vulnificus and V. 
fischeri exhibiting minimum identities of 56% and similarities of 75%. 
Accession# Description Organism E-Value 
gil75826924 AcrA-Iike MFP V. cholerae Se-168 
EAY34826 AcrA-Iike MFP V. cholerae 1 e-166 
AA007917 AcrA-Iike MFP V. vulnificus 6e-113 
BAC97526 AcrA-Iike MFP V. vulnificus 2e-112 
AAW85656 AcrA-Iike MFP of efflux system V. fischeri 2e-90 
More distant alignments hint of a probable involvement with an ABC export or 
macrolide-specific efflux system with homologies compared to Gramella forsetii HlyD 
(CAL65187) and N. gonorrhoeae MacA (AAV85981) with identities of 26 and 25% 
and similarities of 49% and 50%, respectively (E-value 1e-26 and 2e-13, respectively). 
Limiting the BLAST search to the RCSB protein data bank database, a close 
sequence homologue for VarA was identified with an E-value of less than 0.0001. This 
homologue was identified as the MDR MFP, MexA (RCSB PDB: 1 VF7 and accession 
#: P52477) from P. aeruginosa with 21% identity and 41% similarity (E-value of 7e-
07). MexA is also a close sequence homologue of AcrA (Higgins et al., 2004). The 
similarity is sufficient to infer that the previously predicted topological arrangement of 
VarA is comparable to that of MexA. 
Summarised from the above alignments, VarA seems to have closest sequence 
similarity to AcrA orthologs. This is interesting as AcrA is associated with transporters 
of the RND family, whereas VarA is putatively associated with an ABC transporter. 
The homology exhibited by V arA with members from two different transporter 
families, namely the ABC associated MFPs, HlyD and MacA and the RND associated 
MFPs, AcrA and MexA, is perhaps not unexpected. MFPs form a broad family of 
conserved molecule~ (Higgins et al., 2004) and through a gapped-alignment of the MFP 
and lipoyl families, Johnson and Church (1999) have shown that the same residues are 
conserved in both separate and combined alignments of these families. 
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The immense degrees of similarity exhibited by homologues identified from the 
above alignments and the structurally characterised MexA infer a similar function for 
VarA as that of an AcrA-like MFP involved in the formation of a TolC-based export 
system. The TolC-like OMP, VarC, in which VarA is hypothesised to associate with, 
will be discussed in more detail in later sections. 
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3.5 The membrane fusion protein, VarB (ORF VC1564) 
The ORF VC1564 was designated as varB and consists of 120bp that encodes a protein, 
VarB of 40 amino acids (calculated Mr of 4132.46 Daltons). The amino acid sequence is 
deposited in GenBank database under accession number AAF94718. 
3.5.1 The VarB sequence from V. cholerae N16961 
No conserved residues or domains were detected in the amino acid sequence of VarB. 
(1) MVLIADGSAQ GYTAHPVKLG LSDGVQVEIL EGVAKRQHSG (40) 
VarB has been predicted to be not of a globular architecture (Rost et al., 2004). 
3.5.2 Amino acid sequence homology of VarB 
Analysis of the amino acid sequence of VarB using the NCBI database blastp program 
produced 21 significant alignments (Altschul et al., 1997). The majority of these 
alignments showed significant homology to the C-terminal regions (residues 299 
onwards) of both hypothetical and characterised MFPs. The first seven matches are 
listed below. Interestingly, the first three and last two alignments are with the C-
terminal domains of the same MFP proteins discussed in the previous section for VarA. 
However, there was no sequence homology detected between the hypothetical V arB 
MFP and the C-terminal domain of V arA. 
Accession# Description Organism E-Value 
gil75826924 VchoM_02002486 protein* V. cho/erae 3e-10 
gil116217786 VchoV5_02000505 protein* V. cho/erae 3e-10 
gil75815217 Membrane fusion protein V. cholerae 4e-10 
EAS66367 VAS14_13659 protein* V. angustum 2e-04 
EAR54138 SKA34_10258* Photobacterium sp. 3e-04 
BAC97526 Membrane fusion protein V. vulnificus 0.001 
AA007917 Membrane fusion protein V. vulnificus 0.001 
Therefore it is highly likely that VarB could be the result of a frame shift mutation 
leading to partial deletion and subsequent translation of a truncated C-terminal domain 
structure of a previously existent MFP. 
- - - ---
138 
3.6 The outer membrane protein, VarC (ORF VC1565) 
The ORF VC1565 was designated as varC and consists of 1257bp that encodes a 
protein, VarC of 419 amino acids (calculated Mr of 46733.38 Daltons). The amino acid 
sequence is deposited in GenBank database under accession number AAF94719. 
The TolC protein of E. coli, through its interactions with AcrA and AcrB forms 
a continuous channel across the bilayers of the Gram-negative organism that expels a 
wide variety of toxic compounds from the cell (Murakami et al., 2006). Transporters of 
MDR families in E. coli have evolved to share a single tolC allele as their OMP 
component; conversely in other bacterial species, transport systems encode their own 
equivalent TolC homologue (Bina and Mekalanos, 2001). This is true of V. cholerae 
where the TolC homologue, VarC (VC1565) has been proposed to be linked to the 
MFP, VarA, cytoplasmic membrane translocases, VarD and YarE and ATP-binding 
protein, VarF, which all have the hallmarks of being involved in a bacterial transport 
system (Bina and Mekalanos, 2001). This could suggest that TolC recruitment is 
dependent on the substrate profile of the transport system. 
3.6.1 The VarC sequence from V. cholerae Nl6961 
Sequence divergence exists between much of the TolC family members. Nonetheless a 
few amino acids are well conserved and occur at structurally significant points that 
highlight the conservation of the basic fold (Koronakis, 2003). The N- and C-terminal 
halves of these proteins can be structurally superimposed indicating that the family may 
have evolved through a gene duplication event (Johnson and Church, 1999). Sequence 
similarity among TolC homologues are often correlated with substrate specificity 
leading to the formation of three subfamilies corresponding to their roles in protein 
export, cation efflux and drug efflux. TolC homologues of the protein export subfamily 
combine with IMPs of the ABC superfamily, whilst homologues of the cation- and drug 
efflux subfamilies typically cooperate with IMPs of the RND family (Andersen et al., 
2000). However, the V. cholerae TolC homologue goes against this assumed 
assignment and relates with IMPs of the ABC superfamily involved in the putative 
export of antibiotics and antimicrobial peptides. 
Conserved residues in the V arC primary structure were identified by comparison 
of aligned primary sequences of E. coli TolC (AAC76071) and its homologue P. 
aeruginosa OprM (BAA28694) (figure 3.9). As for E. coli TolC, conserved residues 
identified in VarC may have important functional and structural roles (Andersen et al., 
2000). Conserved residues identical in the aligned sequences of E. coli TolC and P. 
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aeruginosa OprM are highlighted red. Conserved residues identical in >50% of aligned 
sequences in blue and those similar in >50% of aligned sequences in green. 
At or near the tunnel entrance, glycine residues (residues 162 and 364) may 
facilitate a tight turn between the helices forming the entrance itself. Alanine and serine 
residues located at the interface of channel forming helices may allow a very dense 
packing that determines tapering and closure. Aspartic acid residues (residues 14 7, 177, 
344, 351, 362, 370 and 373) located near the inner surface of the entrance may maintain 
the electronegativity that influences the movement of the substrate. Proline residues 
(residues 62, 263 and 290) in the loops between ~-strands and the a.-helices may 
promote the transition from the left and right orientations of the ~-barrel and a.-channel 
structures, respectively. 
Figure 3.9 The amino acid sequence of VarC showing conserved identical 
residues highlighted in red and similar residues are highlighted in blue. 
Residues with putative functional and structural roles are highlighted 
green. The predicted secondary structure elements of VarC are drawn 
above the amino acid sequence with the a.-helices and ~-sheets depicted 
as zigzag shapes and turquoise boxes, respectively. 
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Secondary structure predictions have enabled us to predict the topographical 
arrangement of VarC (figure 3.10) which is similar to the structurally characterised 
TalC (Koronakis et al., 2000) and TalC homologue, OprM (Wong et al., 2001; Akama 
et al. , 2004). The overall predicted topological architecture of VarC consists of a near 
perfect structural repeat that may multimerise to form a ~-barrel domain that spans the 
periplasmic membrane and a a-helical coiled-coil channel domain that spans the 
periplasmic space. The sequences encoding the a-helices and ~-strands of the channel 
structure do not vary substantially in length among TalC homologues (Andersen et al., 
2000). The long a-helices of VarC (a5 and a9) are constant at 67 residues and the short 
a-helices are -20 (a3 and a8) and -35 (a6 and alO) residues in length, again 
suggestive of conservation of a basic structural fold. In slight contrast to TalC and 
OprM, the first two a-helices (a1 and a2) of VarC may form coiled-coils at the 
equatorial domain forming a bulkier 'belt' which may enhance the interactions formed 
with its corresponding MFP, VarA. 
Significant sequence gaps were identified in VarC at a position corresponding to 
a TalC ~-strand and a-helix (S2 and H3) and extracellular loop between a ~-strand and 
a-helix (S4 and H7) (data not shown). These gaps were similarly identified in OprM 
(Wong et al., 2001). The deletion in sequences corresponding to TalC (between S4 and 
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H7) as described previously may have subsequently resulted in the loss of a ~-strand in 
V arC, leading to the formation of a structural imperfect repeat that may affect the 
relative rigidity or stability of the ~-barrel in the peri plasmic membrane. The V arC 
primary sequence lacks the last 49 residues of the C-terminal of TolC when aligned. 
These residues, conversely, may not be functionally or structurally important in VarC as 
they were shown to be dispensable for TolC function (Koronakis et al., 2000). VarC has 
been predicted of a compact globular architecture (Rost et al., 2004). 
Figure 3.10 Schematic illustration of the putative topological arrangement of the 
secondary structure of a VarC monomer. Cylinders and arrows 
represent a-helices and ~-strands, respectively. 
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3.6.2 Amino acid sequence homology ofVarC 
A CD search of VarC has identified three conserved regions. The first TolC region (E-
value 3e-34) involves the TolC OMP responsible for cell envelope biogenesis and 
cellular trafficking and secretion of diverse compounds. The second and third regions 
have been identified at theN- and C- termini, respectively, of the same polypeptide. The 
second region, OEP1 (E-value 2e-13) is located between residues 30 to -195 and the 
third region, OEP2 (E-value 2e-8) is located between residues 225 to 405. These OEP 
regions involve a family of OMPs that form trimeric channels that export a wide range 
of substrates in Gram-negative bacteria. Each member of this family is composed of 
two repeats which is consistent with overall predicted topological architecture of V arC 
(Marchler-Bauer and Bryant, 2004). Members of the TolC and OEP families are all 
involved in the formation of functional multi-domain systems. 
Analysis of the amino acid sequence of V arC using the NCBI database blastp 
has identified 101 homologous alignments (Altschul et al., 1997). The majority of the 
homologous alignments showed unequivocally a conserved TolC region. The first 20 
proteins showed alignments of~ 200 amino acids with VarC (data not shown) and the 
first five characterised matches are listed below. The highest scoring match was a TalC-
like OMP from V. cholerae that exhibited a near perfect identity and similarity of 99%. 
The remaining four matches were TolC homologues from the Vibrio species exhibiting 
minimum identities of 47% and similarities of 68%. 
Accession# Description Organism E-Value 
gil75826925 Outer membrane protein V. cholerae 0.0 
AA007916 Outer membrane protein V. vulnificus 2e-98 
BAC97525 Outer membrane protein V. vulnificus 3e-98 
EAP93567 Outer membrane protein V. splendidus 2e-93 
AAZ73116 Outer membrane ToiC V.parahaemolyticus 2e-91 
Limiting the BLAST search to the RCSB protein data bank database, close sequence 
homologues for VarC was identified with an E-value of less than 0.0001. These 
homologues were identified as E. coli TolC (1EK9 and accession #: AAC76071) and P. 
aeruginosa OprM (1 WP 1 and accession #: BAA28694) with 21% and 20% identity, 
respectively, 39% similarity and E-values of 3e-19 and 8e-09, respectively. This is 
consistent with the previously predicted topological arrangement of VarC being similar 
to TolC and OprM. 
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The significant similarity exhibited by homologues identified from the above 
alignments and from the structurally characterised OprM infers a similar function for 
YarC as that of a TalC-like OMP involved in either protein secretion or multidrug 
efflux systems. Earlier indications show YarC is likely to be involved in a tripartite 
complex through interactions with an AcrA-like MFP, YarA. YarA is hypothesised to 
be coupled to its corresponding ABC-type inner membrane transporter forming a 
constitutively assembled complex (Eswaran et al., 2004 ). This pre-formed MFP/IMP 
complex is believed to be required for the recruitment of their associated OMPs 
(Thanabalu et al., 1998), which are often encoded within the same operon (Andersen et 
al., 2000; Igarashi et al., 2004). This is true of YarC where adjacent ORFs encode YarA 
and the putative ABC-Type IMPs, YarD and YarE. These IMPs will be discussed in 
more detail in the following sections. 
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3.7 The inner membrane protein, VarD (ORF VC1566) 
The ORF YC1566 was designated as varD and consists of 1212bp that encodes a 
protein, YarD of 404 amino acids (calculated Mr of 44652.82 Daltons). The amino acid 
sequence is deposited in GenBank database under accession number AAF94720. 
3.7.1 The VarD sequence from V. cholerae N16961 
YarD exhibits a typical configuration of bacterial ABC transporters, whereby the TMDs 
and NBDs are expressed as separate units (Schneider and Hunke, 1998). Considerable 
sequence divergence is exhibited between the TMD of ABC transporters, which 
generally reflect their diverse substrate specificities. Irrespective of the diversity of the 
TMDs, amino acid homology is often universally conserved in their corresponding 
NBDs. Although much sequence diversity is exhibited in the TMDs of ABC 
transporters, structural homology is often preserved (Saier and Paulsen, 2001 ). 
Secondary structure and topological predictions indicate that YarD consists of 
four transmembrane helices (TMH) (figure 3.11 ), which is identical to the predicted 
topology of MacB (Kobayashi et al., 2003). However, this is unusual for MacB as half 
transporters are usually expected to encompass six TMH (van Yeen et al., 2000; 
Kobayashi et al., 2001). Although YarD shows no half transporter characteristics, it 
exhibits remarkable amino acid sequence similarity with the C-terminal TMD (residues 
258-646) of E. coli MacB (BAB64542). A gapped-alignment shows an identity of 24% 
and similarity of 47% with an E-value of 2e-21 (data not shown). Conserved residues 
identical in the aligned sequences of MacB are highlighted red and similar conserved 
residues are highlighted in blue. Sequence similarity is most dense at the terminal 
residues of YarD (residues 281-404 ), which may infer a conserved structural function. 
Secondary structure predictions also indicate the presence of a large periplasmic loop 
located between TMH 1 and TMH2 that may be important for association with the MFP 
and OMP of a tripartite complex. 
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Figure 3.11 The amino acid sequence of VarD showing conserved identical 
residues are highlighted in red and similar residues are highlighted in 
blue. The predicted secondary structure elements of VarD are drawn 
above the amino acid sequence with the a-helices and ~-sheets depicted 
as zigzag shapes and turquoise boxes, respectively. Horizontal arrows 
drawn above secondary structure depict protein topology with regards to 
the inner membrane of a Gram-negative organism (Blue arrow indicates 
cytoplasmic domain, red arrow indicates membrane spanning domain 
and green arrow indicates periplasrnic domain) . 
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The predicted topological architecture of YarD consists of three domains; a a-helical 
cytoplasmic transmembrane domain, and two periplasmic domains each with a ~-sheet 
surrounded by a-helices (figure 3.12). This is consistent with predictions of globularity 
that suggest YarD is not globular but of an expanded architecture (Rost et al., 2004). 
This overall arrangement, although less densely packed, is interestingly similar to the 
structurally characterised bacterial MDR transporter AcrB (Murakami et al., 2002; Yu 
et al., 2003b) from the RND family. The structure of AcrB consists of a 50A TMD, a 
pore domain and a TolC docking/ funnel domain that spans 70A into the periplasmic 
space (Murakami et al. , 2002). However, YarD may trimerise to form a transporter with 
only 12 TMHs that is in agreement with the canonical ABC exporter topology (Dawson 
and Locher, 2006), unlike the 36 TMHs exhibited for AcrB (Murakami et al., 2002). 
Due to the structural similarity, an alignment of YarD with E. coli AcrB (liWG) was 
performed to identify the existence of any sequence similarity. The results showed weak 
identity with the first N-terminal residues 1-472 (Identity of 5.1% and similarity of 
12.8%) with no homology being detected with the remainder of the AcrB amino acid 
sequence (data not shown). Alignment of YarD with the first N-terminal474 residues of 
AcrB only failed to improve overall homology (identity of 10.8% and similarity of 
27.2%). Therefore it can be concluded that although YarD shows structural homology 
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with AcrB, no sequence homology is detected and VarD is an unlikely member of the 
RND family (data not shown). 
Figure 3.12 Schematic illustration of the putative topological arrangement of the 
secondary structure of a VarD monomer. Adapted from Murakami et 
al., 2002. Cylinders and arrows represent a-helices and ~-strands, 
respectively. 
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The NBDs of ABC transporters must interact with the TMDs to enable conformational 
changes to be propagated during ATP-binding and hydrolysis. This is readily achieved 
in half transporters where the physical proximity is produced from the fusion of the two 
domains; however, multicomponent ABC transporters require specific recognition sites 
on their TMD (Schneider and Hunke, 1998). Mutational analysis has identified that 
crucial subunit interactions are mediated by the a -helical C-terminal domains, mainly 
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by the intracellular loops between the TMH of ABC transporters (Mourez et al., 1997). 
In line with this, the structure of the S. aureus ABC transporter, Sav1866 has identified 
the presence of 'coupling helices' in the TMD that form intimate connections with the 
NBD (Dawson and Locher, 2006). Although Sav 1866 is a half transporter, the 
elucidated structure provides insights into the interactions between the two domains that 
may be extrapolated to multicomponent ABC transporters. 
The secondary structure predictions of YarD show similar promise to Sav 1866, 
with a P-strand (p 12) and a-helix (a9) in the cytoplasmic loop between the TMH2 and 
TMH3 and a a-helix (al2) at the C-termini that may form crucial contacts with the 
NBDs. This is consistent with sequence analysis and alignment of YarD with the C-
terrninal residues of E. coli MacB which shows dense sequence conservation in the 
residues forming these secondary structures. The overall topological arrangement of 
MacB may be similar to that predicted for YarD as the secondary structure and 
structural information for MacB, at present (May 2007), remains unsolved. 
3.7.2 Amino acid sequence homology ofVarD 
A CD search of YarD has identified three conserved regions. The first LolE region (E-
value 3e-7) involves an ABC transporter, LolE, involved in lipoprotein release during 
cell envelope biogenesis. The second SalY region (E-value 5e-17) is involved in a 
defence mechanism and includes the SalY antimicrobial peptide transporter. The third 
FtsX region (2e-8) involves a family of hypothetical permeases and transmembrane 
proteins, possibly in the transport of lipids and may require A TP for functioning 
(Marchler-Bauer and Bryant, 2004) 
Analysis of the amino acid sequence of YarD using the NCBI database blastp 
program has identified 100 homologous matches (Altschul et al., 1997). Of these 14 
proteins showed alignment of ;:: 200 amino acids with YarD and the first five 
characterised matches are listed on the following page. The majority of these showed 
unequivocally the conserved LolE, SalY and FtsX regions. The highest scoring 
characterised match was an ABC-type antimicrobial peptide permease component from 
V. cholerae that exhibited a near perfect identity of 99% and similarity of 99%. The 
second and third matches were also ABC-type antimicrobial peptide permease 
components but from V. vulnificus that both exhibited identical identities of 53% and 
similarities of 70%. The fourth match was an ABC export transpctrter from V. fischeri 
with an identity of 47% and similarity of 68%. The fifth match was the TMD of an 
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ABC efflux pump from Acidobacteria bacterium with an identity of 28% and similarity 
of 49%. 
Accession# Description Organism E-Value 
gil75826926 ABC-type antimicrobial peptide permease V. cholerae 0.0 
BAC97524 ABC-type antimicrobial peptide permease V. vulnificus ae-109 
AE016811 ABC-type antimicrobial peptide permease V. vulnificus Se-109 
AAW85658 Export ABC transporter permease protein V. fischeri 3e-104 
ABF43630 ABC efflux pump inner membrane subunit A. bacterium Se-35 
More distant alignments hint of an involvement with macrolide-specific ABC-type 
permease components, MacB (AA W35780) from Campylobacter jejuni (E-value of 6e-
25) and Burkholderia pseudomallei (CAH38081, E-value of 7e-26). Both show 
identities of 25% and similarities of 47% and 49%, respectively. 
The relative degrees of homology exhibited by orthologs identified from the 
BLAST searches infer a similar function for YarD as an antimicrobial peptide or 
macrolide-specific ABC-type transporter. YarD may interact and communicate with its 
counterpart NBD, YarF, through the ~12, a9 and a12 structures located in the 
cytoplasmic loop between TMH2 and TMH3 and the C-terminal. YarD is also likely to 
associate with its counterparts IMP YarE, the MFP, YarA, and OMP TolC for correct 
transporter assembly and function. 
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3.8 The inner membrane protein, VarE (ORF VC1567) 
The ORF YC1567 was designated as varE and consists of 1305bp that encodes a 
protein, YarE of 435 amino acids (calculated Mr of 46325.44 Daltons). The amino acid 
sequence is deposited in GenBank database under accession number AAF947121. 
3.8.1 The VarE sequence from V. cholerae N16961 
Like YarD, YarE exhibits considerable sequence divergence in its TMD compared to 
other ABC transporters. This can be exemplified by the sequence alignment of YarE 
with its homologous counterpart YarD which shows sequence disparity throughout the 
whole polypeptide (data not shown). The results demonstrate an identity of 24.7% and 
similarity of 42%, which could account for YarE having greater substrate specificity for 
antimicrobial peptides than for macrolide antibiotics as for YarD. However, secondary 
structure and topology predictions show the overall folds of YarD and YarE to be very 
similar (figure 3.13). Consistent with YarD, YarE contains four TMHs and a large 
peri plasmic loop is located between TMH 1 and TMH2. The presence of these 
heterologous IMPs may therefore provide V. cholerae with the opportunity to alternate 
its substrate profile through selection and expression of either a homo- (YarD or YarE) 
or hetero-oligomeric (YarDE) transporter according to the environmental threat. 
As for YarD, YarE exhibits amino acid sequence similarity with the C-terminal 
(residues 258-646) of E. coli MacB (BAB64542). A gapped-alignment shows an 
identity of 22% and similarity of 42%. Conserved residues identical in the aligned 
sequences of MacB are highlighted red and similar conserved residues are highlighted 
in blue. Like YarD, sequence similarity is most dense at the terminal residues of YarE 
around the predicted all between TMH2 and TMH3 and a.l6 and a.17 near the C-
terminal (residues 279-435), which again may infer a conserved structural function. 
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Figure 3.13 The amino acid sequence of VarE showing conserved identical 
residues are highlighted in red and similar residues are highlighted in 
blue. The predicted secondary structure elements of YarE are drawn 
above the amino acid sequence with the a-helices and ~-sheets depicted 
as zigzag shapes and turquoise boxes, respectively. Horizontal arrows 
drawn above secondary structure depict protein topology with regards to 
the inner membrane of a Gram-negative organism (Blue arrow indicates 
cytoplasmic domain, red arrow indicates membrane spanning domain 
and green arrow indicates periplasmic domain). 
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Secondary structure and topological predictions have identified a topological 
arrangement of VarE (figure 3.14) that is very similar to VarD (figure 3.12). Such is the 
structural likeliness, the two topological patterns of VarD and VarE are virtually 
superimposable, and therefore they may have the potential to associate to form a 
functional transporter as postulated previously. 
As described previously for VarD, secondary structure predictions of VarE have 
identified a all in the cytoplasmic loop between the TMH2 and TMH3 and a16 and 
al7 at the C-terminal that may form crucial contacts with the NBDs. 
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Figure 3.14 Schematic illustration of the putative topological arrangement of the 
secondary structure of a VarE monomer. Cylinders and arrows 
represent a-helices and ~-strands, respectively. 
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A CD search of YarE has identified conserved domains, LolE (E-value 3e-17) and SalY 
(E-value Se-28), as exhibited in YarD (Marchler-Bauer and Bryant, 2004). 
Analysis of the amino acid sequence of YarE using the NCBI database blastp 
program has identified 100 homologous matche (Altschul et al., 1997). Of these 20 
proteins showed alignment of ~ 200 amino acids with YarE and the first four 
characterised matches are listed on the following page. The majority of these showed 
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unequivocally the conserved LolE, SalY and FtsX regions. The highest scoring match 
was an ABC-type antimicrobial peptide permease component from V. cholerae that 
exhibited a near perfect identity of 99% and similarity of 99%. The second and third 
matches were also ABC-type antimicrobial peptide permease components but from V. 
vulnificus that both exhibited identical identities of 62 % and 61%, and similarities of 
76% and 75%, respectively. The last functional match was an ABC export transporter 
from V. fischeri with an identity of 54% and similarity of 76%. 
Accession# Description Organism E-Value 
gil75826927 ABC-type antimicrobial peptide permease V. cholerae 0.0 
BAC97523 ABC-type antimicrobial peptide permease V. vulnificus 4e-146 
AA007914 ABC-type antimicrobial peptide permease V. vulnificus 3e-145 
AAW85659 Export ABC transporter permease protein V. fischeri 1e-134 
More distant alignments hint of an involvement with macrolide-specific ABC-type 
permease components, MacB (AA Y85982) from N. gonorrhoeae with an E-value of 8e-
23 and Pseudomonas syringae (AA056331) with an E-value of le-22. Both show 
identities of 23% and similarities of 46%. Like YarD, YarE exhibits sequence similarity 
with the last 255 C-terminal residues of E. coli MacB. 
The relative degrees of homology exhibited by homologues identified from the 
BLAST searches infer a similar function for YarE as an antimicrobial peptide or 
macrolide-specific permease of an ABC-type transport system. Like YarD, YarE may 
interact and receive indications of conformational changes from its NBD counterpart, 
YarF, through all located in the cytoplasmic loop between TMH2 and TMH3 and al6 
and al7 at the C-terminal. YarE is also likely to associate with its counterparts IMP 
YarD, the MFP, YarA, and OMP TolC for correct transporter assembly and function. 
The ATPase, Y arF, and will be examined in the following section. 
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3.9 The ATP-binding cassette (ABC-ATPase), VarF (ORF VC1568) 
The ORF VC1568 was designated as varF and consists of 729bp that encodes a protein, 
VarF of 243 amino acids (calculated Mr of 25360.70 Daltons). The amino acid sequence 
is deposited in GenBank database under accession number AAF94722. 
3.9.1 The VarF sequence from V. cholerae N16961 
As mentioned previously, much disparity is exhibited between the TMD of ABC 
transporters. In contrast, their NBD counterparts show sequence homology throughout 
the vast proportion of the polypeptide, which suggests they share a common functional 
mechanism. A number of NBDs from various ABC transporters have been isolated and 
structurally characterised (Hung et al., 1998; Diederichs et al., 2000; Hopfner et al., 
2000; Yuan et al., 2001; Karpowich et al., 2001; Gaudet & Wiley, 2001; Locher et al., 
2002; Smith et al., 2002; Schmitt et al., 2003; Verdon et al., 2003; Watanabe et al., 
2005; Dawson and Locher, 2006). For the context of this section, NBDs from the ABC 
superfamily will be referred to as ABC-A TPases. 
An amino acid sequence alignment of VarF with other ABC-ATPases (E. coli 
MacB YBJZ (N-terrninal residues 1-224 only), L. lactis LmrA 1MV5, S. solfataricus 
Glcv 10XV, S. typhymurium HisP lBOU, T. litoralis MalK 1029, and T. thermophilius 
SufC 2D2F) has identified six putative conserved domains characteristic of members 
from the ABC superfamily (figure 3.16). These are the highly conserved ATP-binding 
Walker A motif (residues 46-54, PROSITE entry: PS00017), the Q-loop (residue 93-98) 
the ABC signature LSGGQxQR (residues 150-157, PROSITE entry: PS00211), the 
Walker B motif (residues 170-175), the D-loop (residues176-82) and the switch region 
(residues 201-207). Conserved residues understood to be essential for ATP-binding and 
hydrolysis and which are identically in the motifs of all ABC-ATPases are highlighted 
in red in figure 3.15. Conserved residues that are identical in >50% of aligned 
sequences are highlighted in blue and similar residues in >50% of aligned sequences in 
green. 
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Figure 3.15 The amino acid sequence of VarF showing identically conserved 
residues including the A TP-binding motifs are highlighted in red. Similar 
conserved residues are highlighted in blue and residues with putative 
roles in green. The predicted secondary structure elements of VarF are 
drawn above the amino acid sequence with the a-helices and ~-sheets 
depicted as zigzag shapes and turquoise boxes, respectively. 
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Secondary structure and topological predictions of VarF have identified a~- and a-
helical domains that are typical features of structurally characterised ABC-ATPases 
(figure 3.16). The a~-domain consists of two ~-sheets (~-sheet I and II) surrounded by 
a-helices in which most of the conserved motifs, apart from the ABC signature, are 
located. The ABC signature motif is hypothesised to be located in the a-helical domain. 
Like the previously described ABC-A TPases in chapter one, the structural arrangements 
of the conserved motifs suggest VarF may dimerise to form a functioning unit that 
hydrolyses ATP at the interface of the two subunits. 
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Figure 3.16 Schematic illustration of the putative topological arrangement of the 
secondary structure of a VarF monomer. Adapted from Hung et al. , 
1998. Cylinders and arrows represent a-helices and ~-strands, 
respectively. Red dashed boxes enclose area of putative conserved 
motifs. 
1: 
'iij 
E 
0 
c 
co. 
~ 
Switch 
= 
I 
I 
' I 
/Walker A 
3.9.2 Amino acid sequence homology of VarF 
ABC 
S? 
::r 
~ 
c;· 
!. 
c 
0 
3 
! . 
:::J 
A CD search of V arF has identified two conserved regwns. The first 
ABC_MJ0796_LolCDE_FtsE region (E-value 1e-84) is a family that includes the 
A TPase MJ0796, the macrolide-specific ABC-type efflux system, MacAB and proteins 
involved in cell division (FtsE) and lipoprotein release (LolCDE). The second SalX 
region (E-value 8e-84) is involved in a defence mechanism and includes the A TPase 
SalX of the SalY antimicrobial peptide transporter (Marchler-Bauer and Bryant, 2004). 
Analysis of the amino acid sequence of VarF using the NCBI database blastp 
program has identified 100 homologous matches all showing alignments with ;?: 200 
amino acids (Altschul et al., 1997). All the alignments showed unequivocally the 
conserved ABC_MJ0796_LolCDE_FtsE and SalX regions. The first five matches are 
listed on the following page. The two highest scoring matches were ABC-A TPases from 
V. cholerae that exhibited a near perfect identity of 99% and similarity of 99%. The 
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third and fourth matches were also A TP-binding proteins but from V. vulnificus that 
both exhibited identical identities of 78% and similarities of 89%. The last functional 
match was an ABC export transporter from V. parahaemolyticus with an identity of 
78% and similarity of 89%. 
Accession# Description Organism E-Value 
EAX61687 ATP-binding protein V. cholerae Se-125 
EAY39774 ATP-binding protein V. cholerae Se-124 
BAC97522 ATP-binding protein V. vulnificus 4e-97 
AA007913 ATP-binding protein V. vulnificus ae-97 
BAC60258 ATP-binding protein V. parahaemolyticus 2e-96 
More distant alignments show homology with ATP-binding proteins involved with 
MacB homologues from Bartonella henselae (CAF28309, E-value 1e-66) and B. 
bacilliformis (ABM44873, E-value 4e-66). Both show identities of 52% and 54% and 
similarities of 74% and 75%, respectively. 
Limiting the BLAST search to the RCSB protein data bank database, close 
sequence homologues for VarF were identified with an E-value of less than 0.0001. 
These homologues were identified as Salmonella typhimurium HisP (lBOU), Sulfolobus 
solfataricus Glcv (lOXV, 10XU, 10XT and 10XS), Thermococcus litoralis MalK 
(1G29), L. lactis LmrA (1MV5), E. coli BtuD (1L7V), Methanococcus jannaschii 
MJ0796 (Y796), and Thermus thermophilius SufC (2D2F). These ABC transporters are 
representative of the ABC ATPase subfamily involved in interactions with the 
membrane-spanning domains and transport across membranes (Gaudet and Wiley, 
2001). Of all the well studied ABC-ATPases aligned, VarF showed closest sequence 
homology with the first 226 N-terminal residues of E. coli MacB exhibiting an identity 
of 49.8% and similarity of 63.5% (YBJZ and BAB64542). 
The homology exhibited by ABC-A TPase orthologs identified from the BLAST 
searches and the significant conservation of structural elements infer a similar function 
for V arF as an A TP-binding protein possibly associated with a antimicrobial peptide 
and/or macrolide-specific ABC transporter. 
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3.10 Discussion of the VarCADEFz transport system 
Current structurally characterised ABC transporters are limited to those from Gram-
positive S. aureus (Sav 1866) where the requirement for tripartite systems is not 
necessary or in Gram-negative E. coli (BtuCD) where the structures do not indicate the 
ability to form these complex systems. Other ABC transporters that are known to 
associate with TolC to form tripartite complexes in Gram-negative organisms are the E. 
coli HlyDB-TolC (Thanabalu et al., 1998) and MacAB-TolC (Kobayashi et al., 2001) 
systems. However, the structures of MacB and HlyB have yet to be determined thus 
ensuring their exact interactions with TolC in the formation of these systems remain 
elusive. 
This thesis proposes an ABC transporter, VarACDEF2 that is hypothesised to 
function as a tripartite complex in order to actively extrude antimicrobials across both 
membranes of V. cholerae. The components of this ABC complex differ from that of 
the MacAB and HlyBD systems, in that the IMPs, VarD and VarE and the ATP-binding 
protein, VarF are expressed separately and not consecutively as a fusion as for MacB 
(Kobayashi et al., 2001) and HlyB (Koronakis et al., 1993). 
Poor sequence similarities exist between the transmembrane domains of ABC 
transporters that may reflect their divergent substrate specificities (Locher et al., 2002). 
This is likely to be a result of an evolution from an ancestral permease to accommodate 
different substrates (Kerppola et al., 1992). Conversely, these diverging sequences often 
form homologous structures that can infer a similar mechanism of transport. This can be 
exemplified by the divergent sequences of VarD and VarE that form a similar structural 
arrangement. This suggests they may have the potential to form a heterooligomeric 
(dimer or trimer) arrangement with one another to form a functional translocation 
channel. However, the lack of half transporter characteristics could mean that YarD and 
VarE may also homooligomerise, independently of one another forming a more 
versatile and enhanced resistance mechanism. Either way, these IMPs are likely to 
associate with their cognate MFP VarA, TolC-like OMP VarC and ATP-binding 
protein, VarF for formation of a VarCADF2 or VarCAEF2 or VarCADEF2 transporter 
complex. 
The overall structural arrangement of the VarCADEF2 transporter complex 
would be similar to that described for the E. coli maltose-maltodextrin (as reviewed by 
Boos and Shuman, 1998) and the histidine systems (Kerppola et al., 1991; Liu et al., 
1999) which utilise two homologous IMP. In the maltose-maltodextrin (Mal) system, 
the IMPs MalF and MalG, associate with the MFP MalE and A TP-binding protein 
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MalK to form the translocation complex, MalEFGK2 (Boos and Shuman, 1998). Like 
the Mal system, the IMPs HisM and HisQ of the histidine system, associate with its 
corresponding MFP HisJ and ABC-A TPase HisP to form HisJQMP2 transporter 
(Kerppola et al., 1991; Lui et al., 1999). However, dissimilar from the IMPs of the Mal 
and His systems, YarD and YarE consist of only four TMH, whereas both HisM and 
HisQ consist of five TMHs (Kerppola et al., 1992) and MalF and MalG consist of eight 
and six TMHs, respectively (Boos and Shuman, 1998). Therefore YarD and YarE, 
although not half transporters, show closer transmembrane topology to the C-terminal 
residues of MacB (residues 255-648) which also consists of four TMHs (Kobayashi et 
al., 2003 ). YarD and YarE each have the same number of TMH and are superimposable 
leading to the previous assumption that they may associate with one another. This is 
consistent with HisM and HisQ that are hypothesised to maintain similar structural 
characteristics in order to perform similar functions (Kerppola et al., 1992). 
In agreement with MacB and MalF, theN- and C-termini of YarD and YarE are 
predicted to be located within the cytoplasm and a large periplasmic loop is predicted 
between TMH1 and TMH2 (corresponding TMH3 and TMH4 for MalF). This 
periplasmic loop may be responsible for formation of the periplasmic structures as seen 
in AcrB that are necessary for association with the other components of the tripartite 
system such as the MFPs. Similar to both IMPs of the Mal and His systems and for 
MacB, YarD and YarE consist of a cytoplasmic loop located between the C-terminal 
TMHs that contain a dense population of conserved residues that may be responsible for 
interacting with their corresponding ABC-ATPase. In contrast to these IMPs, both YarD 
and YarE lack the typical consensus sequence EAA-X3-G-X9-I-X-LP in their 
cytoplasmic loop that is hypothesised to form the interactions with their associated 
ABC-ATPase (Kerppola et al., 1992; Boos and Shuman, 1998). Nonetheless, these 
conserved cytoplasmic loop residues in the TMD may be responsible for formation of 
the structures required for propagation of conformational changes from the ABC-
A TPase as seen in the structure of Btu CD and Sav 1866. 
YarF, the ATP-binding component of YarD and YarE transporters has 
remarkable sequence similarity to theN-terminal residues of MacB (residues 1-226). As 
both YarD and YarE also have remarkable sequence similarity with the C-terminal of 
MacB (residues 255-646), this leads to the assumption that YarD and YarE may have 
each existed with YarF at some point as a half transporter similar to MacB. Selection 
pressures may have forced these genes to segregate or diversify resulting in the separate 
conformations that exist at present. This theory can be substantiated by the location of 
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the conserved switch region that has been proposed to play a role in the propagation of 
conformational changes triggered by A TP hydrolysis (Schneider and Hunke, 1998). 
This region is located near the end of the e-terminal of VarF which if V arF was once 
fused to theN-terminal of either VarD or VarE like MacB, would allow conformational 
changes to be propagated to the proximally located TMD. However, this mechanism of 
action would still be likely in the separate conformations if the e-terminal of a dimeric 
V arF complex were to associate with the cytoplasmic face of the V arD and/ or VarE 
TMDs. 
Interestingly, VarD and VarE both have a predicted overall similar structure 
(though with only a third of the number of TMH for AcrB) to the RND transporter 
AcrB which associates with its MFP, AcrA and the OMP Tole to mediate resistance 
against a wide array of structurally diverse substrates (figure 3.17) (Murakami et al., 
2002). This would prove interesting as the AcrAB-Tole system also has the ability to 
confer resistance to ~-lactam antibiotics (Mazzariol et al., 2000). The ability of RND 
transporters to confer resistance to antibiotics that target periplasmic enzymes involved 
with cell wall biosynthesis is intriguing as these transporters generally do not export 
substrates from the periplasm (Murakami et al., 2002). However, the crystal structure of 
AcrB provides insights into how this may be achieved. The structure of AcrB 
establishes the presence of vestibules that opens to the periplasm at the side of the 
transporter where the transition between the TMD and the porter domain occurs 
(Murakami et al., 2002; Yu et al., 2003b). This allows direct access of the substrates 
from the periplasm into the translocation channel where extrusion is driven by a proton 
motive force (Murakami et al., 2002). 
The VareADEF2 transporter complex may have adopted a resistance mechanism 
similar to that of the AcrAB-TolC system, to supplement or enhance activity of the 
metallo-~-lactamase, VarG that is also encoded in the var operon. This may be in 
response to selective pressures as a consequence of exposure to newer carbapenem ~­
lactam antibiotics or their compounds. 
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Figure 3.17 Structure of the MDR E. coli AcrAB-TolC system. (A) Crystal 
structure of AcrB, (B) and (C) Proposed arrangement of the AcrAB-TolC 
system. Adapted from Murakami et al., 2002. 
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Consistent with predictions that the ABC-type V arDE transporter may adopt a fold 
similar to that of the RND family IMP; AcrB, VarA shows remarkable sequence 
similarity to AcrA-like orthologs and has an overall predicted topological arrangement 
similar to MexA. VarC also shows significant similarity with E. coli TolC and P. 
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aeruginosa TolC homologue, OprM. The crystal structures of E. coli TolC (Koronakis 
et al., 2000), AcrB (Murakami et al., 2002), and P. aeruginosa MexA (Higgins et al., 
2004) have been elucidated and afford an insight into the cooperative assembly and 
function of a MDR system in Gram-negative organisms (Eswaran et al., 2004). This 
insight may be extrapolated to the putative YarACDE transport system which exhibits a 
similarly predicted structural arrangement. 
Liu and associates (1999) propose a model for the engagement, activation and 
dissociation of a tripartite complex that can be extrapolated to other members of the 
ABC superfamily. Through adaptations of this mechanism, and using the functional 
knowledge gained from the HlyBD-TolC system (Thanabalu et al., 1998; Balakrishnan 
et al., 2001) and the structural knowledge from the tripartite complex AcrB-MexA-TolC 
(Eswaran et al., 2004) and S. aureus Sav1866 ABC transporter (Dawson and Locher, 
2006) the YarACDEF2 transporter complex may function as follows. In the resting 
state, the YarADEF2 complex may be constitutively formed with the subunits of dimeric 
YarF marginally associated. In this state the substrate translocation pathway remains 
completely sealed from the cytoplasmic end. Due to the lack of substrate bound 
structures for ABC transporters, the binding site for AcrB (Yu et al., 2003a) will be 
assumed for the purposes of this hypothesis. Substrates may enter via the predicted 
vestibules, as in AcrB, or through the cytoplasmic entrance and engage with the TMD 
of the YarDE transporter. Binding at the cytoplasmic entrance may cause signal 
transduction that propagates from the N-terminal cytoplasmic domain through to the 
large periplasmic domain of YarA. This triggers the recruitment of the TolC homologue 
YarC to the YarDEF2 complex forming the full transporter YarCADEF2 complex. ATP 
binding to Y arF may induce a conformational change that brings both subunits of the 
dimer into closer proximity in preparation for hydrolysis. This may also result in the 
propagation of another signal through YarA which causes a conformational change that 
constricts Yare at the equatorial domain, subsequently opening the entrance of the 
channel and allowing the substrate to enter into the YarCADEF2 complex. Upon ATP 
hydrolysis, conformational changes causes YarA to relax constriction at the equatorial 
domain, closing the entrance to the channel and allowing translocation of the substrate 
out into the extracellular milieu. Rounds of ATP binding and hydrolysis therefore may 
be required to open and close the IMP entrance, which may be inversely correlated with 
the state of the TolC entrance, so that the channel would open at one end or the other, 
but not both. The end result would be a repeated engagement and expulsion of substrate 
(Thanabulu et al., 1998). 
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3.11 The regulatory regions of the var operon, varRG, varGA and varBC 
The putative regulatory regions of the var operon show promise as promoters and are 
believed to be regulated at the transcriptional level by the divergently transcribed 
repressor and/or activator, VarR. Three potential binding sites for VarR have been 
identified within the operon, which suggest it has the potential to regulate 
simultaneously at different locations. This could allow VarR to switch 'on' or 'off' 
expression of certain genes m response to certain environmental conditions. The first 
promoter, termed varRG, 1s located in the intergenic region (IR) between the 
divergently transcribed LTTR, varR gene and the M~l , varG gene (figure 3.18). The 
second promoter, termed varGA , is located between the varG gene and the MFP, varA 
gene. The third promoter, termed varBC, is located between the varB gene and the 
TolC-like OMP, varC gene. The presence of three promoter regions for VarR may 
allow sequential expression of two potential resistance mechanisms in the form of a 
M~l , VarG, and a tripartite ABC-type transporter complex, VarCADEF2 . Putative RNA 
polymerase binding sites at the varRG and varGA promoters were identified by Dr Gary 
Sharples, with much appreciation. 
Figure 3.18 The var operon illustrating the nucleotide sequences in the putative 
varRG, varGA and varBC promoter regions. 
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L TTRs tend to engage long sequences of 50-60bp frequently interacting at multiple 
sites within their promoters suggesting that LTTRs bind as a tetramer (or as a dimer of 
dimers) in its biologically active form (Bishop and Weiner, 1993; Choi et al., 2001; 
Muraoka et al., 2003). These promoter regions are hypothesised to encode a -15bp 
partially palindromic binding site, which has the conserved T-NwA motif proven 
critical for binding of LTTR proteins (Schell, 1993). The T-NwA motif may act as a 
general guide for LTTR binding, whist the adjacent nucleotides of the dyad are 
responsible for recognition specificity. This binding site, termed the recognition-binding 
site (RBS), is generally centred at 65 base pairs (bps) from the transcriptional start site 
of the regulated gene and often overlaps the promoter of the LTTR. Binding at the RBS 
is may also be responsible for autoregulation of the LTTR. LTTRs also bind to a 
dissimilar sequence, termed the activation binding site (ABS), that overlaps the -35 
RNA polymerase binding site. Binding of LTTRs to this site may induce a bend in the 
DNA that masks the -35 site preventing the RNA polymerase from binding effectively 
to the promoter. Dissociation of LTTRs from these sites requires the presence of a 
cognate substrate, which is a prerequisite for transcriptional activation. Substrate-
binding to LTTR may relax bending of promoter DNA, exposing the -35 transcriptional 
start site that enables the RNA polymerase to bind with increased affinity for initiating 
transcription (Henikoff eta!., 1988; Schell, 1993). 
3.11.1 The varRG Intergenic Region 
The initiation codons of the ORFs of varR and varG have been identified in the varRG 
IR and are highlighted in green with the deduced amino acid positioned above (figure 
3.19). The correct start codon for varG was identified to be located 48bp further 
downstream from its assumed start site. The absence of a ribosome-binding site at the 
assumed start site prompted sequence analysis further downstream, which identified a 
likely ribosome binding site that corresponds to the probable start site of varG. 
Establishment of the start codons of the varR and varG genes resulted in the formation 
of an 111 bp varRG IR. 
The 111 bp varRG IR accommodates two putative overlapping promoters, one 
for varR and the other for varG, therefore VarR has the potential to control transcription 
in a bidirectional manner. Within the 111 bp varRG IR, putative -10 and -35 sites and 
two T-Nu-A motifs were identified for each of the varR and varG promoters. Upstream 
from the initiation codon of varG, a likely bacterial promoter was found with a -35 
region (TTGATA) and a -10 region (TATCTT) separated by 15bp. Divergent to the 
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varG ORF, a promoter was found upstream of the initiation codon of varR containing a 
-35 region (T ACGT A) and a -10 region (TCGTGC) separated by 17bp. The base pair 
separation between these putative promoter regions has been demonstrated to be 
optimal for promoter strength (Jaurin et al., 1982). Base pair substitutions in the 
promoter regions from the general prokaryotic consensus sequence of TAT AA T for the 
-10 site and TTGACA for the -35 site has been suggested to weaken promoter strength 
and/or even cause the loss of promoter activity (Stryer, 1999). On the contrary, 
mutations resulting in sequence changes in both the conserved (TTG in the -35 region 
and TA---T in the -10 region) and less conserved bases in the promoter can give rise to 
dramatic increases in initiation of transcription and thus resistance (J aurin et al., 1982; 
Siu et al., 2003). 
Figure 3.19 The nucleotide sequence of the lllbp varRG intergenic region 
containing the putative promoter sequences represented by -35 and -10 
regions (highlighted red). The Shine-Dalgamo sequence is highlighted 
blue. The operator site which is hypothesised to act as the binding site 
for V arR is highlighted purple and/or underlined if overlapping with 
promoter sites. The start codons and the deduced amino acid for V arR 
and V arG are highlighted in green. 
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Within the varRG IR, a likely -65 RBS incorporating the T-N11 -A motif was identified 
for varG, which overlaps the -35 site for the varR. Operator sites with full or partial 
inverted repeats were also identified and are highlighted in purple or underlined due to 
overlap with the putative RNA polymerase initiation sites. These operator sites are 
hypothesised to be repressor binding sites for V arR and binding at these sites may 
prevent transcription of varG and its own expression through autoregulation. 
The organisation of the promoters of these two genes are similar to that of the 
well characterised Enterobacteriacae ~-lactamase ampR-ampC regulatory systems of C. 
freundii (Lindberg et al., 1985; Lindquist et al., 1989), E. cloacae (Lindberg and 
Normark, 1987) and P. aeruginosa (Lodge et al., 1990). VarR may recognise a 
promoter pattern similar to that recognised by the LTTR AmpR, which controls AmpC 
serine-~-lactamase expression. These promoter sequences are suggested to be universal 
in most Gram-negative bacteria with inducible chromosomal ~-lactamase leading to a 
similar mechanism of induction (Lindberg and Normark, 1987). The close similarities 
between the varRG promoter region with that of the ampRC system, may also 
extrapolate to its mechanism of induction. 
The mechanism of AmpC induction by AmpR is a complex process that 
involves two other genes, AmpD and AmpG, and is intricately linked to peptidoglycan 
(or murein) cell wall recycling (Lindberg et al., 1985, 1987; Korfmann and Sanders, 
1989; Jacobs et al., 1994). Bacterial peptidoglycan is a dynamic surface and is 
continuously remodelled through synthesis and degradation as the bacterium grows and 
divides (Jacobs et al., 1997; Chahbourne et al., 2005). Bactericidal ~-lactam antibiotics 
were developed specifically to disrupt this balance, which has ultimately led to the 
evolution of bacterial defence mechanisms, such as ~-lactamase production against 
these agents (Jacobs et al., 1997). AmpC synthesis is therefore activated in the presence 
of ~-lactam antibiotics as a result of AmpR derepression. However, as ~-lactams are not 
known to enter the cytoplasm (Bartowsky and Normark, 1993), AmpR has been 
suggested to be activated by an indirect mechanism (Lindquist et al., 1989). This 
mechanism involves disruption of the peptidoglycan by ~-lactams that leads to 
increased periplasmic accumulation of cell wall precursors and degradation products 
(muropeptides). A cytoplasmic membrane permease, AmpG, has specificity for these 
muropeptides and transports them into the cytoplasm. Within the cytoplasm, 
muropeptides derepress-AmpR leading to induction of AmpC (Dietz et al., 1997; Jacobs 
et al., 1997). A cytosolic protein, AmpD encoded on a different operon from the ampR 
and ampC genes (Lindberg et al., 1987), is responsible for degradation of these 
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muropeptides which are regenerated into precursors for peptidoglycan synthesis. 
However, both AmpD and AmpG are also essential for the regulation of P-lactamase 
activity (Jacobs et al., 1994). A mutation in ampD leads to an accumulation of 
muropeptides that continually activates AmpR leading to continued AmpC expression 
(Lindberg et al., 1987; Poirel et al., 1999; Juan et al., 2005). Mutational inactivation of 
AmpG renders the bacterium AmpC non-inducible due to the absence of these 
activating muropeptides (Jacobs et al., 1994; Cheng and Park, 2002; Chahbourne et al., 
2005). This demonstrates a close association between P-lactamase induction and 
peptidoglycan recycling (Jacobs et al., 1997). 
3.11.2 The varGA Intergenic Region 
The initiation codon of the ORF for varA has been identified in the varGA IR and is 
highlighted in green with the deduced amino acid positioned above (figure 3.20). A 
palindromic self-complementary GC-rich region followed by a series of thymidine 
nucleotides is located at the terminating sequences of V arG and may form a hairpin that 
corresponds to a rho-independent terminator signal. Establishment of the stop and start 
codons of the varG and varA genes, respectively results in the formation of a 176bp 
varGA IR. 
The 176bp varGA IR accommodates a putative promoter for varA with putative 
-10 and -35 sites and three T-N wA motifs identified. Upstream from the initiation 
codon of varA, a likely bacterial promoter was found with a presumed -35 region 
(TTGATA) and a -10 region (TATCTT) separated by 15bp. Like the varRG promoter, 
these regions consist of base pair substitutions that deviate from the general consensus 
sequence, which may affect promoter strength. Similar to the varRG IR, putative 
operator sequences have been identified which overlap the putative RNA polymerase 
initiation sites. Multiple putative -65 LTTR recognition-binding sites incorporating the 
T-NwA motif were also identified for varA. The relative length of theIR could mean 
that VarR may form multimeric species to span the length of the promoter. 
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Figure 3.20 The nucleotide sequence of the 176bp varGA intergenic region 
containing the putative promoter sequences represented by -35 and -10 
regions (highlighted red). The Shine-Dalgarno sequence is highlighted 
blue. An operator site is highlighted in purple or underlined if 
overlapping with promoter sites. The terminator site is highlighted in 
grey. The start and stop codons and the deduced amino acid for VarA 
and VarG, respectively, are highlighted in green. 
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3.11.3 The varBC Intergenic Region 
The initiation codon of the ORF of varC has been identified in the varBC IR and is 
highlighted in green with the deduced amino acid positioned above (figure 3.21). 
Establishment of the stop and start codons of the varB and varC genes, respectively 
results in the formation of the 25bp varBC IR. 
However, a putative promoter region upstream from the initiation codon of varC 
was identified and appears to penetrate the terminal sequences of the varB gene. Likely 
RNA polymerase initiation sites were found with a presumed -35 region (AAGACA) 
and a -10 region (AATAAC) separated by 12bp. Like the previous promoters, these 
regions consist of base pair substitutions that deviate from the general consensus 
sequence, which may affect promoter strength. A putative -65 recognition-binding site 
incorporating the T-N wA motif, which lies within the C-terminal of varB was also 
identified for varC. 
Figure 3.21 The nucleotide sequence of the varBC intergenic region containing the 
putative promoter sequences represented by -35 and -10 regions 
(highlighted red). The Shine-Dalgamo sequence is highlighted blue. The 
start and stop codons and the deduced amino acid for VarC and VarB, 
respectively, are highlighted in green. An operator site is highlighted in 
purple or underlined if overlapping with promoter sites. 
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3.12 Discussion of the regulatory regions varRG, varGA and varBC of the 
var operon 
The organisation of the varR-varG regulatory system closely resembles that of the 
ampR-ampC system. Although the ubiquitous nature of the ampR-ampC regulatory 
system (Lau et al., 2005) and its association with peptidoglycan recycling have been 
well documented, the exact regulatory mechanism of AmpR derepression leading to 
AmpC induction remains elusive. The crystallisation and structural characterisation of 
AmpR in the presence of its hypothesised inducer of muropeptides and/or promoter 
DNA, may provide insights into the differential conformational changes and mechanism 
of dissociation from its promoter. Antimicrobial susceptibility testing could be 
performed with ampR or !1ampR-ampRC-ampC as a fusion to a reporter gene with 
muropeptides as the experimental substrate. If muropeptides were found to dissociate 
AmpR from its promoter leading to the expression of the reporter, this would 
consequently confirm it as an inducer in the ampR-ampC system and also substantiate 
its intimate association with peptidoglycan recycling. 
The relative distances between the operator sites in all the promoters of the var 
operon indicate that V arR may bind as a dimer of dimers as has been described for 
AmpR (Bishop and Weiner, 1993). Other LTTRs show similar mechanisms of binding 
to their respective operator regions. For example, NodD which is a dimer binds to 
tandem operators. However, it has been suggested that binding to both operators 
simultaneously is dependent on the presence of inducers. This can be exemplified by 
Trpl which in the absence of its inducer binds only the left half of its 40bp operator. 
However, in the presence of inducer Trpl binds both halves that induce activation of its 
regulated gene. Therefore single or tandem occupation of LTTR operators may 
determine the switch between repression and activation of transcription (Bishop and 
Weiner, 1993). 
The expression levels of certain genes may occur as a result of induction 
efficiency of regulators in response to their inducer. As is the case for the ampR-ampC 
regulatory system, the presence of other genes such as ampD and ampG are essential for 
inducer-based AmpC expression and mutations in these genes leads to differential 
AmpC expression levels (Lindberg et al., 1987; Jacobs et al., 1994; Poirel et al., 1999; 
Cheng and Park, 2002; Chahbourne et al., 2005; Juan et al., 2005). Induction and 
expression levels of certain genes may also be mediated by mutations in the regulator 
and/or mutations in the RNA polymerase initiation sites leading to an increase or 
decrease in translational efficiency (Jaurin et al., 1982). This could be true for the 
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promoters of the var operon as the -35 and -10 sites all consist of at least one mismatch 
base compared to the E. coli consensus sequence. Indeed, a one base change in a -35 
promoter region of another analogous regulatory system, smeR-smeA leads to high 
expression of a class C ~-lactamase, SmeA, even in the absence of the LTTR, SmeR 
(Naas et al., 1995). Control of expression has even been suggested to be regulated at the 
level of mRNA half-life in which mRNA stability determines the efficiency of 
translation by RNA polymerase (Mahlen et al., 2003). Hence there are many factors that 
could influence the regulation of ~-lactamases, other than through its corresponding 
inducer-activated regulator, which may affect the intrinsic resistance of bacteria that 
harbour these enzymes. 
This chapter presents significant sequence observations in support of a novel 
antibiotic resistance operon in V. cholerae, which may employ two distinct mechanisms 
for overcoming a broad range of structurally diverse antimicrobial agents. The 
following chapters aspire to further contribute to the existing literature through 
elucidation of the functional and structural characteristics of each component that 
creates the var operon. This thesis also aims to bring new insights into the regulatory 
mechanism of ~-lactamase induction and the simultaneous expression of an ABC-type 
tripartite complex. At present (May 2007), this novel antibiotic resistance operon would 
be the first of its type to be described in V. cholerae. 
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Chapter 4 Cloning, expression, and purification of the 
LysR-type transcriptional regulator, VarR 
The completed genome of V. cholerae 01 Biovar Eltor strain N16961, which is 
deposited in the NCBI database was a source of sequence information for the 
construction and cloning of genes of the var operon. The V. cholerae vaccine strain, 
CVD101, a non-toxigenic (non-01) derivative of the Classical Ogawa 395 strain was 
used as a source of chromosomal DNA for all experiments for this thesis. Previous 
studies reported that the nucleotide and amino acid sequences of 01 and non-0 1 V. 
cholerae strains are >97% similar with some putative genes being 100% identical (Huda 
et al., 2001, 2003; Begum et al., 2005). However, the existence of these slight 
differences between the strains will require the nucleotide sequences of CVD 101 and 
N 16961 to be compared in order to identify any significant changes that may 
consequently lead to functional or structural differences. This will be achieved through 
DNA sequencing of successfully amplified and cloned genes and will be detailed in 
respective sections. 
The varR gene of V. cholerae was amplified by polymerase chain reaction 
(PCR) which incorporated artificial restriction enzyme (RE) sites, suitable for cloning 
into a chemically inducible expression vector. A list of oligonucleotides/ primers and 
reaction mixes used during PCR can be found in Table 2.5 in Chapter 2 Materials and 
Methods. The intention was to produce sufficient quantities of the LTTR protein, V arR, 
for use in further studies in order to elucidate its functional and structural 
characteristics, and ultimately its role in the antibiotic resistance var operon. The 
expression and purification of V arR was fraught with substantial difficulties due to 
toxicities experienced by the E. coli hosts and in the maintenance of solubility following 
purification. This is a common trait of most L TTRs and the problem reflects previous 
attempts made by other research groups to maintain them in solution. Eventually, after 
much perseverance VarR was successfully overexpressed and purified in a form that 
maintained solubility. The trials and tribulations are discussed throughout this chapter. 
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4.1 Cloning, overexpression and purification of VarR from pET21a 
4.1.1 Cloning of varR into pET21a expression vector 
PCR amplification of varR 
The forward primer, var1Fwd, and reverse pnmer, varlRev, were designed to 
incorporate theRE sites, Ndel and Xhol, at the 5' and 3' ends of the amplified varR, 
respectively. The native start codon was maintained in the Fwd primer by the Ndel site 
and the stop codon was eliminated from the Rev primer. A HotStart Taq polymerase 
PCR (Chapter 2 section 2.6.1) was performed with an annealing temperature of 65°C, 
extension time of 1 minute 20 seconds, and 30 cycles of amplification. Figure 4.1 shows 
the successful amplification of varR (lanes 2 to 5) which is consistent with the predicted 
size of 930bp. 
Figure 4.1 PCR amplification of varR gene from V. cholerae CVD101. Lane 1= 
molecular weight (Mr) marker. Lanes 2-5 show individual PCR 
amplification reactions. 
3Kb ______. 
2Kb ______. 
1 Kb ______. 
500bp ______. 
1 2 3 4 5 
+---- Amplified varR 
gene {930bp) 
The amplified varR gene was extracted and purified from the agarose gel following 
visual identification and ligated into the commercial T-A propagation vector, pGEM-T 
Easy. he ligation mixture was transformed into chemically competent E. oli 
NovaBlue. Plasmid DNA purified from recombinant colonies was digested with Ndel 
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and Xhol to confirm the presence of inserted DNA. Figure 4.2 shows the result of three 
pGEM-T Easy vector digests. Positively identified recombinant clones were used in the 
following expression vector sub-cloning procedure (figure 4.3). 
Figure 4.2 Restriction analysis of three pGEM-T Easy/ varR vectors. Lane 1= Mr 
marker. Lanes 2 and 3 exhibiting the presence of the varR gene and lane 
4 shows a partially digested vector containing the inserted gene. 
3Kb---+ 
2Kb---+ 
1Kb---+ 
1 2 3 4 
Partially 
digested 
recombinant 
pGEM-T Easy 
vector (-4Kb) 
pGEM-T Easy 
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Inserted varR 
gene (930bp) 
500bp---+ 
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Figure 4.3 Schematic illustration of a general sub-cloning procedure 
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Subcloning of varR into pET21a expression vector 
Recombinant pGEM-T Easy vectors were digested with Ndel and Xhol to excise the 
inserted varR gene. pET21a expression vectors were also digested simultaneously with 
Ndel and Xhol. The digests were separated by gel electrophoresis and the varR gene 
and linear pET21 a were purified by the gel extraction method. 
Linear pET21a was treated with shrimp alkaline phosphatase prior to ligation 
with varR using the cohesive end ligation (T4 DNA ligase) method. The ligation 
mixture was transformed into chemically competent E. coli NovaBlue. Eight ampicillin 
resistant colonies were chosen for colony PCR identification of inserted varR from 
recombinant pET21a. Figure 4.4 shows the result of PCR based identification of 
inserted varR from recombinant pET21a. Lanes 4, 5, 6, 7, and 9 show the successful 
amplification of varR that indicates its presence in the recombinant pET21 a vectors 
from the chosen colonies. 
Figure 4.4 
2kb _____. 
1 Kb_____. 
650bo _____. 
1 
PCR identification of inserted varR in pET21a. Colony PCR of 
individual recombinant colonies (lanes 2-9) using varRlFwd and Rev 
primers. Lane 1 = Mr marker. 
2 3 4 5 6 7 8 9 
+-- varRgene 
(930bp) 
Three positively identified recombinant pET21a colonies were cultured overnight. 
Glycerol stocks of these cultures were prepared for -80°C storage and recombinant 
pET21a recovered from NovaBlue by the plasmid DNA mini preparation method. The 
resulting purified recombinant pET21a vectors were sent for DNA sequencing to ensure 
sequence integrity. The C-terminal of varR gene in the pET21a expression construct is 
fused consecutively to six histidines (His6). 
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4.1.2 Overexpression of VarR from BL21 Star(DE3) or BL21-AI/pET21a 
The VarR-pET21a expression construct was transformed into BL21 Star(DE3) for 
protein production. Expression of V arR from pET21 a results in a fusion to a His6-tag at 
the C-terminal and is referred to as VarR-His6. 
Bacterial cultures were prepared as described in Chapter 2 section 2.10.1 
incorporating lOOJ.lg/rnl carbenicillin. At mid-log phase (00600 of 0.5-0.6), 
overexpression of VarR-His6 from BL21 Star (DE3) was induced with 0.5mM IPTG 
and expressed for a further 3 hours at 37°C. Relative toxicity was experienced with 
cultures becoming translucent and weak indicating the demise and/or lysis of cells. This 
could be due to a several fold increase in transcription by T7 RNA polymerase 
compared to that of its native RNA polymerase, where transcription surpasses 
translation, resulting in the formation of unstable mRNA (Miroux and Walker, 1996; 
Baneyx, 1999). This may produce a metabolic burden in the overwhelmed bacterium 
provoking a lethal SOS response (Miroux and Walker, 1996). To slow the rate of 
protein synthesis, subsequent cultures were induced and expressed overnight with 
conditions of 25°C with l20rpm rotary agitation for 16 hours. Cultures once again 
showed immense toxicity having lysed following overnight expression, therefore 
recombinant pET21a was transformed into a highly regulated expression strain, BL21-
AI. 
BL21-AI lacks the DE3 lysogen allowing rapid and vigorous growth. Induction 
of T7 RNA polymerase from the araBAD promoter is mediated by L-Arabinose, which 
displaces the araC repressor. This minimises basal expression of the regulated protein. 
Bacterial cultures were prepared as described in Chapter 2 section 2.1 0.1. At 
mid-log phase (00600 of 0.5-0.6), expression of T7 RNA polymerase was induced with 
0.02% L-arabinose and expression of VarR from the T7 promoter from pET21a induced 
with 0.2mM IPTG. These were optimised concentrations determined from titration 
experiments (data not shown). Due to the toxicities exhibited in the previous expression 
method, induction conditions were maintained and cultures were expressed at 25°C with 
120rpm rotary agitation for 16 hours. 
4.1.3 IMAC purification ofVarR-His6 expressed from pET21a 
The soluble fraction containing VarR-His6 (36761.23Da) from 4 litres of culture was 
obtained by differential centrifugation (Chapter 2 Section 2.11.1 ). The calculated 
isoelectric point (pi) of VarR-His6 was 7.47, and so a pH of 8.0 was used for all 
purification buffers to give VarR-His6 an overall negative charge. 
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Var-His6 was purified from the soluble fraction by metal affinity chromatography using 
Ni2+ agarose (chapter 2 section 2.11.2). 
The packed column was initially washed with lOrnl of 20rnM Tris-HCl pH 8.0, 
600rnM NaCl, 10% glycerol, 30rnM Imidazole and 1rnM THP buffer. A second wash 
incorporated 10rnl of 20rnM Tris-HCl pH 8.0, 800rnM NaCl, 10% glycerol, 60rnM 
imidazole and 1rnM THP. A third wash incorporated 10rnl of 20rnM Tris-HCl pH 8.0, 
300rnM NaCl, 10% glycerol, 60rnM imidazole and 1rnM THP. Each wash step was 
held for 5 minutes prior to eluting from the column and the flow through was collected 
for later reference. VarR-His6 was eluted from the column using buffer A containing a 
500rnM imidazole, in 1rnl volumes (up to a total of 8rnl) and held for 5 minutes each 
time. 
The efficiency of expression and purification of VarR-His6 was determined by 
SDS-PAGE (Chapter 2 section 2.12.1) and can be seen in figure 4.5. The wash fractions 
(lanes 1-3) show the varying degrees of contaminants, but no major protein bands. The 
migration of a protein band (lanes 5 to 10) around 39kDa of the SeeBlue protein marker 
(lane 4) is consistent with that of VarR-His6 with a calculated molecular weight of 
-36.8kDa. A possible dimer of VarR-His6 (lanes 5 to 10) can be seen at -64kDa. 
Possible degradation products of VarR-His6 are located around 28kDa. 
Figure 4.5 SDS-PAGE of VarR-His6 expressed from BL21(AI)/ pET21a. Lanes 
1-3; wash fractions 1-3, respectively. Lane 4= Mr marker. Lanes 5-10; 
fractions eluted by 500rnM imidazole. 
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SDS-PAGE analysis shows the presence of a possible dimer of VarR-His6, which may 
be due to the formation of a disulphide bond between two of the three cysteine residues 
(C75, C180 and C196) present in VarR. This is not unexpected as purification proceeds 
under aerobic conditions therefore encouraging the oxidation of the cysteines leading to 
the formation of a heterogeneous sample. In an attempt to address if the higher 
oligomeric arrangement was caused by disulphide cross links, VarR-His6 was purified 
once again, however, with 5mM THP (tris(hydroxypropyl)phosphine) as a reducing 
agent was incorporated into the purification buffers. Subsequent analysis by SDS-PAGE 
(figure 4.6, lane 2) showed that this treatment had no effect on the putative dimer band, 
as did treatment with an excess of reducing agent, 5% v/y ~-mercaptoethanol, and 
denaturant, 8M Urea (lane 3). Heat treatment at 100°C for 5 minutes also failed to fully 
dissociate the putative dimer (fig. 4.6, lanes 4 and 5). This leads to the conclusion that 
disulphide linkage does not participate in the formation of this higher oligomeric state 
and that bond formation is most likely irreversible. In this state, VarR is insoluble and 
probably lacks biological activity. 
Figure 4.6 Treatment of VarR-His6 with P-mercaptoethanol, urea and heat. 
Lane 1= Mr marker. Lanes 2-3; treatment with reducing agents, 5mM 
THP and 5% b-mercaptoethanol /8M urea, respectively. Lanes 4-5; heat 
treatment (100°C, 5 min). 
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· or contaminants 
·--+-- VarR-His6 monomer 
181 
(36.8kDa) 
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products 
From the SDS-PAGE we see that the yield of VarR-His6 is unusually low for an 
overexpressed soluble protein. It was assumed that the majority of the VarR-His6 may 
have formed insoluble aggregates or inclusion bodies, which is consistent with the 
results of another study purifying the LTTR, AmpR (Bishop and Weiner, 1993). The 
cell pellet obtained from ultracentrifugation was examined for the presence of these 
insoluble aggregates through the treatment with 8M Urea and resolution by SDS-PAGE 
(figure 4.7). From the SDS-PAGE gel we see that a large proportion of the contents of 
the pellet are indeed inclusion bodies of VarR-His6 (lanes 2 to 6). 
Figure 4.7 Inclusion body formation. Solubilisation of pellet of VarR- His6 
obtained from ultracentrifugation with 8M urea. Lane 1= Mr marker. 
Lanes 2-6; soluibised cell pellet. 
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Inclusion body formation occurs as a result of high expression of foreign proteins that 
accumulate as insoluble, denatured aggregates caused by improper folding of the protein 
(Baneyx, 1999; Baneyx and Mujacic, 2004). These proteins are often inactive and 
ineffective for further functional studies (Villaverde and Carrio, 2003). However, 
inclusion bodies can be solubilised by further purification and refolding methods, but 
these methods often subject the proteins to harsh and detrimental conditions. These 
conditions may affect the integrity of the refolded protein (Sorensen and Mortensen, 
2005), altering the ability of the protein to attain optimum functional efficiency or may 
even cause loss of function altogether (Makrides, 1996). Even if the inclusion bodies are 
182 
successfully solubilised, the yield of biologically active proteins may not be significant 
(Baneyx, 1999) and it may be difficult to increase the protein to a necessary 
concentration for crystallisation without causing further aggregation or precipitation 
(Golovanov et al., 2004). 
The use of such high concentrations of THP in the buffers could affect the 
ability of VarR-His6 to bind Ni-NTA effectively during purification and may affect the 
formation of the correct oligomeric species (through disulphide linkage) essential for 
binding DNA during electrophoretic mobility shift assays (EMSAs). On the basis of this 
and to improve the soluble yield of VarR-His6, a modified strategy where lower inducer 
concentrations of 0.1 and 0.2mM IPTG and 0.0002, 0.002, and 0.02% L-Arabinose 
were adopted accordingly and temperatures of 25, 20 and 16°C were used for expression 
following induction. Lower induction conditions have been suggested to increase the 
stability and potential for correct folding of proteins (Baneyx and Mujacic, 2004; 
Sorensen and Mortensen, 2005). However, these conditions failed to improve the 
solubility of VarR-His6, and so varR was cloned into an alternative expression vector, 
pQE-100, and expressed from M 15 which incorporates a lac repressor protein on the 
plasmid pREP4. This combination allows for tighter regulated expression of V arR 
through repression at the T5 promoter prior to induction. The cloning of varR into pQE-
100, and the overexpression and purification of VarR-His6 proceeded as described 
previously unless stated otherwise. 
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4.2 Cloning, overexpression, and purification of VarR from pQE-100 
4.2.1 Cloning of varR into pQE-100 expression vector 
PCR amplification of varR 
The forward primer, var2Fwd, and reverse primer, var2Rev, were designed to 
incorporate theRE sites, BamHI and Hindill, at the 5' and 3' ends of amplified varR, 
respectively. The STOP codon, TTA, was maintained prior to the Hindill site at the 3' 
end. A HotStart Taq polymerase PCR (Chapter 2 section 2.6.1) was performed with an 
annealing temperature of 65°C, extension time of 1 minute 20 seconds, and 30 cycles of 
amplification. Figure 4.8 shows the successful amplification of varR (lanes 2 to 5) 
which is consistent with the predicted size of 930bp. 
Figure 4.8 
2Kb 
PCR amplification of varR gene from V. cholerae CVD101. Lane 1= 
Mr marker. Lanes 2-5 show individual PCR amplification reactions. 
1 2 3 4 5 
._,__ Amplified varR 
gene (930bp) 
The amplified varR gene was purified, cloned into pGEM-T Easy vector and 
transformed into NovaBlue as described in section 4.1.1. Plasmid DNA purified from 
recombinant colonies was digested with BamHI and Hindill to confirm the presence of 
inserted DNA. Figure 4.9 shows the result of three pGEM-T Easy vector digests. 
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Figure 4.9 
3Kb----+ 
2Kb-----+ 
1Kb-----+ 
500bp _____.. 
Restriction analysis of three pGEM-T Easy/ varR vectors. Lane 1= Mr 
marker. Lanes 2-4 exhibiting the presence of the inserted varR gene. 
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Cloning of varR into pQE-100 expression vector 
The varR gene was cloned into the pQE-100 expression vector as described previously 
in section 4.1.1. Figure 4.10 shows colony PCR of eight recombinant colonies. Lanes 2-
3 and 5-9 show the successful amplification of varR that indicates its presence in the 
recombinant pQE-1 00 vectors from the chosen colonies. 
Figure 4.10 PCR identification of inserted varR in pQE-100. Colony PCR of 
individual recombinant colonies (lanes 2-9) using varR2Fwd and Rev 
primers. Lane 1 = Mr marker. 
1 2 3 4 5 
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The resulting purified recombinant pQE-100 vectors were sent for DNA sequencing to 
ensure sequence integrity and transformed into a chemically competent expression 
strain of E. coli M15 that carries the repressor plasmid pREP4. This combination results 
in the efficient repression of recombinant V arR expression prior to induction and thus 
minimise toxicity as exhibited previously. 
4.2.2 Overexpression of VarR-His6 from MIS [pREP4]/pQE-100 
Expression of VarR from pQE-100 results in a fusion to a His6-tag at theN-terminal and 
is referred to as His6-VarR. 
Bacterial cultures were prepared as described in Chapter 2 section 2.10.2 
incorporating 100J..lg/ml carbenicillin and 25J..lg/ml kanamycin. At an OD6oo of 0.5-0.6, 
overexpression of His6-VarR from M15 [pREP4] was induced with 0.1mM IPTG 
(optimised concentration determined from titration experiments, data not shown) and 
expressed with low induction conditions of 25°C with 120rpm rotary agitation for 16 
hours. 
4.2.3 IMAC purification of VarR-His6 expressed from pQE-100 
The soluble fraction containing His6-V arR (36761.23Da) from 4 litres of culture was 
obtained by differential centrifugation (chapter 2 section 2.11.1) and purified by metal 
affinity chromatography using Ni2+ agarose (chapter 2 section 2.11.2). 
The packed column was initially washed with 20ml of 20mM Tris-HCl pH 8.0, 
800mM NaCl, 10% glycerol, 50mM Imidazole and 1mM THP buffer. A second wash 
incorporated 10ml of 20mM Tris-HCl pH 8.0, 300mM NaCl, 10% glycerol, 70mM 
imidazole and 1mM THP. His6-VarR was eluted from the column using buffer A 
containing a 500mM imidazole. 
Figure 4.11 shows the efficiency of expression and purification of His6-V arR 
was determined by SDS-PAGE. Similarities can be seen with the expression of VarR-
His6 from BL21-AJJ pET21a. The wash fractions (lanes 2-3) show the varying degrees 
of contaminants, but no major protein. The migration of a protein band (lanes 5 to 1 0) 
around 39kDa of the SeeBlue protein marker (lane 1) is consistent with that of His6-
VarR with a calculated molecular weight of -36.8kDa. A possible dimer of His6-VarR 
(lanes 5 to 10) can be seen at -64kDa. Possible degradation products of His6-V arR are 
located around 28kDa. However, these are less than that seen previously from the 
expression from BL21-AJJ pET21a; suggesting His6-VarR may be expressed in a more 
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stable conformation or purified in optimum conditions that reduce proteolytic 
degradation. 
Figure 4.11 SDS-PAGE of His6-VarR expressed from MlS [pREP4]/ pQE-100. 
Lane 1= Mr marker. Lane 2-3; wash fractions 1 and 2, respectively. 
Lanes 5-10; fractions eluted by 500mM imidazole. 
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To improve the homogeneity of the preparation, the protocol was modified to include an 
increase in the imidazole concentration to 90mM in the final wash and 2mM THP was 
incorporated into all buffers. Figure 4.12 shows the purification of His6-VarR to >98% 
purity. 
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Figure 4.12 SDS-PAGE of His6-VarR expressed from M15 [pREP4]/ pQE-100. 
Lanes 1-2; wash fractions 1 and 2, respectively. Lane 3= Mr marker. 
Lanes 4-9; fractions eluted by 500mM imidazole. 
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In order to remove the imidazole from the preparation, the elutions of His6- V arR were 
dialysed using the dialysis cassette method (Chapter 2 Section 2.12.3) against buffer B 
consisting of 20mM Tris-HCl pH 8.0, 300mM NaCl, 10% glycerol, 2mM THP. The 
concentration of His6- V arR was determined to be -1-1.5mg/rnl using the Coomassie 
(Bradford) protein assay as described in Chapter 2 section 2.12.5. A sample of His6-
VarR from lane 5 of figure 4.12 was taken to positively identify VarR through 
florescence specific detection of its Histidine tag (see next section). His6-VarR was snap 
frozen in 1 OOj..tl aliquots using a dry ice/ ethanol mix and stored at -80°C or used 
immediately for EMSAs. 
The relative toxicity experienced in host E. coli prior to induction and instability 
of VarR in the previous expression experiments from the vectors pET21a and pQE-100, 
may have been a result of leaky transcription from the lac-derived promoters (Baneyx, 
1999). The concentration of His6-VarR expressed from Ml5 [pREP4]/pQE-100 was 
also insufficient for structural crystallisation. Therefore it was necessary to express 
VarR from an alternative expression vector, pBAD/Myc-His B, from the strain LMG194 
(discussed in section 4.3). The pBAD/Myc-His B expression vector was chosen due to 
its high level expression of soluble, recombinant proteins from the araBAD promoter 
(PaAD) upon induction with the sugar, L-arabinose. The strain LMG 194 ensures low 
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basal expression of toxic genes which can be further repressed at PsAD by growth on 
minimal media and glucose (Guzman et al., 1995; Invitrogen, 2001). 
4.2.4 Identification of His-tagged VarR using fluorescence detection 
Histidine-tagged VarR from lane 5 of figure 4.12 was identified through the 
fluorescence detection method (chapter 2 section 2.12.2.2). Figure 4.13 shows 
positively identified His6-tagged VarR (lane 1). 
Figure 4.13 Fluorescence detection of His6.VarR from MlS [pREP4]/ pQE-100. 
Lane 1= His6-VarR. Lane 2= Mr marker. Lane 3= positive control. 
His6-VarR --•., 
(36.8kDa) 
1 2 
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4.3 Cloning, overexpression, purification and identification of VarR from 
pBAD/Myc-His B 
4.3.1 Cloning of varR into pBAD/Myc-His B (pBAD-B) expression vector 
PCR amplification of varR 
The forward primer, var3Fwd, and reverse pnmer, var3Rev, were designed to 
incorporate RE sites, Ncol and Xbal, at the 5' and 3' end of amplified varR, 
respectively. A single guanine nucleotide was introduced to follow the Ncol site at the 
5' end of the var3Fwd primer. This ensured the reading frame was preserved with the 
START codon when cloned into the resulting pBAD-B expression vector. Specificity 
for guanine ensured a stable, neutral glycine residue was expressed (N-end rule, 
V arshavsky 1996), which is unlikely to affect the functional or structural characteristics 
of the protein. A His6-tag followed by a STOP codon was integrated prior to the Xbal 
site at 3' end of the reverse primer, var3Rev. This was to ensure that VarR was 
expressed as a fusion to a C-terminal His6-tag (VarR-His6) and that intervening 
sequences from the vector were eliminated. 
A HotStart Taq polymerase PCR (Chapter 2 section 2.6.1) was performed with 
annealing temperatures of 62°C and 66°C, extension times of 1 minute 30 seconds, and 
20 and 15 cycles of amplification, respectively for each annealing temperature. Figure 
4.14 shows the successful amplification of varR (lanes 2 to 5) which is consistent with 
the predicted size of 930bp. 
Figure 4.14 PCR amplification of varR from V. cholerae CVD101. Lane 1= 
molecular weight (Mr) marker. Lanes 2-5 show individual PCR 
amplification reactions. 
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Initial screening of three recombinant colonies through digests with Neal and Xbal 
failed, which was thought to be due to errors in the amplification of the RE sites and so 
the recombinant vectors were ~ent for sequencing. Upon return of the DNA sequencing 
results, perfect sequence integrity was exhibited with intact RE sites, artificially 
incorporated nucleotides and the 3' end His6-tag. However, it was established that the 
Xbai site partially overlapped a dam methylation site (GATC). Therefore cleavage by 
Xbal was blocked due to DNA methylation by Dam methylase. Inserted varR was 
successfully released from pGEM-T Easy using Neal and EcoRI thereby confirming 
that Xbal was the problematic site. Figure 4.15 shows the results of three recombinant 
pGEM-T Easy digests with Neal and EcoRI. 
Figure 4.15 Restriction analysis of three pGEM-T Easy/ varR vectors. Lane 1= Mr 
marker. Lanes 2-3 exhibit the presence of the varR gene. 
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Cloning of varR into pBAD-B expression vector 
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pGEM-T Easy 
(3Kb) 
The varR gene was cloned into the pBAD-B expression vector as described previously 
in section 4.1.1. Figure 4.16 shows EcoRI digest of four recombinant pBAD-B vectors. 
A DNA bind that migrates at -5Kb (lane 2-5) i consistent with the pBAD-B vector 
incorporating inserted varR. 
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Figure 4.16 Restriction analyses of four recombinant pBAD-B expression 
vectors. Lane 1= Mr marker. Lanes 2-5 exhibiting a linear fragment 
incorporating the pBAD-B vector and the inserted varR gene. 
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The resulting purified recombinant pBAD-B vectors were sent for DNA sequencing to 
ensure sequence integrity and transformed into a chemically competent expression 
strain of E. coli LMG 194. 
4.3.2 Overexpression of VarR-His6 from LMG194/pBAD-B 
Bacterial cultures were prepared as described in Chapter 3 section 2.10.3 incorporating 
lOOj..Lg/rnl carbenicillin. At an OD6oo of 0.5-0.6, overexpression of VarR-His6 from 
LMG194 was induced with a final concentration of 0.02% (v/v) L-Arabinose and 
expressed at 37°C with 180-200rpm rotary agitation for 3 hours (optimised conditions 
determined from titration and time based experiments, data not shown). 
4.3.3 Purification and Concentration of VarR-His6 from pBAD-B 
IMAC purification ofVarR-His6 from LMG194/pBAD-B 
From herein all manipulations were carried out at 4°C, unless otherwise stated. The cell 
pellet harvested from overexpression of VarR from LMG 194/pBAD-B was resuspended 
in buffer A at pH8.25. The soluble fraction containing VarR-His6 (36761.23Da) from 4 
litres of culture was obtained by differential centrifugation (chapter 2 section 2.11.1) 
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and purified by metal affinity chromatography using Ni2+ sepharose (chapter 2 section 
2.11.2). 
The packed column was initially washed with 20ml of 20mM Tris-HCl pH 8.25, 
800mM NaCl, 10% glycerol, 50mM imidazole and 1mM THP buffer. A second wash 
incorporated 10ml of 20mM Tris-HCl pH 8.25, 300mM NaCl, 10% glycerol, 70mM 
imidazole and 1mM THP. VarR-His6 was eluted from the column using buffer A 
containing a 500mM imidazole. Initially VarR-His6 seemed soluble upon elution; 
however, within 30 minutes on ice a white, cloudy precipitate had formed in elutions 5 
to 7 suggesting that the preparation was unstable. Interestingly, as elutions 8 to 9 failed 
to precipitate, it seems as if at lower concentrations V arR was maintained in solution. 
Figure 4.17 shows the efficiency of expression and purification of VarR-His6 by SDS-
PAGE. Lanes 1 and 2 show theFT from washes 1 and 2, respectively. Lane 3 contains 
the SeeBlue protein marker and lanes 4 to 9 show elution fractions 1 to 6, respectively. 
A possible dimer located at approximately -64kDa can be seen. 
Figure 4.17 SDS-PAGE of VarR-His6 expressed from LMG194/pBAD-B. Lanes 
1-2; wash fractions 1 and 2, respectively. Lane 3= Mr marker. Lanes 4-9; 
fractions eluted by 500mM imidazole. 
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Curiously, to determine if any VarR remained in solution, the precipitate from elution 5 
was removed by centrifugation at 13K rpm for 1 minute and the soluble fraction once 
again analysed by SDS-PAGE. Intriguingly, a substantial amount of VarR remained in 
th oluble fraction similar to that seen in elution 8 and 9. This shows that VarR-His6 is 
seemingly soluble at lower concentrations, reflecting previous studies that have 
experienced precipitation of LTTRs at concentrations around 1-1.5mg/ml (Verschueren 
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et al., 2001). It could be that VarR-His6 is purified as a heterogeneous mixture of 
oligomeric states and that above a critical concentration it forms a specific stable 
oligomeric conformation that remains in solution, with all other unstable oligomeric 
states precipitating out of solution. Figure 4.18 shows the SDS-PAGE of VarR extracted 
from the precipitate of elution 5. 
Figure 4.18 SDS-PAGE of VarR-His6. Lane 1= Soluble VarR-His6 extracted from 
the precipitate of elution 5. Lane 2= Mr marker. 
Soluble ---+ 
VarR-His6 (36.8kDa) 
With this in mind, further modifications during purification were undertaken to improve 
solubility at higher protein concentrations, which is essential for progressing the 
structural characterisation of VarR. It was hypothesised that aggregation could have 
been mediated by ionic interactions as most LTTRs require NaCl and imidazole 
concentrations to improve their solubility (Stec et al., 2004). Therefore a series of NaCl 
concentrations ranging from 300mM to 1M were incorporated into the purification 
buffer to mediate solubility. However, the use of such high concentrations of salt will 
dramatically reduce downstream purification processes such as anion exchange 
chromatography, which are often adopted for intermediate purification of proteins. 
Structural studies such as circular dichroism and crystallisation are also unable to 
tolerate such high N aCl concentrations, due to interference in absorption and formation 
of salt crystals, respectively. High salt concentrations may disrupt or cause the loss of 
binding ability for DNA during EMSAs or substrate during crystallisation (Muroaka et 
al., 2003). Therefore the use of hlgh NaCl concentration would not be desirable. 
Nevertheless, the addition of high concentrations of NaCl failed to prevent precipitation 
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of VarR-His6 in solution (data not shown), concluding that insolubility was not due to 
ionic interactions. 
The pH was adjusted from pH8.25 to pH6.5 to determine if this was a factor for 
the insolubility issues. However, this led to the elution of VarR-His6 at lower 
concentrations and over numerous fractions , suggesting that this pH was favourable for 
a greater affinity for the immobilised nickel. The results can be seen in figure 4.19 
where lane 1 shows theFT from column packing, lane 2FT from wash 3, and lanes 4 to 
10 elution 1 to 7, respectively. 
Figure 4.19 SDS-PAGE of VarR-His6 purified at pH6.5. Lanes 1-2; wash fractions 
1 and 2, respectively. Lane 3= Mr marker. Lanes 4-10; fractions eluted 
by 500mM imidazole. 
1 2 3 4 5 6 7 8 9 10 
V arR at these concentrations 1s inefficient and would be preferable at higher 
concentrations per elution. The therefore the pH was readjusted back to pH8.25 and 
alternative methods were utilised. 
To improve the solubility of the VarR-His6 preparation, the purification protocol 
was modified at the wash stages. Golovanov and associates (2004) demonstrated that 
addition of charged amino acids L-Arg and L-Glu at 50mM each to purification buffers 
dramatically increased the solubility of non-membrane proteins at high concentrations. 
They also found that this was effective for preventing aggregation and precipitation and 
improves long term stability of the protein preparation by preventing proteolytic 
degradation. It was also demonstrated that these additives did not adver ely affect 
specific protein-protein and protein-DNA interaction, which would be ideal for the 
crystallisation of VarR in the presence of its substrates and/or cognate promoter DNA. 
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On the basis of these findings, the packed column was washed and VarR-His6 eluted as 
described previously with buffers supplemented with 50mM L-Arginine and L-
Glutamine. Fmstratingly, the eluted preparations once again precipitated within an hour 
on ice. Figure 4.20 shows the efficiency of purification, solubilisation and stabilisation 
of VarR-His6 using the additive assisted method. Lanes 1 and 2 show the flow through 
from washes 1 and 2, respectively. Lane 3 contains the SeeBlue protein marker and 
lanes 4 to 9 show elution fractions 1 to 6, respectively. 
Figure 4.20 VarR-His6 purification using the L-Arg/ L-Glu additive method. 
Lanes 1-2; wash fractions 1 and 2, respectively. Lane 3= Mr marker. 
Lanes 4-10; fractions eluted by 500mM imidazole. 
1 2 3 4 5 6 7 8 9 10 
+-- VarR-His6 (36.8kDa) 
As VarR is a DNA binding protein, it was hypothesised that purification in the presence 
of its cognate 30bp promoter DNA could stabilise VarR in a conformation that would 
prevent aggregation or precipitation in the purified preparation. This method has been 
used successfully to resolubilise the transcriptional activator, BrnrR, which precipitated 
following IMAC purification (Heldwein and Brennan, 2001). The purification protocol 
was once again modified at the level of elution to improve the solubility of the VarR-
His6 preparation. From the previous purifications, we estimate that a maximum of 
8mg/ml of VarR was eluted per 1rnl of elution buffer. As LTTRs are hypothesised to 
bind promoter DNA as a tetrarneric species and assuming VarR is monomeric, a 1:4 
molar ratio of dsDNA to VarR was added to the elution buffer and also directly to the 
eluted preparation, respectively. The 30bp duplex DNA encompassed the operator 
sequence for VarR from the varRG IR, which has been determined from EMSAs to be 
bound by VarR (see Chapter 5). The packed column was washed as described 
previously and VarR-His6 eluted with elution buffer supplemented with 50~ varRG 
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DNA. Frustratingly, the eluted preparations once again precipitated within an hour on 
ice and could not be re-solubilised upon direct addition of the 30bp varRG DNA. Figure 
4.21 shows the efficiency of purification of VarR-His6 using the DNA stabilisation 
method. Lane 1 contains the SeeBlue marker and lanes 2 and 3 show the flow through 
from washes 1 and 2, respectively. Lanes 4 to 8 show elution fractions 1 to 5, 
respectively. 
Figure 4.21 VarR-His6 purification using the varRG DNA stabilisation method. 
Lane 1= Mr marker. Lanes 2-3; wash fractions 1 and 2, respectively. 
Lanes 4-8; fractions eluted by 500mM imidazole. 
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Due to the relative expense of synthesising the promoter DNA used in this purification, 
it was not sustainable to continue in this manner and so an alternative method was 
employed. Previous expression of 1.5mg/rnl of VarR from pET21a was successfully 
soluble. This has led to hypothesis that aggregation and precipitation at higher 
concentrations could be due to collisions and/or hydrophobic interactions between and 
within proteins as a result of being in closer proximity. As VarR is theoretically a 
soluble protein these hydrophobic interactions are likely to be localised hydrophobic 
patches. Therefore a small concentration of detergent, n-Dodecyl ~-D-maltoside (DDM) 
was used to mask these potential hydrophobic patches in VarR-His6 during purification 
(typical detergent concentrations for the solubilisation of integral membrane proteins are 
1-4% ). DDM was chosen over other detergents for its non-ionic and non-denaturing 
properties that would allow further purification using ion-exchange chromatography. 
Also the aggregation number (98) was considerably smaller than for other non-ionic 
detergents such as Triton X-100 (100-155) which enables purification by SEC method 
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and DNA binding studies using analytical SEC. The presence of aromatic residues that 
absorb at 260nm-280nm in Triton X-100 also ruled out its use, due to its ability to affect 
downstream purification and analytical SEC methods that require UV monitoring of 
protein and DNA concentration. Triton X-100 has also been known to contain peroxides 
as contaminants, which could influence the proteins molecular properties such as 
disulphide bond linkage (Calbiochem). 
On the basis of these findings, the packed column was washed as described 
previously and VarR-His6 eluted with buffers supplemented with 0.5% (w/v) DDM (n-
Dodecyl ~-D-maltoside). Annoyingly, the incorporation of DDM in the wash buffers 
seemed to have weakened or masked the affinity of VarR-His6 for Ni2+-sepharose 
resulting in almost total loss of protein during the wash stages (data not shown). 
Therefore VarR-His6 was once again purified with 0.5% (w/v) DDM being added only 
to the elution buffer. The addition of DDM to the elution buffer successfully solubilised 
VarR-His6 and seemed to beneficially concentrate it into a lesser number of fractions 
compared to previous purifications. Therefore we can be sure that insolubility was 
mediated by hydrophobic interactions. Figure 4.22 shows the efficiency of purification 
and solubilisation of VarR-His6 by the detergent assisted method. Lanes 1 and 2 show 
the flow through from washes 1 and 2, respectively. Lane 3 contains the SeeBlue 
protein marker and lanes 4 to 9 show elution fractions 1 to 6, respectively. 
Figure 4.22 VarR-His6 purification using the detergent assisted method. Lanes 1-
2; wash fractions 1 and 2, respectively. Lane 3= Mr marker. Lanes 4-9; 
fractions eluted by 500mM imidazole. 
12 3 4 5 67 89 
198 
Possible VarR-His6 
Dimer 
VarR-His6 (36.8kDa) 
In order to reduce the concentration of free detergent micelles present in the protein 
preparation, V arR was concentrated by anion-exchange. It was anticipated that this 
would allow VarR-His6 to retain optimum biological activity for future studies. Through 
trial and error, the lowest concentration of DDM that could be present in the eluent 
before the precipitation of VarR-His6 was 0.35% (w/v) (data not shown). 
As non-protein impurities may limit protein solubility, the purity of VarR-His6 
was further refined by anion exchange (intermediate) and size exclusion 
chromatography (polishing) in preparation for crystallisation trials. 
Anion exchange purification of VarR-His6 
Anion exchange (AnionEx) chromatography was performed as described in Chapter 2 
section 2.11.3 using a HiTrap Q sepharose high performance column (5ml, Amersham). 
VarR-His6 was buffer exchanged into the following low ionic strength buffer: 
20mM Tris-HCl pH8.5, 50mM NaCl, 10% glycerol, lmM THP, 0.35% DDM. PD-10 
desalting and buffer exchange columns (Amersham) were employed for this process due 
to the relative instability exhibited by VarR-His6 in the purification experiments. The 
PD-1 0 columns were equilibrated as per manufacturer's instruction. 
AnionEx chromatography was performed on an AKTA purifier system 
(Amersham) and monitored using 280nm UV absorbance. All buffers and water used 
were distilled and degassed through surfactant-free cellulose acetate 0.2J..LM filters 
(Nalgene) and a flow rate of 1 millilitre per minute was applied through the column 
(maximum pressure limit of 0.5MPa), unless otherwise stated. The AKTA purifier 
system was initially flushed with water until the UV and conductivity reached a steady 
baseline and was then equilibrated with low ionic strength buffer (LIS buffer). The 
HiTrap Q column was then attached to the system and equilibrated with 5-10 column 
volumes of water and 5-8 column volumes (CV) of LIS buffer, respectively. Desalted 
VarR-His6 was applied to the HiTrap Q column and washed with five CV of LIS buffer 
or until no material appeared in the effluent. A high ionic strength (HIS) buffer of 
20mM Tris-HCl pH 8.5, 1M NaCl, 10% Glycerol, lmM THP, 0.35% DDM was used in 
combination with the LIS buffer to form a continuous ionic gradient for elution of 
VarR-His6 from the column. The continuous gradient increased was programmed to run 
from the AKTA purifier up to a maximum of 0.5M NaCl over 20 CV. The elution of 
VarR-His6 from the column was monitored at an UV absorbance of 280nm and 
collected. Figure 4.23 shows a chromatogram from anion exchange purification of 
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VarR-His6 with the corresponding collected peak fractions, numbered according, shown 
in the SDS-PAGE. 
Figure 4.23 Chromatogram of VarR-His6 purified from anion exchange 
chromatography with the correspondingly numbered protein 
fractions identified in the SDS-PAGE . 
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The elution profile from the chromatogram shows two peaks that could correspond to 
two oligomeric states of V arR. The first peak could be either a monomer or dimer 
arrangement of VarR that has a lower affinity for the column compared to the second 
peak that could correspond with either a dimer or tetramer form with a higher affinity. 
The ability of V arR to form different oligomeric states is not unusual as it has been 
proven that LTTRs such as AmpR, CysB and CbnR are capable of forrning dimers and 
tetramers in solution, but are tetrameric upon binding DNA (Miller and Kredich, 1987; 
Bishop and Weiner, 1993; Verschueren et al., 2001; Muroaka et al., 2003). This is also 
true of other multidrug-binding proteins such as QacR and V ceR that exist as dimers in 
solution, but bind its promoter as a tetramer formed from a dimer of dimers (Grkovic et 
al., 2001; Borges-Walmsley et al., 2005). V arR may therefore exist as dimer and 
tetramer conformations in solution, and could be stabilised into a predominantly 
tetrameric conformation when bound to its cognate promoter DNA in vivo. This would 
be functionally feasible as the predicted operator sites for VarR spans 56bp of the 
putative varRG promoter and 62bp of the varGA promoter. This would require VarR to 
be in a tetrameric conformation, possibly as a dimer of dimers, for all four DBDs to 
bind to these sites. This would be similar to the predicted binding manner of tetrameric 
OxyR (Tyrrell et al., 1997) and CbnR to its 60bp cognate promoter, whereby both HTH 
in each dimer contacts each half site of the operator that overlaps the recognition and 
activation binding sites, respectively (Muraoka et al., 2003). Therefore what we see in 
figure 4.23 could be a tetrameric fir t peak and a dimeric second peak of VarR. 
However, this can only be confirmed through analytical SEC or ultracentrifugation 
studies, which will be discussed in Chapter 6. 
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The eluted peak fractions of VarR-His6 were desalted into a LIS buffer, 
respectively, using PD-10 column as described previously in preparation for AnionEx 
concentration. Due to the maximum sample load volume of 1% of the total column 
volume for size exclusion chromatography (SEC) based purification, it was necessary to 
concentrate VarR-His6 using AnionEx. Also this method minimises the concentration of 
detergent present in the sample as they cannot be easily removed through buffer 
exchange. This ensures that any biological activity is maintained and the column back 
pressure during SEC is reduced. 
Anion exchange concentration ofVarR-His6 
Desalted VarR-His6 was loaded onto the HiTrap Q column as described previously and 
eluted using the following buffer: 20mM Tris-HCl pH 8.25, 1M NaCI, 10% Glycerol, 
0.4% DDM, and 2mM THP. Figure 4.24 shows the chromatogram from anion exchange 
concentration of VarR-His6 (from Peak 1 only as elution profile similar for peak 2) with 
the corresponding collected peak fractions, numbered according, shown in the SDS-
PAGE. 
Figure 4.24 Chromatogram of VarR-His6 concentrated through anion exchange 
chromatography with the correspondingly numbered protein 
fraction identified in the SDS-PAGE. 
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The eluted fractions of VarR-His6 were desalted into a LIS buffer using the PD-10 
columns as described previously in preparation for SEC. The presence of a 
heterogeneous sample of VarR further complicates the interpretation of results during 
functional studies due to the uncertainty regarding the number of active binding species. 
Therefore it is necessary to obtain VarR as in a homogenous preparation, which was 
achieved through preparatory SEC. 
Preparatory size exclusion chromatography purification of VarR-His6 
SEC of VarR-His6 was performed as described in Chapter 2 section 2.11.4 using a 
Supedex200PrepGradeHiLoadl6/60 column. All buffers and water used were distilled 
and degassed through surfactant-free cellulose acetate 0.2!J.M filters (Nalgene) and a 
flow rate of 1 millilitre per minute was applied through the column (maximum pressure 
limit of 0.5MPa), unless otherwise stated. 
In brief, the column was equilibrated with 3 CV of water and 3 CV of buffer A 
at pH8.25 and 0.25% (w/v) DDM. As the back pressure of the column was influenced 
by the viscosity of the buffer, the DDM concentration was kept to a minimum during 
purification. Proteins naturally dilute as they passes through the column, therefore 
should be sufficiently dilute to be maintained in solution in the presence of low 
detergent concentrations. Desalted VarR-His6 was applied to the column followed by 
3m1 bolu of buffer A to improve separation. Peak fractions of VarR-His6 were 
collected as they eluted from the column following the application of 1 CV of buffer A. 
The efficiency of preparatory SEC purification of VarR-His6 (from peak 2 from 
AnionEx) can be seen in figure 4.25. The numbers on the peak fraction in the 
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chromatogram correspond to the protein in the lanes of the SDS-PAGE. From the SDS-
PAGE we can see that VarR-Hiss is >98% pure, which is sufficient for crystallisation. 
Figure 4.25 Chromatogram of VarR-His6 purified from preparatory SEC (from 
peak 2 from AnionEx) and the correspondingly numbered fractions 
analysed by SDS-PAGE. 
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Interestingly, a higher molecular weight peak can be seen prior to the main protein peak 
of VarR-His6, which could be indicative of VarR existing in two different oligomeric 
states. This is consistent with previous predictions of V arR forming multiple oligomeric 
states in solution. This may reflect its ability to adopt different oligomeric states when 
bound to promoters of differing lengths. 
Temperature may affect the long term stability of VarR-His6 due to the seeming 
increased formation of a higher oligomeric species when kept at 4°C overnight. Figure 
4.26 shows the chromatogram from preparatory SEC of VarR-His6 (from peak 2 from 
AnionEx) following storage at 4°C overnight. 
Figure 4.26 Chromatogram of VarR-His6 purified from preparatory SEC after 
overnight storage at 4°C. 
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The eluted fractions 1 to 5 of VarR-His6 were desalted into a LIS buffer using the PD-
10 columns as described previously in preparation for AnionEx concentration. AnionEx 
was used to concentrate VarR-His6 prior to further concentration with molecular weight 
(MW) cut off spin columns to minimise the concentration of free detergent present in 
the final sample. 
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Anion exchange concentration of VarR-His6 from SEC 
AnionEx concentration and desalting into Buffer A (incorporating 0.35% w/v DDM) 
was performed as previously described. 
Concentration of VarR-His6 using Vivaspin centrifugal columns 
The concentration of VarR-His6 using centrifugal concentrators (Satorius) was 
performed as described in Chapter 2 section 2.11.4 and the results can be seen in figure 
4.27. Lane 1 contains concentrated VarR-His6 corresponding to peak 2 of AnionEx 
purification and Lane 2 of concentrated VarR-His6 corresponding to peak 1. 
Figure 4.27 SDS-PAGE of concentrated VarR-His6 using centrifugal 
concentrators. Lane 1-2; individually concentrated VarR-His6. 
1 2 
+--- VarR-His6 (36.8kDa) 
The concentration of His6-V arR was determined to be -7 -8mg/ml using the Coomassie 
(Bradford) protein assay as described in Chapter 2 section 2.12.5. Therefore 
approximately 2mg/ml of high purity (>98%) protein can be obtained from one litre of 
culture. However, this does not account for the loss of some protein during purification, 
which could be up to 1-2mg/ml. VarR-His6 was snap frozen in 50~1 aliquots using a dry 
ice/ ethanol mix and stored at -80°C or used immediately for crystallisation trials. 
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4.3.4 Western blot analysis of VarR-His6 
Two different samples of VarR-His6 from the initial detergent purification method were 
taken for Western Blot identification of its His6 tag (chapter 2 section 2.12.2.1) and the 
positive results can be seen in figure 4.28. Lane 1 contains the SeeBlue protein marker, 
lanes 3 and 4 contain different samples of VarR-His6 and lane 7 contains a His6-tagged 
control. Interestingly, western blot failed to detect the putative dimer at approximately 
64kDa. 
Figure 4.28 SDS-PAGE and X-ray film from Western Blot of VarR-His6. Lane 1= 
Mr marker. Lanes 3 and 4; VarR-His6. Lane 7; positive control. 
123 4 567 
+------ VarR-Hiss 
(36.8kDa) 
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4.4 Overexpression and purification of Mutant VarR (C75, 180, 196A) 
The mutation of the cysteines in VarR to alanines (C75A, C180A, C196A) was 
performed to determine if cysteine cross linking was essential for correct protein folding 
and the cause of the insolubility issues seen in wild-type VarR. Insolubility of the DNA-
binding regulator, QacR, was rectified through mutations of integral cysteines (Grkovic 
et al., 2001b). If mutation results in successful solubilisation of VarR, then detergent 
assisted purification could be eliminated and thus the number of screens (detergent) 
dramatically reduced during crystallisation. Crystallisation in the absence of detergent 
may also allow us to determine the interactions formed between VarR and its substrates 
and/or DNA as close to its native state as possible. Site directed mutagenesis of VarR 
was also employed to determine if these residues were essential for promoter DNA 
and/or substrate binding. The QuikChange Multi Site-Directed Mutagenesis system 
(Stratgene) was employed for In vitro site directed mutagenesis experiments. 
4.4.1 In vitro site directed mutagenesis of varR 
Site directed mutagensis of VarR-His6 was performed as described in chapter 2 section 
2.9. The three mutagenic primers, C75A Fwd, C180A Fwd and C196A Fwd, used are 
detailed in Table 2.6. The methylated pBAD-B-varR ds-DNA template was purified 
from the dam+ E. coli strain TOP10 by the plasmid purification method. Mutant strand 
synthesis using PCR was achieved with an extension time of 10 minutes. 
4.4.2 Overexpression of mutant VarR (C75, 180, 196A) 
Mutant VarR-His6 from LMG194/ pBAD-B was overexpressed as described previously. 
4.4.3 Purification of mutant VarR (C75, 180, 196A) by IMAC 
Mutant VarR-His6 was purified as described previously in this chapter section 4.3.3 (in 
the absence of detergent DDM). Unfortunately, the sample precipitated exactly as 
described previously. Therefore precipitation of VarR-His6 is not due to cysteine cross-
linking and is most likely to be a result of hydrophobic interactions. Figure 4.29 shows 
the efficiency of expression and purification of mutant VarR-His6 by SDS-PAGE. 
Lanes 1 and 2 show the flow through from washes 1 and 2, respectively. Lane 3 
contains the SeeBlue protein marker and lanes 4 to 10 show elution fractions 1 to 7 of 
mutant VarR-His6, respectively. 
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Figure 4.29 SDS-PAGE of mutant VarR-His6 expressed and purified from 
LMG194/pBAD-B. Lanes 1-2; wash fractions 1 and 2, respectively. 
Lane 3= Mr marker. Lanes 4-10; fractions eluted by 500mM imidazole. 
1 2 3 4 5 6 7 8 9 10 
+---- VarR-His6 (36.8kDa) 
4.5 Discussion 
The pressures we exert on bacteria to artificially overexpression foreign proteins can 
cause many problems such as toxicity and insolubility. The resultant proteins are often 
forced into adopting conformations that are not found physiologically. The extensive 
insolubility issues seen in this chapter may be a natural response to the constraints 
exerted on proteins in a highly concentrated preparation. 
This chapter presents the successful purification of a full length L TTR, VarR, 
which maintains solubility at a concentration necessary for structural studies. However, 
maintaining the solubility of VarR required numerous exhaustive changes to both 
expression and purification protocols, which involved the use of alternative expression 
systems and strains, buffer conditions and purification methods to improve yield, 
homogeneity and purity. The use of fusion proteins such as GST or MBP to improve 
solubility were ruled out as their relative sizes may impede the formation of correct 
oligomeric states required for binding its cognate DNA. These fusion proteins would 
also contribute substantially to the spectroscopic signal generated from circular 
dichroism spectroscopy of VarR (Kelly et al., 2005). The use of high salt concentrations 
of >0.5M are often used for maintaining solubility (Bishop and Weiner, 1993). 
However, the presence of high salt concentrations is not suitable for cry tallisation, 
which inevitably leads to the formation of salt crystals. Therefore the use of detergents 
in these preparations was essential and necessary for further progression of structural 
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studies. The successful solubilisation of V arR using detergent may indicate potential 
hydrophobic entities that require masking to maintain a soluble state. However, the 
presence of excess detergent may affect protein packing and lattice formation during 
crystallisation or may interrupt the interactions within and between proteins and their 
substrates and/or DNA. Excess detergent may even inhibit the biological activity of the 
protein. Therefore at every stage of purification, the detergent conditions were 
optimised to ensure the minimum concentration was present in the protein preparations. 
It must be noted that the concentration of protein used in the V arR preparations was 
only a fraction of that used for membrane protein solubilisation. The presence of 
biological activity of the purified protein preparations will not be known until further 
biochemical studies are performed. 
The successful purification of VarR was in spite of LTTRs being notoriously 
recalcitrant to solubilisation with studies having to resort to the purification of truncated 
forms of the proteins, often the C-terminal substrate binding domains to progress 
structural characterisation (Tyrrell et al., 1997; Choi et al., 2001; Stec et al., 2006). This 
suggests that theN-terminal DBDs are attributable to the insolubility of these proteins. 
A hydrophobic core of residues in the DBD and a cluster in the linker domain (a4) has 
been identified and is highly conserved between members of the LTTR family 
(Muraoka et al., 2003; Zaim and Kierzek, 2003). This could be the cause of the related 
insolubility issues exhibited by members of this family and would be consistent with the 
requirement for low concentrations of detergent in the purification of V arR. However, 
the use of detergents in the masking of hydrophobic regions in the N-terminal DBD 
may lead to alterations in the surface of the DBD that could disrupt oligomerisation and 
DNA-binding activity (Zaim and Kierzek, 2003). Therefore, detergent was used only in 
the solubilisation of VarR at high concentrations (>6mg/ml) for structural studies with 
low concentrations of protein ( < 1 mg/ml) dedicated for EMS As being purified in the 
absence of detergent. 
Crystal structures of C-terminal LTTRs are unable to show the arrangement of 
the DNA binding domains and how conformational changes may affect binding and 
dissociation from their associated promoters. CbnR is the only LTTR that has been 
successfully purified and crystallised to date that features the N-terminal DBD 
(Muraoka et al., 2003). However, the lack of structural information regarding the 
binding to its cognate promoter and substrates ensures that the regulatory aspect also 
remains elusive. Interestingly, after the extensive functional characterisation of the 
ampR-ampC system in various bacteria, the structure of AmpR has yet to be elucidated. 
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This could be due to the instability and extensive insolubility properties exhibited by the 
protein (Bishop and Weiner, 1993). The successful purification of VarR allows for the 
progression of functional and structural studies that will provide new insights for 
members of the LTTRs family with similar modes of regulation and will be discussed in 
subsequent chapters. 
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Chapter 5 Defining the regulatory role and DNA-binding 
specificity of VarR at the varRG, varGA and 
varBC intergenic regions 
VarR was hypothesised to regulate expression of VarG in a manner similar to AmpR, 
whereby in the absence of ~-lactam antibiotics, AmpC expression is repressed and in 
the presence it is induced (Lindberg et al., 1985; Bennett and Chopra, 1993). This 
mechanism of induction has been suggested to be analogous in Gram-negative bacteria 
with inducible chromosomal ~-lactamase expression (Lindberg and Normark, 1987). 
With this in mind, it was hypothesised that VarR binds to the varRG IR in order to 
regulate the transcription of varG and possibly its own transcription through 
autoregulation. VarR was also hypothesised to simultaneously bind the varGA IR to 
regulate the transcription of varA and the varBC IR to regulate varC, varD, varE and 
varF genes. Therefore electrophoretic mobility shift assays (EMSAs) were employed to 
determine if V arR binds and the specificity of which it does at the varRG, varGA and 
varBCIRs. 
The regulatory effect of V arR at the varRG promoter and its ability to induce the 
~-lactamase, VarG was demonstrated through antimicrobial susceptibility and reporter 
assays. The varRG IR and the varG gene were amplified consecutively in the presence 
and absence of the varR gene by polymerase chain reaction (PCR). These constructs 
were cloned into various vectors and their resistances in the presence of various ~­
lactam antibiotics were elucidated through antimicrobial susceptibility assays. It was 
anticipated that this method could also determine the substrate specificity of VarR. 
However, the antimicrobial susceptibility assays were fraught with many difficulties 
including the total failure of experiments possibly as a consequence of low transcription 
activation from the native promoter and toxicities experienced by the E. coli hosts. 
Eventually, after much perseverance it was demonstrated that VarR represses the 
expression of varG at the varRG IR using reporter assays. The trials and tribulations 
experienced are discussed throughout this chapter. 
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5.1 EMSAs establish that VarR binds to the varRG IR 
5.1.1 VarR used for EMSAs 
VarR (figure 5.1) used for EMSAs was purified as described in chapter 4 section 4.2.3. 
Figure 5.1 
5.1.2 
5.1.2.1 
SDS-PAGE of VarR-Hiss purified from M15 [pREP4]/pQE-100 
Preparation of varRG IR oligonucleotides for EMSAs 
PCR amplification of varRG IR oligonucleotides 
A list of oligonucleotides/ primers and reaction mixes used during PCR can be found in 
Table 2.5 in Chapter 2 Materials and Methods. Using genomic sequencing results of V. 
cholerae N 16961 (Heidelberg et al., 2000), the length of the varRG IR was predicted to 
be 63bp. However, upon closer sequence analysis, the start codon for varG was 
identified to be located 48bp further downstream. Therefore, the actual length of the 
varRG IR was recognised to be 111 bp as depicted in Chapter 3 section 3.11.1. 
However, varying lengths of DNA were designed according to the initial 63bp varRG 
IR, which was subsequently used for EMSAs. The resulting DNA fragments did also 
incorporate the full 111 bp IR, therefore the results from EMS As were not compromised. 
For the purposes of simplicity, all experimental details will be discussed in terms of the 
111 bp varRG IR. 
To determine if VarR binds at the putative varRG promoter and to define the 
binding region, DNA of varying lengths incorporating nucleotides from either side and 
overlapping the lR were designed and amplified by PCR. 
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302bp varRG IR 
The forward primer, var4Fwd, and reverse primer, var4Rev, were designed to amplify a 
blunt ended 302bp DNA fragment (termed 302bp varRG IR) that incorporates the 
111bp varRG IR and 119bp and 72bp either side of the 5' and 3' end, respectively. A 
ProofStart polymerase PCR (Chapter 2 section 2.6.1) was performed with annealing 
temperatures of 53°C and 58°C, extension times of 1 minute, and 20 cycles of 
amplification, respectively. Amplified 302bp varRG IR DNA fragments were visualised 
and purified by agarose gel electrophoresis and gel extraction, respectively. Figure 5.2 
shows the successful amplification of 302bp varRG IR (lanes 2, 3 and 7) visualised 
against a PCR marker (lane 1 ). 
Figure 5.2 PCR amplification of 302bp varRG IR from V. cholerae CVD101. 
Lane 1= Mr marker. Lanes 2-7 show individual PCR amplification 
reactions. 
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The forward primer, var4Fwd, and reverse primer, var5Rev, were designed to amplify a 
blunt ended 151 bp DNA fragment (termed the 151 151 bp varRG IR) that incorporates 
119bp from the start of varR and the first 31 bp of the varRG IR. A ProofS tart 
polymerase PCR (Chapter 2 section 2.6.1) was performed with annealing temperatures 
of 51 °C and 58°C, respectively. Figure 5.3 shows the successful amplification of 151 
151 bp varRG IR (lanes 2-6) visualised against a PCR marker (lane 1 ). 
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Figure 5.3 PCR amplification of 1st 151bp varRG IR from V. cholerae CVD101. 
Lane 1= Mr marker. Lanes 2-6 show individual PCR amplification 
reactions. 
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The forward primer, var6Fwd, and reverse primer, var4Rev, were designed to amplify a 
blunt ended 151bp DNA fragment (termed the 2"d 151bp varRG IR) that incorporates 
72bp from the start of varG and the last 79bp of the varRG IR. A ProofS tart polymerase 
PCR reaction master mix was prepared as described in Chapter 2 section 2.6.1 and the 
cycling parameters used were as described previously with the annealing temperatures 
of 55°C and 60°C, respectively. 
Amplified 2"d 151bp varRG IR DNA fragments were visualised and purified by 
agarose gel electrophoresis and gel extraction, respectively. Figure 5.4 shows the 
successful amplification of 2"d 151 bp varRG IR visualised against a PCR marker. 
Figure 5.4 PCR amplification of 2"d 151bp varRG IR from V. cholerae CVD101. 
Lane 1= Mr marker. Lanes 2-7 show individual PCR amplification 
reactions. 
1 2 3 4 5 6 
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Amplified 2"d 151bp 
varRGIR 
5.1.2.2 Spectrophotometric quantification of amplified DNA 
Figure 5.5 shows 302bp, 1st 151bp and 2nd 151bp varRG PCR fragments (lanes 1, 2 and 
3, respectively) concentrated and purified from gel extraction. The concentration of 
302bp, 1st 151 bp and 2nd 151 bp varRG PCR amplified DNA fragments were determined 
by spectrophotometric quantification (as described in Chapter 2 section 2.7.6) to be 443, 
480 and 487~g/rnl, respectively. 
Figure 5.5 Concentrated and purified 302bp, 151 151bp and 2nd 151bp varRG. 
Lane 1= 302bp varRG DNA. Lane 2= 1st 151bp varRG DNA. Lane 3= 
2nd 151bp varRG DNA. Lane 4= PCR Mr marker. 
1 2 3 4 
5.1.2.3 Radiolabelling and annealing of varRG IR oligonucleotides 
300ng of each 302bp, 1st 151 bp and 2nd 151 bp varRG dsDNA were labelled and purified 
as described in Chapter 2 section 2. 13.3. The oligonucleotides described below were 
synthesised by Invitrogen (except the HPSF var9Fwd and var9Rev and MtrlFwd and 
MtrlRev which were synthesised by MWG-Biotech) on a 50nmol scale (desalted), 
labelled with [y_32P] ATP and annealed as described in Chapter 2 section 2.13.3. The 
concentration of annealed duplex DNA was determined prior to EMSAs using a liquid 
scintillation counter as described in Chapter 2 section 2.13.3. 
1st 31bp varRG IR 
The 1st 31 bp varRG oligonucleotide consists of the first 31 bp of 111 bp varRG IR. 
Oligonucleotides var7Fwd used for labelling and var7Rev used for annealing. 
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2nd 32bp varRG IR 
The 2nd 32bp varRG oligonucleotide consists of 32bp preceding the above 
oligonucleotide of 111 bp varRG IR. Oligonucleotides var8Fwd used for labelling and 
var8Rev used for annealing. 
30bp varRG :O:R 
The 30bp varRG fragment consists of a putative operator site for VarR. 
Oligonucleotides var9Fwd used for labelling and var9Rev used for annealing. 
30bp non-specific DNA 
The 30bp non-specific DNA served as a control. Oligonucleotides varlOFwd used for 
labelling and varlORev used for annealing. 
31bp Mtrl 
The 31 bp Mtrl DNA served as a control for positive binding. Mtrl corresponds to the 
known region in the mtrC promoter for which MtrR binds (Lucas et al., 1997). 
Oligonucleotides MtrlFwd used for labelling and MtrlRev used for annealing. 
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5.1.3 VarR binds to the varRG IR of the var operon 
Electrophoretic mobility shift assays were performed as described in Chapter 2 section 
2.13.3. EMSAs were employed to examine whether VarR binds at the varRG IR and the 
specificity to which it does. From figure 5.6 we can see retardations with 0.08ng 302bp, 
l s1 and 2nd 15lbp and 2nd 32bp varRG IR DNA fragments following incubation with 0, 
50, 200ng VarR, respectively. However, the 1st 31bp varRG IR was not retarded by 
VarR. A positive control of MtrR with 31bp dsDNA Mtrl was used during the EMSAs 
(Lucas et al., 1997). 
Figure 5.6 EMSA of VarR with 302bp, 1st + 2"d 151bp, 1st 31bp, 2"d 32bp of the 
varRG IR Titrations of VarR (0, .50, 200ng, respectively) with 0.08ng of 
302bp varRG IR (Lanes 1 to 3), 1st 151 bp varRG IR (Lanes 4 to 6), 2nd 
151bp varRG IR (Lanes 7 to 9), 1st 3lbp varRG IR (Lanes 10 to 12), and 
2nd 3lbp varRG IR (13 to 15). Lanes 16 and 17, 0.08ng 31bp Mtrl DNA 
with Ong and 200ng MtrR, respectively. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
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Increasing titrations of VarR with 30bp putative operator varRG IR 
To define the region to which V arR binds specifically in the 111 bp varRG IR, a region 
which incorporates the second half of the putative operator site for VarR, termed 30bp 
varRG IR was designed and used for EMS As. V arR binds specifically to the 30bp 
varRG IR, which also overlaps the -35 RNA polymerase transcriptional initiation site 
for both VarG and VarR. Therefore binding at this site by VarR may negatively regulate 
transcription of the varG gene and that of its own through autoregulation. However, as 
LTTRs are known to engage long operator sites, VarR may also bind the first half of its 
predicted operator site located upstream of this 30bp varRG IR. Figure 5.7 shows 
increasing concentrations of VarR (5, 12, 50, 100, 150, 200, 250, 300, 350ng, 
respectively) with 0.08ng of the putative operator 30bp varRG IR. 
Figure 5.7 EMSA using increasing concentrations of VarR with 30bp putative 
operator varRG IR Lane 1, 0.08ng 30bp varRG IR only. Lanes 2 to 10 
Titrations ofVarR.(5, 12, 50, 100, 150,200,250,300, 350ng, 
respectively) with 0.08ng 30bp varRG IR DNA. 
VarR 
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Increasing titrations of VarR with 30bp putative operator varRG IR and 30bp non-
specific DNA- VarR binds to the E. coli arsD promoter 
To define the concentration and specificity to which VarR binds to the 30bp putative 
operator varRG IR, lower titrations of VarR (0, 1.25, 2.5, 5, 10, 25, 50, 100, 200ng, 
respectively) were incubated with 0.08ng 30bp varRG IR DNA (figure 5.8). 
Simultaneously, titrations of VarR (0, 5, 10, 50, lOOng, respectively) with 0.08ng 30bp 
non-specific DNA (E. coli arsD) were executed to confirm the specificity of the 
interactions (figure 5.8). Unsuspectingly, figure 5.8 shows the retardation of the 30bp E. 
coli arsD DNA following incubation with VarR. 
Figure 5.8 EMSA using increasing titrations of VarR with 30bp putative 
operator varRG IR including 30bp non-specific E. coli arsD DNA 
Lanes 1 to 9 Titrations of VarR (0, 1.25, 2.5, 5, 10, 25, 50, 100, 200ng, 
respectively) with 0.08ng 30bp varRG IR. Lanes 10 to 15, Titrations of 
VarR (0, 5, 10, 50, 100, 200ng, respectively) with 0.08ng 30bp non-
specific E. coli arsD DNA. 
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Upon closer inspection of the nucleotide sequence of the 30bp E. coli arsD DNA, 5' -
ATTAATCATATGCGTTTTTGGTTATGTGTT-3 ', it was revealed that we had 
inadvertently used a promoter sequence similar to that of the 30bp varRG IR DNA. In 
fact, through a gapped alignment, the E. coli arsD promoter DNA reveals -60% 
sequence identity and consensus with the 30bp varRG DNA (figure 5.9). 
Figure 5.9 A gapped alignment of the 30bp putative operator varRG IR DNA 
and the 30bp non-specific E. coli arsD DNA 
30bp arsD DNA 
3 Obp varRG DNA 
Consensus 
--ATTAATCATATGCGTTTTTGGTTATGTGTT 
CTATAACAAGCATGCATTTTTGAT- ATGTTT-
--AT-A-----ATGC-TTTTTG-T-ATGT-T-
This chance discovery could serve as an example for the potential global regulatory 
property of V arR, for it is not uncharacteristic for LTTRs to act at the local and/or 
global level in the transcriptional regulation of linked target genes and at unlinked 
regulons (Schell, 1993; Kong et al., 2005). The regulatory mechanisms elucidated from 
this chapter may therefore be extrapolated to other bacterial species with similar 
regulatory systems. This has already been demonstrated with the varR-varG system 
from V. cholerae that shows similarities to the ampR-ampG transcriptional regulatory 
system in C. freundii (Lindquist et al., 1989) and E. cloacae (Lindberg and Normark, 
1987). 
Nevertheless, to define the concentration and specificity to which V arR binds to 
the 30bp putative operator varRG IR, an EMSA was performed as described above, 
however, using an alternative non-specific 30bp DNA from E. coli . The nucleotide 
sequence for the 30bp non-specific DNA used in all successive EMSAs is as follows , 
5'-ATTCCCGTTTCAGTTGACTTGCGACCAGCG-3'. Figure 5.10 shows increasing 
binding affinity of VarR for 30bp varRG IR DNA and no affinity for the 30bp non-
specific, unrelated DNA, which confirms the specificity of the interactions. 
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Figure 5.10 EMSA using increasing titrations of VarR with 30bp putative 
operator varRG IR including 30bp non-specific DNA Lanes 1 to 9 
Titrations of VarR (0, 1.25, 2.5, 5, 10, 25, 50, 100, 200ng, respectively) 
with 0.08ng 30bp varRG IR. Lanes 10 to 15, Titrations of VarR (0, 5, 10, 
50, 100, 200ng, respectively) with 0.08ng 30bp Non-specific DNA. 
VarR 
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EMSAs of VarR/30bp varRG IR complex in competition with increasing titrations 
of unlabelled 30bp varRG IR DNA 
VarR is able to dissociate from the labelled 30bp varRG IR DNA complex and bind to 
unlabelled 30bp varRG IR DNA during competitive EMSAs, which indicate that 
interactions are highly specific (Figure 5.11). 
Figure 5.11 EMSA of SOng VarRI 0.08ng 30bp varRG IR DNA (labelled) complex 
with titrations of unlabelled 30bp varRG DNA Lane 1, 0.08ng 30bp 
varRG IR DNA only. Lanes 2 to 10, Competition assay of 50ngVarR/ 
0.08ng 30bp varRG IR DNA (labelled) complex with titrations of 
unlabelled 30bp varRG IR DNA (0, 0.125, 0.25, 0.5, 1, 2, 5, 10, 20ng, 
respectively). 
Unlabelled 30bp varRG IR DNA 
1 2 3 4 5 8 7 8 9 10 
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EMSAs of SOng VarR! 0.08ng 30bp varRG IR complex in competition with 
increasing titrations of Penicillin G antibiotic 
It is hypothesised that VarR regulates the putative M~l, VarG at the varRG IR. As a 
M~l, VarG is hypothesised to have substrate specificities for a broad range of antibiotics 
that include the ~-lactams. Like other regulators that control multidrug resistance 
mechanisms, VarR may also have the same substrate specificity as their regulated 
counterparts (Schumacher and Brennan, 2002). Therefore an EMSA (figure S.12) was 
performed with SOng VarR/ 0.08ng 30bp VarRG IR DNA (labelled) complex with 
increasing titrations of Penicillin G (0, O.S, 1, 2, 4, 8, 16, 32, 64, 128, S12, 1024ng, 
10)lg, lOO)lg, respectively). Penicillin G is unable to dissociate VarR from the 30bp 
varRG IR DNA even in excess concentrations. It could be that instead of binding 
Penicillin G directly, VarR may bind intermediates from peptidoglycan biosynthesis 
pathway as a result of ~-lactam activity in a similar manner to AmpR of the ampR-
ampC system (Jacobs et al., 1994, 1997). 
Figure 5.12 EMSA of VarR/30bp varRG IR DNA complex with increasing 
titrations of Penicillin G Lane 1 0.08ng 30bp varRG IR DNA only. 
Lanes 2 to 16 SOng VarR/ 0.08ng 30bp varRG DNA complex with 
increasing titrations of Penicillin G (0, O.S, 1, 2, 4, 8, 16, 32, 64, 128, 
2S6, S12, 1024ng, 10, lOO)lg, respectively). 
Penicillin G 
1 2 3 4 5 8 7 8 9 10 1 12 141 1 
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5.2 VarR repression at the varRG IR 
Having identified that VarR binds at the varRG IR with high specificity, the next stage 
was to determine its regulatory role at this site. It was anticipated that VarR would 
repress transcription from the native varRG promoter, and thus that of the varG gene. 
To test this hypothesis, antimicrobial susceptibility assays were conducted to determine 
the differences in the MICs of E. coli harbouring the varRG-varG construct in the 
presence and absence of the varR gene when exposed to various ~-lactams. 
5.2.1 
5.2.1.1 
Antimicrobial susceptibility of pET33b- varRG-varG ± varR 
PCR amplification of varRG-varG 
The forward primer, var11Fwd, and reverse primer, var11Rev, were designed to 
incorporate theRE sites, Ndel and Xhol, at the 5' and 3' ends of the amplified varRG-
varG, respectively. The native start codon was maintained in the Fwd primer by the 
Ndel site and the stop codon was eliminated from the Rev primer. A HotStart Taq 
polymerase PCR (Chapter 2 section 2.6.1) was performed with annealing temperatures 
of 56°C and 59°C, extension times of 2 minutes, and 15 and 20 cycles of amplification, 
respectively for each annealing temperature. Figure 5.13 shows the successful 
amplification of varRG-varG (lanes 2 to 5) which is consistent with the predicted size 
of 1233bp. 
Figure 5.13 PCR amplification of varRG-varG DNA from V. cholerae CVD101. 
Lane 1= Mr marker. Lanes 2-5 show individual PCR amplification 
reactions. 
1 2 3 4 
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•~-- Amplified varRG-
varG DNA (1233bp) 
5.2.1.2 PCR amplification of varR-varRG-varG 
The forward primer, var12Fwd, and reverse primer, var12Rev, were designed to 
incorporate the RE sites, Ndel and Xhol, at the 5' and 3' ends of the amplified varR-
varRG-varG, respectively. The native start and stop codons were maintained in the Fwd 
primer by the Ndel site and in the Rev primer prior to the Xhol site. A HotStart Taq 
polymerase PCR (Chapter 2 section 2.6.1) was performed with annealing temperatures 
of 58°C and 63°C, extension times of 2 minutes 30 seconds, and 15 and 20 cycles of 
amplification, respectively for each annealing temperature. Figure 5.14 shows the 
successful amplification of varR-varRG-varG which is consistent with the predicted 
size of 2160bp. 
Figure 5.14 PCR amplification of varR-varRG-varG DNA from V. cholerae 
CVD101. Lane 1= Mr marker. Lanes 2-5 show individual PCR 
amplification reactions. 
1 2 3 4 5 
a.-- Amplified varR-varRG-varG 
DNA (2160bp) 
The amplified varRG-varG and varR-varRG-varG DNA fragments were purified, 
cloned into pGEM-T Easy vector and transformed into NovaBlue as described in 
section 4.1.1. Plasmid DNA purified from recombinant colonies was digested with Ndel 
and Xhol to confirm the presence of inserted DNA. Figure 5.15 shows varRG-varG 
DNA inserts at -1200bp from three recombinant pGEM-T Easy vector digests. Figure 
5.16 shows varR-varRG-varG DNA inserts at -2100bp from three recombinant pGEM-
T Easy vector digests. 
226 
Figure 5.15 Ndel and Xhol digest of three recombinant pGEM-T Easy vectors. 
Lane 1= Mr marker. Lanes 2-4 exhibiting the presence of the inserted 
varRG-varG DNA. 
1 2 3 4 
pGEM-T Easy 
...,.__(3Kb) 
Inserted varRG-varG 
4----- DNA (1233bp) 
Figure 5.16 Ndel and Xhol digest of two recombinant pGEM-T Easy vectors. 
Lanes 1 and 3 exhibiting the presence of the inserted varR-varRG-varG 
DNA. Lane 2= Mr marker. 
1 2 
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pGEM-T Easy 
• ._ __ (3Kb) 
Inserted varR-varRG-
varG DNA (2160bp) 
5.2.1.3 Subcloning of varRG-varG ± varR into pET33b 
The pET33b expression vector was chosen for its kanamycin resistance selection 
marker. This was to ensure that the ampicillin resistance gene encoded on other 
expression vectors does not interfere with the antimicrobial susceptibility tests when 
performed in the presence of ~-lactam antibiotics. 
The varRG-varG and varR-varRG-varG DNA fragments were cloned into the 
pET33b expression vector, respectively, as described previously in section 4.1.1. Figure 
5.17 shows colony PCR of eight recombinant colonies. Lanes 1, 2, 4, 5, 7, 8 and 9 show 
the successful amplification of varRG-varG DNA that indicates its presence in the 
recombinant pET33b vectors from the chosen colonies. Figure 5.18 shows successful 
restricition analysis of all five recombinant colonies with Ndel and Xhol, indicating the 
presence of varR-varRG-varG DNA in the recombinant pET33b vectors. 
Figure 5.17 PCR identification of inserted varRG-varG DNA in pET33b. Colony 
PCR of individual recombinant colonies (lanes 1-5 and 7-9) using 
varR11Fwd and Rev primers. Lane 6 = Mr marker. 
1 2 3 4 5 6 7 8 9 
varRG-varG DNA 
(1233bp) 
Figure 5.18 Ndel and Xhol digestion of recombinant pET33b vectors. 
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Linear pET33b 
(-5.3Kb) 
Inserted varR-varRG-
varG DNA (2160bp) 
The resulting purified recombinant pET33b vectors were sent for automated DNA 
sequencing to ensure sequence integrity and transformed into a chemically competent E. 
coli strain, KAM3. KAM3 is a highly susceptible E. coli strain that has a deletion in the 
chromosomal acrAB genes, which encodes a major efflux system of E. coli (Morita et 
al., 1998). 
DNA sequencing of pET33b!varRG-varG and pET33b/varR-varRG-varG 
constructs have revealed that the varR and varG genes and varRG IR are identical in 
CVD101 and N16961. 
5.2.1.4 Results and discussion of the antimicrobial susceptibility assays of 
pET33b/varRG-varG ± varR 
Microdilution techniques were utilised to determine the in vitro susceptibility of KAM3 
harbouring recombinant pET33b vectors. It was anticipated that transcriptional 
initiation would occur from the native varRG promoter of the recombinant 
pET33b/varRG-varG, resulting in the expression of VarG and thus development of 
resistance against the tested ~-lactam antibiotic. The presence of VarR in recombinant 
pET33b/varR-varRG-varG, was hypothesised to repress expression at the varRG 
promoter and thus yield a two fold decrease in the minimal inhibitory concentrations 
(MIC) of the ~-lactams tested. The MIC is defined as the lowest concentration of drug 
that inhibits more than 99% of the bacterial population or prevents visible growth of a 
microorganism (NCCLS, 2003). This will determine the regulatory role of VarR at the 
varRG IR and thus the transcriptional regulation of the ~-lactamase, VarG. 
Antimicrobial susceptibility testing using the microdilution broth method was 
performed as described in chapter 2 section 2.13.1. The ~-lactam antibiotics tested were 
penicillin G, ampicillin, carbenicillin and amoxicillin. The results of the antimicrobial 
susceptibility tests were taken from an average of three independent experiments and 
are as listed on the following page. 
E. coliKAM3 
~-lactam MIC (J.Lg/ml) 
Amoxicillin Ampicillin Carbenicillin Penicillin G 
pET33b only 8 4 8 4 
pET33b/ 16 8 16 16 
varRG-varG 
pET33b/ 8 4 8 4 
varR-varRG-varG 
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A two fold decrease in the MIC of penicillin G for construct pET33b/varR-varRG-varG 
compared to pET33b/varRG-varG would be consistent with VarR acting as a repressor 
at the varRG promoter. However, the presence of only a one fold difference in the 
remaining MICs ensures that the overall result cannot be relied upon to infer either 
substrate specificity for VarR or its repression. The relatively low MICs seen for 
pET33blvarRG-varG could be a result of the low copy number of the pET33b vector 
leading to the generation of a weak signal from the native varRG promoter This signal 
may be insufficient to induce expression of varG and thus may lead to a greater 
susceptibility of the host E. coli when exposed against the ~-lactams. 
Regarding the pET33b/varR-varRG-varG construct, the presence of weak 
initiation sites for RNA polymerase, compounded with the weak promoter signal, could 
ensure that V arR is insufficiently expressed leading to reduced repression at the varRG 
IR. Strong promoters often have sequences corresponding closely to the consensus 
sequences, and the frequency of transcriptional initiation is as often as every two 
seconds in E. coli. In contrast, genes with weak promoters due to multiple substitutions 
at the -10 and -35 sites are transcribed approximately once every 10 minutes (Stryer, 
1999). Therefore to compensate for the existence of a weak promoter, the varRG-varG 
and varR-varRG-varG constructs were cloned into a high copy, kanamycin resistant 
vector, pSMART HC-Kan, designed specifically for transcriptional initiation of genes 
from native promoters (Clontech). 
5.2.2 
5.2.2.1 
Antimicrobial susceptibility of pSMART- varRG-varG ± varR 
PCR amplification of varRG-varG 
The 5' ends of the forward primer, var13Fwd, and reverse primer, var13Rev, were 
phosphorylated to facilitate blunt ended cloning of amplified varRG-varG into 
pSMART vector. The native stop codon from varG was maintained the reverse primer 
to ensure that the transcription of exogenous DNA was kept to a minimum. A ProofStart 
polymerase PCR (Chapter 2 section 2.6.1) was performed with an annealing 
temperature of 54°C, extension time of 4 minute, and 40 cycles of amplification. Figure 
5.19 shows the successful amplification of varRG-varG which is consistent with the 
predicted size of 1233bp. 
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Figure 5.19 PCR amplification of varRG-varG from V. cholerae CVD101. Lane 
1= Mr marker. Lanes 2-4 show individual PCR amplification reactions 
1 2 3 4 
5.2.2.2 PCR amplification of varR-varRG-varG 
varRG-varG DNA 
(1233bp) 
The 5' ends of the forward primer, var14Fwd, and reverse primer, var13Rev, were 
phosphorylated to facilitate blunt ended cloning of amplified varR-varRG-varG into 
pSMART vector. The native stop codon from varG was maintained the reverse primer 
to ensure that the transcription of exogenous DNA was kept to a minimum. A ProofStart 
polymerase PCR (Chapter 2 section 2.6.1) was performed with an annealing 
temperature of 50°C and 55°C, extension times of 5 minute, and 20 cycles of 
amplification, respectively. Figure 5.20 shows the successful amplification of varR-
varRG-varG which is consistent with the predicted size of 2160bp. 
Figure 5.20 PCR amplification of varR-varRG-varG from V. cholerae CVD101. 
Lane 1= Mr marker. Lanes 2-4 show individual PCR amplification 
reactions. 
1 2 3 4 
+--- varR-varRG-varG DNA 
(2160bp) 
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5.2.2.3 Cloning of varRG-varG ± varR into pSMART HCKan vector 
Ligation into pSMART vectors and transformations into E.cloni were performed as 
described in Chapter 2 section 2.6.2 and 2.8.3, respectively. Plasmid DNA purified from 
recombinant colonies were identified using colony PCR or digested with BamHI and 
Hindiii to confirm the presence of inserted DNA. Figure 5.21 shows the results from 
PCR identification of varRG-varG inserts from eight recombinant pSMART vectors, 
which are consistent with the predicted size of 1233bp. Figure 5.22 shows the insert 
released from EcoRI digestion of six recombinant vectors, which is consistent with the 
predicted size of varR-varRG-varG at 2160bp. 
Figure 5.21 PCR identification of inserted varRG-varG DNA in pSMART. Lanes 
1-4 and 6-9 show individual PCR amplification reactions. Lane 5= Mr 
marker. 
1 2 3 4 5 6 7 8 9 
varRG-varG DNA 
(1233bp) 
Figure 5.22 EcoRI digestion of recombinant pSMART/varR-varRG-varG. Lane 
1= Mr marker. Lanes 2-7 exhibiting the presence of the inserted varR-
varRG-varG DNA. 
1 2 3 4 5 6 7 
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Linear pSMART 
(1788bp) 
Inserted varR-varRG-
varG DNA (2160bp) 
The resulting purified recombinant pSMART vectors were sent for automated DNA 
sequencing to ensure sequence integrity and transformed into a chemically competent 
KAM3. 
5.2.2.4 Results and discussion of the antimicrobial susceptibility assays of 
pSMART/varRG-varG ± varR 
Antimicrobial susceptibility testing using the microdilution broth method was 
performed as described in chapter 2 section 2.13 .1. The ~-lactam antibiotics tested were 
amoxicillin, ampicillin, carbenicillin, nafcillin and penicillin G. The results of the 
antimicrobial susceptibility tests were taken from an average of three independent 
experiments and are as follows: 
E. coli P-lactam MIC (JJ.g/ml) 
KAM3 Amoxicillin Ampicillin Carbenicillin Nafcillin Penicillin G 
pSMART 128 0.5 0.5 1 8 only 
pSMART/ 1024 2 2 4 16 
varRG-varG 
pSMART/ 
varR-varRG- 512 1 1 2 16 
varG 
There were no significant differences exhibited by the ~-lactam MICs (except for 
amoxicillin) for E. coli harbouring the varR deletion construct (pSMART/varRG-varG) 
and those in the presence of varR (pSMART/varR-varRG-varG). Interestingly, both 
constructs have a high resistance to amoxicillin compared to the control (pSMART 
only). However, the result is unlikely to be accurate after comparison with the results of 
the other ~-lactams tested. One theory could be that amoxicillin was solubilised in an 
alkaline 1M ammonium hydroxide solution (as per manufacturer's instruction), which 
could reduce the efficacy of amoxicillin and thus reflect in the MICs observed. One 
would also assume that the alkalinity of ammonium hydroxide may have the potential to 
be bactericidal. However, the presence of bacterial growth in all wells up to the MIC for 
amoxicillin states otherwise. The reason for this anomaly is at present unknown. 
The similarities in the MICs for both constructs could be a result of V arR having 
a similar substrate profile to VarG. Consequently when E. coli harbouring the varR 
constructs are exposed to ~-lactam antibiotics, VarR may bind these molecules and 
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dissociate from the varRG promoter leading to the induction varG. This is not unusual 
as most LTTRs require the presence of an inducing ligand for the transcriptional 
activation of their target genes (Schell, 1993). This would therefore account for the 
indifference seen in the results generated by E. coli harbouring a deletion in varR. 
The comparison of the result for ampicillin with that obtained from the study by 
Lau and colleagues (2005) on the ampC-ampR system greatly differ. E. coli harbouring 
the ampR deletion constructs show an MIC to ampicillin of 128mg/rnl compared to E. 
coli harbouring the full-length ampR-ampC construct of 16rnlrnl. This indicates that the 
expression of ampC is negatively regulated by ampR. However, these constructs were 
expressed from an E. coli strain that does not contain a deletion in the acrAB genes, 
which encode a major multiple drug resistance efflux system in E. coli (Ma et al., 
1993). The E. coli strain may therefore harbour a degree of intrinsic resistance that may 
be responsible for the P-lactam resistance observed. Also the use of the pACYC184 
expression vector for antimicrobial susceptibility testing may result in vector driven 
transcription through the inserted constructs, leading to increased ampC transcription 
and thus increased resistance against P-lactams tested. For these reasons the var 
constructs were cloned into pSMART, which consists of terminating sequences either 
side of the multiple cloning site. 
Instead of dissociating from the varRG promoter m response to ~-lactam 
antibiotics, V arR may also be responding to secondary molecules such as the 
muropeptides generated from P-lactam mediated peptidoglycan degradation (Jacobs et 
al., 1994 & 1997). These muropeptides may bind to the substrate binding site at the C-
terminus of V arR causing a conformational change in VarR that reduces its affinity 
and/or release from the promoter and therefore allowing RNA polymerase to initiate 
transcription of the varG gene. 
The relatively low MICs detected could reflect the low inducibility of varG from 
the varRG promoter. This could be similar to the ampC-ampR system, where 
inducibility depends on the availability of other factors such as AmpD and AmpG 
(Lindberg et al., 1987; Bennett and Chopra, 1993; Jacobs et al., 1994). On the basis of 
this hypothesis it was decided that the varG gene be replaced by a chloramphenicol 
resistance gene (CmR) to eliminate the similarities in the MICs between the two 
constructs. VarR is not known to have substrate specificity for chloramphenicol and nor 
does chloramphenicol disrupt bacterial peptidoglycan. In the presence of 
chloramphenicol the regulatory activity of VarR at the varRG promoter should not be 
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affected, and thus there should be an increase in the MICs of E. coli harbouring a 
deletion in varR. 
5.2.3 
5.2.3.1 
Antimicrobial susceptibility of pSMART/varRG-CmR ± varR 
PCR amplification of varR-varRG-CmR 
PCR amplification of varR-varRG 
The forward primer, var15Fwd, and reverse primer, var15Rev, were designed to 
incorporate the RE sites, Xbal and Ndel, at the 5' and 3' ends of the amplified varR-
varRG, respectively. The native stop codon for varR was maintained by the Rev primer 
prior to the Xbal site. A HotStart Taq polymerase PCR (Chapter 2 section 2.6.1) was 
performed with annealing temperatures of 51 °C and 53°C, extension times of 1 minute 
30 seconds, and 15 and 20 cycles of amplification, respectively. Figure 5.23 shows the 
successful amplification of varR-varRG which is consistent with the predicted size of 
1002bp. 
Figure 5.23 PCR amplification of varR-varRG from V. cholerae CVD101. Lanes 
1-4 and 6-9 show individual PCR amplification reactions. Lane 5= Mr 
marker. 
1 2 3 4 5 6 7 8 9 
PCR amplification of chloramphenicol resistance gene (CmR) 
varR-varRG DNA 
(1002bp) 
The forward primer, var16Fwd, and reverse primer, var16Rev, were designed to 
incorporate the RE sites, Ndel and Xhol, at the 5' and 3' ends of the amplified CmR, 
respectively. The native start codon for CmR was maintained by the Ndel site in the Fwd 
primer and the stop codon by the Rev primer prior to the Xhol site. A HotStart Taq 
polymerase PCR (Chapter 2 section 2.6.1) was performed with annealing temperatur s 
of 54°C and 67°C, extension times of 1 minute, and 15 and 20 cycles of amplification, 
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respectively. Figure 5.24 shows the successful amplification of CmR which is consistent 
with the predicted size of 669bp. 
Figure 5.24 PCR amplification of CmR from pACYC vector DNA. Lanes 1-4 and 
6-9 show individual PCR amplification reactions. Lane 5= Mr marker. 
1 2 3 4 5 6 7 8 9 
CmR (669bp) 
The amplified varR gene was purified and cloned into pOEM-T Easy vector and 
transformed into NovaBlue as described in section 4.1.1. Plasmid DNA purified from 
recombinant colonies was digested with Xbal or Xhol and Ndel to confirm the presence 
of inserted DNA. Figure 5.25 shows DNA inserts following Xbal and Ndel digestion of 
four recombinant pGEM-T Easy vectors. The DNA insert from lane 3 is consistent with 
the size of varR-varRG at -lOOObp. Figure 5.26 shows the DNA inserts released 
following Ndel and Xhol digestion of recombinant pGEM-T Easy vectors, which are 
consistent with the size of CmR of 669bp. 
Figure 5.25 Xbal and Ndel digestion of recombinant pGEM-T Easy vectors. 
Lane 1= Mr marker. Lanes 3= presence of inserted varR-varRG DNA. 
1 2 3 4 5 
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Linear pGEMT-T 
+--- (-3kb) 
___ Inserted varR-varRG 
DNA (1002bp) 
Figure 5.26 Ndel and Xhol digestion of recombinant pGEM-T Easy vectors 
5.2.3.2 
Linear pGEMT-T 
(-3kb) 
CmR (669bp) 
Molecular cloning into pET28b expression vector 
The following figure 5.27 illustrates the sub-cloning procedure adopted for cloning of 
varR-varRG and CmR into pET28b. The varR-varRG and CmR DNA inserts were sub-
cloned into the pET28b vector to form a continuous varR-varRG-CmR DNA template 
for PCR amplification. 
Figure 5.27 Schematic illustration of the sub-cloning procedure for pET28blvarR-
varRG-CmR 
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' 
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The varR-varRG and CmR DNA was cloned into the pET28b vector as described 
previously in section 4.1.1. Plasmid DNA purified from recombinant colonies was 
digested with Xbal and Ndel or Xhol to confirm the presence of inserted DNA. Figure 
5.28 shows the presence of varR-varRG that indicates its presence in the recombinant 
pET28b vectors from the chosen colonies. Figure 5.29 shows inserts at -1600bp that is 
consistent with size of varR- varRG-CmR of 1671 bp. 
Figure 5.28 Xbal and Ndel digestion of recombinant pET28b vectors 
pET28b (-5.3kb) 
.-.-. varR-varRG 
(1002bp) 
Figure 5.29 Xbai and Xhol digestion of pET28blvarR-varRG-CmR 
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pET28b (-5.3kb) 
varR-varRG-CmR 
(1671bp) 
5.2.3.3 PCR amplification of varRG-CmR from pET2Sb/varR-vaRG-CmR 
The 5' ends of the forward primer, var14Fwd, and reverse primer, var17Rev, were 
phosphorylated to facilitate blunt ended cloning of amplified varRG-CmR into the 
pSMART vector. The native stop codon of CmR was maintained in the reverse primer to 
ensure that the transcription of exogenous DNA was kept to a minimum. A ProofStart 
polymerase PCR (Chapter 2 section 2.6.1) was performed with annealing temperatures 
of 55°C and 63°C, extension times of 1 minute, and 15 and 20 cycles of amplification, 
respectively. pET28blvarR-varRG-CmR was used as template DNA. Figure 5.30 shows 
the successful amplification of varRG-CmR which is consistent with the predicted size 
of722bp. 
Figure 5.30 PCR amplification of varRG-CmR from pET28b/ varR-varRG-CmR . 
.__ varRG-CmR 
(722bp) 
5.2.3.4 Molecular cloning of varRG-CmR ± varR into pSMART 
Cloning of varRG-CmR into pSMART 
Amplified varRG-CmR was purified, ligated into pSMART vector and transformed into 
E.cloni as described in Chapter 2 section 2.6.2 and 2.8.3, respectively. Plasmid DNA 
purified from recombinant colonies was digested with EcoRI to confirm the presence of 
inserted DNA. Figure 5.31 shows the insert released from EcoRI digestion of six 
recombinant pSMART vectors (lanes 2, 3, 5-7), which is con i tent with the predicted 
size of varRG-CmR at 722bp. 
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Figure 5.31 EcoRI digestion of varRG-CmR from pSMART. Lanes 2, 3, 5, 6 and 7 
= presence of inserted varRG-CmR DNA. Lane 4= Mr marker. 
1 2 3 4 
Cloning of varR-varRG-CmR into pSMART 
5 6 7 
Linear pSMART 
(-1.7kb) 
varRG-CmR 
(722bp) 
Recombinant pET28b/varR-varRG-CmR was digested with Xbal and Xhol to release 
varR-varRG-CmR from pET28b. 5' overhangs were repaired using T4 DNA polymerase 
as described in Chapter 2 section 2.7.4. Ligation into pSMART vectors and 
transformations into E.cloni were performed as described in Chapter 2 section 2.6.2 and 
2.8.3, respectively. Plasmid DNA purified from recombinant colonies was digested with 
Xbal and Xhol to confirm the presence of inserted DNA. Figure 5.32 shows the insert 
released following digestion of four recombinant pSMART vectors (lanes 4-5), which is 
consistent with the predicted size of varR-varRG-CmR at 1671bp. 
Figure 5.32 Xbal and Xhol digestion of pSMART/varR-varRG-CmR. Lane 1= Mr 
marker. Lanes 2-5; individual Xbal and Xhol digests of recombinant 
vectors. 
1 2 3 4 
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Linear pSMART 
~ (-1.7kb) 
varR-varRG-CmR 
{1671bp) 
The resulting purified recombinant pSMART vectors were sent for automated DNA 
sequencing to ensure sequence integrity and transformed into a chemically competent E. 
coli strain, KAM3. DNA sequencing of pSMART/varRG-CmR and pSMART/varR-
varRG-CmR constructs revealed that sequence integrity was maintained. 
5.2.3.5 VarR acts as a repressor at the varRG IR 
Antimicrobial susceptibility testing using the microdilution broth method was 
performed as described in chapter 2 section 2.13 .1 using the following constructs 
pSMART/varRG-CmR and pSMART/varR-varRG-CmR. Chloramphenicol was used as 
the test antibiotic and the results reported below were taken from an average of three 
independent experiments. 
E. co/iKAM3 Chloramphenicol MIC (J.Lg/ml) 
pSMARTonly 1 
pSMART/ 128 varRG-CmR 
pSMART/ 2 varR-varRG-CmR 
The assays yielded substantial differences in the MICs between the two constructs 
tested. For pSMART-varRG-CmR, there is a 12-fold increase in resistance (128f..lg/ml) 
for chloramphenicol when compared to the construct harbouring the varR gene 
(2f..lg/ml). This implies that transcription of the CmR gene is repressed by V arR at the 
varRG promoter. Consistent with this observation, pSMART-var-varRG-CmR shows a 
comparable MIC of 2f..lg/ml to the 1 f..lg/ml resistance observed for the control. Therefore 
VarR is likely to act as a repressor at the varRG IR leading to transcriptional repression 
of the varG gene and thus ~-lactamase expression. 
Having failed to determine the substrate specificity of VarR and if binding 
results in its dissociation from the varRG IR, VarG together with varR-varRG IR was 
fused to the enhanced cyan fluorescent protein, ECFP (varR-varRG-varG::ECFP). It is 
anticipated that a substrate profile for V arR could be generated by monitoring the 
change in fluorescence upon incubation with various ~-lactam and macrolide 
antibiotics. This is discussed in more detail in the subsequent section. 
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5.3 Establishing the substrate profile for VarR and if binding leads to 
induction of varG transcription 
The purpose of this section is to elucidate the substrate profile for VarR and to 
determine whether binding results in the expression of the VarG::ECFP fusion. It is 
anticipated that in the absence of substrate, VarR will repress varG::ECFP transcription 
at the varRG IR leading to basal fluorescence and in the presence of substrate would 
allow transcription to precede, thus leading to an increase in fluorescence. However, the 
extent of dissociation of V arR from the varRG IR, whether partial or full, would not be 
known. 
5.3.1 
5.3 .1.1 
Cloning of varR-varRG-varG::ECFP into pSMART vector 
PCR amplification of varR-varRG-varG and ECFP 
PCR amplification of varR-varRG-varG 
The forward primer, var18Fwd, and reverse primer, var18Rev, were designed to 
incorporate the RE sites, Xbal and Ndel, at the 5' and 3' ends of the amplified varR-
varRG-varG, respectively. The native stop codon for varR was maintained by the Rev 
primer prior to the Xbal site. A HotS tart Taq polymerase PCR (Chapter 2 section 2.6.1) 
was performed with annealing temperatures of 53°C and 57°C, extension times of 2 
minutes 30 seconds, and 15 and 20 cycles of amplification, respectively. Figure 5.33 
shows the successful amplification of varR-varRG-varG which is consistent with the 
predicted size of 2175bp. 
Figure 5.33 PCR amplification of varR-varRG-varG from V. cholerae CVD101. 
Lanes 1-4 and 6-9 show individual PCR amplification reactions. Lane 5= 
Mr marker. 
1 2 3 4 5 6 7 
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8 9 
varR-varRG-varG 
DNA (2175bp) 
PCR amplification of ECFP 
The forward primer, var19Fwd, and reverse primer, var19Rev, were designed to 
incorporate theRE sites, Ndel and Xhol, at the 5' and 3' ends of the amplified ECFP 
gene, respectively. The native start codon for the ECFP gene was maintained by the 
Ndel site in the Fwd primer and the stop codon by the Rev primer prior to the Xhol site. 
A HotStart Taq polymerase PCR (Chapter 2 section 2.6.1) was performed with 
annealing temperatures of 63°C and 66°C, extension times of 1 minute, and 15 and 20 
cycles of amplification, respectively. Figure 5.34 shows the successful amplification of 
ECFP gene which is consistent with the predicted size of 729bp. 
Figure 5.34 PCR amplification of the ECFP gene from vector pECFP. 
-.-- ECFP gene 
(729bp) 
The amplified varR-varRG-varG DNA and ECFP gene were purified and cloned into 
pGEM-T Easy vector and transformed into NovaBlue as described in section 4.1.1. 
Plasmid DNA purified from recombinant colonies was digested with Xbal or Xhol and 
Ndel to confirm the presence of inserted DNA (figures 5.35 and 5.36). 
Figure 5.35 Xbal and Ndel digestion of recombinant pGEM-T Easy vectors. 
Lane 1= Mr marker. Lanes 2, 3 and 5; exhibit the presence of varR-
varRG-varG DNA. 
1 2 3 4 5 
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(-3kb) 
Inserted varR-varRG-varG 
DNA (2175bp) 
Figure 5.36 Ndel and Xhol digestion of recombinant pGEM-T Easy vectors. 
5.3.1.2 
Lane 1= Mr marker. Lanes 2-5; exhibit the presence of the ECFP gene. 
1 2 3 4 5 
Linear pGEMT-T 
(-3kb) 
+--- ECFP gene (729bp) 
Sub-cloning of varR-varRG-varG and ECFP in pET28a 
The varR-varRG-varG and ECFP gene inserts were sub-cloned into the pET28b vector 
to form a continuous varR-varRG-varG::ECFP DNA template for PCR amplification. 
Plasmid DNA purified from recombinant colonies was digested with Xbal and Ndel or 
Xhol to confirm the presence of inserted DNA. Figure 5.37 shows the presence of varR-
varRG-varG that indicates its presence in the recombinant pET28b vectors from the 
chosen colonies. Figure 5.38 shows inserts at -2900bp that is consistent with size of the 
varR-varRG-varG::ECFP fragment. 
Figure 5.37 Xbal and Ndel digestion of recombinant pET28b vectors 
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+-- pET28b (-5.3kb) 
+-- varR-varRG-varG 
(2175bp) 
Figure 5.38 Xbal and Xhol digestion of pET2SblvarR-varRG-varG::ECFP 
5.3.1.3 
pET28b (-5.3kb) 
varR-varRG-varG::ECFP 
(2898bp) 
Cloning of varR-varRG-varG::ECFP into pSMART vector 
Recombinant pET28blvarR-varR-varG::ECFP was digested with Xbal and Xhol to 
release varR-varR-varG: :ECFP from pET28b. 5' overhangs were repaired using T4 
DNA polymerase as described in Chapter 2 section 2.7.4. Ligation into pSMART 
vectors and transformations into E.cloni were performed as described in Chapter 2 
section 2.6.2 and 2.8.3, respectively. Plasmid DNA purified from recombinant colonies 
was digested with Xbal and Xhol to confirm the presence of inserted DNA. Figure 5.39 
shows the insert released from Xbal and Xhol digestion of four recombinant pSMART 
vectors, which is consistent with the predicted size of varR-varRG-varG::ECFP at 
2898bp. 
Figure 5.39 Xbal and Xhol digestion of pSMART!varR-varRG-varG::ECFP 
~~~:=::pj.-- varR-varRG-varG::ECFP 
(2898bp) 
Linear pSMART 
(-1.7kb) 
The resulting purified recombinant pSMART vectors were sent for automated DNA 
sequencing to ensure sequence integrity and transformed into a chemically competent E. 
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coli strain, C43. DNA sequencing of pSMART/varR-varRG-varG::ECFP constructs 
revealed that sequence integrity was maintained. 
5.3.2 In vivo fluorescence measurements of pSMART/varR-varRG-
varG::ECFP in the absence and presence of antibiotics 
The theory whereby VarR induces VarG expression upon binding to substrate was 
tested through in vivo measurements of ECFP fluorescence upon incubation with the P-
lactam penicillin G. This method has the potential to elucidate a substrate profile for 
VarR, which so far been unresolved by previous methods. Borges-Walmsley and 
associates (2005) have successfully used this technique to demonstrate the in vivo 
regulatory activity of the repressor, V ceR, at the vee promoter. They show that 
increasing concentrations of substrate, CCCP, enhances the expression of ECFP in a 
sigmoidal manner. 
To determine the substrate profile for VarR and to ascertain whether V arR 
shows a similar ECFP expression profile, fluorescence emission data was collected in 
the presence and absence of substrate. In brief, a colony of C43/pSMART-varR-varRG-
varG::ECFP was used to inoculate 5ml LB broth supplemented with 25).lg/ml 
kanamycin and cultured overnight at 220rpm at 37°C. One millilitre of this overnight 
culture was used to inoculate 50ml of fresh LB broth and cultured to an 00600 of 0.4. 
Upon reaching mid-log phase, penicillin G was added to a final concentration of 0, 0.5, 
1, 1.5, 2, 2.5, 3).lM (no penicillin G was added to control cells). Cultures were incubated 
for a further 20 hours at 200rpm at 37°C and then harvested by low speed 
centrifugation. The cell pellets were washed twice with 20mM Tris.HCl pH 8.0, 
300mM NaCl physiological buffer. Cells were excited at 433nm in a Jasco FP750 
fluorimeter set to 20°C and ECFP expression was monitored by measuring the 
fluorescence emission at 475nm. 
Unfortunately, very little ECFP fluorescence emission could be detected in both 
control and test strains (data not shown). This could be suggestive that penicillin G is 
not a substrate for VarR or that an inadequate concentration was added preventing VarR 
from effectively inducing expression of the VarG::ECFP fusion protein. Regrettably, 
time constraints prevented further progression; therefore future directions would be to 
repeat the experiment with a higher concentration range of penicillin G, other P-lactam 
and macrolide antibiotics, possibly the antimicrobial peptides, PC8 and LL-37, and 
muropeptides. 
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5.4 
5.4.1 
5.4.1.1 
EMSAs establish that VarR binds to the varGA IR 
Preparation of varGA IR oligonucleotides for EMSAs 
PCR amplification of varGA IR oligonucleotides 
To determine if VarR binds at the putative varGA promoter and to define the binding 
region, DNA of varying lengths incorporating nucleotides from either side and 
overlapping the IR were designed and amplified by PCR. 
416bp varGA IR 
The forward primer, var20Fwd, and reverse primer, var20Rev, were designed to 
amplify a blunt ended 416bp DNA fragment (termed 416bp varGA IR) that incorporates 
the 17 6bp varGA IR and 120bp either side of the 5' and 3' ends of this region. A 
ProofStart polymerase PCR (Chapter 2 section 2.6.1) was performed with annealing 
temperatures of 55°C and 63°C, extension times of 1 minute, and 15 and 20 cycles of 
amplification, respectively. Figure 5.40 shows the successful amplification of 416bp 
varRG IR (lanes 2, 3 and 6) visualised against a PCR marker (lane 1). 
Figure 5.40 PCR amplification of 416bp varGA IR. Lane 1= PCR Mr marker. 
Lanes 2-6; individual PCR amplification reactions. 
1 2 3 
1st 207bp varGA IR 
4 5 6 
Amplified 416bp 
varGA IR 
The forward primer, var20Fwd, and reverse primer, var21Rev, were designed to 
amplify a blunt ended 207bp DNA fragment (termed the 1st 207bp varGA IR) that 
incorporates 120bp from the end of varG and the first 88bp of the varGA IR. A 
ProofStcut polymerase PCR (Chapter 2 section 2.6.1) was performed with an annealing 
temperature of 55°C, extension time of 45 seconds, and 35 cycles of amplifi ation. 
Figure 5.41 shows the successful amplification of 1st 207bp varGA IR (lanes 2, 4 and 7) 
visualised against a PCR marker (lane 1). 
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Figure 5.41 PCR amplification of 1st 207bp varGA IR. Lane 1= PCR Mr marker. 
Lanes 2-9; show individual PCR amplification reactions. 
1 2 3 4 5 6 7 8 9 
...__ Amplified 1st 207bp 
varGA IR 
2"ct 208bp varGA IR 
The forward primer, var22Fwd, and reverse pnmer, var20Rev, were designed to 
amplify a blunt ended 208bp DNA fragment (termed the 2"ct 208bp varGA IR) that 
incorporates the last 88bp of the varGA IR and the first 120bp of varA. A ProofStart 
polymerase PCR (Chapter 2 section 2.6.1) was performed with annealing temperatures 
of 55°C and 63°C, extension times of 45 seconds, and 15 and 20 cycles of amplification, 
respectively. Figure 5.42 shows the successful amplification of 2"d 208bp varGA IR 
(lanes 2 to 7) visualised against a PCR marker Lane 1). 
Figure 5.42 PCR amplification of 2"d 208bp varGA IR. Lane 1 = PCR Mr marker. 
Lanes 2-9; show individual PCR amplification reactions. 
1 2 3 4 5 
176bp varGA IR 
6 7 8 9 
Amplified 2"a 208bp 
varGA IR 
The forward primer, var23Fwd, and reverse primer, var23Rev, were designed to 
amplify a blunt ended 176bp DNA fragment (termed the 176bp varGA IR) that contain 
the whole 176bp varGA IR. A ProofStart polymerase PCR (Chapter 2 section 2.6.1) was 
performed with annealing temperatures of 51 °C and 53°C, extension times of 45 
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seconds, and 15 and 20 cycles of amplification, respectively. Figure 5.43 shows the 
successful amplification of l76bp varGA IR visualised against a PCR marker. 
Figure 5.43 PCR amplification of 176bp varGA IR. Lane 1= PCR Mr marker. 
1 
Lanes 2-9; show individual PCR amplification reactions. 
2 3 4 5 6 7 8 9 
Amplified 176bp 
varGA IR 
1st 88bp varGA IR 
The forward primer, var23Fwd, and reverse pnmer, var24Rev, were designed to 
amplify a blunt ended 88bp DNA fragment (termed the 1st 88bp varGA IR) that contains 
the 1st 88bp of the 176bp varGA IR. A ProofS tart polymerase PCR (Chapter 2 section 
2.6.1) was performed with annealing temperatures of 53°C and 55°C, extension times of 
45 seconds, and 15 and 20 cycles of amplification, respectively. Figure 5.44 shows the 
successful amplification of 1st 88bp varGA IR visualised against a PCR marker. 
Figure 5.44 PCR amplification of 151 88bp varGA IR. Lane 1= PCR Mr marker. 
1 
Lanes 2-9; show individual PCR amplification reactions. 
2 3 4 5 6 7 8 
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Amplified 181 88bp 
varGA IR 
2"d 88bp varGA IR 
The forward primer, var25Fwd, and reverse pnmer, var23Rev, were designed to 
amplify a blunt ended 88bp DNA fragment (termed the 2"d 88bp varGA IR) that 
contains the last 88bp of the 176bp varGA IR. A ProofS tart polymerase PCR (Chapter 2 
section 2.6.1) was performed with an annealing temperature of 51 °C, extension time of 
45 seconds, and 35 cycles of amplification. Figure 5.45 shows the successful 
amplification of 2"d 88bp varGA IR visualised against a PCR marker. 
Figure 5.45 PCR amplification of 2"d 88bp varGA IR. Lane 1= PCR Mr marker. 
Lanes 2-7; show individual PCR amplification reactions. 
1 2 3 4 5 6 7 
Amplified 2"d 88bp 
varGA IR 
5 .4.1 .2 Radio labelling and annealing of varGA IR oligonucleotides 
300ng of each 416bp, 1st 207bp, 2nd 208bp, 176bp, ls1 88bp and 2nd 88bp varGA dsDNA 
were labelled and purified as described in Chapter 2 section 2.13.3 . The 
oligonucleotides described below were synthesised by Invitrogen on a 50nmol scale 
(desalted), labelled with [y-32P] ATP and annealed as described in Chapter 2 section 
2.13.3. The concentration of annealed duplex DNA was determined prior to EMSAs 
using a liquid scintillation counter as described in Chapter 2 section 2.13.3 . 
30bp varGA 1 IR 
The 30bp varGA1 oligonucleotide consists of the last 12bp of varG and the first 18bp of 
the 176bp varGA IR. Oligonucleotides var26Fwd used for labelling and var26Rev used 
for annealing. 
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30bp varGA2 IR 
The 30bp varGA2 oligonucleotide consists of the next 30bp following 30bp varGA 1 of 
the 176bp varGA IR. Oligonucleotides var27Fwd used for labelling and var27Rev used 
for annealing. 
30bp varGA3 IR 
The 30bp varGA3 oligonucleotide consists of the next 30bp following 30bp varGA2 of 
the 176bp varGA IR. Oligonucleotides var28Fwd used for labelling and var28Rev used 
for annealing. 
30bp varGA4 IR 
The 30bp varGA4 oligonucleotide consists of the next 30bp following 30bp varGA3 of 
the 176bp varGA IR. Oligonucleotides var29Fwd used for labelling and var29Rev used 
for annealing. 
30bp varGAS IR 
The 30bp varGA5 oligonucleotide consists of the next 30bp following 30bp varGA4 of 
the 176bp varGA IR. Oligonucleotides var30Fwd used for labelling and var30Rev used 
for annealing. 
30bp varGA 6 IR 
The 30bp varGA6 oligonucleotide consists of the next 30bp following 30bp varGA5 of 
the 176bp varGA IR. Oligonucleotides var31Fwd used for labelling and var31Rev used 
for annealing. 
30bp varGA 7 IR 
The 30bp varGA 7 oligonucleotide consists of the next 30bp following 30bp varGA6 of 
the 176bp varGA IR. Oligonucleotides var32Fwd used for labelling and var32Rev used 
for annealing. 
30bp varGA8 IR 
The 30bp varGA8 oligonucleotide incorporates the putative -35 and -10 sites of the 
176bp varGA IR. Oligonucleotides var33Fwd used for labelling and var33Rev used for 
annealing. 
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5.4.2 VarR binds to the varGA IR of the var operon 
Electrophoretic mobility shift assays were performed as described in Chapter 2 section 
2.13.3. EMSAs were employed to examine whether VarR binds at the varGA IR and the 
specificity to which it does. From figure 5.46 we can see retardations with 0.08ng 
415bp, 1 51207bp, 2nd 208bp, 176bp, 151 and 2nd 88bp varGA IR DNA fragments 
following incubation with 0, 50, 200ng VarR, respectively. A positive control of VarR 
with 30bp varRG IR DNA was used during the EMSAs. 
Figure 5.46 EMSA of VarR with 415bp, 1 st207bp, 2"d 208bp, 176bp, 1st and 2"d 
88bp of the varGA IR Lanes 1 and 2, VarR (Ong and SOng, respectively) 
with 0.08ng 30bp varRG IR DNA (control). VarR (0, 50, lOOng, 
respectively) with 415bp (Lanes 3 to 5), 151 207bp (Lanes 6 to 8), 2nd 
208bp (Lanes 9 to 11), 176bp (Lanes 12 to 14), 1st 88bp (lanes 15 to 17) 
and 2nd 88bp varGA IR DNA (lanes 18 to 20). 
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DNA-binding specificity ofVarR for the varGA IR 
To define the region to which VarR binds specifically in the 176bp varGA IR, 30bp 
DNA fragments that span the entire varRG IR were designed and used for EMSAs. 
VarR binds specifically to a 30bp varGAl IR DNA fragment, which incorporates the 
last 12bp of the varG gene and the first 18bp of the varGA IR. Therefore binding at this 
site by VarR may negatively regulate transcription of the varG gene. Figure 5.47 shows 
EMSA of VarR (0 and 50ng, respectively) with 0.08ng of varGA 1 (lanes 3 & 4), 
varGA2 (lanes 5 & 6), varGA3 (lanes 7 & 8), varGA4 (lanes 9 & 10), varGA5 (lanes 11 
& 12), varGA6 (lanes 13 & 14), varGA7 (lanes 15 & 16), and varGA8 IR DNA (lanes 
17 & 18). 
Figure 5.47 EMSA of VarR with varGA IR DNA Lanes 1 and 2, 0 and 50ng of 
VarR with 0.08ng 30bp varRG IR DNA (control). Lanes 3 to 18, VarR 
(0 and 50ng, respectively) with 0.08ng 30bp varGA IR DNA fragments 1 
to 8, respectively. 
Interestingly, the binding site for VarR in the varGA IR was unexpected. The predicted 
likely binding site was mapped to an area covered by the 30bp varGA8 IR DNA 
fragment, which incorporates the putative -35 and -10 sites of the 176bp varGA IR. The 
reason for which V arR binds to this alternative 30bp varGA 1 region ha yet to be 
established. However, it could be likely that V arR binds to multiple regions of this large 
promoter. As LTTRs are known to bind their promoters as tetramers (Miller and 
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Kredich, 1987; Verschueren et al., 2001; Muroaka et al., 2003), the relatively small 
lengths of the DNA fragments used during these EMSAs may not be sufficient to allow 
VarR to form an effective binding conformation. 
Increasing titrations of VarR with 30bp varGAl IR and non-specific DNA 
To define the concentration and specificity to which V arR binds to the 30bp varGA 1 IR, 
lower titrations of VarR (0, 1.25, 2.5, 5, 10, 25, 50, 100, 200ng, respectively) were 
incubated with 0.08ng 30bp varGA 1 IR DNA (figure 5.59). Simultaneously, titrations of 
VarR (0, 5, 10, 50, 100, 200ng, respectively) with 0.08ng 30bp non-specific DNA were 
executed to confirm the specificity of the interactions (figure 5.48). 
Figure 5.48 EMSA using increasing titrations of VarR with 30bp varGAl IR 
DNA including 30bp non-specific DNA Lanes 1 and 2, VarR (0 and 
SOng) with 0.08ng 30bp varRG IR DNA (control). Lanes 3 to 11 , 
Titrations of VarR (0, 1.25, 2.5, 5, 10, 25, 50, 100, 200ng, respectively) 
with 0.08ng 30bp varGA1 IR DNA. Lanes 12 to 17, Titrations of VarR 
(0, 5, 10, 50, 100, 200ng, respectively) with 0.08ng 30bp Non-specific 
DNA. 
VarR VarR 
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EMSAs of VarR/ 30bp varGAl IR complex in competition with increasing 
titrations of unlabelled 30bp varGA 1 IR DNA 
VarR is able to dissociate from the labelled 30bp varGA1 IR DNA complex and bind to 
unlabelled 30bp varGA 1 IR DNA during competitive EMSAs, which indicate that 
interactions are highly specific (Figure 5.49). 
Figure 5.49 EMSA of SOng VarR/ 0.08ng varGAJ DNA (labelled) complex with 
titrations of unlabelled 30bp varGAJ DNA Lanes 1 and 2, VarR (0 and 
Sng) with 0.08ng 30bp varRG IR DNA (control). Lanes 3 to 11, 
Competition assay of SOng VarRJ 0.08ng 30bp varGAl IR DNA 
complex with titrations of unlabelled 30bp varGA 1 IR DNA (0, 0.125, 
0.25, 0.5, 1, 2, 5, 10, 20ng, respectively). 
Unlabelled 30bp varGA1 IR DNA 
1 2 3 4 5 8 7 8 9 10 11 
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EMSAs of VarRI 30bp varGAl IR complex in competition with increasing 
titrations of unlabelled 30bp varRG IR DNA 
To define the specificity to which V arR binds to the 30bp varGA 1 IR compared to the 
varRG IR, a competitive assay was performed to determine the minimum concentration 
of unlabelled 30bp varRG IR DNA that is required to dissociate SOng VarR from 0.08ng 
labelled 30bp varGAl IR DNA. Figure S.SO shows that VarR has an equal affinity for 
both the 30bp varRG IR DNA and the 30bp varGA1 IR DNA with 1ng of 30bp varRG 
IR DNA sufficient to dissociate VarR from the complex. This is comparable with the 
competitive assays of VarRJ varGA1 IR DNA complex with unlabelled varGA1 IR 
DNA (figure S.49). 
Figure 5.50 Competitive EMSA of VarRJO.OSng varGAl DNA complex with 
unlabelled varRG IR DNA. Lane 1 and 2, 0 and SOng V arR with 0.08ng 
varGA1 IR DNA, respectively. Lanes 3 to 12, competitive assay of SOng 
VarR/ 0.08ng varGA1 IR DNA complex with titrations of unlabelled 
30bp varRG IR DNA (0.12S, 0.2S, O.S, 1, 2, 4, 8, 16, 32, 64ng, 
respectively). 
Unlabelled 30bp varRG IR DNA 
1 2 3 4 5 8 7 8 9 10 11 12 
2S7 
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5.5.1.1 
EMSAs establish that VarR binds to the varBC IR 
Preparation of varBC IR oligonucleotides for EMSAs 
PCR amplification of oligonucleotides 
To determine if VarR binds at the putative varBC promoter and to define the binding 
region, DNA of varying lengths incorporating nucleotides from either side and 
overlapping the IR were designed and amplified by PCR. 
195bp varBC IR 
The forward primer, var34Fwd, and reverse primer, var34Rev, were designed to 
amplify a blunt ended 195bp DNA fragment (termed 195bp varBC IR) that incorporates 
the last 50bp of varB, 25bp varBC IR and the first 120bp of varC. A ProofStart 
polymerase PCR (Chapter 2 section 2.6.1) was performed with an annealing 
temperature of 58°C, extension time of 45 seconds, and 35 cycles of amplification. 
Figure 5.51 shows the successful amplification of 195bp varBC IR (lanes 3-9) 
visualised against a PCR marker. 
Figure 5.51 PCR amplification of 195bp varBC IR. Lane 1= PCR Mr marker. 
Lanes 2-9; show individual PCR amplification reactions. 
1 2 3 4 5 6 
1st 97bp varBC IR 
7 8 9 
._ Amplified 195bp 
varBCIR 
The forward primer, var34Fwd, and reverse primer, var35Rev, were designed to 
amplify a blunt ended 97bp DNA fragment (termed the 1st 97bp varBC IR) that 
incorporates the first half of the 195bp varBC IR. A ProofStart polymerase PCR 
(Chapter 2 section 2.6.1) was performed with an annealing temperature of 58°C, 
extension time of 45 seconds, and 35 cycles of amplification. Figure 5.52 shows the 
successful amplification of 1st 97bp varBC IR (lanes 2-5) visualised against a PCR 
marker. 
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Figure 5.52 PCR amplification of 151 97bp varBC IR. Lane 1= PCR Mr marker. 
Lanes 2-5; show individual PCR amplification reactions. 
1 2 3 4 5 
.___ Amp I ified 1 '1 97bp 
varBCIR 
2"d 98bp varBC IR 
The forward primer, var36Fwd, and reverse pnmer, var34Rev, were designed to 
amplify a blunt ended 98bp DNA fragment (termed the 2"d 98bp varBC IR) that 
incorporates the last half of the 195bp varBC IR. A ProofStart polymerase PCR 
(Chapter 2 section 2.6.1) was performed with an annealing temperature of 57°C, 
extension time of 45 seconds, and 35 cycles of amplification. Figure 5.53 shows the 
successful amplification of 2"d 98bp varBC IR (lanes 2-5) visualised against a PCR 
marker. 
Figure 5.53 PCR amplification of 2"d 98bp varBC IR. Lane 1= PCR Mr marker. 
Lanes 2-5; show individual PCR amplification reactions. 
1 2 3 4 5 
5.5.1.2 Radiolabelling and annealing of oligonucleotides 
The oligonucleotides described below were synthesised by Invitrogen on a 50nmol scale 
(desalted) , labelled with ['Y-32P] TP and annealed as described in Chapter 2 section 
2.13.3. 300ng of each 195bp, 1st 97bp and 2"d 98bp varBC dsDNA were labelled and 
purified as described in Chapter 2 section 2.13.3 . The concentration of annealed duplex 
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DNA was determined prior to EMSAs using a liquid scintillation counter as described 
in Chapter 2 section 2.13. 3. 
25bp varBC IR 
The 25bp varBC oligonucleotide incorporates the 25bp varBC IR. Oligonucleotides 
var37Fwd used for labelling and var37Rev used for annealing. 
5.5.2 VarR binds to the varBC IR of the var operon 
EMSAs were employed to examine whether VarR binds at the varBC IR and the 
specificity to which it does. From figure 5.54 we can see retardations with 0.08ng 
195bp, 151 97bp, 2nd 98bp and 25bp varBC IR DNA fragments following incubation 
with 0, 50, 200ng VarR, respectively. A positive control of VarR with 30bp varRG IR 
DNA was used during the EMSAs. 
Figure 5.54 EMSA of VarR with 195bp, 1st 97bp, znd 98bp and 25bp the varBC 
IR Titrations of VarR (0, 50 and 200ng, respectively) with 0.08ng 195bp 
varBC IR DNA (Lanes 1 to 3), 1st 97bp varBC IR DNA (Lanes 4 to 6), 
2nd 98bp varBC IR DNA (Lanes 7 to 9), and 25bp varBC IR DNA 
(Lanes 10 to 12). Lanes 13 and 14, Ong and 50ng VarR with 0.08ng 30bp 
varRG IR DNA (control), respectively. 
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Increasing titrations of VarR with 30bp varBC IR and 30bp non-specific DNA 
To define the concentration and specificity to which VarR binds to the 25bp varBC IR, 
lower titrations of VarR (0, 1.25, 2.5, 5, 10, 25, 50, 100, 200ng, respectively) were 
incubated with 0.08ng 25bp varBC IR DNA. Simultaneously, titrations of VarR (50, 
100, 200ng, respectively) with 0.08ng 30bp non-specific DNA were executed to 
confirm the specificity of the interactions. Figure 5.55 shows binding of VarR to 25bp 
varBC IR DNA is specific. 
Figure 5.55 EMSA using increasing titrations of VarR with 25bp varBC IR DNA 
including 30bp non-specific DNA Lanes 1 to 10, Titrations of VarR (0, 
1.25, 2.5, 5, 10, 25, 50, 100, 200, 400ng, respectively) with 0.08ng 25bp 
varBC IR DNA. Lanes 11 to 13, Titrations of VarR (0, 50 and 200ng, 
respectively) with 0.08ng 30bp Non-specific DNA. Lanes 14 and 15, 0 
and 50ng VarR with 0.08ng 30bp varRG IR DNA (control). 
VarR VarR 
J ...--:::::::1 
1 2 3 4 5 8 7 8 9 10 11 12 13 14 15 
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EMSAs of VarR/30bp varBC IR complex in competition with increasing titrations 
of unlabelled 30bp varBC IR DNA 
VarR is able to dissociate from the labelled 30bp varBC IR DNA complex and bind to 
unlabelled 30bp varBC IR DNA during competitive EMSAs, which indicate that 
interactions are highly specific (Figure S.S6). 
Figure 5.56 EMSA of SOng VarR! 0.08ng 25bp varBC IR DNA (labelled) complex 
with titrations of unlabelled 30bp varBC DNA Lanes 1 and 2, Ong and 
SOng VarR with 0.08ng 30bp varRG IR DNA (control). Lanes 3 to 12, 
Competitive assay of SOng VarRI 0.08ng 2Sbp varBC IR DNA complex 
with titrations of unlabelled 0.08ng 2Sbp varBC IR DNA (0, 0.12S, 0.25, 
O.S, 1, 2, S, 10, 20, and 40ng, respectively). 
Unlabelled 25bp varBC IR DNA 
1 2 3 4 5 8 7 8 9 10 11 12 
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EMSAs of SOng VarR/ 0.08ng 25bp varBC IR complex in competition with 
increasing titrations of erythromycin antibiotic 
It is hypothesised that Y arR regulates the putative antimicrobial resistance transporter, 
YarACDEF, at the varBC IR. As YarD and YarE are both thought to harbour specificity 
for macrolide antibiotics such as erythromycin, it could be likely that YarR may also 
have the same substrate specificity. Therefore an EMSA (figure 5.57) was performed 
with 50ng YarR/ 0.08ng 25bp varBC IR DNA (labelled) complex with increasing 
titrations of erythromycin (0, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 512, 1 024ng, lO~g. lOO~g. 
respectively). 
Figure 5.57 EMSA of VarR/25bp varBC IR DNA complex with increasing 
titrations of erythromycin Lane 1 0.08ng 25bp varBC IR DNA only. 
Lanes 2 to 16 50ng YarR/ 0.08ng 30bp varBC DNA complex with 
increasing titrations of erythromycin (0, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 
256, 512, 1024ng, 10, lOO~g. respectively). 
Erythromycin 
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Erythromycin was unable to_ dissociate VarR from the JObp varBC IR DNA even in 
excess concentrations. However, the inability to dissociate VarR from both varRG 
(figure 5.12) and varBC promoters at these concentrations of antibiotic does not imply 
that the tested antibiotics are not substrates for VarR. Rather it has been proven that 
some LTTRs show indifference to binding to promoter DNA in the presence or absence 
of substrate (Lindquist et al., 1989). A study by Kong and associates (2005) has shown 
that the presence of ampR is required for ampC expression. This could be a 
consequence of the dual regulatory functions of LTTRs (Schell, 1993), whereby in the 
absence of substrate, LTTRs may constitutively bind their promoters to form a 
repressive state, but in the presence of substrate they may activate, but only partially 
dissociate from the promoter in a manner that exposes the -35 site to RNA polymerase 
for transcriptional initiation of target gene(s). 
5.6 Discussion 
The LTTR family of DNA-binding proteins are involved in the regulatory control of a 
diverse range of biological mechanisms (Henikoff et al., 1988). VarR is no exception 
having been demonstrated to bind within the varRG, varGA and varBC intergenic 
regions of an antibiotic resistance operon (see vertical arrows in figure 5.58 on the 
following page). The binding of VarR to three different 30bp sites within the same 
operon is the first such case to be demonstrated for a member of the LTTR family. 
Like other LTTRs, VarR binds to putative operator sites harbouring imperfect 
repeats that contain the characteristic conserved LysR-type T-N 11 -A element motif 
recognised specifically by members (Schell, 1993). Although binding by VarR has been 
located specifically to 30bp in each putative promoter, LTTRs are notorious for binding 
sites that span the length of the promoter. Therefore V arR has the potential to 
simultaneously bind adjacent operator sequences upon formation of higher oligomeric 
states. 
A conserved LysR-type motif in the ampR-ampC intergenic region for AmpR in 
C. freundii and E. cloacae has been determined to be 5'-TCTGCTGCTAAATTT-3' 
(Lindquist et al., 1989). However, analysis of the binding sites for VarR has failed to 
identify a similar sequence. This could be due to the differences in the nature of the 
regulated target gene, with AmpR regulating a serine-~-lactamase and VarR regulating 
a M~l. 
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Figure 5.58 (A) The V. cholerae var operon depicting the three binding sites in 
the putative promoters, varRG, varGA and varBC. (B) VarR has been 
shown to bind at distinct locations within these putative promoters in 
which the nucleotide sequences within vertical arrows delineate the 
binding sites. 
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The binding of V arR to the arsD promoter may be an example of the potential global 
regulatory property of LTTRs and therefore the ability of V arR to regulate at unrelated 
promoters. The regulatory mechanisms elucidated from this chapter may therefore be 
extrapolated to other bacterial species with similar regulatory systems. This has already 
been demonstrated with the varR-varG system from V. cholerae that shows similarities 
to the ampR-ampC transcriptional regulatory system in C. freundii (Lindquist et al., 
1989) and E. cloacae (Lindberg and Normark, 1987). 
Antimicrobial susceptibility assays have established that VarR acts as a 
repressor of varG expression at the varRG IR. However, the regulatory roles of VarR at 
the varGA and varBC IRs have yet to be established. Future directions for the 
continuation of this are described in the next section. 
Antimicrobial susceptibility failed to determine the substrate specificity for 
VarR, with high concentrations of likely antibiotics failing to dissociate the 
VarR/promoter DNA complexes in the EMSAs. However, DNA binding may be 
indifferent whether in the presence or absence of substrate (Lindquist et al., 1989). 
Therefore it could be likely that differential binding of V arR to operator sites may be a 
consequence of formation of different oligomeric states that determine the switch 
between repression and transcriptional activation. One theory could be that VarR 
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represses transcription at the varRG intergenic region through the N-terminal DNA-
binding domain. In the presence of co-activator substrate, VarR binds the substrate by 
the C-terminal substrate-binding domain. This may result in a conformational change in 
the regulator that partially disrupts binding to the promoter and exposes the -35 element, 
which allows productive interaction with the RNA polymerase. Transcriptional 
initiation of the target genes may then proceed. 
However, this does not explain the indifference seen in the MICs exhibited by 
the strains harbouring the test and control constructs. There are two plausible 
explanations for this, the first being that V arG is inefficiently produced, possibly as a 
consequence of a weak promoter leading to reduced translational efficiency by RNA 
polymerase (see chapter 3 section 3.11.1). Mutations at the varRG IR promoter sites 
may be required to increase transcriptional efficiency of VarG. A good example is that 
of the chromosomally encoded AmpC ~-lactamase, which is produced at low basal 
levels in wild-type E. coli (Jaurin et al., 1982). However, in clinically resistant E. coli 
strains, AmpC has been hyperproduced as a consequence of mutational insertion of 
nucleotides between the -10 and -35 promoter sequences that optimises the distance for 
RNA polymerase based transcriptional activation (Siu et al., 2003; Fermindez-Cuenca et 
al., 2005). Alternatively, the deletion of the attenuator region of ampC results in an 
increased transcription rate (Fermindez-Cuenca et al., 2005; Tracz et al., 2005). The 
second justification is that as M~ls require zinc cofactors for catalytic hydrolysis of ~­
lactam antibiotics (Wang and Benkovic, 1998), therefore the lack of zinc co-factors in 
the assay preparation could explain the seemingly deficient activity observed for VarG. 
Much of the regulatory aspects of VarR and its potentially hostile role in the 
control of antibiotic resistance determinants still remain to be elucidated. Future 
directions to assist in the characterisation of this captivating LTTR are outlined in the 
following section. 
5.7 Future directions 
Autoregulation of VarR at the varRG intergenic region 
To assess whether VarR regulates its own expression at the varRG IR, the 5' end of 
varR could be fused as a translational fusion to a reporter gene such as ~-galactosidase 
(lacZ). The presence of ~-galactosidase activity from the lacZ-varRG translational 
fusion in the absence of VarR and the absence of activity in the presence of VarR 
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introduced from a co-resident plasmid would confirm that VarR is autogenously 
controlled. 
Mapping the exact -10 and -35 sites within varRG, varGA and varBC 
The DN asel footprinting technique can be used to determine the exact region where 
RNA polymerase binds and initiates transcription in the promoter regions. In brief, the 
5' end of a specific promoter region is labelled with 32P. RNA polymerase is with the 
labelled DNA and the complex is then digested with DNasel. Simultaneously, an 
aliquot of the same labelled DNA without RNA polymerase is treated in the same 
manner to serve as a control. DNasel results in the extensive digestion of unprotected 
DNA and the resultant fragments are separated by gel electrophoresis and exposed to 
autoradiographic film. The resultant gel pattern should contain certain fragments that 
are present in the control, but absent in the sample containing the RNA polymerase (the 
'footprint'). The binding site of RNA polymerase lies within those DNA fragments 
absent in the test sample compared to the control. 
Mapping the exact VarR operator sites within varRG, varGA and varBC 
To map the exact VarR binding site, DNasel footprinting could be performed as 
described previously, however, substituting RNA polymerase for high purity VarR. 
Mutations in the varRG promoter sites to improve transcriptional initiation and 
expression of VarG 
Site directed mutagenesis could be employed to introduce nucleotide substitutions in the 
-10 and -35 promoter sequences or ribosome binding site in the varRG IR similar to the 
typical bacterial consensus sequences. Antimicrobial susceptibility assays, similar to 
that described previously for the pSMART/varRG-varG ± varR constructs, could then 
be conducted. 
Estimating the minimum concentration of VarR required for binding 
The concentration of V arR required for binding at each promoter may also be estimated 
by varying the concentration at which these assays are conducted. The binding affinity 
is the minimum concentration of V arR at which the footprint is observed. 
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Elucidating the regulatory role ofVarR at the varGA and varBC IRs 
It is unsure if V arR represses or activates at these sites. The potential for both is its 
nature for LTTRs. To establish its regulatory role, varR can be cloned into separate 
vector to the varGA::lacZ and varBC::lacZ constructs, respectively and its activities 
analysed in the absence and presence of the varR on media supplemented with IPTG 
(for native promoter) and X-gal. lacZ is a reporter gene encoding for ~-galactosidase. In 
the absence of substrate, ~-galactosidase expressing bacteria will appear blue in the 
absence of varR and may be clear or white in the presence of varR due to its repression. 
Substrates can then be tested to see if it can dissociate V arR from cells containing both 
varR and varGA::lacZ or varBC::lacZ and therefore the substrate specificity can also be 
determined. 
Establishing the regulatory role of VarR at the varRG promoter 
As M~ls require zinc cofactors for catalytic hydrolysis of ~-lactam antibiotics, 
antimicrobial susceptibility assays using pSMART/varRG-varG ± varR in the presence 
of lOOJ.tM Zn2+ in Muller-Hinton broth should be conducted. 
Establishing the substrate profile for VarR through ECFP fluorescence 
measurements 
Substrates for VarR may be determined through monitoring for increases in ECFP 
fluorescence associated with ECFP expression, upon incubations with increasing 
concentrations of putative substrates. 
Elucidating if VarR can respond to and have substrate specificity for intermediates 
from peptidoglycan degradation 
In order to elucidate if VarR responds to muropeptides from peptidoglycan degradation, 
varR-varRG could be created as a fusion to lacZ. E. coli harbouring var-vaRG-lacZ can 
then be grown in the presence and absence of these muropeptides in solid media 
supplemented with IPTG and X-gal. In the absence of muropeptides, E. coli should be 
repressed by VarR from expressing ~-galactosidase activity, whereas the presence E. 
coli should constitutively express ~-galactosidase resulting in the formation of blue 
colonies. 
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Chapter 6 Structural characterisation of VarR using 
analytical SEC, colorimetric assay, stopped-flow 
and CD spectroscopy and crystallisation 
The 3D structural characterisation of VarR would elucidate information regarding 
protein function that otherwise would not be detected from secondary sequence data 
alone. Structural data for VarR was obtained through analytical SEC and 
ultracentrifugation studies, colorimetric assays, circular dichroism (CD) and stopped-
flow spectroscopy and crystallography. The overall combined data would allow for a 
reasonably sound structural insight for VarR. 
6.1 Analytical SEC of VarR 
Analytical size exclusion chromatography (SEC) was used to determine statistically the 
average molecular weights and molecular weight distribution of oligomeric complexes 
in apo (DNA- and substrate free state) and DNA-bound forms of VarR. Analytical SEC 
of VarR was performed on an AKTA Purifier (Amersham Biosciences) using a 
Superdex200PC3.2/30 column (Amersham Biosciences) as described in Chapter 2 
section 2.14.2. All buffers and water used were distilled and degassed through 
surfactant-free cellulose acetate 0.2J..lM filters (Nalgene) and a flow rate of 20 
microlitres per minute was applied through the column (maximum pressure limit of 
0.5MPa), unless otherwise stated. The buffer composition used for all experiments 
(including for the molecular weight standards) was 20mM Tris-HCl pH8.25, 50mM 
NaCl, 10% glycerol, 1mM DTT and 0.2% DDM. The column was equilibrated with 1 
CV of water and 2 CV of buffer prior to all chromatographic elutions. The elution 
profiles of DNA were monitored by the 260nm absorbance and proteins by the 280nm. 
6.1.1 Molecular weight determination of protein standards 
The apparent molecular weight (Mr) of VarR was determined by comparison of the 
elution profiles to protein standards of known Mr. Dextran blue 2000 (lmg/ml) was 
applied to the column prior to the protein standards to determine the void volume (V0 ) 
of the column. The molecular standards were grouped into two chromatographic runs, 
the 1st included ribonuclease A, ovalbumin, aldolase and ferritin. The 2"d run included 
chymotrypsinogen A, albumin and catalase. Using the elution volumes (Ve) of these 
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standards and the Yo from dextran blue determined as 1.05ml, the Kav values were 
calculated and are listed below. 
Molecular Weight Molecular Concentration Ve (ml) .Cav==Ve·Vcl\ft-Vo Standard weight (kDa) (mglml) 
Ribonuclease A 13.7 10 2.00 0.70 
Chymotrypsinogen A 25 3 1.60 0.40 
Ovalbumin 43 7 1.75 0.51 
Albumin 67 7 1.96 0.67 
Aldolase 158 2 1.46 0.30 
Catalase 232 5 1.49 0.32 
Ferritin 440 0.5 1.33 0.20 
The Kav values for the protein standards were plotted on a logarithmic scale against the 
corresponding Mr and a line of best fit was drawn (figure 6.1). 
Figure 6.1 Calibration curve of molecular weight standards on Superdex 200 
5.8 
5.6 
5.4 
5.2 
:i 5 
Cl 
0 4.8 
4.6 
4.4 I 4.2 I 4 Ribonuclease A 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 
270 
6.1.2 Molecular weight determination ofVarR 
The calculated Mr of VarR (purified with detergent) in its apo form was determined 
under ambient and non-denaturing conditions. Fifty J..Ll of a 4.5mg/rnl VarR was applied 
to the column and the Ve was determined to be 1.4rnl (figure 6.2). This gives a 
corresponding Kav value of 0.25 consistent with VarR forming a complex with a Mr of 
-300kDa (figure 6.3). 
Figure 6.2 
mAU 
350 
300 
250 
200 
150 
100 
50 
Elution profile for VarR on Superdex 200 The absorbance at 280nm 
(blue trace) corresponds to VarR. The absorbance at 260nm (red trace) 
corresponds to DNA. The Ve of the protein standards are shown as 
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Figure 6.3 
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Calibration curve of VarR on Superdex 200. The Mr of VarR was 
determined to be approximately 300kDa, which is consistent with VarR 
forming an octomer. 
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The calculated Mr of 300kDa would be consistent with apo V arR forming an octo mer. 
This would not be unusual as other DNA-binding proteins have been proven to bind as 
higher molecular weight species to their cognate promoter DNA (Engohang-Ndong et 
al., 2004). A repressor protein, EthR from the TetR family of transcriptional regulators 
has been shown to octamerise on its operator site (Engohang-Ndong et al., 2004). The 
authors suggest that this multimerisation of EthR could be a consequence of binding an 
unusually long 55bp region, which would be consistent with VarR binding to its 
putative 56bp operator site in the varRG IR. 
6.1.2 Molecular weight determination of VarR with promoter DNA 
In order to elucidate if V arR adopts different oligomeric conformations when bound to 
each of the three promoter sites in the var operon, analytical SEC was performed to 
determine the Mr of VarR in complex with the 30bp varRG, varGA and varBC IR DNA, 
respectively. 
Firstly, to calculate the Mr of the protein-DNA complex, the Mr of the 30bp 
DNA fragment alone was required in order to calculate the number of protein species 
present within the complex. lOOf.ll of a 5mg/ml 30bp varRG IR DNA applied to the 
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column and the Ve was determined to be 1.9ml (figure 6.4) from the 260nm absorbance 
peak. Fractions containing protein or nucleic acid were identified by the A26oiA2so ratio 
(Warburg and Christian, 1942). The A26o/A280 ratio for the trace of 30bp varRG DNA is 
approximately 1.4, which is typical of a sample predominated by nucleic acids 
(Warburg and Christian, 1942). This gives a corresponding Kav value of 0.63, which is 
consistent with a Mr of -20KDa (calculated Mr of 18.4kDa). 
Figure 6.4 
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As most LTTRs are hypothesised to bind their promoters as tetramers, VarR was mixed 
with 30bp varRG IR DNA in a molar ratio of 4:1. The absorbance peak of VarR bound 
to 30bp varRG DNA can be seen in figure 6.5. The peak has an A26oiA2so ratio of 
approximately 0.66, which is typical of a sample predominated by protein (Warburg and 
Christian, 1942). 
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Figure 6.5 Elution profile of the 4:1 VarR/ 30bp varRG IR DNA complex. The 
blue curve (Abs280) and the red curve (Abs260) in the first large peak 
correspond to VarR and 30bp varRG DNA in complex, respectively. The 
last peak predominated by the Abs260 relates to the unbound 30bp varRG 
DNA. The Ve of the protein standards are shown as vertical arrows. 
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The elution profile of 1.4ml for the 4:1 VarR-DNA complex has not deviated from that 
determined for V arR alone, indicating the formation of a 300kDa oligomeric species. 
This could be due to loss of binding affinity exhibited by V arR due to the presence of 
the detergent, DDM. This would be likely as it is unlikely for VarR to form an octomer 
in the presence of a 30bp DNA fragment that only harbours the second half of the 
predicted operator site. To determine if the oligomeric state can be altered, the molar 
concentration of DNA was increased. The theory was that at higher molar 
concentrations of DNA, one would expect the profile of VarR to shift from a higher Mr 
to a lower Mr consistent with V arR shifting from an octomeric to tetrameric 
conformation. 
A 1:4 molar ratio of VarR to 30bp varRG DNA was applied to the column and 
the Ve was determined to be 1.4ml (data not shown). This gives a corresponding Kav 
value of 0.25 consistent with VarR forming a complex with a Mr of -300kDa, which 
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again does not deviate from that observed for VarR as described previously. However, it 
could be that adoption of this conformation may be specific for binding at the varRG 
IR. Therefore the elution profile of VarR in complex with the 30bp varGA DNA in a 
molar ratio of 1:4 was determined (figure 6.6). 
Figure 6.6 
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correspond to VarR and 30bp varGA DNA in complex, respectively. The 
larger last peak is predominated by the Abs260 and relates to the unbound 
30bp varGA DNA. The Ve of the protein standards are shown as vertical 
arrows. 
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Once again, the calculated Mr of -300kDa did not diverge from the results of the 
previous experiments. The same conclusions were attained from the analytical SEC of a 
1:4 molar ratio of VarR to 30bp varBC DNA (figure 6.7). 
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Figure 6.7 Elution profile of the VarR/ 30bp varBC IR DNA complex. The blue 
curve (Abs280) and the red curve (Abs260) in the first large peak 
correspond to VarR and 30bp varBC DNA in complex, respectively. The 
larger last peak is predominated by the Abs260 and relates to the unbound 
30bp varBC DNA. The Ve of the protein standards are shown as vertical 
arrows. 
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The inability to distinguish the oligomeric state of VarR upon binding to its cognate 
promoter DNA could be a result of the presence of the detergent, DDM that was used to 
aid its solubilisation. Theoretically, DDM was used to mask the predicted hydrophobic 
patches located at the N-terminal DNA-binding domain (chapter 4), which may 
interrupt the possible interactions between V arR (purified in the absence of DDM) and 
its cognate promoter DNA as identified during EMSAs (chapter 5). The presence of 
DDM may also result in a faster passage of VarR and/or the VarR-DNA complex 
through the SEC column resulting in elution at an earlier stage than if determined in the 
ab ence of detergent. The molar ratio of DDM to apo V arR can be calculated through a 
colorimetric assay, which should determine the exact oligomeric state of VarR bound to 
DNA. Interactions involving apo VarR and/or the VarR-DNA complex with the solid 
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matrix of the SEC column or impedance in the presence of DDM may also interfere 
with the elution profiles during analytical SEC. Therefore analytical ultracentrifugation 
was adopted to determine the subunit stoichiometry and interactions formed between 
VarR and promoter DNA, respectively. As these experiments are performed in free 
solution, there should be limited complications associated with interactions with 
matrices or surfaces that could obscure the interpretation (Cole and Hansen, 1999; 
Schuck, 2000). 
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6.2 Colorimetric assay of VarR 
The colorimetric assay (Butler et al, 2004) was performed as described in chapter 2 
section 2.14.3 to determine the amount of DDM (through the sugar component) bound 
to VarR. The molar ratio between apo VarR and DDM was then calculated in order to 
determine the amount of DDM bound in the 300kDa VarR-DNA complex identified 
from analytical SEC. This would allow the approximation of the oligomeric state of 
VarR in the complex through deduction of the Mr inferred by DDM. 
A standard curve (figure 6.8) containing six points between O!lg to 20!lg of DDM was 
produced with a line of best fit (r2 >0.97). 
Figure 6.8 Colorimetric assay standard curve of DDM. 
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The peak fraction eluted from anion-exchange based concentration of VarR (fraction 4) 
was used for the colorimetric assays (figure 6.9). The flow through eluted following 
binding of VarR to the anion-exchange column was retained to adjust for the 
background DDM present in the buffer. 
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Figure 6.9 Anion-exchange chromatography of 4.5mglml VarR for colorimetric 
assays 
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The colorimetric assays were performed in triplicate and in two dilutions (1 :5 and 1: 10) 
to ensure that the amount of DDM detected was within the range of the standard curve. 
Using the equation generated from the standard curve, the amount of DDM bound to 
V arR was calculated as described in figure 6.1 0. 
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Figure 6.10 Colorimetric assay data for DDM in the fractions of 4.5mglml VarR 
Sample A (Dilution of 1 :5) 
Amount of Average Adjusted due to 
Reading Abs4so DDM in ~g amount of dilution factor (x5) DDM (~M) (Tread line DDM (~g) (~g DDM/60~1) Adjusted) 
1 0.178 40.17391304 
2 0.189 42.56521739 40.53623188 202.6811594 6615.78 
3 0.172 38.86956522 
Sample B (Dilution of 1:10) 
Amount of Average Adjusted due to 
Reading Abs4so DDM in ~g amount of dilution factor DDM (~M) (Tread line (x10) 
Adjusted) DDM (~g) (~g DDM/60~1) 
1 0.0817 19.23913043 
2 0.0821 19.32608696 19.0942029 190.942029 6232.60 
3 0.0793 18.7173913 
As 4.5mg/ml VarR = 122.4lJ.lM, the molar ratio of VarR to DDM is as follows: 
Molar ratio 
Sample VarR DDM 
A (1 :5) 1 54.05 
8(1:10) 1 50.92 
The Mr of DDM is 510.6 therefore the combined VarR-DDM complex is as follows: 
Molecular weight (Mr) 
Sample Mr of VarR Mr of DDM per Total Mr VarR 
A (1 :5) 36761.23 27595.59 64356.82 
8(1:10) 36761.23 25997.27 62758.50 
The number of VarR molecules bound to DDM in the VarR/DDM complex can be 
calculated as described on the following page. 
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Mrof Number of 
VarRIDNAIDDM Mr of complex VarR Sample Mrof dsDNA 
complex from minus Mrof molecules in dsDNA VarRIDDM Analytical SEC 
complex 
A (1 :5) 18400 300000 281600 4.38 
8(1:10) 18400 300000 281600 4.49 
The above data infers that approximately four molecules of VarR exists in the 300kDa 
VarR/DNA complex determined from analytical SEC when the Mr contributed by DDM 
was taken into account. This assumes that VarR exists as a minimum in a tetrameric 
form in solution (unbound DNA state) and when in complex with its cognate promoter 
DNA. This is consistent with literature that haven shown that LTTRs exist as tetramers 
in solution and when bound to DNA as a dimer of dimers (Miller and Kredich, 1987; 
Schell et al., 1990; Bishop and Weiner, 1993; Verschueren et al., 2001; Muraoka et al., 
2003). 
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6.3 Analytical ultracentrifugation 
The analytical ultracentrifugation (AUC) experiments were performed by Professor 
Steve Harding and Dr Kenneth Davis at the University of Nottingham. 
AUC is a versatile tool for the identification of the oligomeric state (Lebowitz et 
al., 2002) and the characterisation of interactions of purified proteins (>95% purity) in 
dilute solutions. The application of AUC involves the monitoring of protein 
sedimentation under centrifugal force through real-time observations (Balbo and 
Schuck, 2007). Two types of experiment exist and are referred to as sedimentation 
velocity and sedimentation equilibrium. Sedimentation velocity observes the separation 
of proteins due to their different rates of migration in the centrifugal field (Balbo and 
Schuck, 2007). This method (Harding and Windzor, 2001) was undertaken to determine 
the heterogeneity, molecular mass and subunit stoichiometry of VarR in the presence 
and absence of DNA. 
The Beckman Optima XL-I analytical ultracentrifuge was used to perform 
sedimentation velocity experiments on VarR samples in 20mM Tris-HCl, 50mM NaCl, 
10% glycerol, 0.35% DDM, and 1mM THP buffer. Sedimentation velocity experiments 
were conducted at 20.1 (±0.1) °C, at a speed of 40k rpm to minimise the effects of 
diffusion (Balbo and Schuck, 2007) and absorbance data was acquired at a wavelength 
of 280nm. The density of the buffer was measured at 1.03115g/ml and viscosity was 
1.489 centipoises (cP). The weight average sedimentation coefficient, S2o,w was 
determined using the public domain software program, SEDNTERP 
(http://www.rasmb.bbri.org/), to be 1.3525 Sobs· The apparent differential sedimentation 
coefficient distribution g*(s) was obtained by the least-squares g*(s) method (ls-g*(s)) 
during size distribution analysis (Schuck, 2000; Dam and Schuck, 2004). In general, the 
s-value based on a spherical monomer is -2.7S, dimer is -4.1S, tetramer (of linear 
arrangement of subunits is -5.4S and tetramer of tetrahedral arrangement is -6.5S). 
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The results from the sedimentation velocity experiments are summarised in table 6.1 
below. 
Table 6.1 Summary of sedimentation velocity assays on VarR 
[P] [DNA] Szo,w(S) Szo,w(S) Szo,w(S) Run J.1M J.1M Szo,w(S) %* "dimer" %* "tetra mer" %* high n-mer 
A 37 - - - 4.1 10 5.7-7.0 75 9-14 
B 48 - - - 4.1 10 5.7-7.0 70 9-14 
c 55 - - - - - 5.7-7.0 45 9-14 
D 55 13 1.5-2 55 - - 5.7-7.0 40 9-14 
E 55 26 1.5-2 65 - - 5.7-7.0 35 -
*% of UV absorbance at 280nm 
The corresponding g*(s) sedimentation distribution plots for the above results are 
detailed below. 
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The data gathered in table 6.1, indicate that V arR is quite heterogeneous with the main 
component is consistent with a tetramer. At the lowest loading concentration of 37J..LM 
(1.36mg/ml) apo VarR, 75% appears in a tetrameric form with a small proportion being 
dimeric (10%) and of higher molecular weight material (15%). This observation is 
consistent with proteins from the LTTRs family forming tetramers in solution (Miller 
and Kredich, 1987) and possibly higher-order oligomers in vivo (Schell et al., 1990; 
Bishop and Weiner, 1993). As the loading concentration of VarR is steadily increased to 
55J..LM (2.02mg/ml) the dimer disappears and a greater proportion of aggregate appears -
suggesting some degree of reversible associative equilibrium between the oligomeric 
forms. This seems to be consistent with previous observations that V arR precipitates at 
concentrations ~1.5mg/ml, which could be suggestive of alternation between oligomeric 
states. 
The addition of the 30bp varRG DNA reveals a component sedimenting at 1.5-
2.0S (the estimated percentage is by absorbance - because of the high extinction, more 
appears than the protein). Intriguingly the relative proportion of protein aggregate to 
tetramer drops significantly, although there is no clear evidence for DNA binding. 
However, that this does not discount the ability of VarR to bind to the 30bp varRG 
DNA, rather if binding was present it could not be seen due to the degree of protein 
heterogeneity. 
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6.4 Stopped- flow spectroscopy 
Stopped-flow spectroscopy was employed to monitor the transient changes in the 
steady-state fluorescence of V arR upon binding to its cognate promoter DNA and/or 
substrate. This technique exploits the intrinsic fluorescence produced by naturally 
occurring fluorophores of phenylalanine, tryptophan and tyrosine residues within VarR. 
Generally, the emission spectra of the dominant fluorophore, tryptophan, are monitored 
due to the sensitive nature of its fluorescence to changes in its local environment. 
Binding of DNA and/or substrate to VarR may induce a quench in fluorescence due to 
burial of the aromatic residues or changes in protein conformation. Alternatively, this 
quench may be caused through the physical interaction with the fluorophore that alters 
the polarity of its environment and/or its accessibility to the solvent (Ladokhin, 2000). 
The difference in fluorescence profiles can therefore be compared between the protein-
substrate complex and that of liberated protein or substrate. 
The presence of two tryptophan residues (W281 and W293) at the putative C-
terminal substrate binding domain of VarR make it an ideal candidate for conducting 
fluorescence-based studies in order to identify likely substrates (figure 6.11 ). 
Figure 6.11 Amino acid sequence of VarR. Residues highlighted red indicates the 
tryptophan residues. 
( 1) MVAPEINLRS IDLNLLTILE KLLIHKHISQ AAQALNMSQP ( 40) 
( 41) AVSRALMRLR EQFGDPLLVK VKNEYRLTAK GERLCSELER ( 8 0) 
( 81) TLNTIRHMLV DDKFDPMHYS GVFTIGALDF EMMMIVPKLL ( 12 0) 
( 121) ARFQQRAPNL KLQIVPYNAY MPLHDYLEKV ADLLLYSTDE ( 160) 
( 161) SPTNVFKQRL FNDNYAVVMC RNHPLANQPI TLESYCQSRH ( 2 0 0) 
(2 01) VIISGNGLGK TDMDHELKKL NYQREVVASL PHFSMVPELL ( 24 0) 
(241) INTDLIATLP RRLVTHLGQR YEITVADLPF YTADFRVEQF (280) 
(281) WHLIHHSSPI HQWVRQEIKN LVYEEIDKK ( 309) 
Spectral measurements were made with an SX.18MV stopped-flow spectrophotometer 
(Applied Photophysics, UK). An excitation wavelength of 285nm was generated by two 
serially connected monochromators for the specific excitation of tryptophans. 
Fluorescence emission was selected and changes in fluorescence were measured using a 
320nm cut-off filter attached to a photomultiplier detection tube. Experimental data 
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generated was analysed by the SpectraKinetic workstation interfaced with the 
spectrophotometer. 
All stopped-flow determinations were measured in 20mM Tris pH 8.25 and 
1 OOmM sodium fluoride buffer. A typical experiment involved one syringe containing 
5j..LM VarR (2.5j..LM final concentration) and another with either 20j..LM DNA (final 
10j..LM) or varying concentrations (40j..LM to lmM) of antibiotic in solution, respectively. 
Each experiment involved equal volumes of both solutions that were mixed in a mixing 
chamber and the changes in the absorbance were monitored above 320nm over a 50 
second time period. Controls of 2.5j..LM apo VarR, lOj..LM DNA and 250j..LM antibiotic 
were performed. Unfortunately little change in the fluorescence signal was detected for 
2.5j..LM VarR with 10j..LM varRG and varGA DNA, respectively, compared to the 
controls (data not shown). Fluorescence signals were generated through combination of 
VarR with varBC DNA and/or erythromycin and are shown on the following page. 
There seems to be an increase in fluorescence when VarR is incubated in the presence 
of DNA and/or substrate, rather than an anticipated quench generated by masking of the 
tryptophan residues. Figure 6.12 shows the signal generated from 2.5mM apo VarR 
only. Figure 6.13 shows the signal generated from 250j..LM erythromycin antibiotic only. 
Figure 6.14 and 6.15 shows the signal generated from 2.5j..LM VarR with lOj..LM varBC 
DNA and 250j..LM erythromycin antibiotic, respectively. Figure 6.16 shows the signal 
generated from 2.5j..LM VarR I 10j..LM varBC DNA and 250j..LM erythromycin. 
Unfortunately, the signals generated were as a consequence of the ethanol present in the 
erythromycin preparation, which was required for its solubilisation. Stopped-flow 
spectroscopy has therefore failed to generate any conclusive data that would indicate 
interactions between VarR and its cognate promoter DNA. This is suggestive of VarR 
being unable to bind the promoter DNA, which conflicts with the data presented during 
EMSAs that shows' binding is highly specific. 
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Figure 6.12 The fluorescence signal generated from 2.5~ VarR only 
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Figure 6.13 The fluorescence signal generated from 250~ erythromycin only 
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Figure 6.14 The fluorescence signal generated for 2.5J.LM VarR in association 
with 10J.LM varBC DNA 
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Figure 6.15 The fluorescence signal generated for 2.5J.LM VarR in association 
with 250J.LM erythromycin 
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Figure 6.16 The fluorescence signal generated for 2.5J.LM VarR/ lOJ.LM varBC 
DNA complex upon addition of 250J.LM erythromycin. 
0 
-0.1 
iii -0.2 
c: 
a 
iii 
..().3 
-0.4 
-0.5 
Wavelength = 285nm 
10 20 30 40 50 
Time (s) 
Alternative methods are therefore required to identify conformational changes that may 
occur in VarR upon binding its substrate and /or promoter DNA. Circular dichroism 
spectroscopy was therefore enlisted to hopefully elucidate these structural changes. 
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6.5 Circular Dichroism Spectroscopy 
Circular dichroism (CD) spectroscopy was used to detect conformational changes in the 
secondary structure content that may occur in VarR upon binding DNA and/or 
substrate. CD spectra generated in the far UV region (190-250nm) often arise from 
peptide transitions, and analysis of which may provide an insight into the secondary 
structural a-helical and ~-content. CD spectra generated in the near UV (260-320nm) 
arise from aromatic side chain transitions that offer insights into the tertiary structure. 
CD spectroscopy and data collection was achieved using an Applied Photophysics 
PiStar-180 Kinetic CD instrument resolved under nitrogen. All CD experimental 
parameters and methods were performed with reference to Kelly and Price (2000) and 
Kelly et al. (2005). 
Apo VarR used for the CD spectroscopy experiments was typically 5J.LM (final 
concentration of 2.5J.LM), >95% purity and purified in the absence of DDM. All VarR 
samples were centrifuged at 5,000xg for 5 minutes to remove traces of insoluble 
aggregates that may interfere with the CD spectra. To reduce absorption in the far UV 
region buffers of low molarity were used, chloride ions were also substituted for 
fluoride ions in the buffers used and pH adjustment was with sulphuric acid rather than 
HCl. All CD experiments were conducted over a wavelength range of 180-320nm to 
ensure that peptide and aromatic side chain transitions were detected. A blank CD 
spectrum was performed with the buffer, 20mM Tris pH 8.25 and lOOmM sodium 
fluoride, to ensure that the components did not result in excessive noise or present 
artefacts in the spectra. 
Changes in the secondary structure content of apo V arR was elucidated through 
comparisons of the CD spectra generated following binding of 2.5J.LM V arR to lOJ.LM 
promoter DNA and/or 250J.LM antibiotic. Figure 6.17 shows the CD spectra of 2.5J.LM 
apo VarR (black spectra), 2.5J.LM VarR with lOJ.LM 30bp varRG DNA (red spectra) and 
2.5J.LM VarR with lOJ.LM 30bp varRG DNA and 250J.LM penicillin G (blue spectra). 
Secondary conformational changes were greater for 2.5J.LM VarR bound to 10J.LM 30bp 
varGA DNA (figure 6.18) than when bound to 10J.LM 30bp varRG DNA (figure 6.17). 
In general, apo VarR imparts a typical CD spectra (black spectra) associated with 
having substantial a-helical secondary content (Kelly and Price, 2000; Kelly et al., 
2005). This is consistent with the secondary structure predictions of VarR that show an 
overall 45.95% a-helical, 14.56% ~-content and 39.48% other structure including 
interconnecting loop regions (Rost and Sander, 1993; Rost et al., 1996). 
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Figure 6.17 CD Spectroscopy of VarR with varRG DNA. 2.51-LM apo VarR (black 
spectra), 2.51-LM VarR with 10!-LM 30bp varRG DNA (red spectra) and 
2.51-LM VarR with 250!-LM penicillin G (blue spectra). 
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Figure 6.18 CD Spectroscopy of VarR with varGA DNA. 2.5!-LM apo VarR (black 
spectra), 2.51-LM VarR with 10!-LM 30bp varGA DNA (red spectra) and 2.5!-LM VarR 
with lOrnM 30bp varGA DNA and 250!-LM penicillin G (blue spectra). 
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There appears to be a significant change in the secondary structure content for the 
VarR-DNA complex in both figure 6.17 and 6.18, upon binding to penicillin G (blue 
line). However, this CD spectrum may have been influenced by the high concentrations 
of penicillin G within the preparation as the CD spectrum for 250~M penicillin G alone 
and with 2.5~M VarR generate almost identical signals (data not shown). The chirality 
of penicillin G ensures that such high concentrations may produce a signal that 
dominates and masks the true signal seen for V arR. Therefore the CD signal generated 
for VarR-DNA in the presence of antibiotic is likely to be that of penicillin G. One 
would also expect that binding of penicillin G at the predicted substrate binding domain 
of V arR would result in a change in spectra in the near UV region consistent with side 
chain transitions of the two C-terminally located tryptophans. This would correlate with 
other LTTRs such as Cbl (Stec et al., 2006) that have been shown to bind substrates at 
their C-terminal through fluorescence emission spectroscopy. Cbl exhibited a typical 
tryptophan emission spectrum with a Amax at 336nm, and in which the fluorescence 
intensity significant decreased upon addition of its substrate, APS. This would be 
consistent with binding at the C-terminal substrate-binding domain in which five 
tryptophan residues are located. 
Figure 6.19 shows the CD spectra of 2.5~M apo VarR (black spectra), 2.5~M 
VarR with lO~M 30bp varBC DNA (red spectra) and 2.5~M VarR with lO~M 30bp 
varBC DNA and 250~M erythromycin (blue spectra). Relatively little change in 
secondary structure content was observed in the far UV region in the CD spectra for 
VarR when in association with 30bp varBC DNA (red spectra), with most observed in 
the near UV. A slight increase in the CD spectra between 250 and 300nm may indicate 
that binding of VarR to the 30bp varBC DNA may cause conformational changes 
involving the side chains of aromatic residues. 
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Figure 6.19 CD Spectroscopy of VarR with varBC DNA. 2.5~ apo VarR (black 
spectra), 2.5!-lM VarR with 10!-lM 30bp varBC DNA (red spectra) and 
2.51J.M VarR with lOrnM 30bp varBC DNA and 250~ erythromycin 
(blue spectra). 
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Careful precautionary measures were taken to reduce the noise in the far UV region 
such as purging the system with nitrogen gas for an hour before experiments were 
undertaken, and the choice of buffer components as described previously. However, 
apparent in all the figures shown is the inability to sufficiently resolve data below 
200nm. This is most likely due to the unavoidable presence of low concentrations of 
NaCl and glycerol within the protein preparation that show strong absorption at this 
wavelength. 
The data gathered from analytical SEC, analytical ultracentrifugation, 
colorimetric assays and CD spectroscopy give a sound insight into the biochemical 
characteristics of VarR when in bound and unbound states. However, in order to fully 
understand the mechanism of DNA and/or substrate-binding by V arR and to 
complement the data gathered, crystallisation and x-ray structural determination is 
required and will be discussed in the following section. 
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6.6 Crystallisation 
Protein crystallisation was employed to obtain VarR crystals that are of x-ray diffraction 
quality (>3A resolution) for the 3D structural characterisation of apo VarR and when in 
complex with its cognate promoter(s) and/or substrate. 
6.6.1 Preliminary sparse matrix screen ofVarR 
V arR ( -8mg/ml) used in all crystallisation experiments was purified in a buffer of 
20mM Tris-HCl pH 8.25, 50mM NaCl and 10% glycerol as described in chapter 4 
section 4.3.3. Crystals formation requires that the purity of the VarR preparation be 
>98% pure and homogeneous in order form uniform ordered repeat structures. Figure 
6.20 presents the SDS-P AGE of VarR used in all crystallisation experiments that shows 
homogeneity and >98% purity. 
Figure 6.20 SDS-PAGE of VarR used for crystallisation. 
Preliminary crystallisation trials of V arR were conducted using sparse matrix screens 
that enveloped a wide parameter of conditions such as the type of precipitant, salt and 
pH, in order to discover a suitable starting condition. Commercial sparse matrix screens 
used were Wizard I and II (EBS-WIZ-1&2, Emerald Biosystems) and Structure screens 
1 and 2 (Molecular Dimensions Ltd). Crystallisation trials were undertaken using 1~1 of 
VarR in the vapour diffusion hanging drop method on 24-well crystallisation supports 
and tools (EasyXtal, Qiagen) as described in chapter 2 section 2.14.4.1. Greater than 
295 
50% precipitation in the preliminary matrix screens was observed when VarR was 
added, which indicates that the concentration of the VarR was correct (Qiagen, 2006). 
The crystals of many structurally characterised regulatory proteins were often obtained 
within a week of incubation (Tyrrell et al. , 1997; Verschueren et al., 2001; Alekshun et 
al. , 2001), with some taking up to several months to reach the desired dimension 
(Schumacher et al., 2002). Therefore crystal development was monitored intermittently 
at time periods of 24 hours, 3 days, 1 week, 2 weeks , 1 month and 6 months by light 
ffilcroscopy. 
Preliminary crystal screens were monjtored for characteristic development of 
certain phases, which indicate potential microcrystal formation. Once a promising 
starting condition was identified, the condition was further optimised to improve crystal 
quality through adjustments in precipitant and salt concentration, and pH ranges. Figure 
6.21 shows the results from a sparse matrix screening condition used for the 
crystallisation of VarR. Phase separation with 'Quasi ' protein crystals can be seen 
within 24 hours, indicating conditions were suitable for initial crystal development. 
Figure 6.21 Photograph of phase formation taken under light microscopy Phase 
separation with 'Quasi' crystals indicative of initial microcrystal 
development identified from #41 Wizard I sparse matrix screen (Emerald 
Biosciences ). 
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After three days, preliminary crystals of VarR were grown from 30% (v/v) polyethylene 
glycol of molecular weight 3000 Da (PEG 3000), and 0.1M CHES pH 9.5 (#41) of the 
Wizard I sparse matrix screen (EBS-WIZ-1&2, Emerald Biosystems). These crystals 
will be referred to as microcrystals (also commonly referred to as nuclei) due to the 
relatively small dimensions that are inadequate for diffraction. Microcrystal 
development was rapid often appearing within three days with no further increase in 
size observed following a month of incubation at 16°C. A photograph of VarR 
microcrystals surrounded by precipitate, visualised under a light microscope, can be 
seen in figure 6.22. 
Figure 6.22 Photograph of preliminary VarR microcrystals, taken under light 
microscope, obtained from the sparse matrix screening condition of 30% 
(v/v) PEG 3000 and 0.1M CHES pH 9.5. 
As a diffraction pattern could not be obtained for these VarR crystals to ensure their 
integrity as protein crystals, an alternative method was used in the form of a crystal 
violet stain. Protein crystals contain solvent channels that absorb the dye and stain; 
however, salt crystals do not possess these channels and remain colourle s (Hampton 
Research). Crystal violet staining determined that the observed crystals were true VarR 
protein crystals (data not shown). 
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To improve the macromolecular growth and morphology of the VarR crystals, the 
preliminary condition was optimised as described in the following section. 
6.6.2 Optimisation of crystallisation conditions 
To improve the quality of V arR microcrystal growth, the preliminary screenmg 
condition was adjusted to determine which component influences and improves the 
crystallisation of VarR. Finding the ideal condition was necessary to allow 
supersaturation to be reached more slowly and thus improve the quality and shape of the 
resultant crystal. Using the preliminary screening condition of 30% PEG 3000 and O.lM 
CHES pH 9.5, the components were adjusted from 10-35% (v/v) PEG 3000 in 5% 
increments, the molarity of CHES from 0.05-0.5M in 0.05M increments and the pH 
from 8.0 to 10.5 in 0.5 unit increments. The total number of possible condition 
combinations identified was 360. An optimised condition of 25% (v/v) PEG 3000 and 
0.15M CHES pH 9.0 was identified to give the best VarR microcrystal growth after 3 
days at 16°C. However, microcrystal growth was still observed over a narrow range 
between 25-30% PEG 3000 and 0.1-0.15 CHES pH9.0-9.5. A photograph of optimised 
VarR microcrystals visualised under a light microscope can be seen in figure 6.23. 
Figure 6.23 Photograph taken under light microscope of optimised VarR 
crystals obtained from an optimised screening condition of 25% (v/v) 
PEG 3000 and 0.15M CHES pH 9.0. 
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Crystal growth usmg the optimised condition had seemingly reached its maximum 
within a month of incubation at 4 °C and l6°C, respectively. This observation was noted 
following intermittent monitoring for up to 6 months, which failed to detect any 
improvement in the growth and size of the V arR crystals after a month (data not 
shown). At this stage the V arR microcrystals showed inadequate dimensions ( <200j.LM 
in length using the light microscope size reference guide) and were still unsuitable for 
diffraction. 
It was hypothesised that addition of 30bp varRG IR dsDNA may stabilise and 
possibly improve the macromolecular growth and morphology of the VarR 
microcrystals. Therefore, 30bp varRG IR DNA was added in 1: 1, 1:2 and 1:4 molar 
ratios to the VarR preparation and incubated on ice for three hours prior to use in the 
hanging drop. All molar ratios generated similarly sized microcrystals. Figure 6.24 
shows a photograph of the rod-like VarR-DNA (1 :4 molar ratio) microcrystals 
generated after a three day incubation period at 16°C. 
Figure 6.24 Photograph taken under light microscope of VarR-DNA (1:4 molar 
ratio) microcrystals obtained from condition of 25% (v/v) PEG 3000 
and 0.15M CHES pH 9.0 at l6°C. 
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There seems to be an improvement in the morphology of the microcrystals obtained, 
however, the size failed to advance after 3 months when compared to the previous 
crystallisation conditions used. Future directions would be to improve the size of the 
microcrystals through the use of additives or by streak-seeding into commercial screens 
that have been optimised for larger crystal growth. 
6.7 Discussion 
This chapter was intended to elucidate the quaternary structure adopted by VarR in 
solution and the possible changes during binding to promoter DNA and/or substrate. 
Analytical SEC demonstrated that VarR assumed an octomeric conformation. However, 
with the large body of evidence suggestive of LTTRs forming either dimers or tetramers 
in solution and tetramers upon binding their cognate promoters (Miller and Kredich, 
1987; Bishop and Weiner, 1993; Verschueren et al., 2001; Muraoka eta!., 2003), the 
result seemed unlikely. It was proposed that the migration of VarR could be have been 
artificially accelerated by the presence of DDM in the protein preparation. A 
colorimetric assay of the VarR-DDM preparation identified that the overall amount of 
DDM bound to VarR imparted nearly half the total Mr of the migrating species 
identified from analytical SEC. This suggests that VarR actually migrates as a tetramer 
in both DNA-bound and unbound states, which is also consistent with the result 
obtained from analytical ultracentrifugation. In summary, the experimental details 
indicate that VarR is likely to predominate as a tetramer in solution and when bound to 
its operator on promoter DNA. Unfortunately, attempts to identify if the tetrameric state 
of VarR adopts different structural conformations upon binding DNA and/or substrate 
were hindered by the limited knowledge in CD spectroscopy. 
It is anticipated that the successful structural determination of V arR through 
crystallography would complement and confirm the functional data obtained. Although 
we have yet to elucidate the crystal structure for V arR, crystallisation trials have 
successfully yielded full-length VarR microcrystals that bring us a step closer to 
realising this potential. The successful crystallisation of the full-length VarR is a great 
achievement in itself, due to the immense difficulties experienced by other studies with 
regards to the general low solubility of LTTRs (Verschueren et a!., 2001; Stec et al., 
2004). As a result many groups have often resorted to crystallisation of the truncated 
forms of the protein (Tyrrell et al., 1997; Choi et al., 2001; Verschueren et al., 2001; 
Stec et al., 2004). Further attempts to increase the macromolecular growth of these 
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microcrystals through optimisation of conditions have proven futile; however 
alternative methods that could be further adopted are outlined in the future directions. 
Due to time constraints, this chapter has only revealed slight insights into the 
possible structural roles of V arR with much still remaining to be elucidated, and which 
warrants further investigation. 
6.8 Future directions 
Further optimisation of crystallisation conditions to improve macromolecular 
growth of microcrystals 
Additives are often used to improve the morphology, quality and size of microcrystals 
following preliminary screening of conditions. These include multivalent cations, 
carbohydrates, salts, amino acids, chaotropic agents, palmers, chelating agents, 
detergents and reducing agents. Commercially sourced screening kits are readily 
available (Emerald BioSystems and Hampton Research) that incorporate the majority of 
these additives and are a useful starting point for elucidating certain supportive 
additives. 
Another technique involves streak-seeding or transfer of microcrystals generated 
from preliminary conditions into commercial screens that have been optimised for 
macromolecular crystal growth. Surprisingly, the most effective method of transferring 
these microcrystals is through the use of a fine cat whisker! The size and nature of the 
grooves in the hair shaft make it an ideal candidate for the uptake and rapid seeding of 
these crystals. Streak-seeding can be performed as follows. A whisker should be 
de greased with ethanol or methanol and rinsed with distilled water. Microcrystals (or 
seeds) can be dislodged with the whisker by touching an existing crystal or stroking the 
whisker through microcrystalline precipitate. These seeds are then introduced into a 
fresh drop by stroking whisker in straight line through drop. 
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Chapter 7 Characterisation of the ~-lactamase, VarG 
P-lactam antibiotics have been used successfully since the 1940's for the treatment of a 
broad range of bacterial infections. Consequently, the prevalent use of P-lactams has 
encouraged the evolution of bacterial defences against these mediators in the form of P-
lactamases. P-lactamase activity remains the most abundant cause of bacterial resistance 
to P-lactam antibiotics in Gram-negative bacteria (Nass and Nordmann, 1994). 
Metallo-P-lactamases (MPls) are of fast emerging clinical importance (Fritsche 
et al., 2005; Thomson and Bonomo, 2005) owing to their ability to hydrolyse all 
existing P-lactams including the newer generation cephalosporins and carbapenems. To 
exacerbate the situation the activity of these enzymes cannot be neutralised by current 
P-lactamase inhibitors and the implementation of such therapeutic inhibitors may take 
several years (Walsh et al., 2005). 
Although the structure of chromosomally encoded MPls have been well 
characterised, both in the presence (Garcfa-Saez et al., 2003a, 2003b) and absence of 
potential inhibitors (Carfi et al., 1995; Concha et al., 1996; Fabiane et al., 1998; Ullah 
et al., 1998; Garcfa-Saez et al., 2003b), only one structure has been characterised at 
present (April 2007) in complex with a P-lactam antibiotic (Garau et al., 2005). 
Understanding the catalytic mechanisms by which MPls bind to and hydrolyse P-
lactams is of utmost importance for the future development of novel antibiotics and 
inhibitors against these mediators. 
This chapter reports the cloning, overexpression and purification of a soluble, 
chromosomally encoded putative Mpl, VarG, at concentrations suitable for functional 
and structural studies. 
7.1 Cloning of varG into the pET28b expression vector 
7 .1.1 PCR amplification of varG 
The forward primer, var38Fwd, and reverse primer, var38Rev, were designed to 
incorporate the RE sites, Ndel and Xhol, at the 5' and 3' ends of the amplified varG, 
respectively. The native stop codon was maintained in the reverse primer prior to the 
Xhol site. A HotStart Taq polymerase PCR (Chapter 2 section 2.6.1) was performed 
with annealing temperatures of 55°C and 57°C, extension times of 1 minute 30 seconds, 
and 15 and 20 cycles of amplification, respectively. Figure 7.1 shows the successful 
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amplification of varG (lanes 2 to 4) which is consistent with the predicted size of 
1203bp. 
Figure 7.1 PCR amplification of varG gene from V. cholerae CVD101. Lane 1= 
Mr marker. Lanes 2-4 show individual PCR amplification reactions. 
3Kb~ 
2Kb~ 
1Kb ~ 
500bp ~ 
1 2 3 4 
...___ Amplified varG 
gene (1203bp) 
The amplified varG gene was purified and cloned into pGEM-T Easy vector and 
transformed into NovaBlue as described in section 4.1.1. Plasmid DNA purified from 
recombinant colonies was digested with Ndel and Xhol to confirm the presence of 
inserted DNA. Figure 7.2 shows the result of three pGEM-T Easy vector digests, with 
all lanes exhibiting the presence of the varG gene. 
Figure 7.2 Restriction analysis of three pGEM-T Easy/ varG vectors. Lane 1= 
Mr marker. Lanes 2-4 exhibiting the presence of the inserted varG gene. 
1 2 3 4 
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7 .1.2 Cloning of varG into pET28b expression vector 
The varG gene was cloned into the pET28g expression vector. Recombinant pGEM-T 
Easy vectors were digested with Ndel and Xhol to excise the inserted varG gene. Figure 
7.3 shows the presence of the varG insert in lanes 3 to 6. 
Figure 7.3 Ndel and Xhol digest of recombinant pET28b/varG. Lane 1= Mr 
marker. Lanes 2-6; shows individual digests of recombinant pET28b. 
1 2 3 4 5 6 
Linear pET28b 
(-5.3Kb) 
Inserted varG 
gene (1203bp) 
The resulting purified recombinant pET28b vectors were sent for DNA sequencing to 
ensure sequence integrity and transformed into a chemically competent expression 
strain of E. coli BL21-AI and antimicrobial susceptibility strain KAM3 (see section 7.6 
for antimicrobial susceptibility assays). DNA sequencing revealed that the nucleotide 
sequence of varG from CVD101 was identical to that of its corresponding gene 
sequence VC1561 in strain N16961. 
7.2 Overexpression of His6-VarG from BL21-AIIpET28a 
Bacterial cultures were prepared as described in Chapter 3 section 2.10.3 incorporating 
25J..Lg/rnl kanamycin and expressed at 37°C with 180-200rpm rotary agitation. At an 
OD6oo of 0.5-0.6, expression of T7 RNA polymerase was induced with 0.02% L-
arabinose and expression of V arR from the T7 promoter of pET28b was induced with 
0.5mM IPTG and cultures were expressed for a further 3 hours. Expression of V arG 
from pET28b results in a fusion to an N -terminal hexahistidine tag (His6-V arG). 
7.3 Purification of ~-lactamase, VarG by IMAC 
The soluble fraction containing His6-VarG (44414.36Da) from 4 litres of culture was 
obtained by differential centrifugation (chapter 2 section 2.11.1) and purified by metal 
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affinity chromatography using Ni2+ sepharose (chapter 2 section 2.11.2). The calculated 
pi of His6-V arG was 6.23, and so a pH of 7.25 was used in all purification buffers. 
The packed column was initially washed with 20ml of 20mM Tris-HCl pH 7.25, 
800mM NaCl, 10% glycerol, and 50mM Imidazole buffer. A second wash incorporated 
lOml of 20mM Tris-HCl pH 7.25, 600mM NaCl, 10% glycerol and 60mM imidazole 
buffer. The final wash consisted of 20ml 20mM Tris-HCl pH 7.25, 300mM NaCl, 10% 
glycerol and 70mM imidazole buffer. His6-VarG was eluted from the column using 
buffer A containing a 500mM imidazole. Figure 7.5 shows the efficiency of expression 
and purification of His6-VarG by SDS-PAGE. As expected, His6-VarG is soluble when 
expressed and has a Mr of -44.4kDa. Lanes 1, 2 and 3 show theFT from washes 1, 2, 
and 3, respectively. Lane 4 contains the SeeBlue protein marker and lanes 5 to 9 show 
elution fractions 1 to 5, respectively. A significant amount of possible dimer is located 
at approximately -64kDa and can be seen in lanes 6, 7 and 8. 
Interestingly, the formation of a higher oligomeric state, possibly a dimer, must 
be mediated by alternative mechanism other than disulfide linkage due to the absence of 
cysteine residues in the secondary sequence of VarG. His6-VarG was buffer exchanged 
into the following storage buffer: 20mM Tris-HCl pH 7.25 , 300mM NaCl and 10% 
glycerol using PD-10 desalting columns (Amersham) as per manufacturer' s instruction. 
It appears that some soluble His6-V arG may have been eluted from the column during 
the three wash stages. Western blot analysis will be performed in the next section to 
confirm this and to positively identify VarG by means of detecting its His6 tag. 
Figure 7.4 SDS-PAGE of His6-VarG purified from BL21-AI/pET28b. Lanes 1-3; 
wash fractions 1, 2 and 3, respectively. Lane 4= Mr marker. Lanes 5-9; 
fractions eluted by 500mM imidazole. 
123 4 567 89 
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7.4 Western Blot analysis of VarG 
A sample of purified His6-VarG (figure 5, lane 6) was diluted with an equal volume of 
storage buffer and fully denatured by heating at l00°C for 5 minutes for Western Blot 
identification. A sample of the Ff from wash three (figure 5, lane 3) was also taken to 
determine if His6- V arG had been eluted. Western blot analysis using the colorimetric 
detection method was performed as described in Chapter 2 section 2.12.2.1 and the 
positive identification of His6- V arG can be seen in figures 7.5 and 7 .6. Lane 1 contains 
a positive His6-tagged control (VarR-His6 of 36.7kDa), lane 2 the SeeBlue protein 
marker, lane 3 non-related protein, lane 4 sample of the Ff from wash three and lane 5 
contains putatively expressed His6-VarG. Interestingly, western blot failed to detect the 
presence of His6-tags in the sample of Ff from wash three; therefore His6-V arG was not 
eluted at this stage. 
Figure 7.5 SDS-PAGE of His6-VarG for Western blot analysis. Lane 1= Positive 
control. Lane 2= Mr marker. Lanes 4 and 5; elutions of VarG from wash 
step 3 and purification fraction 2, respectively. 
1 2 3 4 5 
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Figure 7.6 The PVDF membrane from Western blot analysis (chromogenic 
method) of protein transferred from above SDS-PAGE. Lane 1= 
Positive control ( -37kDa). Lanes 4 and 5; elutions of VarG ( -44kDa) 
from wash step 3 and purification fraction 2, respectively. 
1 2 3 4 5 
7.5 VarG shows preliminary ~-lactamase activity 
7.5 .1 Nitrocefin disk method using VarG as the test enzyme 
Disks impregnated with Nitrocefin (Fluka) were used in the preliminary detection of ~­
lactamase activity in VarG. The experiment was performed as described in chapter 2 
section 2.13 .2 using purified His6-V arG and heat treated His6-V arG (1 00°C for 5 
minutes) and 10mM EDTA inactivated His6-VarG to serve as the control. A negative 
outcome results in no colour change while the development of a red colour indicates a 
positive test, which is interpreted as resistance to penicillin or cephalosporin activity. 
Figure 7.7 shows the outcome from the Nitrocefin disk test with the control (left) 
exhibiting no colour change and His6-V arG engendering the development of a positive 
red test colour (right). This demonstrates that VarG does indeed posses some ~­
lactamase activity. Although a positive test was attained, further inve tigation is 
required for a definitive demonstration that VarG is indeed a functional ~-lactamase. 
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Figure 7.7 Nitrocefin disk method for the analysis of ~-lactamase activity in VarG 
The nitrocefin disk method does not provide information regarding the type of ~­
lactamase present. Therefore further antimicrobial susceptibility assays were conducted 
to determine the substrate profile, and thus confirm the ~-lactamase classification for 
VarG. 
7.6 Antimicrobial susceptibility assay of ~-lactamase VarG 
Antimicrobial susceptibility assays were performed as described in chapter 2 section 
2.13.1 (with lmM IPTG induction) using KAM3/pET28b-varG, KAM3/pET28b 
(control) and the ~-lactams ampicillin, arnoxicillin, carbenicillin, penicillin G, and 
nafcillin as the test substrates. 
Unfortunately, initial assays failed to observe any increase in resistance in 
KAM3/pET28b-varG compared to the control. This was hypothesised to be due to the 
absence of a chromosomal T7 RNA polymerase in the hypersusceptibility E. coli strain 
KAM3. Therefore the strain E. coli KAM3 was integrated with A-DE3 bacteriophage, 
which encapsulates the gene for T7 RNA polymerase by using a commercially available 
A.DE3 lysogenisation kit (Novagen) as described in chapter 2 section 2.4.3. 
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Antimicrobial susceptibility assays using KAM3 (DE3)/pET28b-varG were 
once again initiated, however to no avail even though V arG was expressed (data not 
shown). The possible reasons for these failures are presented in the final discussion. 
7.7 Discussion 
Sequence analysis and alignment of VarG with other MPl members show that 
considerable sequence diversity is exhibited (see chapter 3 section 3.3). Despite this 
diversity, VarG encompasses a consensus sequence typically associated with forming 
two zinc active sites in MPls. At present only one structurally characterised Mpl, CphA, 
in complex with a P-lactam, biapenem, has been published (Garau et al., 2005). 
However, CphA is a monozinc carbapenemase that only requires a single zinc ion 
(Zn2+) for the hydrolysis of P-lactams at the active site (Garau et al., 2005). At present 
(April 2007), no crystal structure is available for a bizinc-MPl that utilises two Zn2+ for 
the catalytic hydrolysis of P-lactam antibiotics. 
Analysis of the amino acid sequence of VarG has revealed the substitution of a 
single conserved cysteine residue (C257D) believed to be essential for coordination of 
the Zn2+ for P-lactam hydrolysis in monozinc-MPls (see chapter 3 section 3.3.1). In 
contrast, mutational analysis has suggested the irrelevance of this cysteine for binding 
and hydrolysis in the bizinc enzyme as the respective cysteine was substituted and still 
demonstrated the ability of the mutant to bind two Zn2+ ions (Paul-Soto et al., 1999; Xu 
et al., 2006). Therefore VarG has the potential to exist as a bizinc-MPl that requires two 
Zn2+ for the effective hydrolysis of P-lactam antibiotics. The successful structural 
characterisation of VarG in complex with a P-lactam would be the first such case to be 
demonstrated and would convey crucial insights into how bizinc enzymes coordinate 
two Zn2+ in the hydrolysis of P-lactam antibiotics. These fundamentals would bring a 
greater understanding into the mechanism of MPl action and thus enable the rational 
development of novel antibiotics and inhibitors that are at present urgently needed. 
VarG was successfully overexpressed and purified as a fusion to an N-terminal 
hexahistidine tag. Although VarG expressed successfully at concentrations necessary 
for structural studies, the purity of the preparation was not satisfactory and will require 
further refinement by chromatographic methods. Interestingly, SDS-PAGE analysis of 
the purified His6- V arG preparation shows the presence of a putative dimer that migrates 
around the 64kDa molecular weight marker. 
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Fascinatingly, western blot ofthe flow through from wash three (figure 7.8 lane 
4), which incorporated a protein identified at -39kDa from SDS-PAGE (figure 6 lane 
3), failed to detect the presence of His6-tagged VarG. As MPls are often co-expressed 
with other P-lactamases (Wang et al., 1999; Walsh et al., 2005), the expression of VarG 
may have subsequently led to the induction of the chromosomally encoded serine-P-
lactamase, AmpC ( -41.5kDa) in the E. coli host strain. However, the mechanism by 
which AmpC is co-expressed with VarG in the E. coli host is not understood as V arG 
was expressed in the absence of its regulatory protein, VarR, E. coli also lacks the 
regulatory gene, ampR, in the ampC region (Honore et al., 1986) and no P-lactam 
antibiotics were present. Therefore activation of AmpC expression would have 
proceeded by a mechanism other than by regulatory protein and P-lactam-based 
induction. 
The failure of the antimicrobial susceptibility assays may have been a 
consequence of a lack of Zn2+ co-factor essential for hydrolysis of P-lactam antibiotics 
at the active sites of MPls. This conclusion was made following analysis of cells from 
the induced KAM3(DE3)/pET28b-varG culture that revealed the presence of expressed 
VarG and which was absent in the control cells (data not shown). Although VarG was 
constitutively expressed, it was unable to hydrolyse the P-lactam antibiotics during 
antimicrobial susceptibility assays due to the absence of the Zn2+ co-factors, therefore 
leading to the results observed. 
The functional and structural role of VarG still remains elusive and requires 
further biochemical investigation to elucidate its mechanism of P-lactam hydrolysis and 
inactivation. The methods in which this can be achieved are outlined in the following 
future directions. 
7.8 Future directions 
Catalytic activation of VarG 
To ensure competent catalytic function of VarG, lOOJ.LM Zn2+ should be incorporated 
into the purified His6- V arG preparation by dialysis prior to performing any 
experimental work. 
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Further clarification and detection of M~l activity in VarG 
Antimicrobial susceptibility assays using the carbapenems ceftazidime, imipenem and 
meropenem in the presence and absence of inhibitor EDT A ( lOrnM) should be 
conducted to determine true M~l activity of VarG. All assays should be performed in 
the presence of 1 OOJ...LM Zn2+ in the test media. 
Elucidating the kinetic mechanism of ~-Iactam catalysis by VarG 
Stopped-flow spectroscopy studies, as described by Wang and associates (1998, 1999b), 
should be conducted to determine the kinetic mechanism of ~-lactam hydrolysis by 
VarG and thus establish if VarG is actually a bizinc-M~l. 
Increasing the purity of VarG for structural characterisation 
The purity of VarG should be refined to >95% through further purification usmg 
chromatographic methods such as ion-exchange and preparatory SEC as described 
previously in chapter 4. 
Structural characterisation of VarG by protein crystallography 
As structural information has yet to be elucidated for a bizinc-M~l in the presence of 
carbapenem antibiotic, crystallisation trials of V arG should be conducted in the 
presence and absence of these antibiotics in order to obtain crystals for X-ray 
diffraction. It is anticipated that structural characterisation of VarG ±substrate by X-ray 
diffraction would elucidate the mechanism of substrate recognition and to provide 
insights into the mechanism of coordination of Zn2+ during ~-lactam hydrolysis. 
311 
Chapter 8 
8.1 
Functional characterisation of the var ABC-type 
antibiotic resistance transporter 
The VarACDEF2 ABC-type antibiotic resistance transporter 
As described previously in chapter 3, the ABC-type var transporter (figure 8.1 ), is 
hypothesised to function as a tripartite complex in order to actively extrude 
antimicrobial agents across both membranes of V. cholerae (figure 8.2). The amino acid 
sequences of VarD and VarE are highly divergent, however, are hypothesised to form a 
similar structural arrangement. This suggests they may have the potential to form a 
heterooligomeric (dirner or higher) arrangement with one another to form a functional 
translocation channel. However, the lack of half transporter characteristics could mean 
that VarD and VarE may also homooligomerise, independently of one another forming 
a more versatile and enhanced resistance mechanism. Nonetheless, these IMPs are 
likely to associate with their cognate MFP VarA, TolC-like OMP VarC and ATP-
binding protein, VarF for formation of a VarCADF2, VarCAEF2 and/or VarCADEF2 
transporter complex. 
Interestingly, the transporter is understood to adopt a structural arrangement 
with both RND and ABC-type characteristics. Both V arD and V arE are hypothesised to 
form a typical functional arrangement of ABC-transporters where they span the 
cytoplasmic membrane and are associated with a likely dime ric A TPase, V arF2, at the 
cytoplasmic face. However, unlike typical ABC-transporters both IMPs have a 
predicted extensive periplasmic feature that is assumed to form a structural arrangement 
similar to that of the RND-type transporter, AcrB (Murakami et al., 2006). In support of 
this, both ABC-type IMPs are believed to associate with VarA, which has also been 
predicted to show structural homology to the RND-type MFP, AcrA (Higgins et al., 
2004). Finally, VarC has a predicted structural homology similar to the TolC-like OMP, 
OprM of the MexAB RND system (Akama et al., 2004), which extends the 
translocation pathway out to the extracellular space. If this structural arrangement is 
deemed to be accurate, then the var transporter system would present a novel transporter 
class perhaps having evolved as a result of immense selective pressures exerted upon 
Gram-negative V. cholerae. 
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Figure 8.1 
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Schematic representation of the Vibrio cholerae antibiotic resistance 
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Figure 8.2 Schematic representation of the putative tripartite VarACDEF2 
transporter. YarD and/or YarE (ABC-type IMPs) utilise the energy 
derived from ATP hydrolysis by YarF (ATPase) to drive efflux and are 
located in the cytoplasmic membrane. In the periplasmic space, YarA 
(AcrA-like MFP) interacts with YarC (TolC-like OMP) and the IMPs to 
form a continuous translocation pathway, whereby antimicrobial agents 
are extruded from the intracellular cavity out into the extracellular space. 
Perinlasmic Membrane 
Cvtonlasmic Membrane 
ATPase 
ATP ADP+Pi 
Antimicrobial 
In order to determine the role of the ABC-type var transporter, the m vitro 
susceptibility of bacteria harbouring this var transporter were tested through 
antimicrobial susceptibility assays with antimicrobial peptides, LL-37 and PC8, and 
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macrolide antibiotics, azithromycin, erythromycin, oleandomycin and spiramycin. 
These drugs are known substrates for homologous systems identified during sequence 
analysis of the YarD and YarE transporters. It is anticipated that this would also 
elucidate the substrate profile for the YarACDEF2 transporter in order to afford further 
functional and structural insights into this seemingly novel class of transporter. 
8.2 Antimicrobial susceptibility assays of the IMPs and ATPase of the 
var ABC-type transporter 
In order to examine the contributions of YarD and YarE to antimicrobial peptide 
and macrolide resistance, antimicrobial susceptibility assays were conducted with the 
pQE-100 vector incorporating varD and/or varE together with varF. Two constructs 
were cloned into the pQE-100 expression vector; one construct incorporated the varD, 
varE and varF genes amplified in series and the other with only the varE and varF 
genes in series. KAM3 was transformed with each construct and antimicrobial 
hypersusceptibility assays were conducted (as described chapter 2 section 2.13 .1) with 
two fold dilutions of 256J..Lg/ml antimicrobial peptides, LL-37 and PC8, and macrolide 
antibiotics, azithromycin, erythromycin, oleandomycin and spiramycin. KAM3 
containing the pQE-100 vector alone served as the control. 
Unfortunately, the assays failed to detect any resistance against the antimicrobial 
agents tested when compared to the control. This failure could be due to the inefficient 
expression of genes from the vector and therefore the inability to extrude the 
antimicrobial agents from the cytoplasm to reduce concentrations of the antimicrobial 
agents to sub-toxic levels. Alternatively, as the transporter is hypothesised to form a 
multi-protein complex, the two IMPs may not be functioning efficiently in the absence 
of its corresponding MFP and OMP components. The assembly of an imperfect 
complex may cause hypersusceptibility of the cells to the tested antimicrobials due to 
accumulation in the periplasmic space. However, one would expect that even with 
expression of the IMP and ATPase components only, some degree of resistance would 
be exhibited between the test constructs and that of the control. Nevertheless, this was 
not the case, which leads to the conclusion that the genes were not efficiently expressed, 
if at all. This would be consistent with the notion that KAM3 RNA polymerase is 
inefficient for T5 promoter driven gene expression in the pQE-100 vector. 
Therefore to improve the expression of the transporter and thus the antimicrobial 
susceptibility assays, the MFP varA, the OMP varC, the IMPs varD and varE, and the 
A TPase varF were independently amplified and cloned into four separate multiple 
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cloning sites (MCS) of T7-based dual expression vectors, which can be co-expressed in 
the KAM3 (DE3) strain. 
8.3 
8.3 .1 
8.3 .1.1 
Antimicrobial susceptibility assays of the VarACDEF2 transporter 
complex 
Cloning of the components into expression vectors 
Cloning of the MFP, VarA, into pETDuet expression vector 
Unfortunately, due to incompatibility with RE sites in other genes that would 
complicate the cloning procedure, varA was cloned alone into the pETDuet expression 
vector. 
PCR amplification of varA 
The forward primer, var39Fwd, and reverse primer, var39Rev, were designed to 
incorporate the RE sites, Ndel and Xhol, at the 5' and 3' ends of the amplified varA, 
respectively. A HotStart Taq polymerase PCR (Chapter 2 section 2.6.1) was performed 
with annealing temperatures of 58°C and 62°C, extension times of 1 minute 30 seconds, 
and 15 and 20 cycles of amplification, respectively. Figure 8.3 shows the successful 
amplification of varA (lanes 2 to 5) which is consistent with the predicted size of 
1030bp. 
Figure 8.3 PCR amplification of the varA gene from V. cholerae CVD101. Lane 
1= Mr marker. Lanes 2-5 show individual PCR amplification reactions. 
3Kb 
2Kb 
1Kb 
1 2 3 4 5 
.,__ Amplified varA 
gene (1 030bp) 
500bp 
The amplified varA gene was purified and cloned into pGBM-T Easy vector and 
transformed into NovaBlue. Plasmid DNA purified from recombinant colonies was 
digested with Ndel and Xhol to confirm the presence of inserted DNA. Figure 8.4 
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shows the result of three pOEM-T Easy vector digests, with all lanes exhibiting the 
presence of the inserted varA gene. 
Figure 8.4 Ndel and Xhol analysis of three recombinant pGEM-T Easy vectors. 
Lane 1- Mr marker. Lanes 2-4; exhibit the presence of the inserted varA 
gene. 
1 2 3 4 
Linear pGEMT-T 
(-3kb) 
....___ Inserted varA gene 
(1030bp) 
Cloning of varA into the pETDuet expression vector 
The following figure 8.5 illustrates the sub-cloning procedure adopted for cloning of the 
var transporter genes into the Duet expression vectors. BamHI and Hindiii or Ndel and 
Xhol RE digestion of the Duet vectors were performed according to the presence of RE 
sites within certain genes. Generally, if two RE sites in the varl gene were present in 
the var2 gene, then that the varl gene would be cloned first to prevent cleavage of the 
var2 gene and vice versa. 
Figure 8.5 
Ndel 
Schematic illustration of the sub-cloning procedure for the Duet vectors. 
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var1 gene 
The varA gene was cloned into the pETDuet vector and Ndel and Xhol digests were 
performed to identify recombinant vectors from the selected colonies. Figure 8.6 show 
inserts at -1000bp in lanes 4 and 6 that are consistent with the size of varA at 1030bp. 
Figure 8.6 Ndel and Xhol digestion of recombinant pETDuet vectors. Lane 1= 
Mr marker. Lanes 2-4 exhibiting the presence of the inserted varA gene. 
1 2 3 4 5 6 
+--- pETDuet (-5.4kb) 
+--- varA(1030bp) 
The resulting purified recombinant pETDuetlvarA vectors were sent for automated 
DNA sequencing to ensure sequence integrity. DNA sequencing of pETDuetlvarA 
revealed that sequence integrity was maintained. 
8.3.1.2 Cloning of the OMP, VarC into pACYC Duet expression vector 
PCR amplification of varC 
The forward primer, var40Fwd, and reverse primer, var40Rev, were designed to 
incorporate the RE sites, Ndel and EcoRV, at the 5' and 3' ends of amplified varC, 
re pectively. A HotStart Taq polymerase PCR (Chapter 2 section 2.6.1) was performed 
with annealing temperatures of 55°C and 58°C, extension times of 1 minute, and 15 and 
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20 cycles of amplification, respectively. Figure 8.7 shows the successful amplification 
of varC (lanes 2 to 5) which is consistent with the predicted size of 1260bp. 
Figure 8.7 PCR amplification of the varC gene from V. cholerae CVD101. Lane 
1= Mr marker. Lanes 2-5 show individual PCR amplification reactions. 
3Kb 
1Kb 
500bp 
1 2 3 4 5 
+--- Amplified varC 
gene (1260bp) 
Amplified varC was purified, cloned into the pGEM-T Easy vector and transformed inti 
NovaBlue. Figure 8.8 shows the result of four pGEM-T Easy vector digests with Ndel 
and EcoRV, with lanes 2, 4 and 5 exhibiting the presence of the inserted varC gene. 
Figure 8.8 Ndel and EcoRV analyses of four recombinant pGEM-T Easy 
vectors. Lane 1 = Mr marker. Lanes 2, 4 and 5; exhibit the presence of 
the inserted varC gene. 
1 2 3 4 
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Cloning of varC into the pACYCDuet expression vector 
The varC gene was cloned into the pACYCDuet vector and Ndel and EcoRV digests 
were performed to identify recombinant vectors from the selected colonies. Figure 8.9 
shows an insert at -1200bp in lane 2 that is consistent with the size of varC at 1260bp. 
Figure 8.9 Ndel and EcoRV digestion of recombinant pACYCDuet vectors. 
Lane 1= Mr marker. Lanes 2-4 show individual digests. 
1 2 3 4 
pACYCDuet (-4kb) 
varC (1260bp) 
The resulting purified recombinant pETDuetlvarA vectors were sent for automated 
DNA sequencing to ensure sequence integrity. DNA sequencing of pACYCDuetlvarC 
revealed that sequence integrity was maintained. 
8.3 .1.3 Cloning of the IMP, VarD into pACYCDuet-varC vector 
PCR amplification of varD 
The forward primer, var41Fwd, and reverse primer, var41Rev, were designed to 
incorporate theRE sites, BamHI and Hindlll, at the 5' and 3' ends of amplified varD, 
respectively. A HotStart Taq polymerase PCR (Chapter 2 section 2.6.1) was performed 
with an annealing temperature of 58°C, extension time of 1 minute 30 seconds, and 35 
cycles of amplification. Figure 8.10 shows the successful amplification of varD (lanes 2 
to 5) which is consistent with the predicted size of 121lbp. 
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Figure 8.10 PCR amplification of the varD gene from V. cholerae CVD101. Lane 
1= Mr marker. Lanes 2-5 show individual PCR amplification reactions. 
1 2 3 
500bp 
4 5 
Amplified varD 
gene (1211bp) 
The amplified varD gene was purified and cloned into pGEM-T Easy vector and 
transformed into NovaBlue. Plasmid DNA purified from recombinant colonies was 
digested with BamHi and Hinill to confirm the presence of inserted DNA. Figure 8.11 
shows the result of three pGEM-T Easy vector digests, with all lanes exhibiting the 
presence of the inserted varD gene. 
Figure 8.11 BamHI and Hindlll analysis of three recombinant pGEM-T Easy 
vectors. Lane 1- Mr marker. Lanes 2-4; exhibit the presence of the 
inserted varD gene. 
1 2 3 
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Cloning of varD into the pACYCDuet expression vector 
The varD gene was cloned into the pACYCDuet vector and BamBI and Hindiii digests 
were performed to identify recombinant vectors from the selected colonies. Figure 8.12 
shows an insert at -1200bp in lane 2 that is consistent with the size of varD at 1211 bp. 
Figure 8.12 BamHI and Hindlll digestion of recombinant pACYCDuet. Lane 1= 
Mr marker. Lane 2= exhibits the presence of the inserted varD gene. 
1 2 3 4 
+---- pACYCDuet-varC ( -5.2kb) 
var0(1211bp) 
The resulting purified recombinant pACYCDuet/varCD vector was sent for automated 
DNA sequencing to ensure sequence integrity. DNA sequencing of pACYCDuetlvarCD 
revealed that sequence integrity was maintained. 
8.3.1.4 Cloning of the IMP, VarE into pRSFDuet expression vector 
Unfortunately, due to incompatibility with RE sites in other genes that would 
complicate the cloning procedure, varE was cloned alone into the pRSFDuet expression 
vector. 
PCR amplification of varE 
The forward primer, var42Fwd, and reverse pnmer, var42Rev, were designed to 
incorporate the RE sites, Ndel and Xhol, at the 5' and 3' ends of amplified varE, 
respectively. A HotStart Taq polymerase PCR (Chapter 2 section 2.6.1) was performed 
with anneal1ng temperatures of 55°C and 58°C, extension time of 1 minute, and 15 and 
20 cycles of amplification, respectively. Figure 8.13 shows the successful amplification 
of varE (lanes 2 to 5) which is consistent with the predicted size of 1278bp. 
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Figure 8.13 PCR amplification of the varE gene from V. cholerae CVD101. Lane 
1= Mr marker. Lanes 2-5 show individual PCR amplification reactions. 
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The amplified varE gene was purified, cloned into pGEM-T Easy vector and 
transformed into NovaBlue. Plasmid DNA purified from recombinant colonies was 
digested with Ndel and Xhol to confirm the presence of inserted DNA. Figure 8.14 
shows the result of three pGEM-T Easy vector digests with Ndel and Xhol, with lanes 3 
and 4 exhibiting the presence of the inserted varE gene. 
Figure 8.14 Ndel and Xhol analysis of three recombinant pGEM-T Easy vectors. 
Lane 1= Mr marker. Lanes 3-4; exhibit the presence of the inserted varA 
gene. 
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Cloning of varE into the pRSFDuet expression vector 
The varE gene was cloned into the pRSFDuet vector and Ndel and Xhol digests were 
performed to identify recombinant vectors from the selected colonies. Figure 8.15 
shows an insert at -1200bp in lane 5 that is consistent with the size of varE at 1278bp. 
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Figure 8.15 Ndel and Xhol digestion of recombinant pRSFDuet vectors. Lane 1 = 
Mr marker. Lanes 5 exhibiting the presence of the inserted varE gene. 
1 2 3 4 5 
~ pRSFDuet (-3.8kb) 
~ varE(1278bp) 
The resulting purified recombinant pRSFDuet/varE were sent for automated DNA 
sequencing to ensure sequence integrity. DNA sequencing of pRSFDuet/varE revealed 
that sequence integrity was maintained. 
8.3.1.5 Cloning of the A TPase, VarF into pCDFDuet vector 
Unfortunately, due to incompatibility with RE sites in other genes that would 
complicate the cloning procedure, varF was cloned alone into the pCDFDuet expression 
vector. 
PCR amplification of varF 
The forward primer, var43Fwd, and reverse primer, var43Rev, were designed to 
incorporate theRE sites, BamHI and Sacl, at the 5' and 3' ends of amplified varF, 
respectively. A HotStart Taq polymerase PCR (Chapter 2 section 2.6.1) was performed 
with annealing temperatures of 60°C and 62°C, extension times of 1 minute, and 15 and 
20 cycles of amplification, respectively. Figure 8.16 shows the successful amplification 
of varF (lanes 2 to 5) which is consistent with the predicted size of 702bp. 
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Figure 8.16 PCR amplification of the varF gene from V. cholerae CVD101. Lane 
1= Mr marker. Lanes 2-5 show individual PCR amplification reactions. 
3Kb ----+ 
2Kb ----+ 
1Kb ----+ 
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The amplified varF gene was purified and cloned into pGEM-T Easy vector and 
transformed into NovaBlue. Plasmid DNA purified from recombinant colonies was 
digested with BamBI and Sacl to confirm the presence of inserted DNA. Figure 8.17 
shows the result of three pGEM-T Easy vector digests, with all lanes exhibiting the 
presence of the inserted varF gene. 
Figure 8.17 BamHI and Sacl analysis of three recombinant pGEM-T Easy 
vectors. Lane 1= Mr marker. Lanes 2-4; exhibit the presence of the 
inserted varF gene. 
1 2 3 
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Cloning of varF into the pCDFDuet expression vector 
The varF gene was cloned into the pETDuet vector and BamHI and Sac! digests were 
performed to identify recombinant vectors from the selected colonies. Figure 8.18 
shows inserts at -700bp in lanes 1 and 3 that are consistent with the size of varF at 
702bp. 
Figure 8.18 BamHI and Sacl digestion of recombinant pCDFDuet vectors. Lanes 
1 and 3 exhibiting the presence of the inserted varF gene. Lane 2= Mr 
marker. 
1 2 3 
pCDFDuet (-3.7kb) 
varF (702bp) 
The resulting purified recombinant pCDFDueUvarF were sent for automated DNA 
sequencing to ensure sequence integrity. DNA sequencing of pCDFDueUvarF revealed 
that sequence integrity was maintained. 
8.3.2 Transformation of recombinant pETDuet-varA, pACYCDuet-varC-
varD, pRSFDuet-varE and pCDFDuet-varF vectors into 
KAM3(DE3) 
KAM3 cells were transfected with A-DE3 bacteriophage as described m chapter 2 
section 2.4.3, which encapsulates a gene for T7 RNA polymerase. 
All four recombinant Duet vectors were transformed into KAM3 (DE3) using a 
two step method as follows. Five j.Ll of recombinant pETDuet-varA and pACYC-varC-
varD vector, respectively, were mixed in a 1.5ml microfuge tube prior to addition of 
lOOj.Ll pre-thawed, chemically competent KAM3 (DE3). The mixture was incubated on 
ice for 30 minutes, heat-shocked in a water bath preset to 42°C and further incubated on 
ice for 2 minutes. 500j.Ll of SOC media was added to the transformed cells and 
incubated at 37°C with 225rpm rotary agitation for 1 Y2 hours . 250j.Ll of transformed cells 
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were plated onto 50flg/ml carbenicillin and 15flg/ml chloramphenicol LB agar plates, 
inverted and incubated in a static incubator at 37°C overnight. Chemically competent 
cells were prepared from these recombinant colonies as described in chapter 2 section 
2.8.1. The transformation procedure was repeated for the introduction of recombinant 
pRSF-varE and pCDF-varF vectors, with exception that newly transformed cells were 
plated onto LB agar plates containing 50Jlg/ml carbenicillin, 15flg/ml chloramphenicol, 
15flg/ml kanamycin, and 12.5flg/ml streptomycin. NB-concentrations of antibiotics 
used were half the concentration of those for manipulation under normal working 
conditions. Colonies resistant to all antibiotics were maintained as glycerol stocks and 
stored at -80°C. Antimicrobial susceptibility assays using these recombinant colonies 
were performed as described in the following section. 
8.3.3 Antimicrobial susceptibility assays of the VarACDEF2 transporter 
complex 
All Duet vectors contain two T7lac promoters, one at each MCS, from which the 
expression of the cloned gene(s) was initiated. All proteins are expressed as native, 
unfused proteins upon induction with 1rnM IPTG. KAM3 (DE3) was also transformed 
with native Duet vectors to serve as the control. 
Initial expression of recombinant KAM3 (DE3) at 37°C with 220rpm failed to 
reach mid-log phase (OD625 of 0.6). This could be due to sheer stress exerted on the E. 
coli host as a result of co-expression of these proteins, which may burden the 
transcriptional machinery of the organism. Alternatively, it could be that recombinant 
KAM3 (DE3) is experiencing toxicity due to basal expression of these genes. Therefore 
to reduce basal expression, KAM3 (DE3) was grown in the presence of Muller-Hinton 
broth supplemented with 0.5% glucose. Recombinant KAM3 (DE3) cells were 
successfully cultured using conditions as described previously to an OD625 of 0.5 and 
protein expression from the T7lac promoters was induced using 1rnM IPTG. 
Antimicrobial susceptibility assays, supplemented with 1rnM IPTG, were 
conducted (as described in chapter 2 section 2.13 .1) with double dilutions of 256Jlg/ml 
antimicrobial peptides, LL-37 and PC8, and macrolide antibiotics, azithromycin, 
erythromycin, oleandomycin and spiramycin, respectively. Unfortunately, an average of 
three independent experiments failed to show significant increase in resistance (~4-fold 
in the MIC) in the test strain when compared to the control. The MICs of the 
antimicrobial peptides and macrolide antibiotics observed for KAM3 (DE3) harbouring 
recombinant Duet vectors are shown in table 8.1. A two-fold increase in resistance was 
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observed for the control strain when compared to the test strain for all antimicrobial 
agents, except spiramycin where both strains were equally sensitive. 
Table 8.1 
E. coli 
KAM3 
(DE3) 
Duet 
vectors only 
pETDuet-
varA 
pACYCDuet-
varC-varD 
pRSFDuet-
varE 
pCDFDuet-
varF 
8.4 
Comparisons of the MICs ().lglml) observed for E. coli KAM3 (DE3) 
harbouring recombinant Duet vectors and control in the presence of 
antimicrobial peptides and macrolide antibiotics. 
MIC (J.Lg/ml) 
LL-37 PCB Azithromycin Erythromycin Oleandomycin Spiramycin 
32 32 1 4 16 4 
16 16 0.5 2 4 4 
Discussion 
The lack of resistance observed in the antimicrobial susceptibility assays for KAM3 
(DE3) harbouring pETDuet-varA, pACYCDuet-varC-varD, pRSFDuet-varE and 
pCDFDuet-varF when compared to the control is likely due to the inefficient expression 
of the proteins required to form the var transporter complex. This assumption was made 
as both test and control cultures showed competent growth, reaching an OD625 of 0.5 at 
similar times and well within the average three hours for other general E. coli cultures. 
However, the cultures of KAM3 (DE3) harbouring the recombinant Duet vectors 
showed greater transparency subsequent to induction with lmM IPTG compared to the 
control cultures. This may imply that either the test cells were losing fitness through 
lysis, possibly as a consequence of toxic protein expression, or a slower growth rate was 
adopted due to the overwhelming of the transcriptional machinery for protein 
expression. The latter would be consistent with the results obtained during the assays, 
which show an overall two-fold elevation in the MIC of the antimicrobial agents tested 
for the control when compared to the test strain. 
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The lack of clarity from the antimicrobial susceptibility assays could also be a 
result of inefficient expression or reduced activity from the ABC-ATPase, VarF, which 
is required for energy-dependent transport by V arD and V arE. The lack of V arF 
activity, possibly as an effect of a depleted ATP source, would account for the relatively 
unsuccessful attempts at determining the in vitro susceptibility of E. coli harbouring the 
var transporter. In order to determine if VarF has true ATP-binding and hydrolytic 
capabilities, A TPase assays will be conducted in the next chapter. 
Regardless of the indifference observed between test and control strains, the 
overall resistances observed were still relatively elevated. This could be due to the 
involvement of other resistance mechanisms such as the MDR MacAB-TolC 
(Kobayashi et al., 2001) and/or AcrAB-TolC systems (Tikhonova et al., 2004) also 
present in E. coli. Similar MICs for azithromycin and erythromycin were observed in 
the control strains during assays conducted with a MacAB homologue from N. 
gonorrhoeae, which also exports macrolide antibiotics (Rouquette-Loughlin et al., 
2005). However, expression of the MacAB system was conducted in an E. coli strain 
with a deletion in the acrAB genes therefore ensuring that the AcrAB system (Okusu et 
al., 1996) was not mediating the intrinsic resistances observed. Therefore influences 
through other resistance mechanisms cannot be entirely dismissed. 
The antimicrobial resistance capability of the var transporter still remains 
elusive and requires further biochemical investigation to elucidate its substrate profile. 
The methods in which this can be achieved are outlined in the following future 
directions. 
8.5 Future directions 
Yeast Two-Hybrid studies to determine in vivo protein-protein interactions 
The yeast two-hybrid system is a sensitive genetic technique that uses a transcriptional 
assay for reporting of interactions between proteins in vivo in the yeast Saccharomyces 
cerevisiae (Clontech, 2007). This technique could be used to elucidate how components 
of the var transporter complex interact to form the putative antibiotic resistance 
pathway. Experimental rationales for the use of this technique are outlined as follows. 
1. In order to identify if VarD and YarE act independently as homooligomers or 
mutually as heterooligomers to form an inner membrane translocation pathway. 
2. In order to identify if V arF interacts as a dimer in which residues from the two 
subunits may cooperative to form an interface for ATP hydrolysis. This would 
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provide essential insights into interactions between native ATPase dimers in vivo as 
these subunits are generally purified as monomers or unstable dimers (Nikaido et 
al., 1997). 
3. In order to identify if YarF interacts with either YarD and/or YarE to form a 
complete ABC transporter(s). 
4. In order to identify if Y arC interacts with YarD and/or YarE as there are 
uncertainties as to whether interaction occur directly with the periplasmic end of the 
IMP components to form a complete translocation pathway or if this interaction is 
mediated by a MFP (Eswaran et al., 2004). 
5. In order to identify if YarA interacts with YarD and/or YarE and/or YarC. 
Antimicrobial susceptibility assays in the presence of ATP 
The pressures were exert on E. coli to overexpress the ATPase, YarF, would ultimately 
overwhelm its oxidative phosphorylation processes and leading to the depletion of its 
ATP stores that are not intended to cope with such elevated activity. Therefore to ensure 
that the activity of YarF during antimicrobial susceptibility assays is optimal, 0.25mM 
A TP should be incorporated into the test medium. 
Antimicrobial susceptibility assays of VarD, VarE and VarF only 
To reduce the burden on E. coli resources during protein expression, the varD, varE and 
varF genes could be cloned separately into two Duet vectors and antimicrobial 
susceptibility assays performed as described previously. 
Determine if components of the var transporter complex are expressed 
The induced and uninduced cell extracts from E. coli harbouring the genes of the var 
transporter complex should be examined by SDS-PAGE for expression of the 
corresponding proteins. 
Assay of e4C] erythromycin accumulation in E. coli cells 
In order to determine if macrolide resistance is due to active efflux, the uptake of e4C] 
erythromycin by E. coli KAM3 cells with and without the vector containing the 
YarDEF2 complex can be compared. This method has been successfully used to 
determine the efflux capabilities of the MacAB system in E. coli (Kobayashi et al., 
2001). 
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Chapter 9 Characterisation of the ABC-ATPase, VarF 
Transporters of the ABC superfamily are responsible for the translocation of a 
range of dissimilar substances across the membranes of both prokaryote and eukaryotes 
(Hung et al., 1998). Despite the diverse substrate specificities, ABC transporters share a 
common overall architecture of two transmembrane domains and two highly conserved 
ATP-binding domains (Davidson and Chen, 2004) that form the active powerhouse of 
the system. 
A considerable body of experimental data regarding ATP-binding domains have 
been accrued for MDR ABC transporters in both prokaryotes and eukaryotes. These 
include the human MDR P-glycoprotein, implicated as the principle cause of resistance 
in cancer cells (Jones and George, 1998) and its homologues in Gram-positive bacteria 
including Lactococcus lactis, LmrA (van Yeen et al., 1996) and Staphylococcus aureus, 
Sav1866 (Dawson and Locher, 2006, 2007). The macrolide-specific MacAB system 
was the first MDR ABC transporter to be experimentally established in a Gram-
negative bacterium (Kobayashi et al., 2001). However, biochemical data regarding the 
ATP-binding activities in this system is limited. Unlike the MacAB system where the 
ATP-binding cassette (ABC-ATPase) is constitutively fused to the transmembrane 
domain as a half transporter, YarF is expressed independently of its ABC transporter, 
YarD and/or YarE. This structural arrangement for the var transporter would be the first 
such MDR ABC system to be described in a Gram-negative bacterium. 
Although a substantial number of bacterial ABC-ATPases involved in 
fundamental biological processes have been structurally characterised, only one has 
been revealed that is implicated in MDR (Dawson and Locher, 2006). Unlike YarF, this 
ABC-ATPase was constitutively fused to its TMD as a half-transporter, which revealed 
crucial subunit interactions that proposed a likely mechanism of energy driven 
transport. However, independently expressed ABC-ATPases may bind their cognate 
TMDs in a manner dissimilar to those of half-transporters and diverse substrate 
specificities may further differentiate binding between transporters. This could lead to 
specific structural changes involving conserved motifs within ABC-ATPases that may 
dictate variations in ATP activity. Therefore the functional and structural 
characterisation of YarF, in complex with YarD and/or YarE where possible, would 
provide important insights into the mechanism of subunit recognition and association, 
and the mechanism by which it hydrolyses A TP for energising the transport process. 
From this information, novel targets could be elucidated in which inhibitors could be 
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created to prevent association and thus inactivation of transporter function. However, all 
remains hypothetical until it can be established that V arF is indeed an A TP-binding 
protein. Therefore to elucidate the functional and structural role of VarF in the var 
transporter complex, the varF gene was cloned, overexpressed and purified as a soluble 
protein and examined for ATP hydrolysis using A TPase assays. 
9.1 Cloning, overexpression and purification of VarF from the pET21a 
expression vector 
9 .1.1 Cloning of varF into the pET21a expression vector 
PCR amplification of varF 
The forward primer, var44Fwd, and reverse primer, var44Rev, were designed to 
incorporate the RE sites, Ndel and Not!, at the 5' and 3' ends of the amplified varF, 
respectively. The native start codon was maintained in the Fwd primer by the Ndel site 
and the stop codon prior to the Not! site in the Rev primer. A HotStart Taq polymerase 
PCR (Chapter 2 section 2.6.1) was performed with annealing temperatures of 62°C and 
66°C, extension times of 1 minute, and 15 and 20 cycles of amplification, respectively. 
Figure 9.1 shows the successful amplification of varF (lanes 2 to 5) which is consistent 
with the predicted size of 717bp. 
Figure 9.1 
3Kb 
2Kb 
1Kb 
PCR amplification of the varF gene from V. cholerae CVD101. Lane 
1= Mr marker. Lanes 2-5 show individual PCR amplification reactions. 
1 2 3 4 5 
500bp 
Amplified varF 
gene (717bp) 
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The amplified varF gene was purified, cloned into pGEM-T Easy vector and 
transformed into NovaBlue. Figure 9.2 shows the result of five pGEM-T Easy vector 
digests, with all lanes exhibiting the presence of the inserted varF gene. Plasmid DNA 
purified from recombinant colonies was digested with Ndel and Notl to confirm the 
presence of inserted DNA. 
Figure 9.2 Ndel and Notl analysis of five recombinant pGEM-T Easy vectors. 
Lane 1- Mr marker. Lanes 2-6; exhibit the presence of the inse1ted varF 
gene. 
1 2 3 4 5 6 
Linear pGEMT·T 
(-3kb) 
._,_ Inserted varF gene 
(717bp) 
Sub-cloning of varF into the pET21a expression vector 
The varF gene was cloned into the pET21a vector and Ndel and Notl digests were 
performed to identify recombinant vectors from the selected colonies. Figure 9.3 shows 
an insert at -700bp in lane 3 that is consistent with the size of varF at 717bp. 
Figure 9.3 Ndel and Notl digestion of four recombinant pET21a vectors. Lane 
1= Mr marker. Lane 3 exhibits the presence of the inserted varF gene. 
1 2 3 4 5 
Linear pET21a (-5.4kb) 
varF (717bp) 
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The resulting purified recombinant pET21a-varF vectors were sent for automated DNA 
sequencing to ensure sequence integrity and transformed into a chemically competent 
E.coli strain, BL21-AI. DNA sequencing of pET21a-varF revealed that sequence 
integrity was maintained. 
9.1.2 Overexpression of VarF from BL21-AI/pET21a 
Bacterial cultures were prepared as described in Chapter 2 section 2.10.1. At mid-log 
phase (OD600 of 0.5-0.6), expression of T7 RNA polymerase was induced with 0.02% 
L-arabinose and expression of VarF from the T7 promoter of pET21a with 0.2mM 
IPTG. These were optimised concentrations determined from titration experiments (data 
not shown). Due to the toxicities exhibited in the previous expression method, induction 
conditions were maintained and cultures were expressed at 25°C with 120rpm rotary 
agitation for 16 hours. Expression of VarF from pET21a results in a fusion to a His6-tag 
at the C-terminal (VarF-His6). 
9.1.3 IMAC purification ofVarF-His6 from BL21-AI/pET21a 
The soluble fraction containing VarF-His6 (-26183.54Da) from 4 litres of culture was 
obtained by differential centrifugation (chapter 2 section 2.11.1) and purified by metal 
affinity chromatography using Ni2+ sepharose (chapter 2 section 2.11.2). As the 
calculated pi of VarF-His6 was 9.10, a pH of 8.10 was adopted for use in all purification 
buffers. 
The packed column was washed with 50rnl of 20mM Tris-HCl pH 8.10, 300mM 
NaCl, 10% glycerol, 50mM imidazole and lmM THP buffer, held for 5 minutes prior to 
eluting. VarF-His6 was eluted from the column using buffer A containing a 500mM 
imidazole. 
The efficiency of expression and purification of VarF-His6 was determined by 
SDS-PAGE (performed as described in Chapter 2 section 2.12.1) and can be seen in 
figure 9.4. The flow through (lane 1) and wash fraction (lane 2) show the varying 
degrees of contaminants, with some eluted protein. The migration of a protein band 
(lanes 5 to 7) immediately below the 28kDa SeeBlue protein marker (lane 3) is 
consistent with that of a monomer of VarF-His6 with a calculated molecular weight of 
-26.1kDa. Non-expression products located above 28kDa are characteristic traits of 
BL21-AI E. coli strain when used for the expression of protein. 
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Figure 9.4 SDS-PAGE ofVarF-His6 expressed from BL21-AL/pET21a. Lanes 
1= flow through. Lane 2= wash fraction 1. Lane 3= Mr marker. Lanes 4-
8; fractions eluted by 500rnM imidazole. 
123 4 567 8 
+---- VarF-His6 (26.1k0a) 
Unfortunately, relatively low expression levels of VarF-His6 were observed whilst using 
the pET21a expression vector, the levels of which are insufficient for further 
biochemical ATPase studies. Therefore VarF was expressed using the soluble 
pBAD/Myc-His B vector as described in the next section. 
9.2 Cloning, overexpression, purification and identification of VarF 
from pBAD/Myc-His B (pBAD-B) 
9.2.1 Cloning ofVarF into the pBAD-B expression vector 
PCR amplification of VarF 
The forward primer, var45Fwd, and reverse primer, var45Rev, were designed to 
incorporate the RE sites, Nco! and Bglii, at the 5' and 3' ends of amplified varF, 
respectively. A guanine and cytosine nucleotide was incorporated after the Nco! site in 
the Fwd primer to ensure the reading frame was preserved with the start codon when 
cloned into the pBAD-B vector. A His6-tag followed by a stop codon (TCA) was 
integrated prior to the Bglii site in the reverse primer. A HotStart Tag polymerase PCR 
(Chapter 2 section 2.6.1) was performed with annealing temperatures of 62°C and 66°C, 
extension times of 1 minute, and 15 and 20 cycle of amplification, re pectively. Figure 
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9.5 shows the successful amplification of varF (lanes 2 to 5), which is consistent with 
the predicted size of 734bp. 
Figure 9.5 PCR amplification of the varF gene from V. cholerae CVD101. Lane 
1= Mr marker. Lanes 2-5 show individual PCR amplification reactions. 
1 2 3 4 5 
3Kb 
1Kb 
+---- Amplified varF 
500bp gene (734bp) 
The amplified varF gene was purified, cloned into pGEM-T Easy vector and 
transformed into NovaBlue. Figure 9.6 shows the result of five pGEM-T Easy vector 
digests with Ncol and Bglll, with all lanes exhibiting the presence of the inserted varF 
gene. 
Figure 9.6 Ncol and Bglll analysis of five recombinant pGEM-T Easy vectors. 
Lane 1- Mr marker. Lanes 2-6; exhibit the presence of the inserted varF 
gene. 
1 2 3 4 5 
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6 
Linear pGEMT-T 
+--- (-3kb) 
+--- Inserted varF gene 
(734bp) 
Cloning of varF into pBAD-B expression vector 
The varF gene was cloned into the pBAD-B vector and Nco! and Bglll digests were 
performed to identify recombinant vectors from the selected colonies. Figure 9.7 shows 
inserts at -700bp in all lanes that is consistent with the size of varF at 734bp. 
Figure 9.7 Ncol and Bglll digestion of recombinant pBAD-B vectors. Lane 1= 
Mr marker. Lane 3 exhibits the presence of the inserted varF gene. 
1 2 3 4 5 6 
pBAD-8 vector 
(-4.1kb) 
Inserted varF gene 
(734bp) 
The resulting purified recombinant pBAD-B-varF vectors were sent for automated 
DNA sequencing to ensure sequence integrity and transformed into a chemically 
competent E. coli strain, LMG 194. DNA sequencing of the recombinant pBAD-B-varF 
vector revealed that sequence integrity was maintained. 
9.2.2 Overexpression of VarF from LMG194/pBAD-B 
Bacterial cultures were prepared as described in Chapter 2 section 2.10.3 incorporating 
100j.tg/rnl carbenicillin. At an OD6oo of 0.5-0.6, overexpression of VarF-His6 from 
LMG 194 was induced with a final concentration of 0.02% (v/v) L-Arabinose and 
expressed at 37°C with 180-200rpm rotary agitation for 3 hours (optimised conditions 
determined from titration and time based experiments, data not shown). 
9.2.3 IMAC purification of VarF -Hiss from LMG194/pBAD-B 
The soluble fraction containing VarF-His6 (-26183.54Da) from 4 litres of culture was 
obtained by differential cenu·ifugation (chapter 2 section 2.1 1.1) and purified by metal 
affinity chromatography using Ni2+ sepharose (chapter 2 section 2. 11.2). A the 
calculated pi of VarF-His6 was 9.10, a pH of 8.10 was adopted for use in all purification 
buffers. 
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The packed column was washed with 50ml of 20mM Tris-HCl pH 8.10, 300mM 
NaCl, 10% glycerol, 60mM imidazole and 1mM THP buffer, held for 5 minutes prior to 
eluting. VarF-His6 was eluted from the column using buffer A containing a 500mM 
imidazole, in 1ml volumes (up to a total of 6ml) and held for 5 minutes each time. 
The efficiency of expression and purification of VarF-His6 was determined by 
SDS-PAGE (performed as described in Chapter 2 section 2.12.1) and can be seen in 
figure 9.8. Lanes 1 and 2 show the varying degrees of contaminants eluted in the flow 
through from column loading and wash one, respectively. The migration of a protein 
band (lanes 6 to 9) immediately below the 28kDa SeeBlue protein marker (lane 3) is 
consistent with that of a monomer of VarF-His6 with a calculated Mr of -26.1kDa. 
Figure 9.8 
1 
SDS-PAGE ofVarF-His6 expressed from LMG194/pBAD-B. Lanes 
1= flow through. Lane 2= wash fraction 1. Lane 3= Mr marker. Lanes 4-
9; fractions eluted by 500mM imidazole. 
2 3 4 5 6 7 8 9 
~ VarF-His6 (-26.1kDa) 
The concentration of VarF-His6 was determined to be -10mg/ml using the Coomassie 
(Bradford) protein assay as described in Chapter 2 section 2.12.5. The purity of the 
V arF-His6 preparation was sufficient for use in biochemical A TPase studies. VarF-His6 
was snap frozen in lOOj..ll aliquots using a dry ice/ ethanol mix and stored at -80°C or 
used immediately for Western blot (see next section) and ATPase assays (see section 
9.3). 
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9.2.4 Western Blot analysis of VarF-His6 
A sample of purified VarF-His6 was taken for Western blot analysis of its His6 tag. 
Western blot was performed as described in Chapter 2 section 2.12.2.1 and the positive 
results can be seen in figure 9.9. 
Figure 9.9 (A) SDS-PAGE and (B) PVDF membrane from Western blot 
analysis of VarF-His6. Lane 1= Positive control. Lane 2= Mr marker. 
Lane 3= purified VarF-His6. 
A 
1 
9.3 
8 
2 3 
Positive-His6 
Control 
.-~------;;,,....,..,,---- ( -36. 7kDa) ----... 
+- VarF-Hiss 
(-26.1kDa) 
The ATPase activity ofVarF 
1 2 3 
The ATPase activity of VarF (nmoles/minlmg) was determined using the Malachite 
green microtitre-plate assay (Harder et al., 1994) and the EnzChek phosphate assay 
(Molecular Probes, Invitrogen) as described below. 
9.3.1 The Malachite Green assay 
The Malachite Green assay was used to determine the extent of ATP hydrolysis by 
VarF using a method based on the quantification of a green coloured complex formed as 
a result of inorganic phosphate (Pi) reacting with ammonium molybdate and Malachite 
Green dye. 
A standard curve was generated as described in chapter 2 section 2.13.4. Figure 
9.10 shows a typical standard curve illustrating the amount of Pi released in pi co moles 
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(pmoles) plotted against the absorbance at 610nm (Abs6 1o) using linear regression. 
Points plotted were from an average of three independent experiments. 
Figure 9.10 A standard curve of Pi detected at 610nm following reaction with 
Malachite Green solution. 
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Malachite Green assays were conducted as described in chapter 2 section 2.13.4 using 
1~ VarF and 250j.!M ATP in the presence and absence of lmM MgCl2• The amount 
of Pi released in each sample was measured by the change in Abs6 1o and was calculated 
by using the equation generated from the standard curve. Figure 9.11 illustrates the 
quantity of Pi released in pmoles per sample per time point. 
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Figure 9.11 A graphic illustration of the quantity of Pi generated during 
magnesium-dependent hydrolysis of ATP by lf..LM VarF plotted 
against time (minutes). 
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For the purposes of comparison with other ABC-ATPases, the hydrolytic activity of 
VarF on ATP was measured in terms of nmoles/minfmg of protein. The ATPase activity 
of 1~1M VarF, in nmoles/minfmg of protein, was calculated by adjusting for the total 
reaction volume of 500~1, 0.0262mg/ml of VarF and spontaneous ATP hydrolysis. 
From table 9.1 we see that the calculated rate of Pi formation (adjusted according to the 
gradient of the activity curve of figure 9.14) at 1 minute is 370.llnmoles/minfmg VarF. 
An overall decrease in the rate of Pi formation with increasing time could indicate that 
A TPase activity is dependent on A TP concentration. 
The EnzChek phosphate assay was employed as an alternative method to the 
Malachite Green assay for the continuous spectrophotometric detection of Pi generated 
during V arF ATPase activity. This method was utilised to ensure consistency in the 
results obtained from the Malachite Green assays. 
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Table 9.1 The quantity of Pi generated in terms ofnmoVmin/mg ofVarF. 
Time Adjusted for 
(min) Plus MgCI2 Minus MgCI2 spontaneous ATP nmoles P/min/mg VarF hydrolysis 
0 1812.20 1724.51 87.69 87.69 
1 2118.11 1748.01 370.11 370.11 
2 2424.02 1771.50 652.52 326.26 
3 2729.93 1795.00 934.94 311.65 
4 3035.85 1818.49 1217.35 304.34 
5 3341.76 1841.99 1499.77 299.95 
6 3647.67 1865.49 1782.18 297.03 
7 3953.58 1888.98 2064.60 294.94 
8 4259.49 1912.48 2347.01 293.38 
9 4565.40 1935.97 2629.43 292.16 
10 4871.31 1959.47 2911.84 291.18 
9.3.2 The EnzChek phosphate assay 
A standard curve was generated as described in chapter 2 section 2.13.5. Figure 9.12 
shows a typical standard curve illustrating the amount of Pi released in nanomoles 
(nmoles) plotted against the absorbance at 360nm (Abs360) using linear regression. 
Points plotted were from an average of three independent experiments. 
Figure 9.12 A standard curve of Pi detected at 360nm using the EnzChek 
phosphate assay method. 
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The EnzChek phosphate assay using lJlM VarF 
The EnzChek phosphate assays were conducted as described in chapter 2 section 2.13.5 
using 1j.lM VarF and 1mM ATP (final concentrations) in the presence and absence of 
1mM MgCb. The amount of Pi released in each sample was measured by the change in 
Abs360 and was calculated by using the equation generated from the standard curve. 
Figure 9.13 illustrates the quantity of Pi released in picomoles per sample per time 
point. 
Figure 9.13 A graphic illustration of the quantity of Pi generated during 
magnesium-dependent hydrolysis of ATP by lJ.LM VarF plotted 
against time (minutes). 
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The ATPase activity of lJ..lM VarF, was calculated in terms of nmoles/minlmg, by 
adjusting for the total reaction volume of lOOOj.ll, 0.0262mg/ml of VarF and 
spontaneous ATP hydrolysis. From table 9.2 we see that after 1 minute, the amount of 
Pi generated (adjusted according to the gradient of the activity curve of figure 9.13) in 
the reaction was 449.77nmoles/minlmg VarF. Similar to the results generated from the 
Malachite Green assay, an overall decrease in the rate of Pi formation with increasing 
time could indicate that ATPase activity is dependent on ATP concentration. 
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Table 9.2 The quantity of Pi generated in terms ofnmoles/min/mg ofVarF. 
Time Presence of Absence of Adjusted for 
(min) 1mM MgCI2 1mM MgCI2 spontaneous ATP nmoles/min/mg VarF hydrolysis 
0 1121.22 886.7175573 234.50 234.50 
1 1351.45 901.6793893 449.77 449.77 
2 1581.68 916.6412214 665.04 332.52 
3 1811.91 931.6030534 880.31 293.44 
4 2042.14 946.5648855 1095.57 273.89 
5 2272.37 961.5267176 1310.84 262.17 
6 2502.60 976.4885496 1526.11 254.35 
7 2732.82 991.4503817 1741.37 248.77 
8 2963.05 1006.412214 1956.64 244.58 
9 3193.28 1021.374046 2171.91 241.32 
10 3423.51 1 036.335878 2387.18 238.72 
9.4 Discussion 
The ATP-binding protein, VarF, of the var ABC transporter has been 
successfully purified as a soluble C-terrninal His6-tagged protein and preliminary A TP-
binding capabilities have been investigated. 
Initial results from ATPase assays are consistent with VarF functioning as an 
ATP-binding protein capable of ATP hydrolysis. VarF-associated ATP hydrolysis was 
dependent on the presence of Mg2+ ions provided by the addition of MgCh in the assay 
buffer. The maximum rate of ATP hydrolysis in the Malachite Green reaction was 
determined to be 258.67nmoles/minlmg of VarF, however, in the EnzChek assay the 
maximum rate was 458.83nmoles/minlmg. This apparent increase in ATPase activity 
could be due to the increase in ATP concentration used from 250J.1M to lmM, which 
could indicate that the rate of ATP hydrolysis is dependent on ATP concentration. 
Further experimental methods in which this can be verified are outlined in the future 
directions. 
The measured rate of hydrolysis for V arF from the EnzChek assay was 
comparable to that of the ATP-binding subunit, HisP, of the histidine permease 
(Nikaido et al., 1997). Under standard assay conditions which included 2mM ATP, the 
maximum rate of hydrolysis for HisP was 500nmol/minlmg protein. The similarities are 
more noteworthy considering the likeness in the structural arrangement of the histidine 
permease to that of the var ABC transport system, with two integral membrane proteins, 
HisQ and HisM, and two copies of HisP that carries the A TP-binding motif (Liu et al., 
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1997; Nikaido et al., 1997). However, the ATPase activity measured in vitro may not be 
a true reflection of the actual rate of A TP hydrolysis exhibited by VarF in vivo when in 
a functionally active complex with its transmembrane domains. This assumption was 
also proposed by Liu and authors (1997), where the ATP hydrolytic activity of HisP, 
may be repressed by HisQ and/or HisM (Liu et al., 1997). Consistent with this notion, 
Nikaido and colleagues (1997) demonstrated that isolated and purified HisP(his6) did 
indeed hydrolyse ATP at a higher rate in the presence of Mg2+ when compared to the 
intrinsic activity of the complex. 
Unfortunately, owing to time constraints, further biochemical and structural 
experiments could not be conducted to elucidate the basic parameters of VarF activity 
that would allow for an accurate comparison with other ABC-A TPases. However, the 
methods in which this can be achieved are outlined in the following future directions. 
9.5 Future directions 
Increasing the purity of VarF for structural characterisation 
The purity of VarF could be refined to >95% through further purification using 
chromatographic methods such as ion-exchange and preparatory SEC as described 
previously in chapter 4. 
Structural characterisation of VarF by protein crystallography 
Crystallisation trials of V arF could be conducted in the presence and absence of A TP 
and Mg2+-ATP in order to obtain crystals for X-ray diffraction. It is anticipated that 
structural characterisation of V arF would provide insights into the mechanism of A TP 
recognition and hydrolysis, which could be compared with other known ABC-A TPases 
in order to elucidate differences as described previously. 
Determining the oligomeric state of VarF 
Structural and functional studies have indicated that A TP-binding proteins operate as 
dimers in a 'head-to-tail' arrangement, to form a shared interface with two binding sites 
for the cooperative hydrolysis of ATP (Liu et al., 1997; Nikaido et al., 1997; Hopfner et 
al., 2000; Smith et al., 2002; Hornet al., 2003; Janas et al., 2003; Dawson and Locher, 
2006, 2007). Therefore analytical SEC could be employed as described in chapter 6 
section 6.1 to determine the oligomeric state of purified VarF-His6 and thus its putative 
functional state. 
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Determining if A TPase activity is dependent on A TP concentration 
To determine if the rate of VarF ATP hydrolysis is dependent on ATP concentration, 
Malachite Green assays could be conducted (as described in chapter 2 section 2.13 .4) 
with lJ.lM VarF in the presence of ATP concentrations ranging from OJ.lM to 2mM. The 
Pi content in each sample could be analysed at 1 minute intervals over a 10 minute 
period. A standard curve would be used to determine the amount of Pi accumulated per 
sample per time point, which could then used to calculate the rate of Pi formation in 
terms of nmoles/min/mg. The rate of Pi formation can then be fitted to a single 
hyperbolic (Michaelis-Menten) equation: 
V = Vmax· [S] 
[S] + Km 
where v and [S] refer to the measured rate of Pi formation (nmoles/min/mg) and ATP 
concentration [ATP], respectively. Non-linear regression software such as Sigma Plot 
can be used to obtain the maximum velocity (Vmax) and the Michaelis constant (Km) 
from a graph of [ATP] (J.lM) plotted against the rate of Pi formation (nmoles/min/mg). 
A non-linear or sigmoidal curve with respect to [ATP] implies positive cooperativity 
between A TP-binding sites (Liu et al., 1997), whereas a linear plot indicates that A TP 
hydrolysis is a non-cooperative process. The calculated Km value, which would be a 
measure of the affinity of V arF for A TP can then be compared with other functionally 
characterised ATP-binding proteins. 
The cooperativity of ATP binding to VarF can also be measured by the Hill 
coefficient (n) derived from a Hill plot of the log (v (Vmax-v)) versus log [S]. Where n> 1 
indicates positive cooperativity (also a measure of the number of interacting binding 
sites and thus the multimeric state of the protein), n<1 indicates negative cooperativity 
and n= 1 indicates non-cooperativity or independent binding. 
Determining if A TPase activity is dependent on VarF concentration 
To determine if the rate of V arF A TP hydrolysis is dependent on protein concentration, 
ATPase assays could be conducted as described previously with 1mM ATP in the 
presence of V arF concentrations ranging from OJ.lM to 50J.lM. 
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Chapter 10 Final Discussion 
Since the successful decoding of the genome sequences for many species of the 
prokaryotic and eukaryotic kingdoms, much focus has been directed into interpreting 
the genetic data and the proteins in which it encodes. In light of modem medical 
pressures in antibiotic resistance, MDR transport systems in bacteria have been of 
particular intense interest for researcher's intent on finding a solution. 
Vibrio cholerae is a Gram-negative pathogen and is the aetiological agent of the 
diarrhoeal disease, cholera. Cholera is one of the oldest known diseases and often 
occurs in explosive outbreaks in many countries worldwide. In its severest form, if left 
untreated, death within 24 hours often ensues (WHO, 2003). The treatment of cholera 
typically entails intensive rehydration therapy in developed nations, whereas in 
underdeveloped countries antibiotic use is essential. However, the use of antibiotics has 
inevitably led to isolates developing resistances to a range of chemically diverse 
antibiotics (Choudhury and Kumar, 1996), which effectively compromises the 
management of cholera with current treatment regimes. The potential for V. cholerae to 
promiscuously exchange genetic information within its ecological environment, may 
also eventually lead to the spread of resistance to other natural microbial populations. 
Overall, V. cholerae therefore lends itself as an important target for elucidating the 
molecular mechanisms of resistance, and through using the knowledge gained may 
afford new chemotherapeutic strategies to be developed that prevent its spread. The 
evolutionary relatedness and conservation of these resistance mechanisms will also 
allow the information to be related to similar systems in alternative bacterial species. 
Since the complete elucidation of the genome sequence of V. cholerae 01 Biovar 
Eltor strain N16961 (Heidelberg et al.., 2000), more than 28 putative multidrug 
transporter genes has been revealed. Although several publications of multidrug efflux 
systems in V. cholerae have been reported (Colmer et al., 1998; Huda et al., 2001, 
2003; Begum et al., 2005; Woolley et al., 2005; Bina et al., 2006), only one ABC-type 
transporter, YcaM, has been described (Huda et al., 2003). Herein this thesis, we report 
another two putative MDR ABC transporters, YarD and YarE, however unlike YcaM, 
may establish a tripartite complex that bypasses both membranes of Gram-negative V. 
cholerae. 
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10.1 The Vibrio cholerae var operon 
Components of the operon encode two putative antibiotic resistance mechanisms 
conferred by a MPl VarG, and a ABC-type tripartite transport complex, VarACDEF. 
The unique characteristic of this operon is that it is under the control of a single, 
divergently transcribed LTTR protein, V arR, which is understood to co-regulate the 
expression of these resistance mechanisms at three distinct locations, termed the varRG, 
varGA and varBC IR. The ability of the bacterium to regulate at these points may allow 
the 'switching on' or 'off' of expression of either of these resistance mechanisms 
depending on the insult experienced. Generally, MDR systems under the control of 
regulatory proteins have been reported to belong to the secondary transporters of the 
MF and RND family and none to date have been described for an ABC-type transport 
system. To date, no comparable MDR regulatory mechanism or operon has yet been 
elucidated nor reported in a Gram-negative bacterium. Herein this chapter, the findings 
in the attempt to uncover the functional and structural characteristics of individual 
components of this novel antibiotic resistance operon are discussed. 
10.2 The LTTR, VarR 
VarR is a member of the LTTR family. Amino acid sequence analysis of VarR has 
identified anN-terminal DBD (residues 1-64), a LysR region (residues 29-305) and a C-
terminal substrate binding domain (residues 100-300) consistent with LTTRs. Within 
the N-terminal DBD of VarR was a highly conserved HTH motif (PROSITE entry: 
PS00044) common to all transcriptional regulatory proteins (Bairoch et al., 1997). To 
determine if VarR regulates at the varRG, varGA and varBC IR of the var operon, 
EMSAs were employed to determine binding at these regions, which required the 
expression and purification of V arR. 
VarR was purified, in the absence of detergent, at concentrations <l.Smglml. Initial 
attempts to obtain soluble VarR proved unsuccessful and resulted in the formation of 
precipitate or inclusion bodies. This has been a common feature of most L TTR proteins 
(Bishop and Weiner, 1993; Verschueren et al., 2001; Stec et al., 2004), which has 
stunted progress being made to elucidate their structures. However, through adopting a 
different expression system VarR was successfully purified as a soluble protein with a 
C-terminal His6-tag at concentrations of -1 mg/ml, which was sufficient for conducting 
biochemical EMSAs. 
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VarR binds to three different putative promoter sites within the novel var operon. 
Through amino acid analysis of the putative promoter regions of the var operon, three 
likely operator sites were identified for VarR. EMSA shows that VarR binds to various 
lengths of the varRG, varGA and varBC IR and in particular, specifically to a 30bp 
region of each promoter. This is consistent with the premise that L TTRs are notorious 
for binding multiple sites that span approximately 50-60bp of the promoter region 
(Hryniewicz and Kredich, 1994; Tyrrell et al., 1997; Muraoka et al., 2003). The ability 
of VarR to bind such lengths of DNA suggests that it may be required to adopt a higher 
oligomeric state for binding, such as a dimer of dimers. In the varRG promoter, VarR 
binding occurs at a predicted 30bp operator sequence that overlaps the -35 sites for both 
varR and varG. In the varBC promoter, binding occurs at a predicted 30bp operator 
sequence that overlaps the -10 site for varC. Binding by V arR to these sites presumably 
prevents RNA polymerase association and thus expression of the varG, varACDEF 
genes and possibly regulating its own expression through autoregulation. 
The potential global regulatory role of VarR. Interestingly, during specificity assays 
with non-specific DNA during EMSAs, VarR was found to bind to an unrelated E. coli 
promoter termed arsD. Upon closer inspection of the nucleotide sequence of the 30bp 
arsD DNA, 5'-ATTAATCATATGCGTTTTTGGTTATGTGTT-3', it was revealed that 
the sequence consisted of -60% identity and similarity with that of the 30bp varRG 
DNA. This chance discovery could serve as an example for the potential global 
regulatory property of V arR, for it is not uncharacteristic for LTTRs to act at the local 
and/or global level in the transcriptional regulation of linked target genes and at 
unlinked regulons (Schell, 1993; Kong et al., 2005). The regulatory mechanisms 
elucidated from this chapter may therefore be extrapolated to other bacterial species 
with similar regulatory systems. This has already been demonstrated with the varR-
varG system from V. cholerae that shows similarities to the ampR-ampG transcriptional 
regulatory system in C. freundii (Lindquist et al., 1989) and E. cloacae (Lindberg and 
Normark, 1987). 
As the data from EMS As are unable to impute the binding state of V arR, 
analytical SEC was employed to resolve the subunit stoichiometry of apo and DNA-
bound forms of V arR. These studies required VarR to be at concentrations > 1.5mg/ml, 
which was previously shown to cause aggregation. However, thmugh adopting a 
different expression system and purification method that incorporated the detergent, 
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DDM, VarR was successfully purified as a soluble protein with a C-terminal His6-tag at 
concentrations of -8-1 Omg/rnl. 
A possible octomeric state for VarR? Interestingly, through analytical SEC, the Mr of 
both apo and DNA-bound forms of VarR (detergent purified) were calculated to be 
-300kDa, which would be consistent with VarR forming an octomer. This would not be 
unusual as other DNA-binding proteins have been proven to bind as higher molecular 
weight species to their cognate promoter DNA (Engohang-Ndong et al., 2004). A 
repressor protein, EthR from the TetR family of transcriptional regulators has been 
shown to octamerise on its operator site (Engohang-Ndong et al., 2004). The authors 
suggest that this multimerisation of EthR could be a consequence of binding an 
unusually long 55bp region, which would be consistent with VarR binding to its 
putative 56bp operator site in the varRG IR. However, with the large body of evidence 
suggestive of LTTRs forming either dimers or tetramers in solution and tetramers upon 
binding their cognate promoters (Miller and Kredich, 1987; Bishop and Weiner, 1993; 
Verschueren et al., 2001; Muraoka et al., 2003), the result seemed unlikely or albeit 
novel. 
Apo- and DNA-bound VarR are seemingly tetrameric. Colorimetric assays were 
conducted to determine the extent to which DDM imposes on the calculated Mr of VarR 
from analytical SEC. In keeping with the predicted oligomeric states of LTTRs, the 
results of the assays were consistent with VarR migrating as a tetramer in both DNA-
bound and unbound states. This is also in agreement with the results obtained from 
analytical ultracentrifugation and preparatory SEC. The elution profile from SEC 
purification of VarR indicates that VarR may exist in two oligomeric states in solution. 
The ability of apo V arR to form different oligomeric states is not unusual as it has been 
proven that LTTRs such as AmpR, CysB and CbnR are capable of forming dimers and 
tetramers in solution, but become tetrameric upon binding DNA (Miller and Kredich, 
1987; Bishop and Weiner, 1993; Hryniewicz and Kredich, 1994; Verschueren et al., 
2001; Muroaka et al., 2003). This is also true of other regulators involved in MDR such 
as QacR and V ceR that exist as dimers in solution, but bind its promoter as a tetramer 
formed from a dimer of dimers (Grkovic et al., 2001; Borges-Walmsley eta/., 2005). 
However, with the large body of evidence suggestive of LTTRs forming either dimers 
or tetramers in solution and tetramers upon binding their cognate promoters, V arR may 
therefore exist as dimer and tetramer conformations in solution, and could be stabilised 
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into a predominantly tetrameric conformation when bound to its cognate promoter DNA 
in vivo. This would be functionally feasible as the predicted operator sites for VarR 
spans 56bp of the putative varRG promoter and 62bp of the varGA promoter. This 
would require VarR to be in a tetrameric conformation, possibly as a dimer of dimers, 
for all four DBDs to contact these sites. 
DNA-binding by VarR induces secondary structural conformations. Having 
deduced the likely quaternary structure of V arR when bound to DNA, another question 
remains as to whether DNA- and/or substrate-binding to VarR would induce structural 
conformational changes. CD spectroscopy demonstrated a change in the secondary 
content of apo VarR when incubated with all three cognate promoter DNA. This would 
be suggestive of DNA-binding by VarR inducing an overall global conformational 
change in the complex, possibly as a consequence of propagation of the signal to the 
substrate-binding domain to form a substrate-active binding site. This could be in 
preparation for swift full or partial dissociation of the LTTR from the promoter upon 
sensing the presence of substrate. Alternatively, a global conformational change in 
VarR may be induced as a result of structural changes in the DBDs, propagated through 
the dimerisation helix of each subunit, that alter the distances of the HTH motifs for 
efficient binding at two distinct sites, such as the RBS and ABS. The only structure of 
the full length L TTR, CbnR, provides insights into the subunit stoichiometry and 
possible mechanisms of substrate and DNA-binding. However, the question remains as 
to whether all LTTRs adopt a similar structural arrangement. The absence of structures 
of CbnR in complex with DNA and/or substrate, further mystify the mechanism of 
induction of gene expression. These questions may only be addressed upon the 
successful structural characterisation of another LTTR, in the presence and absence of 
DNA and/or substrate. The presence of only one full length crystal structure of a LTTR 
is testament to the difficulties faced by many research groups in striving to obtain 
sufficient quantities of these proteins necessary for structural characterisation. However, 
the successful crystallisation of full-length VarR in the absence and presence of a 30bp 
varRG IR DNA are discussed later in this section and will hopefully provide insights 
into this grey area. 
VarR binding to promoter regions may be indifferent in the presence of substrate. 
To provide insights into the possible mechanism of gene induction, for example if VarR 
can be dissociated from the varRG, varGA and varBC DNA complexes, which could 
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lead to activation of gene expression, EMSAs were conducted with increasing titrations 
of putative antibiotics. Neither, Penicillin G or Erythromycin was able to dissociate 
VarR from the 30bp varRG and varBC IR DNA complex, respectively, even in excess 
concentrations. However, the inability to dissociate VarR from both varRG and varBC 
operator sites at such high concentrations of antibiotic does not imply that the tested 
antibiotics are not substrates for VarR. Rather it has been proven that some LTTRs 
show indifference to binding to their operator sites in the presence or absence of 
substrate (Lindquist et al., 1989; Schell, 1993; Jacobs et al., 1997). A study by Kong 
and associates (2005) has shown that the presence of ampR is required for ampC 
expression. This could be a consequence of the dual regulatory functions of L TTRs 
(Schell, 1993), whereby in the absence of substrate, LTTRs may constitutively bind 
their promoters to form a repressive state, but in the presence of substrate they may 
activate, but only partially dissociate from the promoter in a manner that exposes the -
35 site to RNA polymerase for transcriptional initiation of target gene(s). 
Alternatively, it could be that the switch from repression to transcriptional 
activation may be due to differential binding of V arR to operator sites as a consequence 
of formation of different oligomeric states. One theory could be that binding by a 
tetramer of VarR to the operator site induces a tight bend that protects the -35 site from 
transcriptional initiation through the production of inefficiently spaced promoter sites 
required for RNA polymerase binding. In the presence of substrate, the substrate-bound 
V arR complex may then induce a conformational change, causing a global change in the 
complex that reduces the bend angle of the DNA, resulting in the formation of a 
correctly spaced RNA polymerase sites for efficient transcriptional initiation. Further 
increases in substrate may only further increase the affinity for binding at DNA in order 
to maintain the reduced bend angle of the DNA and correct spacing of RNA 
polymerase. 
However, there is also the possibility that the substrates used were incorrect or 
not recognised by V arR. 
VarR acts as a repressor at the varRG IR. Reporter assays have established that V arR 
acts as a repressor at the varRG IR. Two plasmids were constructed with the varRG IR 
fused consecutively to the chloramphenicol resistance gene in the presence and absence 
of the varR gene. Antimicrobial assays were conducted in the presence of 
chloramphenicol antibiotic. Strains not harbouring the varR gene in the construct 
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showed a 12-fold increase in resistance to chloramphenicol (128J..Lg/ml) when compared 
to the strains with the varR gene (2J..Lg/ml) and control (lJ..Lg/ml). 
The data gathered in this thesis implies that V arR acts as a repressor at the 
varRG IR, which may lead to the repression of VarG expression. In the presence of P-
lactams, substrate-binding by VarR may not cause dissociation from its operator site, 
but rather induce a conformation change in the complex that alters binding, possibly as 
a result of DNA bending. Increases in substrate concentration may only enhance the 
formation of the reduced bend in DNA to maintain transcriptional activation of V arG in 
order to respond effectively to the insult. 
However, we must be open minded to the possibility that V arR may just have a 
modulatory role, and that induction of expression may be regulated by another local or 
global regulator. This can be exemplified by the TetR repressor, AcrR, which prevents 
the excessive expression of the AcrAB transporter, which together with talC is, in tum, 
induced by the global activator MarA (Grkovic et al., 2002). 
VarR was purified at concentrations of -8-lOmg/ml and to a purity >98% for 
crystallisation. Initial attempts in the overexpression and purification of V arR in 
sufficient quantities for crystallisation were fraught with insolubility difficulties. Having 
tried various solubilisation techniques, the use of detergent in these preparations was 
essential and necessary for further progression of structural studies. Similar to 
membrane proteins, VarR was soluble in detergent DDM and that addition of DDM to 
precipitated VarR also aided in its resolubilisation. The requirement for DDM in the 
solubilisation of VarR may indicate potential need to mask hydrophobic entities to 
maintain a soluble state. These insolubility issues are not uncommon for LTTRs and 
mirrors the problems faced and attempts made by other research groups to maintain 
them in solution (Lochowska et al., 2001; Verschueren et al., 2001; Stec et al., 2004). 
Full-length VarR was successful crystallised in the presence and absence of its 
cognate promoter DNA. Although we have yet to elucidate the crystal structure for 
VarR, crystallisation trials have successfully yielded full-length VarR microcrystals that 
bring us a step closer to realising this potential. The successful crystallisation of the full-
length VarR is a great achievement in itself, as the immense insolubility properties have 
often resulted in many groups resorting to crystallisation of the truncated C-terminal 
forms of the protein (Tyrrell et al., 1997; Choi et al., 2001; Verschueren et al., 2001; 
Stec et al., 2004). This suggests that the N-terminal DBDs are attributable to the 
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insolubility of these proteins and would be consistent with the requirement for low 
concentrations of detergent in the purification of V arR. A hydrophobic core of residues 
in the DBD and a cluster in the linker domain (a4) has been identified and is highly 
conserved between members of the LTTR family (Muraoka et al., 2003; Zaim and 
Kierzek, 2003). However, the use of detergents in the masking of hydrophobic regions 
in the N-terminal DBD may lead to alterations in the surface of the DBD that could 
disrupt oligomerisation and DNA-binding activity (Zaim and Kierzek, 2003). Therefore, 
detergent was used only in the solubilisation of VarR at high concentrations (>6mg/ml) 
for structural studies with low concentrations of protein ( <lmg/ml) dedicated for 
EMSAs being purified in the absence of detergent. 
It is anticipated that successful structural determination will elucidate the 
mechanism by which VarR binds to its cognate promoter DNA and induces expression 
of V arG and the var transporter complex components. The crystal structure will also 
provide insights into how structural changes upon DNA- and/or substrate-binding may 
lead to induction of gene expression. 
10.3 The M~l, VarG 
M~ls are of fast emerging clinical importance (Fritsche et al., 2005; Thomson and 
Bonomo, 2005) owing to their ability to hydrolyse all existing ~-lactams including the 
newer generation cephalosporins and carbapenems. To exacerbate the situation the 
activity of these enzymes cannot be neutralised by current ~-lactamase inhibitors and 
the implementation of such therapeutic inhibitors may take several years (Walsh et al., 
2005). At present (May 2007) only one structurally characterised M~l, CphA, in 
complex with a ~-lactam, biapenem, has been published (Garau et al., 2005). However, 
CphA is a monozinc carbapenemase that only requires a single Zn2+ for the hydrolysis 
of ~-lactams at the active site (Garau et al., 2005). No crystal structure has yet been 
reported for a bizinc-M~l that utilises two Zn2+ for catalytic hydrolysis. Elucidation 
would provide crucial insights into how interactions of specific amino acids with two 
Zn2+ leads to the coordinated attack of the ~-lactam ring. These fundamentals would 
bring a greater understanding into the mechanism of M~l action and thus enable the 
rational development of novel antibiotics and inhibitors that are at present urgently 
needed. 
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VarG is a putative Mpl. Analysis of the amino acid sequence of VarG has established 
VarGas a hi-zinc MPI. A C257D substitution at the Zn2 site of VarG, which is believed 
to be conserved and essential in mono-zinc M~ls for the coordination of the Zn2+ for ~­
lactam hydrolysis (see chapter 3 section 3.3.1), may affect hydrolytic activity of VarG. 
However, mutational analysis has suggested the irrelevance of this cysteine for binding 
and hydrolysis in bizinc-M~ls as the respective cysteine was substituted and still 
demonstrated the ability of the mutant to bind two Zn2+ ions (Paul-Soto et al., 1999; Xu 
et al., 2006). The differences in the active sites between the mono- and bizinc-M~ls 
suggest that these enzymes may have evolved two different mechanisms for hydrolysis 
of newer ~-lactams such as the carbapenem antibiotics. 
VarG has been purified as a soluble protein. VarG was successfully overexpressed 
and purified as a fusion to an N-terminal His6-tag. Although VarG was expressed 
successfully at concentrations necessary for structural studies, the purity of the 
preparation was not satisfactory and will require further refinement by chromatographic 
methods. 
Could VarG expression lead to the induction of another chromosomal ~­
lactamase? SDS-PAGE analysis of the wash fraction from His6-VarG purification 
shows the presence of a putative protein that migrates around the 39kDa Mr marker. 
Interestingly, western blot failed to detect the presence of a His6-tag in this wash 
fraction indicating that another protein was seemingly co-expressed. As M~ls are often 
co-expressed with other P-lactamases (Wang et al., 1999; Walsh et al., 2005), the 
expression of VarG may have subsequently led to the induction of the chromosomally 
encoded serine-~-lactamase, AmpC ( -41.5kDa) in the E. coli host strain. However, the 
mechanism by which AmpC could be co-expressed with V arG in the E. coli host is not 
understood as V arG was expressed in the absence of its regulatory protein, V arR. E. coli 
also lacks the regulatory gene, ampR, in the ampC region (Honore et al., 1986) and no 
~-lactam antibiotics were present. Therefore AmpC expression would have proceeded 
by a mechanism other than by regulatory protein and ~-lactam-based induction. 
Conversely, the His6-tag may have been cleaved by an endogenous protease, which 
could explain the failure in detecting the His6-tag during Western blotting. 
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VarG shows preliminary ~-lactamase activity. Preliminary ~-lactamase activity of 
V arG was detected through application of purified His6-V arG onto the surface of a 
nitrocefin disk. The hydrolysis of nitrocefin by VarG was indicated by a colour change 
to red. The presence of functional ~-lactamase activity and the absence of the cysteine 
at Zn2, suggests that VarG has the potential to exist as a bizinc-M~l. Unsuccessful 
attempts were made to elucidate the substrate profile for V arG using antimicrobial 
susceptibility testing. The experimental details in this thesis offer only slight 
advancements for elucidating the functional and structural role of VarG, which still 
remains elusive. Further biochemical and structural investigation is required provide a 
definitive demonstration of ~-lactamase activity in VarG and in order to fully 
understand the mechanism of ~-lactarn hydrolysis and inactivation. 
10.4 The ABC-type transporter complex, VarACDEF 
A BLAST search of the amino acid sequences of components from the var transporter 
complex have identified significant homologies with proteins involved in MDR in a 
number of Gram-negative bacteria including E. coli, N. gonorrhoeae and P. aeruginosa. 
VarD and V arE seem to have closest similarities with ABC transporters with specificity 
to macrolide antibiotics and antimicrobial peptides. Antimicrobial peptides represent the 
first line of host defence against invading pathogens. They are present in certain 
phagocytotic cells and their synthesis can be induced by epithelial cells that line the 
mucosal surfaces of the epithelium following infection (Shafer et al., 1998). The 
macrolide antibiotic, erythromycin, is used as an alternative for the treatment of V. 
cholerae infection when isolates show sensitivity to tetracycline (WHO, 2000). So it is 
not unusual for V. cholerae to have developed a strategy to overcome this lethal 
bombardment to enable it to exert and maintain its pathogenicity upon entering the 
human host. 
Structural similarities of the VarACDE system with the AcrAB-TolC system. 
Interestingly, although the VarACDEF transporter complex has an overall similar 
subunit arrangement with that described for the E. coli maltose-maltodextrin (as 
reviewed by Boos and Shuman, 1998) and the histidine systems (Kerppola et al., 1991; 
Liu et al., 1999), secondary structure predictions are suggestive of the formation of a 
structural arrangement similar to that of the RND-type AcrAB-TolC MDR system in 
E.coli (Murakami et al., 2002, 2006; Tikonova and Zgurskaya, 2004). This would prove 
interesting as the AcrAB-TolC system also has the ability to confer resistance to ~-
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lactam antibiotics (Mazzariol et al., 2000). The ability of RND transporters to confer 
resistance to antibiotics that target periplasmic enzymes involved with cell wall 
biosynthesis is intriguing as these transports generally do·not export substrates from the 
periplasm (Murakami et al., 2002). However, the crystal structure of AcrB provides 
insights into how this may be achieved. The structure of AcrB establishes the presence 
of vestibules that opens to the periplasm at the side of the transporter where the 
transition between the TMD and the porter domain occurs (Murakami et al., 2002; Yu 
et al., 2003b). This allows direct access of the substrates from the periplasm into the 
translocation channel where extrusion is driven by a proton motive force (Murakami et 
al., 2002). Therefore the VarCADEF2 transporter complex may have adopted a 
resistance mechanism similar to that of the AcrAB-TolC system, to supplement or 
enhance activity of the M~l. VarG that is also encoded in the var operon. This may be 
in response to selective pressures as a consequence of exposure to newer carbapenem ~­
lactam antibiotics or their compounds. 
Substrate profiles for the IMPs, VarD and VarE. Antimicrobial susceptibility assays 
were employed to examine the contributions of the IMPs, V arD and V arE, to the 
phenotypic responses of hypersensitive E. coli strains (t-..acrAB KAM3). Strains 
harbouring the plasmids containing either varD and/or varE together with varF in series 
(pQE-100/varEF ± varD) were constructed. Assays were conducted in the presence of 
macrolide antibiotics and antimicrobial pep tides that are assumed substrates for V arD 
and YarE. Unfortunately, the assays failed to detect any resistance against the 
antimicrobial agents tested when compared to the control. This failure could be due to 
the inefficient expression of genes from the vector and therefore the inability to extrude 
the antimicrobial agents from the cytoplasm to reduce concentrations of the 
antimicrobial agents to sub-toxic levels. Alternatively, as the transporter is hypothesised 
to form a multi-protein complex, the two IMPs may not be functioning efficiently in the 
absence of its corresponding MFP and OMP components. The assembly of an imperfect 
complex may cause hypersusceptible of the cells to the tested antimicrobials due to 
accumulation in the periplasmic space. This experiment may inadvertently demonstrate 
the requirement for domain-domain interactions, required for the efficient assembly and 
complete functioning of the transporter complex. 
Therefore to improve the expression of the transporter and thus the antimicrobial 
susceptibility assays, the MFP varA, the OMP varC, the IMPs varD and varE, and the 
ATPase varF were independently cloned into separate MCSs of T7-based dual 
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expression vectors. The lack of resistance observed in the antimicrobial susceptibility 
assays for KAM3 (DE3) harbouring pETDuet-varA, pACYCDuet-varC-varD, 
pRSFDuet-varE and pCDFDuet-varF when compared to the control is likely due to 
incomplete transporter complex formation as a result of overwhelming metabolic 
burden of the E. coli expression host. 
The antimicrobial resistance capability of the var transporter still remains 
elusive and requires further biochemical investigation to elucidate its substrate profile. 
Improved methods are required for the simultaneous overexpression of multiple 
components of the ABC-type var transporter to ensure the successful assembly of a 
fully functioning transport complex. 
10.5 The ABC-ATPase, VarF 
VarF was successfully purified as a soluble protein. VarF was successfully 
overexpressed and purified at high concentrations as a soluble C-terminal His-tagged 
protein and preliminary A TP-binding capabilities have been investigated. 
VarF shows preliminary ATPase activity. Initial results from ATPase assays are 
consistent with VarF functioning as an ATP-binding protein capable of ATP hydrolysis, 
which demonstrates that biological integrity is also preserved following purification. 
VarF-associated ATP hydrolysis was dependent on the presence of Mg2+ ions provided 
by the addition of MgCh in the assay buffer. The maximum rate of ATP hydrolysis in 
the Malachite Green reaction was determined to be 258.67nmoles/min/mg of VarF, 
however, in the EnzChek assay the maximum rate was 458.83nmoles/min/mg. This 
apparent increase in A TPase activity could be due to the increase in ATP concentration 
used from 250J.1M to 1mM, which could indicate that the rate of ATP hydrolysis is 
dependent on A TP concentration. 
The measured rate of hydrolysis for V arF from the EnzChek assay was 
comparable to that of the ATP-binding subunit, HisP, of the Histidine permease 
(Nikaido et al., 1997). Under standard assay conditions which included 2mM ATP, the 
maximum rate of hydrolysis for HisP was 500nmol/min/mg protein. The similarities are 
more noteworthy considering the likeness in the structural arrangement of the histidine 
permease to that of the var ABC transport system, with two integral membrane proteins, 
HisQ and HisM, and two copies of HisP that carries the A TP-binding motif (Liu et al., 
1997; Nikaido et al., 1997). However, the ATPase activity measured in vitro may not be 
a true reflection of the actual rate of ATP hydrolysis exhibited by V arF in vivo when in 
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a functionally active complex with its transmembrane domains. This assumption was 
also proposed by Liu and authors ( 1997), where the A TP hydrolytic activity of the A TP-
binding protein, HisP, may also be repressed by the transmembrane domains, HisQ 
and/or HisM. Consistent with this notion, Nikaido and colleagues ( 1997) demonstrated 
that isolated and purified HisP(his6J did indeed hydrolysed ATP at a higher rate in the 
presence of Mg2+ when compared to the intrinsic activity of the complex. 
Unfortunately, owing to time constraints, further biochemical and structural 
experiments could not be conducted to elucidate the basic parameters of VarF activity 
that would allow for an accurate comparison with other ABC-A TPases. The 
independence of the ABC-ATPase from its cognate TMDs leads to the ultimate 
question of how the ABC-ATPase interacts or docks with the transmembrane 
components to form a functionally active transporter and remains an interesting area for 
future work. 
10.6 Concluding remarks 
The work detailed in this thesis provides a mere fractional insight into the possible 
mechanisms of MDR resistance and regulation afforded by the var operon. Although, 
much remains to be discovered, it is anticipated that the work contained herein may 
form a basis that would ultimately lead to the understanding and elucidation of the 
putative resistance mechanisms encoded within this novel operon. 
Although regulatory proteins are preferred over their regulated transmembrane 
counterparts for structure-function studies, understanding the function of these proteins 
proves to be more challenging due to their extremely diverse regulatory nature, with 
each MDR system seemingly being regulated in a unique manner. 
Increased selective pressures have ensured that bacteria are becoming 
increasingly resistant to current treatment regimes through the exchange and 
employment of different resistance mechanisms. Therefore increasing our 
understanding of the regulatory controls governing these MDR systems, however 
insignificant this may be, could prove essential for future strategies to prevent the 
emergence of MDR microorganisms. 
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